{"PMC3362645": [["IntroductionThe liver flukes, Fasciola hepatica and Fasciola gigantica are the causative agents of fasciolosis, a foodborne zoonotic disease affecting grazing animals and humans worldwide [1].", [["liver flukes", "ANATOMY", 16, 28], ["liver flukes", "DISEASE", 16, 28], ["Fasciola hepatica", "DISEASE", 30, 47], ["Fasciola gigantica", "DISEASE", 52, 70], ["fasciolosis", "DISEASE", 99, 110], ["zoonotic disease", "DISEASE", 124, 140], ["liver", "ORGAN", 16, 21], ["flukes", "ORGANISM", 22, 28], ["Fasciola hepatica", "ORGANISM", 30, 47], ["Fasciola gigantica", "ORGANISM", 52, 70], ["humans", "ORGANISM", 171, 177], ["Fasciola hepatica", "SPECIES", 30, 47], ["Fasciola gigantica", "SPECIES", 52, 70], ["humans", "SPECIES", 171, 177], ["Fasciola hepatica", "SPECIES", 30, 47], ["Fasciola gigantica", "SPECIES", 52, 70], ["humans", "SPECIES", 171, 177], ["The liver flukes", "PROBLEM", 12, 28], ["Fasciola hepatica", "PROBLEM", 30, 47], ["Fasciola gigantica", "PROBLEM", 52, 70], ["fasciolosis", "PROBLEM", 99, 110], ["a foodborne zoonotic disease", "PROBLEM", 112, 140], ["liver", "ANATOMY", 16, 21], ["flukes", "OBSERVATION", 22, 28], ["Fasciola", "OBSERVATION_MODIFIER", 30, 38], ["hepatica", "ANATOMY", 39, 47], ["Fasciola gigantica", "OBSERVATION", 52, 70], ["fasciolosis", "OBSERVATION", 99, 110]]], ["Liver fluke causes economic losses of over US$ 3 billion worldwide per annum to livestock via mortality, reduction in host fecundity, susceptibility to other infections, decrease in meat, milk and wool production and condemnation of livers [1].", [["Liver fluke", "ANATOMY", 0, 11], ["meat", "ANATOMY", 182, 186], ["milk", "ANATOMY", 188, 192], ["livers", "ANATOMY", 233, 239], ["Liver fluke", "DISEASE", 0, 11], ["infections", "DISEASE", 158, 168], ["Liver", "ORGAN", 0, 5], ["fluke", "ORGANISM", 6, 11], ["meat", "ORGANISM_SUBDIVISION", 182, 186], ["milk", "ORGANISM_SUBSTANCE", 188, 192], ["livers", "ORGAN", 233, 239], ["Liver fluke", "PROBLEM", 0, 11], ["host fecundity", "PROBLEM", 118, 132], ["other infections", "PROBLEM", 152, 168], ["fluke", "OBSERVATION", 6, 11], ["host fecundity", "OBSERVATION", 118, 132], ["livers", "ANATOMY", 233, 239]]], ["The disease is increasing in livestock worldwide with contributing factors such as climate change (warmer winters and wetter summers supporting larger intermediate mud snail host populations); fragmented disease management (only treating sheep not cattle and limiting veterinary interaction); encouragement of wet-lands; livestock movement; and/or failure/resistance of chemical control treatments in the absence of commercial vaccines [1], [2].", [["sheep", "SPECIES", 238, 243], ["cattle", "SPECIES", 248, 254], ["sheep", "SPECIES", 238, 243], ["cattle", "SPECIES", 248, 254], ["The disease", "PROBLEM", 0, 11], ["larger intermediate mud snail host populations", "TREATMENT", 144, 190], ["fragmented disease management", "TREATMENT", 193, 222], ["chemical control treatments", "TREATMENT", 370, 397], ["commercial vaccines", "TREATMENT", 416, 435], ["disease", "OBSERVATION", 4, 11], ["increasing", "OBSERVATION_MODIFIER", 15, 25], ["fragmented", "OBSERVATION_MODIFIER", 193, 203], ["disease", "OBSERVATION", 204, 211]]], ["Fasciolosis is also a re-emerging human disease with estimates of between 2.4 and 17 million people infected worldwide [3].", [["Fasciolosis", "DISEASE", 0, 11], ["human", "ORGANISM", 34, 39], ["people", "ORGANISM", 93, 99], ["human", "SPECIES", 34, 39], ["people", "SPECIES", 93, 99], ["human", "SPECIES", 34, 39], ["Fasciolosis", "PROBLEM", 0, 11], ["a re-emerging human disease", "PROBLEM", 20, 47]]], ["In response, the World Health Organisation have added fasciolosis to the preventative chemotherapy concept [4].IntroductionThere are currently no commercial vaccines and triclabendazole (TCBZ) is the most important fasciolicide, as the only drug with significant efficacy against adult worms and juveniles [5].", [["worms", "ANATOMY", 286, 291], ["triclabendazole", "CHEMICAL", 170, 185], ["TCBZ", "CHEMICAL", 187, 191], ["fasciolicide", "CHEMICAL", 215, 227], ["triclabendazole", "CHEMICAL", 170, 185], ["TCBZ", "CHEMICAL", 187, 191], ["fasciolicide", "CHEMICAL", 215, 227], ["triclabendazole", "SIMPLE_CHEMICAL", 170, 185], ["TCBZ", "SIMPLE_CHEMICAL", 187, 191], ["fasciolicide", "SIMPLE_CHEMICAL", 215, 227], ["worms", "SPECIES", 286, 291], ["fasciolosis", "PROBLEM", 54, 65], ["the preventative chemotherapy concept", "TREATMENT", 69, 106], ["commercial vaccines", "TREATMENT", 146, 165], ["triclabendazole (TCBZ)", "TREATMENT", 170, 192], ["adult worms", "PROBLEM", 280, 291]]], ["Evidence from developed countries where TCBZ has been used widely exposes the reliance on this drug as an Achilles heel of liver fluke chemotherapeutic control, with well-established evidence of drug-resistance [5].", [["liver fluke", "ANATOMY", 123, 134], ["TCBZ", "CHEMICAL", 40, 44], ["TCBZ", "CHEMICAL", 40, 44], ["TCBZ", "SIMPLE_CHEMICAL", 40, 44], ["Achilles heel", "ORGANISM", 106, 119], ["liver", "ORGAN", 123, 128], ["TCBZ", "TREATMENT", 40, 44], ["this drug", "TREATMENT", 90, 99], ["liver fluke chemotherapeutic control", "TREATMENT", 123, 159], ["drug-resistance", "PROBLEM", 195, 210], ["Achilles", "ANATOMY", 106, 114], ["liver", "ANATOMY", 123, 128], ["fluke", "OBSERVATION", 129, 134]]], ["Therefore, TCBZ does not offer a long-term sustainable option for livestock farmers worldwide.", [["TCBZ", "CHEMICAL", 11, 15], ["TCBZ", "CHEMICAL", 11, 15], ["TCBZ", "SIMPLE_CHEMICAL", 11, 15], ["a long-term sustainable option", "TREATMENT", 31, 61]]], ["The need for a liver fluke vaccine is further underscored by the fact that the costs associated with anthelmintic intervention for fluke control make short-lived chemotherapy an unsustainable option in developing countries.", [["liver fluke", "ANATOMY", 15, 26], ["liver fluke", "DISEASE", 15, 26], ["liver", "ORGAN", 15, 20], ["fluke", "ORGANISM", 21, 26], ["a liver fluke vaccine", "TREATMENT", 13, 34], ["anthelmintic intervention", "TREATMENT", 101, 126], ["fluke control", "TREATMENT", 131, 144], ["short-lived chemotherapy", "TREATMENT", 150, 174], ["liver", "ANATOMY", 15, 20], ["fluke", "OBSERVATION", 21, 26]]], ["Protein superfamily studies in liver fluke have provided a number of leading vaccine candidates.", [["liver fluke", "ANATOMY", 31, 42], ["liver fluke", "DISEASE", 31, 42], ["liver fluke", "CANCER", 31, 42], ["Protein superfamily studies", "TEST", 0, 27], ["leading vaccine candidates", "TREATMENT", 69, 95], ["liver", "ANATOMY", 31, 36]]], ["High quality one-gene based vaccine discovery research has identified several vaccine candidates from protein superfamilies that provide significant, but often variable protection rates in challenge animal trials against liver fluke.IntroductionFor example, Mu class Glutathione transferase (GSTs) have been widely investigated as vaccine candidates for fasciolosis [6]\u2013[9].", [["liver fluke", "ANATOMY", 221, 232], ["liver fluke", "DISEASE", 221, 232], ["fasciolosis", "DISEASE", 354, 365], ["Glutathione", "CHEMICAL", 267, 278], ["liver", "ORGAN", 221, 226], ["fluke", "ORGANISM", 227, 232], ["Mu class Glutathione transferase", "GENE_OR_GENE_PRODUCT", 258, 290], ["GSTs", "GENE_OR_GENE_PRODUCT", 292, 296], ["fasciolosis [6]\u2013[9]", "SIMPLE_CHEMICAL", 354, 373], ["protein superfamilies", "PROTEIN", 102, 123], ["Mu class Glutathione transferase", "PROTEIN", 258, 290], ["GSTs", "PROTEIN", 292, 296], ["several vaccine candidates", "TREATMENT", 70, 96], ["protein superfamilies", "TREATMENT", 102, 123], ["liver fluke", "PROBLEM", 221, 232], ["Mu class Glutathione transferase (GSTs)", "TREATMENT", 258, 297], ["fasciolosis", "PROBLEM", 354, 365], ["liver", "ANATOMY", 221, 226], ["fluke", "OBSERVATION", 227, 232]]], ["The Mu class GSTs have established roles in general Phase II detoxification of xenobiotic and endogenously derived toxins in F. hepatica within the host bile environment [10].", [["bile", "ANATOMY", 153, 157], ["Mu class GSTs", "GENE_OR_GENE_PRODUCT", 4, 17], ["F. hepatica", "ORGANISM", 125, 136], ["bile", "MULTI-TISSUE_STRUCTURE", 153, 157], ["Mu class GSTs", "PROTEIN", 4, 17], ["F. hepatica", "SPECIES", 125, 136], ["F. hepatica", "SPECIES", 125, 136], ["hepatica", "ANATOMY", 128, 136], ["bile", "ANATOMY", 153, 157]]], ["The general detoxification role is supported by GSTs contributing to 4% of the total soluble protein in F. hepatica, with a widespread tissue distribution.", [["tissue", "ANATOMY", 135, 141], ["GSTs", "GENE_OR_GENE_PRODUCT", 48, 52], ["F. hepatica", "ORGANISM", 104, 115], ["tissue", "TISSUE", 135, 141], ["GSTs", "PROTEIN", 48, 52], ["soluble protein", "PROTEIN", 85, 100], ["F. hepatica", "SPECIES", 104, 115], ["F. hepatica", "SPECIES", 104, 115], ["hepatica", "ANATOMY", 107, 115], ["widespread", "OBSERVATION_MODIFIER", 124, 134], ["tissue", "OBSERVATION", 135, 141], ["distribution", "OBSERVATION_MODIFIER", 142, 154]]], ["Proteomics and EST sequencing approaches have now delineated what members of the GST family are expressed in F. hepatica and two new classes of GST, Sigma and Omega, have been uncovered [11].", [["GST", "GENE_OR_GENE_PRODUCT", 81, 84], ["F. hepatica", "ORGANISM", 109, 120], ["GST", "GENE_OR_GENE_PRODUCT", 144, 147], ["Sigma", "GENE_OR_GENE_PRODUCT", 149, 154], ["Omega", "GENE_OR_GENE_PRODUCT", 159, 164], ["GST family", "PROTEIN", 81, 91], ["GST", "PROTEIN", 144, 147], ["Omega", "PROTEIN", 159, 164], ["F. hepatica", "SPECIES", 109, 120], ["F. hepatica", "SPECIES", 109, 120], ["Proteomics", "TEST", 0, 10], ["EST sequencing approaches", "TREATMENT", 15, 40], ["hepatica", "ANATOMY", 112, 120]]], ["In the related trematode, Schistosoma mansoni, the Sigma class GST (Sm28) has generally shown more robust protection in vaccine trials against schistosome infection [12], than the F. hepatica Mu GSTs against F. hepatica infection.IntroductionSigma class GSTs, unlike Mu Class GSTs, have been characterized as GSH-dependent hematopoietic prostaglandin synthases responsible for the production of prostaglandins in both mammals and parasitic worms [13]\u2013[18].", [["Schistosoma mansoni", "DISEASE", 26, 45], ["schistosome infection", "DISEASE", 143, 164], ["F. hepatica infection", "DISEASE", 208, 229], ["GSH", "CHEMICAL", 309, 312], ["prostaglandin", "CHEMICAL", 337, 350], ["prostaglandins", "CHEMICAL", 395, 409], ["GSH", "CHEMICAL", 309, 312], ["prostaglandin", "CHEMICAL", 337, 350], ["prostaglandins", "CHEMICAL", 395, 409], ["trematode", "ORGANISM", 15, 24], ["Schistosoma mansoni", "ORGANISM", 26, 45], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 51, 66], ["Sm28", "GENE_OR_GENE_PRODUCT", 68, 72], ["schistosome", "ORGANISM", 143, 154], ["F. hepatica", "ORGANISM", 180, 191], ["Mu GSTs", "ORGANISM", 192, 199], ["F. hepatica", "ORGANISM", 208, 219], ["IntroductionSigma class GSTs", "GENE_OR_GENE_PRODUCT", 230, 258], ["Mu Class GSTs", "GENE_OR_GENE_PRODUCT", 267, 280], ["GSH", "SIMPLE_CHEMICAL", 309, 312], ["hematopoietic prostaglandin synthases", "GENE_OR_GENE_PRODUCT", 323, 360], ["prostaglandins", "SIMPLE_CHEMICAL", 395, 409], ["Sigma class GST", "PROTEIN", 51, 66], ["Sm28", "PROTEIN", 68, 72], ["F. hepatica Mu GSTs", "PROTEIN", 180, 199], ["IntroductionSigma class GSTs", "PROTEIN", 230, 258], ["Mu Class GSTs", "PROTEIN", 267, 280], ["GSH-dependent hematopoietic prostaglandin synthases", "PROTEIN", 309, 360], ["Schistosoma mansoni", "SPECIES", 26, 45], ["F. hepatica", "SPECIES", 180, 191], ["F. hepatica", "SPECIES", 208, 219], ["worms", "SPECIES", 440, 445], ["Schistosoma mansoni", "SPECIES", 26, 45], ["F. hepatica", "SPECIES", 180, 191], ["F. hepatica", "SPECIES", 208, 219], ["vaccine trials", "TREATMENT", 120, 134], ["schistosome infection", "PROBLEM", 143, 164], ["hepatica infection", "PROBLEM", 211, 229], ["GSH", "TEST", 309, 312], ["dependent hematopoietic prostaglandin synthases", "TREATMENT", 313, 360], ["the production of prostaglandins", "PROBLEM", 377, 409], ["parasitic worms", "PROBLEM", 430, 445], ["trematode", "OBSERVATION_MODIFIER", 15, 24], ["Schistosoma mansoni", "OBSERVATION", 26, 45], ["more robust", "OBSERVATION_MODIFIER", 94, 105], ["hepatica", "ANATOMY", 183, 191], ["hepatica", "ANATOMY", 211, 219], ["infection", "OBSERVATION", 220, 229], ["both mammals", "ANATOMY", 413, 425]]], ["Prostaglandins have been extensively studied in mammals and are shown to be involved in a range of physiological and pathological responses [19]\u2013[23].", [["Prostaglandins", "CHEMICAL", 0, 14], ["Prostaglandins", "GENE_OR_GENE_PRODUCT", 0, 14], ["Prostaglandins", "TREATMENT", 0, 14]]], ["Parasite-produced prostaglandins may be involved in parasite development and reproduction as well as the modulation of host immunity, allergy and inflammation during establishment and maintenance of a host infection [16], [24]\u2013[28].", [["parasite", "ANATOMY", 52, 60], ["prostaglandins", "CHEMICAL", 18, 32], ["allergy", "DISEASE", 134, 141], ["inflammation", "DISEASE", 146, 158], ["infection", "DISEASE", 206, 215], ["prostaglandins", "CHEMICAL", 18, 32], ["Parasite", "CELL", 0, 8], ["prostaglandins", "SIMPLE_CHEMICAL", 18, 32], ["[24]\u2013[28]", "SIMPLE_CHEMICAL", 222, 231], ["prostaglandins", "TREATMENT", 18, 32], ["allergy", "PROBLEM", 134, 141], ["inflammation", "PROBLEM", 146, 158], ["a host infection", "PROBLEM", 199, 215]]], ["The host protection success of Sigma GST based vaccinations in schistosomiasis may therefore be related to neutralising specific functions in host-parasite interplay, such as prostaglandin synthase activity.IntroductionIn this manuscript we follow four work pathways to functionally characterise the newly identified Sigma GST from F. hepatica.", [["schistosomiasis", "DISEASE", 63, 78], ["prostaglandin", "CHEMICAL", 175, 188], ["F. hepatica", "DISEASE", 332, 343], ["prostaglandin", "CHEMICAL", 175, 188], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 31, 40], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 175, 197], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 317, 326], ["F. hepatica", "ORGANISM", 332, 343], ["Sigma GST", "PROTEIN", 31, 40], ["prostaglandin synthase", "PROTEIN", 175, 197], ["Sigma GST", "PROTEIN", 317, 326], ["F. hepatica", "SPECIES", 332, 343], ["F. hepatica", "SPECIES", 332, 343], ["The host protection", "TREATMENT", 0, 19], ["Sigma GST based vaccinations", "TREATMENT", 31, 59], ["schistosomiasis", "PROBLEM", 63, 78], ["prostaglandin synthase activity", "TREATMENT", 175, 206], ["hepatica", "ANATOMY", 335, 343]]], ["1) We confirm its designation as a Sigma class GST using substrate profiling, 2) we assess prostaglandin synthase activity and its effect on host immune cells, 3) we localise the Sigma GST within adult fluke and between ontogenic stages and 4) assess its potential as a vaccine candidate.Sequence analysis ::: Materials and MethodsGST proteins representative of recognised GST superfamily classes were obtained from European Bioinformatics Institute Interpro database (http://www.ebi.ac.uk/interpro/), and from non-redundant databases at NCBI (http://www.ncbi.nlm.nih.gov/).", [["immune cells", "ANATOMY", 146, 158], ["adult fluke", "ANATOMY", 196, 207], ["prostaglandin", "CHEMICAL", 91, 104], ["prostaglandin", "CHEMICAL", 91, 104], ["GST", "GENE_OR_GENE_PRODUCT", 47, 50], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 91, 113], ["host immune cells", "CELL", 141, 158], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 179, 188], ["adult fluke", "ORGAN", 196, 207], ["GST", "GENE_OR_GENE_PRODUCT", 373, 376], ["Sigma class GST", "PROTEIN", 35, 50], ["prostaglandin synthase", "PROTEIN", 91, 113], ["host immune cells", "CELL_TYPE", 141, 158], ["Sigma GST", "PROTEIN", 179, 188], ["MethodsGST proteins", "PROTEIN", 324, 343], ["GST superfamily classes", "PROTEIN", 373, 396], ["substrate profiling", "TEST", 57, 76], ["prostaglandin synthase activity", "TREATMENT", 91, 122], ["host immune cells", "TREATMENT", 141, 158], ["Sequence analysis", "TEST", 288, 305]]], ["A mammalian and a helminth or invertebrate GST sequence were selected for each GST class where available.", [["GST", "GENE_OR_GENE_PRODUCT", 43, 46], ["GST", "GENE_OR_GENE_PRODUCT", 79, 82], ["mammalian and a helminth or invertebrate GST sequence", "DNA", 2, 55], ["GST class", "PROTEIN", 79, 88], ["invertebrate GST sequence", "TEST", 30, 55]]], ["[30] and sequence identity matrices produced from multiple alignments.", [["sequence identity matrices", "TEST", 9, 35], ["multiple alignments", "OBSERVATION", 50, 69]]], ["Phylogenetic bootstrap neighbour-joining trees were produced as PHYLIP output files in ClustalX Version 1.83 [31] according to the neighbour-joining method of Saitou and Nei [32].", [["Phylogenetic bootstrap neighbour", "TREATMENT", 0, 32]]], ["ClustalX default settings for alignments were accepted using the GONNET protein weight matrices with PHYLIP tree format files viewed within TREEVIEW [33].Recombinant Fasciola hepatica glutathione transferase Sigma class (rFhGST-S1) production ::: Materials and MethodsFull-length cDNA for FhGST-S1 was available in the form of an expressed sequence tag (EST) clone Fhep24h03, details of which can be obtained from the previously published Sigma class GST [11] and is identical to the submitted GenBank accession No.", [["glutathione", "CHEMICAL", 184, 195], ["glutathione", "CHEMICAL", 184, 195], ["Fasciola hepatica", "ORGANISM", 166, 183], ["glutathione transferase Sigma class", "GENE_OR_GENE_PRODUCT", 184, 219], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 221, 230], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 289, 297], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 439, 454], ["GONNET protein weight matrices", "DNA", 65, 95], ["Recombinant Fasciola hepatica glutathione transferase", "PROTEIN", 154, 207], ["rFhGST", "PROTEIN", 221, 227], ["MethodsFull-length cDNA", "DNA", 261, 284], ["FhGST", "DNA", 289, 294], ["S1", "DNA", 295, 297], ["expressed sequence tag (EST) clone Fhep24h03", "DNA", 330, 374], ["Sigma class GST", "PROTEIN", 439, 454], ["Fasciola hepatica", "SPECIES", 166, 183], ["Fasciola hepatica", "SPECIES", 166, 183], ["the GONNET protein weight matrices", "TREATMENT", 61, 95], ["an expressed sequence tag", "TEST", 327, 352], ["Fasciola", "OBSERVATION", 166, 174], ["GenBank accession", "OBSERVATION", 494, 511]]], ["DQ974116.1 (NCBI http://www.ncbi.nlm.nih.gov/).Recombinant Fasciola hepatica glutathione transferase Sigma class (rFhGST-S1) production ::: Materials and MethodsFhGST-S1 was amplified via PCR using the following primer pair: rFhGST-S1 forward primer, 5\u2032 GGAATTCCATATGGACAAACAGCATTTCAAGTT 3\u2032;rFhGST-S1 reverse primer, 5\u2032 ATAAGAATGCGGCCGCCTAGAATGGAGTTTTTGCACGTTTTTT 3\u2032.", [["glutathione", "CHEMICAL", 77, 88], ["glutathione", "CHEMICAL", 77, 88], ["Fasciola hepatica", "ORGANISM", 59, 76], ["glutathione transferase Sigma class", "GENE_OR_GENE_PRODUCT", 77, 112], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 114, 123], ["MethodsFhGST-S1", "GENE_OR_GENE_PRODUCT", 154, 169], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 291, 300], ["Fasciola hepatica glutathione transferase", "PROTEIN", 59, 100], ["rFhGST", "PROTEIN", 114, 120], ["MethodsFhGST", "DNA", 154, 166], ["S1", "DNA", 167, 169], ["primer pair", "DNA", 212, 223], ["rFhGST", "DNA", 225, 231], ["GGAATTCCATATGGACAAACAGCATTTCAAGTT 3\u2032;rFhGST-S1 reverse primer", "DNA", 254, 315], ["Fasciola hepatica", "SPECIES", 59, 76], ["Fasciola hepatica", "SPECIES", 59, 76], ["Fasciola hepatica glutathione transferase", "TEST", 59, 100], ["Materials", "TEST", 140, 149], ["MethodsFhGST-S1", "TREATMENT", 154, 169], ["PCR", "TEST", 188, 191], ["GGAATTCCATATGGACAAACAGCATTTCAAGTT", "TEST", 254, 287], ["rFhGST", "TEST", 291, 297]]], ["Restriction enzyme sites (in bold type and underlined) for NdeI (forward primer) and NotI (reverse primer) were included so that the entire ORF could be directionally cloned into the pET23a (Novagen) vector.", [["NdeI", "GENE_OR_GENE_PRODUCT", 59, 63], ["NotI", "GENE_OR_GENE_PRODUCT", 85, 89], ["pET23a", "GENE_OR_GENE_PRODUCT", 183, 189], ["Novagen", "GENE_OR_GENE_PRODUCT", 191, 198], ["Restriction enzyme sites", "DNA", 0, 24], ["NdeI (forward primer", "DNA", 59, 79], ["NotI", "DNA", 85, 89], ["reverse primer", "DNA", 91, 105], ["ORF", "DNA", 140, 143], ["pET23a (Novagen) vector", "DNA", 183, 206], ["Restriction enzyme sites", "PROBLEM", 0, 24], ["NdeI", "PROBLEM", 59, 63], ["the entire ORF", "PROBLEM", 129, 143], ["the pET23a (Novagen) vector", "TREATMENT", 179, 206], ["sites", "OBSERVATION_MODIFIER", 19, 24]]], ["Recombinant protein was produced in Escherichia coli BL21(DE3) cells (Novagen).Protein purification of rFhGST-S1 and native F. hepatica GSTs ::: Materials and MethodsrFhGST-S1 protein was purified according to the glutathione affinity chromatography method of Simons and Vander Jagt [34] from transformed E. coli cytosol following protein expression.", [["DE3) cells", "ANATOMY", 58, 68], ["cytosol", "ANATOMY", 313, 320], ["glutathione", "CHEMICAL", 214, 225], ["glutathione", "CHEMICAL", 214, 225], ["Escherichia coli", "ORGANISM", 36, 52], ["BL21", "ORGANISM", 53, 57], ["DE3) cells", "CELL", 58, 68], ["Novagen", "GENE_OR_GENE_PRODUCT", 70, 77], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 103, 112], ["F. hepatica", "ORGANISM", 124, 135], ["GSTs", "ORGANISM", 136, 140], ["MethodsrFhGST-S1", "GENE_OR_GENE_PRODUCT", 159, 175], ["glutathione", "SIMPLE_CHEMICAL", 214, 225], ["E. coli", "ORGANISM", 305, 312], ["cytosol", "ORGANISM_SUBSTANCE", 313, 320], ["Recombinant protein", "PROTEIN", 0, 19], ["Escherichia coli BL21(DE3) cells", "CELL_LINE", 36, 68], ["rFhGST", "PROTEIN", 103, 109], ["S1", "PROTEIN", 110, 112], ["native F. hepatica GSTs", "PROTEIN", 117, 140], ["MethodsrFhGST", "PROTEIN", 159, 172], ["S1 protein", "PROTEIN", 173, 183], ["Escherichia coli BL21", "SPECIES", 36, 57], ["F. hepatica", "SPECIES", 124, 135], ["E. coli", "SPECIES", 305, 312], ["Escherichia coli BL21", "SPECIES", 36, 57], ["DE3", "SPECIES", 58, 61], ["F. hepatica", "SPECIES", 124, 135], ["E. coli", "SPECIES", 305, 312], ["Recombinant protein", "TEST", 0, 19], ["Escherichia coli BL21(DE3) cells (Novagen", "TREATMENT", 36, 77], ["Protein purification", "TEST", 79, 99], ["rFhGST", "TEST", 103, 109], ["Materials", "TEST", 145, 154], ["MethodsrFhGST", "TEST", 159, 172], ["the glutathione affinity chromatography", "TEST", 210, 249], ["Simons", "TEST", 260, 266], ["transformed E. coli cytosol", "TREATMENT", 293, 320], ["Escherichia coli BL21", "OBSERVATION", 36, 57], ["S1", "ANATOMY", 110, 112], ["hepatica", "ANATOMY", 127, 135], ["protein expression", "OBSERVATION", 331, 349]]], ["Native GSTs were purified from F. hepatica soluble cytosolic supernatants as previously described [11].", [["cytosolic supernatants", "ANATOMY", 51, 73], ["GSTs", "GENE_OR_GENE_PRODUCT", 7, 11], ["F. hepatica", "ORGANISM", 31, 42], ["GSTs", "PROTEIN", 7, 11], ["F. hepatica", "SPECIES", 31, 42], ["F. hepatica", "SPECIES", 31, 42], ["Native GSTs", "PROBLEM", 0, 11], ["hepatica soluble cytosolic supernatants", "TREATMENT", 34, 73], ["hepatica", "ANATOMY", 34, 42]]], ["Purity of rFhGST-S1 was assessed by electrospray ionisation (ESI) mass spectrometry, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 2DE according to LaCourse et al.[35].Substrate profiling of Sigma GST ::: Materials and MethodsA range of model and natural substrates (see Table 1 for details) were used to profile the Sigma GST.", [["sodium dodecyl sulphate", "CHEMICAL", 85, 108], ["sodium dodecyl sulphate polyacrylamide", "CHEMICAL", 85, 123], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 10, 19], ["sodium dodecyl sulphate polyacrylamide", "SIMPLE_CHEMICAL", 85, 123], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 219, 228], ["GST", "GENE_OR_GENE_PRODUCT", 351, 354], ["rFhGST", "PROTEIN", 10, 16], ["Sigma GST", "PROTEIN", 219, 228], ["Sigma GST", "PROTEIN", 345, 354], ["mass spectrometry", "TEST", 66, 83], ["sodium dodecyl sulphate polyacrylamide gel electrophoresis", "TREATMENT", 85, 143], ["S1", "ANATOMY", 17, 19]]], ["A number of ligands were also assessed for their ability to inhibit GST activity with 1-chloro-2, 4-dinitrobenzene (CDNB) as the second substrate [36].", [["1-chloro-2, 4-dinitrobenzene", "CHEMICAL", 86, 114], ["CDNB", "CHEMICAL", 116, 120], ["1-chloro-2, 4-dinitrobenzene", "CHEMICAL", 86, 114], ["CDNB", "CHEMICAL", 116, 120], ["GST", "GENE_OR_GENE_PRODUCT", 68, 71], ["1-chloro-2, 4-dinitrobenzene", "SIMPLE_CHEMICAL", 86, 114], ["CDNB", "SIMPLE_CHEMICAL", 116, 120], ["GST", "PROTEIN", 68, 71], ["GST activity", "TEST", 68, 80]]], ["Values were reported as the concentration of inhibitor required to bring GST specific activity to 50% of its original activity (IC50).", [["GST", "GENE_OR_GENE_PRODUCT", 73, 76], ["GST", "PROTEIN", 73, 76], ["Values", "TEST", 0, 6], ["the concentration of inhibitor", "TREATMENT", 24, 54]]], ["At least six different inhibitor concentrations were used in each IC50 determination in triplicate.", [["different inhibitor concentrations", "TREATMENT", 13, 47], ["IC50 determination", "TEST", 66, 84]]], ["Inhibitors were pre-incubated for 5 minutes prior to starting reactions.", [["Inhibitors", "TREATMENT", 0, 10]]], ["IC50 values were estimated graphically [37].Substrate profiling of Sigma GST ::: Materials and MethodsProstaglandin synthase activity was assessed via an adapted method based upon those of Sommer et al.[26] and Meyer et al.[16], [38], with extraction modifications based upon Schmidt et al.[39].", [["Prostaglandin", "CHEMICAL", 102, 115], ["Prostaglandin", "CHEMICAL", 102, 115], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 67, 76], ["Prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 102, 124], ["Sigma GST", "PROTEIN", 67, 76], ["Prostaglandin synthase", "PROTEIN", 102, 124], ["IC50 values", "TEST", 0, 11], ["Materials", "TREATMENT", 81, 90], ["MethodsProstaglandin synthase activity", "TREATMENT", 95, 133], ["an adapted method", "TREATMENT", 151, 168], ["extraction modifications", "TREATMENT", 240, 264]]], ["In brief, reactions were performed in glass vials in 2 mM sodium phosphate buffer, pH 7.4, containing 10 mM glutathione, 50 mM NaCl, 0.5 mM tryptophan, 1 \u00b5M hematin, 1 U COX-1 enzyme, 100 \u00b5M arachidonic acid (All Sigma, UK.", [["sodium phosphate", "CHEMICAL", 58, 74], ["glutathione", "CHEMICAL", 108, 119], ["NaCl", "CHEMICAL", 127, 131], ["tryptophan", "CHEMICAL", 140, 150], ["arachidonic acid", "CHEMICAL", 191, 207], ["sodium phosphate", "CHEMICAL", 58, 74], ["glutathione", "CHEMICAL", 108, 119], ["NaCl", "CHEMICAL", 127, 131], ["tryptophan", "CHEMICAL", 140, 150], ["hematin", "CHEMICAL", 157, 164], ["arachidonic acid", "CHEMICAL", 191, 207], ["sodium phosphate buffer", "SIMPLE_CHEMICAL", 58, 81], ["glutathione", "SIMPLE_CHEMICAL", 108, 119], ["tryptophan", "SIMPLE_CHEMICAL", 140, 150], ["hematin", "SIMPLE_CHEMICAL", 157, 164], ["COX-1", "GENE_OR_GENE_PRODUCT", 170, 175], ["arachidonic acid", "SIMPLE_CHEMICAL", 191, 207], ["COX", "PROTEIN", 170, 173], ["2 mM sodium phosphate buffer", "TREATMENT", 53, 81], ["pH", "TEST", 83, 85], ["10 mM glutathione", "TREATMENT", 102, 119], ["0.5 mM tryptophan", "TREATMENT", 133, 150], ["hematin", "TREATMENT", 157, 164], ["COX", "TEST", 170, 173], ["enzyme", "TEST", 176, 182], ["arachidonic acid", "TEST", 191, 207]]], ["COX-1 [C0733]) and rFhGST-S1 at final concentration ranges of 0.1\u2013100.0 \u00b5g/ml.", [["COX-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 19, 28], ["COX", "PROTEIN", 0, 3], ["rFhGST", "PROTEIN", 19, 25], ["COX", "TEST", 0, 3], ["rFhGST", "TEST", 19, 25]]], ["Negative control reactions lacking either GST or COX-1 were also prepared.", [["GST", "GENE_OR_GENE_PRODUCT", 42, 45], ["COX-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["GST", "PROTEIN", 42, 45], ["COX-1", "PROTEIN", 49, 54], ["COX", "TEST", 49, 52]]], ["Reactions were incubated for 5\u201310 min in a water bath at 37\u00b0C. This was followed by 4 minutes incubation at 25\u00b0C in a shaking water bath.", [["C", "SIMPLE_CHEMICAL", 111, 112], ["a water bath", "TREATMENT", 41, 53], ["a shaking water bath", "TREATMENT", 116, 136]]], ["Prostaglandins were extracted by adding 860 \u00b5L of ice-cold ethyl acetate.", [["ice-cold ethyl acetate", "CHEMICAL", 50, 72], ["ethyl acetate", "CHEMICAL", 59, 72], ["Prostaglandins", "SIMPLE_CHEMICAL", 0, 14], ["ethyl acetate", "SIMPLE_CHEMICAL", 59, 72], ["Prostaglandins", "TREATMENT", 0, 14], ["ice-cold ethyl acetate", "TREATMENT", 50, 72]]], ["The upper ethyl acetate layer was retained and solvent was evaporated under a nitrogen stream at 45\u00b0C. The remaining residue was reconstituted in 50 \u00b5l of methanol/water/fomic acid (25\u223675\u22360,1) mix at pH 2.8 and stored at \u221280\u00b0C until ready for mass spectrometry analysis.", [["ethyl acetate", "CHEMICAL", 10, 23], ["methanol", "CHEMICAL", 155, 163], ["fomic acid", "CHEMICAL", 170, 180], ["ethyl acetate", "CHEMICAL", 10, 23], ["nitrogen", "CHEMICAL", 78, 86], ["methanol", "CHEMICAL", 155, 163], ["fomic acid", "CHEMICAL", 170, 180], ["methanol", "SIMPLE_CHEMICAL", 155, 163], ["water", "SIMPLE_CHEMICAL", 164, 169], ["fomic acid", "SIMPLE_CHEMICAL", 170, 180], ["The upper ethyl acetate layer", "TREATMENT", 0, 29], ["a nitrogen stream", "TREATMENT", 76, 93], ["methanol/water/fomic acid", "TREATMENT", 155, 180], ["pH", "TEST", 200, 202], ["mass spectrometry analysis", "TEST", 243, 269], ["upper", "ANATOMY_MODIFIER", 4, 9]]], ["Standards of prostaglandins D2, E2 and F2\u03b1 (Cayman, Ltd) were also prepared in methanol/water/formic acid mix for analysis.Prostaglandin detection ::: Materials and MethodsThe nano LC-MS analyses were performed using a Waters Q-Tof micro mass spectrometer (Waters) coupled to a LC-Packings Ultimate nano LC system (Dionex).", [["prostaglandins", "CHEMICAL", 13, 27], ["E2", "CHEMICAL", 32, 34], ["formic acid", "CHEMICAL", 94, 105], ["Prostaglandin", "CHEMICAL", 123, 136], ["prostaglandins D2, E2 and F2\u03b1", "CHEMICAL", 13, 42], ["methanol", "CHEMICAL", 79, 87], ["formic acid", "CHEMICAL", 94, 105], ["Prostaglandin", "CHEMICAL", 123, 136], ["prostaglandins D2", "SIMPLE_CHEMICAL", 13, 30], ["E2", "SIMPLE_CHEMICAL", 32, 34], ["F2\u03b1", "SIMPLE_CHEMICAL", 39, 42], ["Cayman", "SIMPLE_CHEMICAL", 44, 50], ["Ltd", "GENE_OR_GENE_PRODUCT", 52, 55], ["methanol", "SIMPLE_CHEMICAL", 79, 87], ["water", "SIMPLE_CHEMICAL", 88, 93], ["formic acid", "SIMPLE_CHEMICAL", 94, 105], ["Prostaglandin", "SIMPLE_CHEMICAL", 123, 136], ["prostaglandins D2", "TREATMENT", 13, 30], ["E2 and F2", "TREATMENT", 32, 41], ["methanol/water/formic acid mix", "TREATMENT", 79, 109], ["Prostaglandin detection", "TEST", 123, 146], ["The nano LC", "TEST", 172, 183], ["MS analyses", "TEST", 184, 195], ["a Waters Q-Tof micro mass spectrometer (Waters)", "TREATMENT", 217, 264], ["a LC-Packings Ultimate nano LC system", "TREATMENT", 276, 313]]], ["The pre-column used was a LC Packings C18 PepMap 100 and the nano LC column used was a LC Packings 15 cm PepMap 100 C18 (both Dionex).", [["PepMap 100 C18", "CHEMICAL", 105, 119], ["The pre-column", "TREATMENT", 0, 14], ["a LC Packings C18 PepMap", "TREATMENT", 24, 48], ["the nano LC column", "TREATMENT", 57, 75], ["a LC Packings", "TREATMENT", 85, 98]]], ["Samples were loaded on the pre-column with mobile phase A (25% methanol with 0.1% formic acid added).", [["Samples", "ANATOMY", 0, 7], ["formic acid", "CHEMICAL", 82, 93], ["methanol", "CHEMICAL", 63, 71], ["formic acid", "CHEMICAL", 82, 93], ["methanol", "SIMPLE_CHEMICAL", 63, 71], ["formic acid", "SIMPLE_CHEMICAL", 82, 93], ["Samples", "TEST", 0, 7], ["mobile phase A (25% methanol", "TREATMENT", 43, 71], ["0.1% formic acid", "TREATMENT", 77, 93]]], ["Loading flow rate was 0.03 ml/min for 6 min.", [["Loading flow rate", "TREATMENT", 0, 17]]], ["The samples were eluted on to the nano LC column using mobile phases B (60% acetonitrile) and C (100% methanol).", [["samples", "ANATOMY", 4, 11], ["acetonitrile", "CHEMICAL", 76, 88], ["methanol", "CHEMICAL", 102, 110], ["C", "SIMPLE_CHEMICAL", 94, 95], ["methanol", "SIMPLE_CHEMICAL", 102, 110], ["The samples", "TEST", 0, 11], ["mobile phases B (60% acetonitrile)", "TREATMENT", 55, 89], ["C (100% methanol", "TREATMENT", 94, 110]]], ["A typical gradient profile was 100% B to 100% C in 10 min (flow rate of 0.2 \u00b5l/min) with the column held at 100% C for 1 hour.", [["A typical gradient profile", "TEST", 0, 26], ["flow rate", "TEST", 59, 68], ["the column", "TREATMENT", 89, 99], ["typical", "OBSERVATION_MODIFIER", 2, 9], ["gradient", "OBSERVATION_MODIFIER", 10, 18]]], ["The mass spectrometer was operated in the negative ion nano electrospray mode with a source temperature of 80\u00b0C and capillary voltage 2.8 kV.", [["capillary", "ANATOMY", 116, 125], ["C", "GENE_OR_GENE_PRODUCT", 110, 111], ["capillary", "TISSUE", 116, 125], ["The mass spectrometer", "PROBLEM", 0, 21], ["a source temperature", "TEST", 83, 103], ["C", "TEST", 110, 111], ["capillary voltage", "TEST", 116, 133], ["mass", "OBSERVATION", 4, 8], ["capillary", "ANATOMY_MODIFIER", 116, 125]]], ["The scan range was 40 to 400 Da for 1.5 s.Liver fluke extract and excretory/secretory (ES) product preparation ::: Materials and Methods", [["Liver fluke extract", "ANATOMY", 42, 61], ["The scan range", "TEST", 0, 14], ["Liver fluke extract", "TEST", 42, 61], ["Methods", "TREATMENT", 129, 136], ["Liver", "ANATOMY", 42, 47]]]], "a38fbaf13257461b2cae74f42c90408ed1d5e723": [["IntroductionAs was extensively discussed in other chapters of this handbook, immunosenescence encompasses a number of diverse age-related cellular and extracellular milieu changes that affect cells and molecules of the immune and inflammatory system.", [["cellular", "ANATOMY", 138, 146], ["extracellular", "ANATOMY", 151, 164], ["cells", "ANATOMY", 192, 197], ["cellular", "CELL", 138, 146], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 164], ["cells", "CELL", 192, 197], ["cellular and extracellular milieu changes", "PROBLEM", 138, 179], ["diverse", "OBSERVATION_MODIFIER", 118, 125], ["cellular", "OBSERVATION_MODIFIER", 138, 146], ["extracellular milieu changes", "OBSERVATION", 151, 179], ["inflammatory", "OBSERVATION_MODIFIER", 230, 242]]], ["The very definition of immunosenescence, however, operationally includes not only the decline of immunity with age by itself, but also its most important clinical manifestation, the increased susceptibility to infection and decreased immunosurveillance of cancer.", [["cancer", "ANATOMY", 256, 262], ["infection", "DISEASE", 210, 219], ["cancer", "DISEASE", 256, 262], ["cancer", "CANCER", 256, 262], ["the increased susceptibility to infection", "PROBLEM", 178, 219], ["decreased immunosurveillance of cancer", "PROBLEM", 224, 262], ["immunosenescence", "OBSERVATION", 23, 39], ["increased", "OBSERVATION_MODIFIER", 182, 191], ["infection", "OBSERVATION", 210, 219], ["decreased", "OBSERVATION_MODIFIER", 224, 233], ["immunosurveillance", "OBSERVATION", 234, 252], ["cancer", "OBSERVATION", 256, 262]]], ["Other factors can contribute to the increased exposure to infectious diseases and increased colonization with infectious pathogens (e.g., reduced barrier function of skin and mucosal membranes) with age, and multiple factors certainly strongly contribute to the age-related increase in incidence of cancer.", [["barrier", "ANATOMY", 146, 153], ["skin", "ANATOMY", 166, 170], ["mucosal membranes", "ANATOMY", 175, 192], ["cancer", "ANATOMY", 299, 305], ["infectious diseases", "DISEASE", 58, 77], ["cancer", "DISEASE", 299, 305], ["skin", "ORGAN", 166, 170], ["mucosal membranes", "MULTI-TISSUE_STRUCTURE", 175, 192], ["cancer", "CANCER", 299, 305], ["the increased exposure", "PROBLEM", 32, 54], ["infectious diseases", "PROBLEM", 58, 77], ["increased colonization", "PROBLEM", 82, 104], ["infectious pathogens", "PROBLEM", 110, 130], ["reduced barrier function of skin and mucosal membranes", "PROBLEM", 138, 192], ["cancer", "PROBLEM", 299, 305], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["infectious", "OBSERVATION_MODIFIER", 58, 68], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["colonization", "OBSERVATION_MODIFIER", 92, 104], ["infectious", "OBSERVATION_MODIFIER", 110, 120], ["reduced", "OBSERVATION_MODIFIER", 138, 145], ["barrier function", "OBSERVATION_MODIFIER", 146, 162], ["skin", "ANATOMY", 166, 170], ["mucosal membranes", "ANATOMY", 175, 192], ["increase", "OBSERVATION_MODIFIER", 274, 282], ["cancer", "OBSERVATION", 299, 305]]], ["However, it is clear that the inability to mount rapid and vigorous immune defense once an infectious invasion (and, likely, detectable malignant transformation) had occurred lies at the heart of many of the clinical manifestations of immunosenescence.", [["heart", "ANATOMY", 187, 192], ["malignant transformation", "DISEASE", 136, 160], ["heart", "ORGAN", 187, 192], ["the inability to mount rapid and vigorous immune defense", "PROBLEM", 26, 82], ["an infectious invasion", "PROBLEM", 88, 110], ["detectable malignant transformation", "PROBLEM", 125, 160], ["infectious", "OBSERVATION_MODIFIER", 91, 101], ["invasion", "OBSERVATION", 102, 110], ["malignant", "OBSERVATION_MODIFIER", 136, 145], ["heart", "ANATOMY", 187, 192]]], ["Due to the involvement of numerous other nonimmunological factors in the age-related increase of cancer-related morbidity and mortality, this review will solely deal with infectious diseases.IntroductionIt has long been known that aging is accompanied by an increase in mortality and morbidity from a number of common respiratory infections such as influenza (20,000-40,000 annual deaths in the USA alone) (Bender 2003 ; Betts and Treanor 2000 ; Couch et al. 1986 ; Glezen and Couch 2003 ; High 2004 ; Yoshikawa 2000 ) , pneumococcal pneumonia (Bender 2003 ; High et al. 2005 ; Yoshikawa 2000 ) and RSV (Glezen and Couch 2003 ; High et al. 2005 ; Yoshikawa 2000 ) , and urinary infections (Bender 2003 ; Hazelett et al. 2006 ) .", [["cancer", "ANATOMY", 97, 103], ["respiratory", "ANATOMY", 318, 329], ["urinary", "ANATOMY", 670, 677], ["cancer", "DISEASE", 97, 103], ["infectious diseases", "DISEASE", 171, 190], ["respiratory infections", "DISEASE", 318, 340], ["influenza", "DISEASE", 349, 358], ["deaths", "DISEASE", 381, 387], ["pneumococcal pneumonia", "DISEASE", 521, 543], ["urinary infections", "DISEASE", 670, 688], ["cancer", "CANCER", 97, 103], ["RSV", "ORGANISM", 599, 602], ["urinary", "ORGANISM_SUBSTANCE", 670, 677], ["nonimmunological factors", "PROTEIN", 41, 65], ["pneumococcal", "SPECIES", 521, 533], ["pneumococcal", "SPECIES", 521, 533], ["RSV", "SPECIES", 599, 602], ["numerous other nonimmunological factors", "PROBLEM", 26, 65], ["cancer", "PROBLEM", 97, 103], ["infectious diseases", "PROBLEM", 171, 190], ["an increase in mortality", "PROBLEM", 255, 279], ["morbidity", "PROBLEM", 284, 293], ["common respiratory infections", "PROBLEM", 311, 340], ["influenza", "PROBLEM", 349, 358], ["pneumococcal pneumonia", "PROBLEM", 521, 543], ["RSV", "PROBLEM", 599, 602], ["urinary infections", "PROBLEM", 670, 688], ["numerous", "OBSERVATION_MODIFIER", 26, 34], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["cancer", "OBSERVATION", 97, 103], ["infectious", "OBSERVATION", 171, 181], ["increase", "OBSERVATION_MODIFIER", 258, 266], ["morbidity", "OBSERVATION", 284, 293], ["respiratory", "ANATOMY", 318, 329], ["infections", "OBSERVATION", 330, 340], ["pneumococcal", "OBSERVATION_MODIFIER", 521, 533], ["pneumonia", "OBSERVATION", 534, 543], ["RSV", "ANATOMY", 599, 602], ["urinary", "ANATOMY", 670, 677], ["infections", "OBSERVATION", 678, 688]]], ["Moreover, this vulnerability extends to dangerous established pathogens such as variola (Hanna 1913 ) as well as the newly emerging pathogens that disproportionally affect the elderly such as the West Nile virus (Murray et al. 2006 ) the Severe Acute Respiratory Syndrome-causing Coronavirus (SARS-CoV) (Chan et al. 2007 ; Leung et al. 2004 ) and others.IntroductionSeveral types of age-related defects in the immune function can contribute to this increased susceptibility to infection, including defects in innate immunity, antigen uptake, processing and presentation, provision of second and third signals to the adaptive immune system and impaired humoral immunity, all of which are competently covered in other chapters of this handbook.", [["immune system", "ANATOMY", 625, 638], ["Acute Respiratory Syndrome-causing Coronavirus", "DISEASE", 245, 291], ["SARS", "DISEASE", 293, 297], ["infection", "DISEASE", 477, 486], ["Hanna 1913", "ORGANISM", 89, 99], ["West Nile virus", "ORGANISM", 196, 211], ["SARS-CoV", "ORGANISM", 293, 301], ["antigen", "GENE_OR_GENE_PRODUCT", 526, 533], ["Nile virus", "SPECIES", 201, 211], ["West Nile virus", "SPECIES", 196, 211], ["Severe Acute Respiratory Syndrome-causing Coronavirus (SARS-CoV", "SPECIES", 238, 301], ["this vulnerability", "PROBLEM", 10, 28], ["dangerous established pathogens", "PROBLEM", 40, 71], ["variola", "PROBLEM", 80, 87], ["the newly emerging pathogens", "PROBLEM", 113, 141], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 234, 271], ["Coronavirus", "PROBLEM", 280, 291], ["age-related defects", "PROBLEM", 383, 402], ["this increased susceptibility to infection", "PROBLEM", 444, 486], ["defects in innate immunity", "PROBLEM", 498, 524], ["dangerous", "OBSERVATION_MODIFIER", 40, 49], ["pathogens", "OBSERVATION", 62, 71], ["pathogens", "OBSERVATION", 132, 141], ["Severe", "OBSERVATION_MODIFIER", 238, 244], ["Acute", "OBSERVATION_MODIFIER", 245, 250], ["Respiratory Syndrome", "OBSERVATION", 251, 271], ["defects", "OBSERVATION", 395, 402], ["infection", "OBSERVATION", 477, 486], ["innate immunity", "OBSERVATION_MODIFIER", 509, 524], ["humoral immunity", "OBSERVATION", 652, 668]]], ["However, T-cells have been known to exhibit some of the most pronounced age-related defects (Miller 1996 ) , and intervention to correct these defects resulted in successful correction of the immune function in a number of cases (Effros et al. 1991 ; Haynes et al. 2004 ; Haynes et al. 1999 ; Messaoudi et al. 2006a ).", [["T-cells", "ANATOMY", 9, 16], ["T-cells", "CELL", 9, 16], ["T-cells", "CELL_TYPE", 9, 16], ["related defects", "PROBLEM", 76, 91], ["intervention", "TREATMENT", 113, 125], ["these defects", "PROBLEM", 137, 150], ["the immune function", "PROBLEM", 188, 207], ["most pronounced", "OBSERVATION_MODIFIER", 56, 71], ["defects", "OBSERVATION", 84, 91], ["defects", "OBSERVATION", 143, 150], ["immune function", "OBSERVATION", 192, 207]]], ["These defects can be grossly divided into cell-autonomous defects, which affect T-cells regardless of age-related or compensatory alterations that affect other components of the immune system and which can be detected in assays where T-cells are the only component of the immune system affected by aging; and age-related changes in the T-cell population balance, which mostly involve the initial loss of na\u00efve T-cells and the compensatory, reactive changes aimed to maintain T-cell homeostasis in the face of this loss.", [["cell", "ANATOMY", 42, 46], ["T-cells", "ANATOMY", 80, 87], ["immune system", "ANATOMY", 178, 191], ["T-cells", "ANATOMY", 234, 241], ["immune system", "ANATOMY", 272, 285], ["T-cell", "ANATOMY", 336, 342], ["T-cells", "ANATOMY", 410, 417], ["T-cell", "ANATOMY", 475, 481], ["cell", "CELL", 42, 46], ["T-cells", "CELL", 80, 87], ["T-cells", "CELL", 234, 241], ["immune system", "ANATOMICAL_SYSTEM", 272, 285], ["T-cell", "CELL", 336, 342], ["T-cells", "CELL", 410, 417], ["T-cell", "CELL", 475, 481], ["T-cells", "CELL_TYPE", 80, 87], ["T-cells", "CELL_TYPE", 234, 241], ["na\u00efve T-cells", "CELL_TYPE", 404, 417], ["These defects", "PROBLEM", 0, 13], ["autonomous defects", "PROBLEM", 47, 65], ["compensatory alterations", "PROBLEM", 117, 141], ["the immune system", "PROBLEM", 268, 285], ["the initial loss of na\u00efve T-cells", "PROBLEM", 384, 417], ["reactive changes", "PROBLEM", 440, 456], ["this loss", "PROBLEM", 509, 518], ["defects", "OBSERVATION", 6, 13], ["cell", "OBSERVATION", 42, 46], ["autonomous defects", "OBSERVATION", 47, 65], ["compensatory", "OBSERVATION_MODIFIER", 117, 129], ["alterations", "OBSERVATION", 130, 141], ["immune system", "OBSERVATION", 178, 191], ["immune system", "OBSERVATION", 272, 285], ["compensatory", "OBSERVATION_MODIFIER", 426, 438], ["reactive", "OBSERVATION_MODIFIER", 440, 448], ["cell homeostasis", "OBSERVATION", 477, 493], ["loss", "OBSERVATION", 514, 518]]], ["This chapter will focus upon the latter changes, given that other aspects of T-cell dysfunction will be covered in other chapters of this volume.", [["T-cell", "ANATOMY", 77, 83], ["T-cell", "CELL", 77, 83], ["T-cell dysfunction", "PROBLEM", 77, 95], ["cell dysfunction", "OBSERVATION", 79, 95]]], ["Moreover, we will discuss the impact of a specific type of age-related T-cell disturbances, T-cell clonal expansions (TCE) (Callahan et al. 1993 ; Hingorani et al. 1993a ; Posnett et al. 1994 ) , upon immune defense and pathogen resistance, highlighting the extent and the limits of our current knowledge, and the tasks and problems that need to be solved before we can fully understand and treat these disturbances.T-cell Homeostasis and Development of T-cell Clonal Expansions (TCE)The current evidence strongly suggests that the involution of the thymus and the decline in production of new na\u00efve T-cells are the initiating factors behind the generation of at least some TCE (Messaoudi et al. 2006b ), whereas latent persistent viral infections may be the perpetrators driving other types of TCE .", [["T-cell", "ANATOMY", 71, 77], ["T-cell", "ANATOMY", 92, 98], ["T-cell", "ANATOMY", 416, 422], ["T-cell", "ANATOMY", 454, 460], ["thymus", "ANATOMY", 550, 556], ["T-cells", "ANATOMY", 600, 607], ["TCE", "CHEMICAL", 118, 121], ["TCE", "CHEMICAL", 674, 677], ["viral infections", "DISEASE", 731, 747], ["TCE", "CHEMICAL", 795, 798], ["TCE", "CHEMICAL", 795, 798], ["T-cell", "CELL", 71, 77], ["T-cell clonal", "CELL", 92, 105], ["T-cell", "CELL", 416, 422], ["T-cell", "CELL", 454, 460], ["thymus", "ORGAN", 550, 556], ["T-cells", "CELL", 600, 607], ["na\u00efve T-cells", "CELL_TYPE", 594, 607], ["T-cell disturbances", "PROBLEM", 71, 90], ["T-cell clonal expansions", "PROBLEM", 92, 116], ["pathogen resistance", "PROBLEM", 220, 239], ["these disturbances", "PROBLEM", 397, 415], ["T-cell Clonal Expansions", "PROBLEM", 454, 478], ["the thymus", "PROBLEM", 546, 556], ["the decline", "PROBLEM", 561, 572], ["new na\u00efve T-cells", "PROBLEM", 590, 607], ["latent persistent viral infections", "PROBLEM", 713, 747], ["cell disturbances", "OBSERVATION", 73, 90], ["pathogen resistance", "OBSERVATION", 220, 239], ["cell Homeostasis", "OBSERVATION", 418, 434], ["T-cell", "OBSERVATION", 454, 460], ["Clonal Expansions", "OBSERVATION", 461, 478], ["involution", "OBSERVATION", 532, 542], ["thymus", "ANATOMY", 550, 556], ["decline", "OBSERVATION_MODIFIER", 565, 572], ["new", "OBSERVATION_MODIFIER", 590, 593], ["persistent", "OBSERVATION_MODIFIER", 720, 730], ["viral infections", "OBSERVATION", 731, 747]]], ["Moreover, homeostatic mechanisms that are activated as a consequence of na\u00efve T-cell loss may themselves participate in the onset and/or maintenance of TCE (Messaoudi et al. 2006b (Messaoudi et al. , 2006c .", [["T-cell", "ANATOMY", 78, 84], ["TCE", "CHEMICAL", 152, 155], ["T-cell", "CELL", 78, 84], ["na\u00efve T-cell loss", "PROBLEM", 72, 89], ["cell loss", "OBSERVATION", 80, 89]]], ["Therefore, at the risk of being redundant, we will very briefly review thymic T-cell production, involution, latent persistent infections and T-cell homeostasis.", [["thymic T-cell", "ANATOMY", 71, 84], ["T-cell", "ANATOMY", 142, 148], ["infections", "DISEASE", 127, 137], ["thymic T-cell", "CELL", 71, 84], ["T-cell", "CELL", 142, 148], ["involution", "PROBLEM", 97, 107], ["latent persistent infections", "PROBLEM", 109, 137], ["T-cell homeostasis", "PROBLEM", 142, 160], ["redundant", "OBSERVATION", 32, 41], ["latent", "OBSERVATION_MODIFIER", 109, 115], ["persistent", "OBSERVATION_MODIFIER", 116, 126], ["infections", "OBSERVATION", 127, 137], ["cell homeostasis", "OBSERVATION", 144, 160]]], ["For a more detailed review of these topics, the reader is encouraged to read sections of this handbook devoted to thymic involution, as well as the recent volume of Seminars in Immunology devoted to T-cell rejuvenation (Nikolich-\u017dugich 2007 ; Zuniga-Pflucker and van den Brink 2007 ).Homeostatic Maintenance of T-cell SubsetsT-cell homeostasis is defined here as maintenance of na\u00efve and memory T-cell pool numbers and diversity and the ability to restore these numbers and diversity following antigenic (Ag) challenge.", [["thymic", "ANATOMY", 114, 120], ["T-cell", "ANATOMY", 199, 205], ["T-cell", "ANATOMY", 311, 317], ["cell", "ANATOMY", 327, 331], ["memory T-cell", "ANATOMY", 388, 401], ["Ag", "CHEMICAL", 505, 507], ["Ag", "CHEMICAL", 505, 507], ["thymic", "ORGAN", 114, 120], ["T-cell", "CELL", 199, 205], ["T-cell SubsetsT-cell", "CELL", 311, 331], ["T-cell", "CELL", 395, 401], ["Nikolich-\u017dugich 2007 ; Zuniga-Pflucker and van den Brink 2007 )", "SPECIES", 220, 283], ["thymic involution", "PROBLEM", 114, 131], ["T-cell rejuvenation", "TREATMENT", 199, 218], ["Zuniga", "TREATMENT", 243, 249], ["antigenic (Ag) challenge", "TREATMENT", 494, 518], ["thymic", "ANATOMY", 114, 120], ["involution", "OBSERVATION", 121, 131], ["T-cell", "OBSERVATION", 311, 317], ["cell homeostasis", "OBSERVATION", 327, 343]]], ["T-cell homeostasis is regulated by the response of T-cells to environmental trophic and survival signals and by the presence and availability of such signals.", [["T-cell", "ANATOMY", 0, 6], ["T-cells", "ANATOMY", 51, 58], ["T-cell", "CELL", 0, 6], ["T-cells", "CELL", 51, 58], ["T-cells", "CELL_TYPE", 51, 58], ["cell homeostasis", "OBSERVATION", 2, 18]]], ["The most important and best understood of these signals are the common \u03b3-chain cytokines (most notably IL-7, IL-15 and IL-2) and self-peptide: MHC (pMHC) complexes.", [["IL-7", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL-15", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-2", "GENE_OR_GENE_PRODUCT", 119, 123], ["pMHC", "GENE_OR_GENE_PRODUCT", 148, 152], ["\u03b3-chain cytokines", "PROTEIN", 71, 88], ["IL-7", "PROTEIN", 103, 107], ["IL", "PROTEIN", 109, 111], ["IL", "PROTEIN", 119, 121], ["MHC (pMHC) complexes", "PROTEIN", 143, 163], ["IL", "TEST", 103, 105], ["most important", "OBSERVATION_MODIFIER", 4, 18]]], ["The contribution of each of these signals to homeostatic maintenance varies depending on the T-cell subset.", [["T-cell", "ANATOMY", 93, 99], ["T-cell", "CELL", 93, 99], ["T-cell subset", "CELL_TYPE", 93, 106]]], ["Following maturation and selection in the thymus, new T-cells are released into the periphery as recent thymic emigrants (RTEs) (Scollay et al. 1980 ).", [["thymus", "ANATOMY", 42, 48], ["T-cells", "ANATOMY", 54, 61], ["periphery", "ANATOMY", 84, 93], ["thymic emigrants", "ANATOMY", 104, 120], ["thymus", "ORGAN", 42, 48], ["T-cells", "CELL", 54, 61], ["thymic emigrants", "MULTI-TISSUE_STRUCTURE", 104, 120], ["T-cells", "CELL_TYPE", 54, 61], ["thymic emigrants", "CELL_TYPE", 104, 120], ["selection in the thymus", "TREATMENT", 25, 48], ["thymus", "ANATOMY", 42, 48], ["new", "OBSERVATION_MODIFIER", 50, 53], ["periphery", "ANATOMY_MODIFIER", 84, 93], ["thymic emigrants", "OBSERVATION", 104, 120]]], ["Release of RTEs bearing a variety of randomly rearranged TCRs ensures the diversity of the peripheral T-cell pool.", [["peripheral T-cell", "ANATOMY", 91, 108], ["RTEs", "GENE_OR_GENE_PRODUCT", 11, 15], ["TCRs", "GENE_OR_GENE_PRODUCT", 57, 61], ["peripheral T-cell", "CELL", 91, 108], ["RTEs", "PROTEIN", 11, 15], ["TCRs", "PROTEIN", 57, 61], ["peripheral T-cell pool", "CELL_TYPE", 91, 113]]], ["Once released from the thymus, the RTE join the na\u00efve T-cell pool.", [["thymus", "ANATOMY", 23, 29], ["T-cell", "ANATOMY", 54, 60], ["thymus", "ORGAN", 23, 29], ["T-cell", "CELL", 54, 60], ["na\u00efve T-cell pool", "CELL_TYPE", 48, 65], ["thymus", "ANATOMY", 23, 29]]], ["Na\u00efve T-cells have no preset life spans and are maintained by IL-7 and trophic signals from interaction of their TCR with self-p:MHC complexes (rev. in (Lee and Surh 2005 ) .", [["T-cells", "ANATOMY", 6, 13], ["T-cells", "CELL", 6, 13], ["IL-7", "GENE_OR_GENE_PRODUCT", 62, 66], ["TCR", "GENE_OR_GENE_PRODUCT", 113, 116], ["Na\u00efve T-cells", "CELL_TYPE", 0, 13], ["IL", "PROTEIN", 62, 64], ["TCR", "PROTEIN", 113, 116], ["self-p:MHC complexes", "PROTEIN", 122, 142]]], ["When these two signals are present, na\u00efve T-cells are believed to be able to survive indefinitely, based upon the results of serial transfer experiments (Sprent et al. 1991 ).", [["T-cells", "ANATOMY", 42, 49], ["T-cells", "CELL", 42, 49], ["na\u00efve T-cells", "CELL_TYPE", 36, 49]]], ["Murine RTE proliferate faster than na\u00efve peripheral T-cells in the first three weeks after export, perhaps in order to maximize na\u00efve T-cell diversity, before they equilibrate with other na\u00efve T-cells (Berzins et al. 1998 ).", [["peripheral T-cells", "ANATOMY", 41, 59], ["T-cell", "ANATOMY", 134, 140], ["T-cells", "ANATOMY", 193, 200], ["Murine", "ORGANISM", 0, 6], ["RTE", "CELL", 7, 10], ["peripheral T-cells", "CELL", 41, 59], ["T-cell", "CELL", 134, 140], ["T-cells", "CELL", 193, 200], ["na\u00efve peripheral T-cells", "CELL_TYPE", 35, 59], ["na\u00efve T-cells", "CELL_TYPE", 187, 200], ["Murine", "SPECIES", 0, 6], ["Murine RTE proliferate", "TEST", 0, 22], ["proliferate", "OBSERVATION_MODIFIER", 11, 22], ["faster", "OBSERVATION_MODIFIER", 23, 29]]], ["Na\u00efve T-cells display very low levels of spontaneous (or homeostatic) cycling in vivo.", [["T-cells", "ANATOMY", 6, 13], ["Na\u00efve T-cells", "CELL", 0, 13], ["Na\u00efve T-cells", "CELL_TYPE", 0, 13], ["very low levels", "PROBLEM", 22, 37], ["very", "OBSERVATION_MODIFIER", 22, 26], ["low levels", "OBSERVATION_MODIFIER", 27, 37]]], ["Homeostatic cycling is greatly increased in lymphopenia, where T-cells sense a signal, most likely provided by an excess of unused IL-7 and IL-15 .", [["T-cells", "ANATOMY", 63, 70], ["lymphopenia", "DISEASE", 44, 55], ["T-cells", "CELL", 63, 70], ["IL-7", "GENE_OR_GENE_PRODUCT", 131, 135], ["IL-15", "GENE_OR_GENE_PRODUCT", 140, 145], ["T-cells", "CELL_TYPE", 63, 70], ["IL-7", "PROTEIN", 131, 135], ["IL-15", "PROTEIN", 140, 145], ["Homeostatic cycling", "PROBLEM", 0, 19], ["lymphopenia", "PROBLEM", 44, 55], ["unused IL", "TEST", 124, 133], ["greatly", "OBSERVATION_MODIFIER", 23, 30], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["lymphopenia", "OBSERVATION", 44, 55], ["most likely", "UNCERTAINTY", 87, 98]]], ["Under lymphopenic conditions T-cells undergo Ag-independent homeostatic proliferative expansion (HPE), in a seeming attempt to fill the empty compartment (Fry and Mackall 2005 ; Surh et al. 2006 ) .", [["T-cells", "ANATOMY", 29, 36], ["Ag", "CHEMICAL", 45, 47], ["HPE", "DISEASE", 97, 100], ["Ag", "CHEMICAL", 45, 47], ["T-cells", "CELL", 29, 36], ["Ag", "GENE_OR_GENE_PRODUCT", 45, 47], ["T-cells", "CELL_TYPE", 29, 36], ["Ag", "PROTEIN", 45, 47], ["Ag", "TEST", 45, 47], ["independent homeostatic proliferative expansion", "PROBLEM", 48, 95], ["lymphopenic", "OBSERVATION", 6, 17], ["Ag-independent", "OBSERVATION_MODIFIER", 45, 59], ["homeostatic", "OBSERVATION_MODIFIER", 60, 71], ["proliferative", "OBSERVATION_MODIFIER", 72, 85], ["expansion", "OBSERVATION_MODIFIER", 86, 95]]], ["Unlike na\u00efve T-cells, memory T-cells do not require specific p: MHC contact for survival.", [["T-cells", "ANATOMY", 13, 20], ["memory T-cells", "ANATOMY", 22, 36], ["na\u00efve T-cells", "CELL", 7, 20], ["memory T-cells", "CELL", 22, 36], ["na\u00efve T-cells", "CELL_TYPE", 7, 20], ["memory T-cells", "CELL_TYPE", 22, 36], ["MHC", "PROTEIN", 64, 67]]], ["Instead, their survival is dependent on continued homeostatic proliferation, driven mainly by IL-15, or by IL-7 in the absence of IL-15.", [["IL-15", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-7", "GENE_OR_GENE_PRODUCT", 107, 111], ["IL-15", "GENE_OR_GENE_PRODUCT", 130, 135], ["IL-15", "PROTEIN", 94, 99], ["IL-7", "PROTEIN", 107, 111], ["IL", "PROTEIN", 130, 132], ["IL", "TEST", 94, 96], ["homeostatic proliferation", "OBSERVATION", 50, 75]]], ["Memory cells cycle and self-renew in vivo significantly (up to four times) faster than na\u00efve T-cells and also exhibit faster proliferation during lymphopenia (Surh et al. 2006 ) .", [["Memory cells", "ANATOMY", 0, 12], ["T-cells", "ANATOMY", 93, 100], ["lymphopenia", "DISEASE", 146, 157], ["Memory cells", "CELL", 0, 12], ["T-cells", "CELL", 93, 100], ["Memory cells", "CELL_TYPE", 0, 12], ["na\u00efve T-cells", "CELL_TYPE", 87, 100], ["faster proliferation", "PROBLEM", 118, 138], ["lymphopenia", "PROBLEM", 146, 157], ["faster", "OBSERVATION_MODIFIER", 118, 124], ["proliferation", "OBSERVATION", 125, 138], ["lymphopenia", "OBSERVATION", 146, 157]]], ["It is likely that there may be other, presently unknown pathways regulating T-cell homeostasis, some of which could include energy metabolism regulation (Frauwirth and Thompson 2004 ) .Homeostatic Maintenance of T-cell SubsetsThe above described homeostatic mechanisms function to maintain a balanced and diverse T-cell pool.", [["T-cell", "ANATOMY", 76, 82], ["T-cell", "ANATOMY", 212, 218], ["T-cell", "ANATOMY", 313, 319], ["T-cell", "CELL", 76, 82], ["T-cell", "CELL", 212, 218], ["T-cell", "CELL", 313, 319], ["T-cell Subsets", "CELL_TYPE", 212, 226], ["energy metabolism regulation", "PROBLEM", 124, 152], ["cell homeostasis", "OBSERVATION", 78, 94], ["T-cell Subsets", "OBSERVATION", 212, 226]]], ["Over lifetime this means regulating the process of Ag-driven expansion of na\u00efve T-cells, their contraction, and selection and maintenance of memory T-cells.", [["T-cells", "ANATOMY", 80, 87], ["memory T-cells", "ANATOMY", 141, 155], ["Ag", "CHEMICAL", 51, 53], ["Ag", "CHEMICAL", 51, 53], ["Ag", "GENE_OR_GENE_PRODUCT", 51, 53], ["na\u00efve T-cells", "CELL", 74, 87], ["memory T-cells", "CELL", 141, 155], ["Ag", "PROTEIN", 51, 53], ["na\u00efve T-cells", "CELL_TYPE", 74, 87], ["memory T-cells", "CELL_TYPE", 141, 155], ["Ag", "TEST", 51, 53]]], ["The role of the homeostatic mechanisms is to balance the composition of the T-cell pool so that it contains both na\u00efve precursors with diverse TCRs, as well as Ag-experienced memory T-cells, as both of these subsets are crucial for the health of the host.", [["T-cell", "ANATOMY", 76, 82], ["TCRs", "ANATOMY", 143, 147], ["memory T-cells", "ANATOMY", 175, 189], ["Ag", "CHEMICAL", 160, 162], ["Ag", "CHEMICAL", 160, 162], ["T-cell", "CELL", 76, 82], ["TCRs", "GENE_OR_GENE_PRODUCT", 143, 147], ["Ag", "GENE_OR_GENE_PRODUCT", 160, 162], ["memory T-cells", "CELL", 175, 189], ["na\u00efve precursors", "CELL_TYPE", 113, 129], ["TCRs", "PROTEIN", 143, 147], ["Ag", "PROTEIN", 160, 162], ["memory T-cells", "CELL_TYPE", 175, 189], ["diverse TCRs", "TREATMENT", 135, 147], ["Ag", "TEST", 160, 162], ["diverse TCRs", "OBSERVATION", 135, 147]]], ["The homeostatic forces work very efficiently in adult mice housed under specific pathogen free (SPF) conditions, as evidenced by remarkably similar size and diversity of the T-cell pool among individual mice of the same strain.", [["T-cell", "ANATOMY", 174, 180], ["mice", "ORGANISM", 54, 58], ["T-cell", "CELL", 174, 180], ["mice", "ORGANISM", 203, 207], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 203, 207], ["the same strain", "PROBLEM", 211, 226], ["similar", "OBSERVATION_MODIFIER", 140, 147], ["size", "OBSERVATION_MODIFIER", 148, 152], ["diversity", "OBSERVATION_MODIFIER", 157, 166]]], ["However, maintenance of homeostasis becomes more complicated in the face of constant encounters with new acute pathogens, long-term interactions with persistent pathogens and the aging-associated defects, all of which are discussed below.Disruption of T-cell Homeostasis in AgeingThymic involution begins soon after birth in humans and quickly after puberty in mice, which results in decreased RTE output (Haynes et al. 2000 ; Hirokawa and Utsuyama 1984 ) .", [["T-cell", "ANATOMY", 252, 258], ["T-cell", "CELL", 252, 258], ["humans", "ORGANISM", 325, 331], ["mice", "ORGANISM", 361, 365], ["humans", "SPECIES", 325, 331], ["mice", "SPECIES", 361, 365], ["humans", "SPECIES", 325, 331], ["mice", "SPECIES", 361, 365], ["new acute pathogens", "PROBLEM", 101, 120], ["long-term interactions", "PROBLEM", 122, 144], ["persistent pathogens", "PROBLEM", 150, 170], ["associated defects", "PROBLEM", 185, 203], ["T-cell Homeostasis", "PROBLEM", 252, 270], ["AgeingThymic involution", "PROBLEM", 274, 297], ["decreased RTE output", "PROBLEM", 384, 404], ["new", "OBSERVATION_MODIFIER", 101, 104], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["pathogens", "OBSERVATION", 111, 120], ["long-term", "OBSERVATION_MODIFIER", 122, 131], ["persistent", "OBSERVATION_MODIFIER", 150, 160], ["pathogens", "OBSERVATION", 161, 170], ["defects", "OBSERVATION", 196, 203], ["T-cell Homeostasis", "OBSERVATION", 252, 270], ["AgeingThymic involution", "OBSERVATION", 274, 297]]], ["Thus, 22-mo-old mice receive less than 10% of RTE compared to young adult mice (Hale et al. 2006 ; Heng et al. 2005 ) .", [["mice", "ORGANISM", 16, 20], ["RTE", "ORGANISM", 46, 49], ["mice", "ORGANISM", 74, 78], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 74, 78]]], ["Even in old age the thymus continues to produce RTE proportionally to its overall cellularity, but as the cellularity itself decreases, so does the output (Gruver et al. 2007 ; Hale et al. 2006 ).", [["thymus", "ANATOMY", 20, 26], ["thymus", "ORGAN", 20, 26], ["the output", "TEST", 144, 154], ["thymus", "ANATOMY", 20, 26], ["overall", "OBSERVATION_MODIFIER", 74, 81], ["cellularity", "OBSERVATION", 82, 93], ["cellularity", "OBSERVATION", 106, 117], ["decreases", "OBSERVATION_MODIFIER", 125, 134]]], ["The cause of thymic involution is discussed in more detail elsewhere in this volume.", [["thymic", "ANATOMY", 13, 19], ["thymic", "ORGAN", 13, 19], ["thymic involution", "PROBLEM", 13, 30], ["thymic involution", "OBSERVATION", 13, 30]]], ["From the standpoint of this chapter, thymic involution presents a challenge for the homeostatic mechanisms, which strive to maintain the size and diversity of the peripheral T-cell pool in the face of decreased influx of diverse new T-cells.Disruption of T-cell Homeostasis in AgeingDespite the fact that thymus involution begins early in life, it is only in old age that homeostatic mechanisms falter and allow dysbalance amongst T-cell subsets.Disruption of T-cell Homeostasis in AgeingA marked difference between the adult and old lymphocyte T-cell compartment is an age-related decrease in representation of na\u00efve phenotype T-cells and concomitant increase in frequency and numbers of memory phenotype T-cells.", [["thymic", "ANATOMY", 37, 43], ["peripheral T-cell", "ANATOMY", 163, 180], ["T-cells", "ANATOMY", 233, 240], ["T-cell", "ANATOMY", 255, 261], ["thymus", "ANATOMY", 305, 311], ["T-cell", "ANATOMY", 431, 437], ["T-cell", "ANATOMY", 460, 466], ["lymphocyte T-cell compartment", "ANATOMY", 534, 563], ["T-cells", "ANATOMY", 628, 635], ["memory phenotype T-cells", "ANATOMY", 689, 713], ["thymus involution", "DISEASE", 305, 322], ["thymic", "ORGAN", 37, 43], ["peripheral T-cell", "CELL", 163, 180], ["T-cells", "CELL", 233, 240], ["T-cell", "CELL", 255, 261], ["thymus", "ORGAN", 305, 311], ["T-cell", "CELL", 431, 437], ["T-cell", "CELL", 460, 466], ["lymphocyte T-cell", "CELL", 534, 551], ["T-cells", "CELL", 628, 635], ["T-cells", "CELL", 706, 713], ["peripheral T-cell pool", "CELL_TYPE", 163, 185], ["T-cells", "CELL_TYPE", 233, 240], ["T-cell subsets", "CELL_TYPE", 431, 445], ["na\u00efve phenotype T-cells", "CELL_TYPE", 612, 635], ["memory phenotype T-cells", "CELL_TYPE", 689, 713], ["thymic involution", "PROBLEM", 37, 54], ["the homeostatic mechanisms", "PROBLEM", 80, 106], ["T-cell Homeostasis", "PROBLEM", 255, 273], ["thymus involution", "PROBLEM", 305, 322], ["T-cell Homeostasis", "PROBLEM", 460, 478], ["na\u00efve phenotype T-cells", "PROBLEM", 612, 635], ["concomitant increase in frequency", "PROBLEM", 640, 673], ["thymic", "ANATOMY", 37, 43], ["involution", "OBSERVATION", 44, 54], ["size", "OBSERVATION_MODIFIER", 137, 141], ["peripheral", "ANATOMY_MODIFIER", 163, 173], ["cell pool", "OBSERVATION", 176, 185], ["decreased", "OBSERVATION_MODIFIER", 201, 210], ["influx", "OBSERVATION", 211, 217], ["diverse", "OBSERVATION_MODIFIER", 221, 228], ["new", "OBSERVATION_MODIFIER", 229, 232], ["T-cell Homeostasis", "OBSERVATION", 255, 273], ["thymus", "ANATOMY", 305, 311], ["involution", "OBSERVATION", 312, 322], ["T-cell Homeostasis", "OBSERVATION", 460, 478], ["marked", "OBSERVATION_MODIFIER", 490, 496], ["difference", "OBSERVATION_MODIFIER", 497, 507], ["adult", "OBSERVATION_MODIFIER", 520, 525], ["lymphocyte", "ANATOMY", 534, 544], ["cell compartment", "OBSERVATION", 547, 563], ["decrease", "OBSERVATION_MODIFIER", 582, 590], ["na\u00efve phenotype", "OBSERVATION", 612, 627], ["concomitant", "OBSERVATION_MODIFIER", 640, 651], ["increase", "OBSERVATION_MODIFIER", 652, 660], ["memory phenotype", "OBSERVATION", 689, 705]]], ["The exact mechanisms leading to this population shift were not formally dissected, but are believed to likely involve a combination of 1) decrease in na\u00efve T-cell production, 2) their conversion into effector or memory cells as a result of encounters with pathogens, and 3) changes in the environment, including the availability of homeostatic cytokines (IL-7, IL-15, IL-2).", [["T-cell", "ANATOMY", 156, 162], ["memory cells", "ANATOMY", 212, 224], ["T-cell", "CELL", 156, 162], ["memory cells", "CELL", 212, 224], ["IL-7", "GENE_OR_GENE_PRODUCT", 355, 359], ["IL-15", "GENE_OR_GENE_PRODUCT", 361, 366], ["IL-2", "GENE_OR_GENE_PRODUCT", 368, 372], ["effector or memory cells", "CELL_TYPE", 200, 224], ["homeostatic cytokines", "PROTEIN", 332, 353], ["IL-7", "PROTEIN", 355, 359], ["IL", "PROTEIN", 361, 363], ["IL", "PROTEIN", 368, 370], ["decrease in na\u00efve T-cell production", "PROBLEM", 138, 173], ["memory cells", "PROBLEM", 212, 224], ["pathogens", "PROBLEM", 256, 265], ["homeostatic cytokines (IL", "TREATMENT", 332, 357], ["IL", "TEST", 361, 363], ["decrease", "OBSERVATION_MODIFIER", 138, 146]]], ["For example, IL-2 production by CD4 T-cells is decreased in old mice (Gillis et al. 1981 ; Miller and Stutman 1981 ; Thoman and Weigle 1981 ) .", [["CD4 T-cells", "ANATOMY", 32, 43], ["IL-2", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["mice", "ORGANISM", 64, 68], ["IL", "PROTEIN", 13, 15], ["CD4 T-cells", "CELL_TYPE", 32, 43], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["IL", "TEST", 13, 15], ["CD4 T-cells", "TEST", 32, 43], ["decreased", "OBSERVATION_MODIFIER", 47, 56]]], ["Less is known about age-related changes in IL-7 or IL-15 levels or the expression and function of their receptors on different T-cell subsets.", [["T-cell", "ANATOMY", 127, 133], ["IL-7", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-15", "GENE_OR_GENE_PRODUCT", 51, 56], ["T-cell subsets", "CELL", 127, 141], ["T-cell subsets", "CELL_TYPE", 127, 141], ["related changes in IL", "PROBLEM", 24, 45], ["cell subsets", "OBSERVATION", 129, 141]]], ["In addition, the na\u00efve T-cell pool could be indirectly affected by a growing pool of memory T-cells that may compete with na\u00efve T-cells.", [["T-cell", "ANATOMY", 23, 29], ["memory T-cells", "ANATOMY", 85, 99], ["T-cells", "ANATOMY", 128, 135], ["T-cell", "CELL", 23, 29], ["memory T-cells", "CELL", 85, 99], ["T-cells", "CELL", 128, 135], ["memory T-cells", "CELL_TYPE", 85, 99], ["na\u00efve T-cells", "CELL_TYPE", 122, 135]]], ["Considering that there is some overlap in the use of survival and maintenance cytokines by these two pools, particularly in case of IL-7 (Fry, Mackall 2005 ; Tan et al. 2002 ) , it is possible that the two are not always independently regulated, particularly in aging where there is many fewer na\u00efve T-cells.", [["T-cells", "ANATOMY", 300, 307], ["IL-7", "GENE_OR_GENE_PRODUCT", 132, 136], ["T-cells", "CELL", 300, 307], ["cytokines", "PROTEIN", 78, 87], ["na\u00efve T-cells", "CELL_TYPE", 294, 307], ["survival", "TREATMENT", 53, 61], ["maintenance cytokines", "TREATMENT", 66, 87], ["some", "OBSERVATION_MODIFIER", 26, 30], ["overlap", "OBSERVATION_MODIFIER", 31, 38]]], ["Thus, if na\u00efve T-cells continue to decrease in number, this may lead to an excess of survival and maintenance cytokines which normally would have been consumed by na\u00efve T-cells.", [["T-cells", "ANATOMY", 15, 22], ["T-cells", "ANATOMY", 169, 176], ["T-cells", "CELL", 15, 22], ["na\u00efve T-cells", "CELL", 163, 176], ["na\u00efve T-cells", "CELL_TYPE", 9, 22], ["cytokines", "PROTEIN", 110, 119], ["na\u00efve T-cells", "CELL_TYPE", 163, 176], ["na\u00efve T-cells", "PROBLEM", 9, 22], ["an excess of survival", "PROBLEM", 72, 93], ["maintenance cytokines", "TREATMENT", 98, 119]]], ["This could trigger homeostatic proliferative expansion (HPE) of the remaining na\u00efve T-cells and drive their conversion to memory-phenotype.", [["T-cells", "ANATOMY", 84, 91], ["HPE", "DISEASE", 56, 59], ["T-cells", "CELL", 84, 91], ["na\u00efve T-cells", "CELL_TYPE", 78, 91], ["homeostatic proliferative expansion", "PROBLEM", 19, 54], ["homeostatic", "OBSERVATION_MODIFIER", 19, 30], ["proliferative", "OBSERVATION_MODIFIER", 31, 44], ["expansion", "OBSERVATION_MODIFIER", 45, 54]]], ["This was demonstrated in mice under lymphopenic conditions (Cho et al. 2000 ; Goldrath et al. 2000 ) , and strongly suggestive results were also obtained in aging monkeys (Cicin-Sain et al. 2007 ) and humans (Naylor et al. 2005 ).T-cell Clonal Expansions (TCE)One of the hallmarks of immune aging is loss of TCR repertoire diversity (rev. in (Nikolich-\u017dugich 2005 )), due in large part to the dominance of memory T-cells over the na\u00efve ones.", [["T-cell", "ANATOMY", 230, 236], ["memory T-cells", "ANATOMY", 406, 420], ["mice", "ORGANISM", 25, 29], ["monkeys", "ORGANISM", 163, 170], ["humans", "ORGANISM", 201, 207], ["T-cell", "CELL", 230, 236], ["TCR", "GENE_OR_GENE_PRODUCT", 308, 311], ["memory T-cells", "CELL", 406, 420], ["TCR", "PROTEIN", 308, 311], ["memory T-cells", "CELL_TYPE", 406, 420], ["mice", "SPECIES", 25, 29], ["monkeys", "SPECIES", 163, 170], ["humans", "SPECIES", 201, 207], ["mice", "SPECIES", 25, 29], ["humans", "SPECIES", 201, 207], ["T-cell Clonal Expansions", "PROBLEM", 230, 254], ["immune aging", "PROBLEM", 284, 296], ["loss of TCR repertoire diversity", "PROBLEM", 300, 332], ["cell", "OBSERVATION", 232, 236], ["Clonal Expansions", "OBSERVATION", 237, 254], ["immune aging", "OBSERVATION", 284, 296]]], ["However, on top of that reduction, the CD8 T-cell compartment often shows additional loss of diversity, in the form of large, often clonal expansions of Tcells bearing the same TCR, named T-cell clonal expansions (TCE) (Callahan et al. 1993 ; Hingorani et al. 1993b ; Posnett et al. 1994 ) .", [["CD8 T-cell compartment", "ANATOMY", 39, 61], ["Tcells", "ANATOMY", 153, 159], ["T-cell", "ANATOMY", 188, 194], ["TCE", "CHEMICAL", 214, 217], ["CD8", "GENE_OR_GENE_PRODUCT", 39, 42], ["Tcells", "CANCER", 153, 159], ["TCR", "GENE_OR_GENE_PRODUCT", 177, 180], ["T-cell clonal", "CELL", 188, 201], ["CD8 T-cell compartment", "CELL_TYPE", 39, 61], ["Tcells", "PROTEIN", 153, 159], ["TCR", "PROTEIN", 177, 180], ["that reduction", "TREATMENT", 19, 33], ["the CD8 T-cell compartment", "TEST", 35, 61], ["additional loss of diversity", "PROBLEM", 74, 102], ["large, often clonal expansions of Tcells", "PROBLEM", 119, 159], ["loss", "OBSERVATION_MODIFIER", 85, 89], ["diversity", "OBSERVATION_MODIFIER", 93, 102], ["large", "OBSERVATION_MODIFIER", 119, 124], ["clonal expansions", "OBSERVATION", 132, 149], ["-cell", "OBSERVATION_MODIFIER", 189, 194], ["clonal", "OBSERVATION_MODIFIER", 195, 201], ["expansions", "OBSERVATION_MODIFIER", 202, 212]]], ["Development of TCEs has been documented across mammalian species, including rodents, nonhuman primates, and humans, with fractions between 30 and 60% of individuals surveyed exhibiting one or more age-associated TCE (rev. in (Nikolich-\u017dugich, Messaoudi 2005 ) .", [["TCEs", "CHEMICAL", 15, 19], ["TCE", "CHEMICAL", 212, 215], ["TCEs", "CANCER", 15, 19], ["nonhuman primates", "ORGANISM", 85, 102], ["humans", "ORGANISM", 108, 114], ["humans", "SPECIES", 108, 114], ["humans", "SPECIES", 108, 114], ["TCEs", "PROBLEM", 15, 19], ["TCEs", "OBSERVATION", 15, 19], ["mammalian species", "OBSERVATION", 47, 64]]], ["More on the biology of TCE can be found in the excellent review by Clambey and Marrack elsewhere in this book.", [["TCE", "CHEMICAL", 23, 26], ["TCE", "SIMPLE_CHEMICAL", 23, 26]]], ["However, for the purpose of this chapter, it is most pertinent to classify TCE into at least two types with respect to the mechanism of their generation and/or maintenance.", [["TCE", "CHEMICAL", 75, 78], ["TCE", "CHEMICAL", 75, 78]]], ["Large Ag-independent TCE (AI-TCE) are thought to arise and/or be maintained independently of antigenic stimulation, due to age-related changes in perceiving homeostatic signals.", [["TCE", "CHEMICAL", 21, 24], ["AI-TCE", "CHEMICAL", 26, 32], ["TCE", "CHEMICAL", 21, 24], ["TCE", "CHEMICAL", 29, 32], ["antigenic stimulation", "TREATMENT", 93, 114]]], ["This is based upon: (i) activation marker expression on these cells, which dominantly exhibit central memory phenotype, with no evidence of recent or repeated antigen-driven activation (Callahan et al. 1993 ; Ku et al. 2001 ; Messaoudi et al. 2006c ); (ii) cytokine receptor, specifically IL-7R and IL-15R, expression, which is higher on these cells compared to other memory or na\u00efve T-cells (Messaoudi et al. 2006c ); (iii) the ability of these cells to proliferate upon adoptive transfer (Ku et al. 2001 ) , with a constant rate regardless of whether the recipient is lymphopenic or not (Messaoudi et al. 2006c ) ; and (iv) the ability of manipulations that induce lymphopenia to increase the incidence and accelerate the onset of development of AI-TCE (Messaoudi et al. 2006b ).", [["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 344, 349], ["na\u00efve T-cells", "ANATOMY", 378, 391], ["cells", "ANATOMY", 446, 451], ["lymphopenia", "DISEASE", 667, 678], ["AI-TCE", "CHEMICAL", 748, 754], ["cells", "CELL", 62, 67], ["IL-7R", "GENE_OR_GENE_PRODUCT", 289, 294], ["IL-15R", "GENE_OR_GENE_PRODUCT", 299, 305], ["cells", "CELL", 344, 349], ["na\u00efve T-cells", "CELL", 378, 391], ["Messaoudi et al. 2006c", "CELL", 393, 415], ["cells", "CELL", 446, 451], ["cytokine receptor", "PROTEIN", 257, 274], ["IL-7R and IL-15R", "PROTEIN", 289, 305], ["memory or na\u00efve T-cells", "CELL_TYPE", 368, 391], ["activation marker expression on these cells", "PROBLEM", 24, 67], ["central memory phenotype", "PROBLEM", 94, 118], ["recent or repeated antigen", "PROBLEM", 140, 166], ["cytokine receptor", "TEST", 257, 274], ["IL", "TEST", 289, 291], ["IL", "TEST", 299, 301], ["lymphopenic", "PROBLEM", 570, 581], ["manipulations", "TREATMENT", 641, 654], ["lymphopenia", "PROBLEM", 667, 678], ["AI", "PROBLEM", 748, 750], ["central memory phenotype", "OBSERVATION", 94, 118], ["no evidence of", "UNCERTAINTY", 125, 139], ["higher", "OBSERVATION_MODIFIER", 328, 334], ["lymphopenic", "OBSERVATION", 570, 581], ["lymphopenia", "OBSERVATION", 667, 678]]], ["While these results have been obtained in mice, there is evidence that similar fundamental principles are at work in primates, including humans (Cicin-Sain et al. 2007 ; Naylor et al. 2005 ) .", [["mice", "ORGANISM", 42, 46], ["primates", "ORGANISM", 117, 125], ["humans", "ORGANISM", 137, 143], ["mice", "SPECIES", 42, 46], ["humans", "SPECIES", 137, 143], ["mice", "SPECIES", 42, 46], ["humans", "SPECIES", 137, 143], ["similar", "OBSERVATION_MODIFIER", 71, 78], ["fundamental principles", "OBSERVATION", 79, 101]]], ["In contrast, TCE that have general characteristics consistent with the response to antigen, also called Ag-reactive TCE (AR-TCE), were linked to latent persistent herpesviral infections in mice Karrer et al. 2003 ; Podlech et al. 2000 ) and humans (Almanzar et al. 2005 ; Fletcher et al. 2005 ; Ouyang et al. 2003c ; Pawelec et al. 2004 ) .", [["TCE", "CHEMICAL", 13, 16], ["Ag", "CHEMICAL", 104, 106], ["TCE", "CHEMICAL", 116, 119], ["AR-TCE", "CHEMICAL", 121, 127], ["herpesviral infections", "DISEASE", 163, 185], ["TCE", "CHEMICAL", 13, 16], ["Ag", "CHEMICAL", 104, 106], ["TCE", "CHEMICAL", 116, 119], ["TCE", "CHEMICAL", 124, 127], ["TCE", "SIMPLE_CHEMICAL", 13, 16], ["Ag-reactive TCE", "SIMPLE_CHEMICAL", 104, 119], ["AR-TCE", "GENE_OR_GENE_PRODUCT", 121, 127], ["mice", "ORGANISM", 189, 193], ["humans", "ORGANISM", 241, 247], ["Ag", "PROTEIN", 104, 106], ["AR", "PROTEIN", 121, 123], ["mice", "SPECIES", 189, 193], ["humans", "SPECIES", 241, 247], ["mice", "SPECIES", 189, 193], ["humans", "SPECIES", 241, 247], ["Ag", "TEST", 104, 106], ["latent persistent herpesviral infections", "PROBLEM", 145, 185], ["reactive", "OBSERVATION_MODIFIER", 107, 115], ["latent", "OBSERVATION_MODIFIER", 145, 151], ["persistent", "OBSERVATION_MODIFIER", 152, 162], ["herpesviral", "OBSERVATION_MODIFIER", 163, 174], ["infections", "OBSERVATION", 175, 185]]], ["Broad discussion of these virus-related abnormalities is also presented in other chapters of this handbook.T-cell Clonal Expansions (TCE)TCE can occupy up to 90% of the total murine and up to 50% of the human memory CD8 T-cell pool.", [["T-cell", "ANATOMY", 107, 113], ["memory CD8 T-cell", "ANATOMY", 209, 226], ["TCE", "CHEMICAL", 133, 136], ["TCE", "CHEMICAL", 137, 140], ["T-cell", "CELL", 107, 113], ["murine", "ORGANISM", 175, 181], ["human", "ORGANISM", 203, 208], ["CD8 T-cell", "CELL", 216, 226], ["human memory CD8 T-cell pool", "CELL_TYPE", 203, 231], ["murine", "SPECIES", 175, 181], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["these virus", "PROBLEM", 20, 31], ["related abnormalities", "PROBLEM", 32, 53], ["T", "TEST", 107, 108], ["TCE", "TEST", 137, 140], ["virus", "OBSERVATION", 26, 31], ["cell", "OBSERVATION", 109, 113], ["Clonal Expansions", "OBSERVATION", 114, 131]]], ["TCE themselves are not malignant and do not affect the overall size of the CD8 T-cell pool (there is no increase in total T-cell numbers in individuals carrying TCE).", [["CD8 T-cell", "ANATOMY", 75, 85], ["T-cell", "ANATOMY", 122, 128], ["TCE", "CHEMICAL", 0, 3], ["TCE", "CHEMICAL", 161, 164], ["TCE", "CHEMICAL", 0, 3], ["TCE", "SIMPLE_CHEMICAL", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["T-cell", "CELL", 122, 128], ["CD8 T-cell pool", "CELL_TYPE", 75, 90], ["malignant", "PROBLEM", 23, 32], ["not", "UNCERTAINTY", 19, 22], ["malignant", "OBSERVATION", 23, 32], ["overall", "OBSERVATION_MODIFIER", 55, 62], ["size", "OBSERVATION_MODIFIER", 63, 67], ["no", "UNCERTAINTY", 101, 103], ["increase", "OBSERVATION_MODIFIER", 104, 112]]], ["However, TCE do disturb T-cell homeostasis and diversity (Callahan et al. 1993 ; LeMaoult et al. 2000 ; Posnett et al. 1994 ) and a drastic disturbance of this type can be expected to impair the ability to mount T-cell responses.", [["T-cell", "ANATOMY", 24, 30], ["T-cell", "ANATOMY", 212, 218], ["TCE", "CHEMICAL", 9, 12], ["TCE", "CHEMICAL", 9, 12], ["TCE", "SIMPLE_CHEMICAL", 9, 12], ["T-cell", "CELL", 24, 30], ["T-cell", "CELL", 212, 218], ["a drastic disturbance", "PROBLEM", 130, 151], ["drastic", "OBSERVATION_MODIFIER", 132, 139], ["disturbance", "OBSERVATION", 140, 151]]], ["While T-cell responses are plastic, with a significant reserve that allows T-cells to respond to pathogens despite loss of much of the repertoire, this plasticity is not unlimited (rev. in ).", [["T-cell", "ANATOMY", 6, 12], ["T-cells", "ANATOMY", 75, 82], ["T-cell", "CELL", 6, 12], ["T-cells", "CELL", 75, 82], ["T-cells", "CELL_TYPE", 75, 82], ["pathogens", "PROBLEM", 97, 106]]], ["However, we still do not have precise quantitative understanding of limits of T-cell diversity necessary to mount protective responses against pathogenic challenge, an issue highly relevant from the standpoint of evaluating the impact of TCE upon immune defense.Impact of TCE on Pathogen Resistance-the Mouse ModelThe most important question related to the presence of TCE is related to their impact upon the health of the organism.", [["T-cell", "ANATOMY", 78, 84], ["TCE", "CHEMICAL", 238, 241], ["TCE", "CHEMICAL", 272, 275], ["TCE", "CHEMICAL", 369, 372], ["TCE", "CHEMICAL", 238, 241], ["TCE", "CHEMICAL", 272, 275], ["TCE", "CHEMICAL", 369, 372], ["T-cell", "CELL", 78, 84], ["TCE", "SIMPLE_CHEMICAL", 238, 241], ["Mouse", "ORGANISM", 303, 308], ["Mouse", "SPECIES", 303, 308], ["T-cell diversity", "TREATMENT", 78, 94], ["pathogenic challenge", "PROBLEM", 143, 163], ["Pathogen Resistance", "TREATMENT", 279, 298], ["TCE", "OBSERVATION", 272, 275], ["Pathogen Resistance", "OBSERVATION", 279, 298]]], ["First, TCE could be neutral and not impact the overall health or the immune defense of the old organism.", [["TCE", "CHEMICAL", 7, 10], ["TCE", "CHEMICAL", 7, 10], ["TCE", "SIMPLE_CHEMICAL", 7, 10], ["the old organism", "PROBLEM", 87, 103]]], ["While this possibility is intellectually unexciting, it is likely that many TCE coexist with the state of health based on their high incidence in asymptomatic individuals (Hingorani et al. 1993b ; Posnett et al. 1994 ) .", [["TCE", "CHEMICAL", 76, 79], ["TCE", "CHEMICAL", 76, 79]]], ["Indeed, it is likely that a TCE needs to grow to a certain size before it becomes a problem for its bearer.", [["TCE", "CHEMICAL", 28, 31], ["TCE", "CHEMICAL", 28, 31], ["a TCE", "PROBLEM", 26, 31], ["is likely", "UNCERTAINTY", 11, 20], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["Second, TCE could affect other components of the organism, without impacting immune defense.", [["TCE", "CHEMICAL", 8, 11], ["TCE", "CHEMICAL", 8, 11], ["TCE", "SIMPLE_CHEMICAL", 8, 11], ["the organism", "PROBLEM", 45, 57], ["organism", "OBSERVATION", 49, 57]]], ["Third, TCE could have an active effect, whereby they would secrete cytokines and other short-acting mediators that could alter the function of other components of the immune (and other) systems in the body.", [["body", "ANATOMY", 201, 205], ["TCE", "CHEMICAL", 7, 10], ["TCE", "CHEMICAL", 7, 10], ["TCE", "SIMPLE_CHEMICAL", 7, 10], ["body", "ORGANISM_SUBDIVISION", 201, 205], ["cytokines", "PROTEIN", 67, 76], ["the immune (and other) systems in the body", "PROBLEM", 163, 205], ["active", "OBSERVATION_MODIFIER", 25, 31], ["effect", "OBSERVATION", 32, 38], ["body", "ANATOMY", 201, 205]]], ["This would be akin to the functional shift seen in replicatively senescent fibroblasts, which upon cessation of replication drastically change their secretory properties and have the potential to alter extracellular matrix, neovascularization and other microenvironmental properties (rev. in (Campisi 2002 ) .", [["fibroblasts", "ANATOMY", 75, 86], ["extracellular matrix", "ANATOMY", 202, 222], ["neovascularization", "DISEASE", 224, 242], ["fibroblasts", "CELL", 75, 86], ["extracellular matrix", "CELLULAR_COMPONENT", 202, 222], ["replicatively senescent fibroblasts", "CELL_TYPE", 51, 86], ["senescent fibroblasts", "PROBLEM", 65, 86], ["replication", "TREATMENT", 112, 123], ["alter extracellular matrix", "TREATMENT", 196, 222], ["neovascularization", "PROBLEM", 224, 242], ["senescent fibroblasts", "OBSERVATION", 65, 86], ["neovascularization", "OBSERVATION", 224, 242]]], ["At the present, there is some evidence in support of this possibility (Ortiz-Suarez and Miller 2002 ; Ortiz-Suarez and Miller 2003 ) , but more precise studies at the level of isolated, highly purified TCE are needed.", [["TCE", "CHEMICAL", 202, 205], ["TCE", "CHEMICAL", 202, 205], ["TCE", "SIMPLE_CHEMICAL", 202, 205]]], ["Moreover, the impact of the observed changes upon pathogen resistance remains untested.Impact of TCE on Pathogen Resistance-the Mouse ModelFinally, the role of TCE could be passive, but nevertheless negative.", [["TCE", "CHEMICAL", 97, 100], ["TCE", "CHEMICAL", 160, 163], ["TCE", "CHEMICAL", 97, 100], ["TCE", "CHEMICAL", 160, 163], ["Mouse", "ORGANISM", 128, 133], ["TCE", "SIMPLE_CHEMICAL", 160, 163], ["Mouse", "SPECIES", 128, 133], ["Mouse", "SPECIES", 128, 133], ["pathogen resistance", "PROBLEM", 50, 69], ["pathogen resistance", "OBSERVATION", 50, 69], ["TCE", "OBSERVATION", 97, 100], ["Pathogen Resistance", "OBSERVATION", 104, 123]]], ["Under that scenario, which was invoked by immunologists before (Callahan et al. 1993 ; Hingorani et al. 1993a ; Posnett 1994 , and which will be discussed in more detail as it currently appears the most likely, these accumulating T-cell clones would constrict the repertoire and reduce the useful T-cell repertoire that defends us against new infection.", [["T-cell clones", "ANATOMY", 230, 243], ["T-cell", "ANATOMY", 297, 303], ["infection", "DISEASE", 343, 352], ["T-cell clones", "CELL", 230, 243], ["T-cell", "CELL", 297, 303], ["T-cell clones", "CELL_LINE", 230, 243], ["new infection", "PROBLEM", 339, 352], ["most likely", "UNCERTAINTY", 198, 209], ["new", "OBSERVATION_MODIFIER", 339, 342], ["infection", "OBSERVATION", 343, 352]]], ["Mechanistically, this would most likely occur by these cells gaining a survival/maintenance advantage over other T-cells in the body.", [["cells", "ANATOMY", 55, 60], ["T-cells", "ANATOMY", 113, 120], ["body", "ANATOMY", 128, 132], ["cells", "CELL", 55, 60], ["T-cells", "CELL", 113, 120], ["body", "ORGANISM_SUBDIVISION", 128, 132], ["T-cells", "CELL_TYPE", 113, 120], ["a survival/maintenance advantage", "TREATMENT", 69, 101], ["body", "ANATOMY", 128, 132]]], ["The fact that TCE which occur spontaneously in SPF mice express high levels of IL-7R\u03b1 and IL-2/15R\u03b2 (Messaoudi et al. 2006c ) is consistent with the possibility that TCE operate as IL-7 and/or IL-15 \"cytokine sinks\", taking them slowly away from other T-cells.", [["T-cells", "ANATOMY", 252, 259], ["TCE", "CHEMICAL", 14, 17], ["TCE", "CHEMICAL", 166, 169], ["TCE", "CHEMICAL", 14, 17], ["TCE", "CHEMICAL", 166, 169], ["TCE", "SIMPLE_CHEMICAL", 14, 17], ["SPF mice", "ORGANISM", 47, 55], ["IL-7R\u03b1", "GENE_OR_GENE_PRODUCT", 79, 85], ["IL-2/15R", "GENE_OR_GENE_PRODUCT", 90, 98], ["TCE", "SIMPLE_CHEMICAL", 166, 169], ["IL-7", "GENE_OR_GENE_PRODUCT", 181, 185], ["IL-15", "GENE_OR_GENE_PRODUCT", 193, 198], ["T-cells", "CELL", 252, 259], ["IL-7R\u03b1", "PROTEIN", 79, 85], ["IL", "PROTEIN", 90, 92], ["2/15R", "PROTEIN", 93, 98], ["IL", "PROTEIN", 181, 183], ["IL", "PROTEIN", 193, 195], ["cytokine", "PROTEIN", 200, 208], ["T-cells", "CELL_TYPE", 252, 259], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["cytokine sinks", "PROBLEM", 200, 214], ["consistent with the possibility", "UNCERTAINTY", 129, 160]]], ["Consistent with that, we (Lang et al. submitted) and others (Ely et al., 2007 ) have recently found that often TCE can arise from the pool of cells that respond(ed) to prior acute or latent infection.", [["cells", "ANATOMY", 142, 147], ["TCE", "CHEMICAL", 111, 114], ["infection", "DISEASE", 190, 199], ["TCE", "CHEMICAL", 111, 114], ["cells", "CELL", 142, 147], ["prior acute or latent infection", "PROBLEM", 168, 199], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["latent", "OBSERVATION_MODIFIER", 183, 189], ["infection", "OBSERVATION", 190, 199]]], ["Of interest, once these cells begin to significantly expand in old age, they tend to acquire high levels of IL-7 and IL-15 receptors (Lang et al. submitted), raising the possibility that the \"cytokine sink\" may be the unifying mechanism by which both \"spontaneous\" and antigen-specific large TCE constrict the remainder of useful T-cell repertoire.", [["cells", "ANATOMY", 24, 29], ["T-cell", "ANATOMY", 330, 336], ["TCE", "CHEMICAL", 292, 295], ["cells", "CELL", 24, 29], ["IL-7", "GENE_OR_GENE_PRODUCT", 108, 112], ["IL-15 receptors", "GENE_OR_GENE_PRODUCT", 117, 132], ["antigen", "GENE_OR_GENE_PRODUCT", 269, 276], ["TCE", "SIMPLE_CHEMICAL", 292, 295], ["T-cell", "CELL", 330, 336], ["IL-7 and IL-15 receptors", "PROTEIN", 108, 132], ["cytokine", "PROTEIN", 192, 200], ["high levels of IL", "TREATMENT", 93, 110], ["the \"cytokine sink", "PROBLEM", 187, 205], ["raising the possibility", "UNCERTAINTY", 158, 181]]], ["In fact, it is likely that the \"spontaneous\" TCE designation simply covers up the fact that we don't know the original antigen that was recognized by these cells, and that may be irrelevant if indeed these cells primarily respond to cytokines once they become TCE.Impact of TCE on Pathogen Resistance-the Mouse ModelIn order for a TCE to have a demonstrably negative effect upon immune defense via TCR repertoire constriction, such a TCE needs to sufficiently erode the numbers and diversity of other T cells needed to respond to a new pathogen.", [["cells", "ANATOMY", 156, 161], ["cells", "ANATOMY", 206, 211], ["T cells", "ANATOMY", 501, 508], ["TCE", "CHEMICAL", 45, 48], ["TCE", "CHEMICAL", 260, 263], ["TCE", "CHEMICAL", 274, 277], ["TCE", "CHEMICAL", 331, 334], ["TCR", "CHEMICAL", 398, 401], ["TCE", "CHEMICAL", 434, 437], ["TCE", "CHEMICAL", 260, 263], ["TCE", "CHEMICAL", 274, 277], ["TCE", "CHEMICAL", 331, 334], ["cells", "CELL", 156, 161], ["cells", "CELL", 206, 211], ["Mouse", "ORGANISM", 305, 310], ["TCR", "GENE_OR_GENE_PRODUCT", 398, 401], ["T cells", "CELL", 501, 508], ["cytokines", "PROTEIN", 233, 242], ["TCR", "PROTEIN", 398, 401], ["T cells", "CELL_TYPE", 501, 508], ["Mouse", "SPECIES", 305, 310], ["the \"spontaneous\" TCE designation", "PROBLEM", 27, 60], ["these cells", "PROBLEM", 200, 211], ["cytokines", "TREATMENT", 233, 242], ["Pathogen Resistance", "TREATMENT", 281, 300], ["a TCE", "PROBLEM", 329, 334], ["TCR repertoire constriction", "TREATMENT", 398, 425], ["a TCE", "PROBLEM", 432, 437], ["other T cells", "PROBLEM", 495, 508], ["a new pathogen", "PROBLEM", 530, 544], ["is likely", "UNCERTAINTY", 12, 21], ["Pathogen Resistance", "OBSERVATION", 281, 300]]], ["Numerous studies have shown that manipulations which take away up to half or more of TCR diversity are reasonably compatible with T-cell responsiveness (rev. in ).", [["T-cell", "ANATOMY", 130, 136], ["TCR", "GENE_OR_GENE_PRODUCT", 85, 88], ["T-cell", "CELL", 130, 136], ["TCR", "PROTEIN", 85, 88], ["Numerous studies", "TEST", 0, 16], ["T-cell responsiveness", "PROBLEM", 130, 151]]], ["However, in other models losses of this or greater magnitude have been shown to impair responsiveness to certain antigens (rev in. ) and references therein).", [["antigens", "PROTEIN", 113, 121], ["rev", "PROTEIN", 123, 126]]], ["In terms of the impact of TCE upon the residual diversity of aged na\u00efve T-cells in relationship to immune defense against infectious diseases, it is important to consider the overall diversity and overall numbers of T-cells involved in a typical response to a pathogen.", [["T-cells", "ANATOMY", 72, 79], ["T-cells", "ANATOMY", 216, 223], ["TCE", "CHEMICAL", 26, 29], ["infectious diseases", "DISEASE", 122, 141], ["TCE", "CHEMICAL", 26, 29], ["T-cells", "CELL", 72, 79], ["T-cells", "CELL", 216, 223], ["aged na\u00efve T-cells", "CELL_TYPE", 61, 79], ["T-cells", "CELL_TYPE", 216, 223], ["infectious diseases", "PROBLEM", 122, 141], ["a pathogen", "PROBLEM", 258, 268]]], ["Exciting new studies with direct measuring of precursor T-cell frequencies concur that on the average a hundred, and in some cases as few as 15-20 CD4 or CD8 T-cells may be responding to a single epitope (Badovinac et al. 2007 ; Moon et al. 2007 ).", [["precursor T-cell", "ANATOMY", 46, 62], ["CD4", "ANATOMY", 147, 150], ["CD8 T-cells", "ANATOMY", 154, 165], ["T-cell", "CELL", 56, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD4", "PROTEIN", 147, 150], ["CD8 T-cells", "CELL_TYPE", 154, 165], ["new studies", "TEST", 9, 20], ["a single epitope (Badovinac et", "TREATMENT", 187, 217]]], ["Even if this is an underestimation, reducing that number by 90%, or even by half, due to the presence of a TCE, certainly has the potential to diminish and cripple the response to epitopes where few T-cell precursors exist.", [["T-cell", "ANATOMY", 199, 205], ["TCE", "CHEMICAL", 107, 110], ["TCE", "CHEMICAL", 107, 110], ["T-cell", "CELL", 199, 205], ["epitopes", "PROTEIN", 180, 188], ["T-cell precursors", "CELL_TYPE", 199, 216], ["epitopes", "PROBLEM", 180, 188], ["underestimation", "OBSERVATION", 19, 34]]], ["This low responsiveness would be further compounded by an already diminished overall reserve of na\u00efve T-cells in aging, as well as by the blunted T-cell signaling (Tamir et al. 2000 ) .", [["T-cells", "ANATOMY", 102, 109], ["T-cell", "ANATOMY", 146, 152], ["na\u00efve T-cells", "CELL", 96, 109], ["T-cell", "CELL", 146, 152], ["na\u00efve T-cells", "CELL_TYPE", 96, 109], ["This low responsiveness", "PROBLEM", 0, 23], ["diminished", "OBSERVATION_MODIFIER", 66, 76], ["overall", "OBSERVATION_MODIFIER", 77, 84], ["reserve", "OBSERVATION_MODIFIER", 85, 92]]], ["On the other hand, most pathogens present multiple epitopes to the immune system, and even if one accounts for immunodominance, usually a handful of epitopes are available for T-cell stimulation.", [["immune system", "ANATOMY", 67, 80], ["T-cell", "ANATOMY", 176, 182], ["T-cell", "CELL", 176, 182], ["epitopes", "PROTEIN", 51, 59], ["epitopes", "PROTEIN", 149, 157], ["immunodominance", "PROBLEM", 111, 126], ["T-cell stimulation", "TREATMENT", 176, 194]]], ["Moreover, in many cases other arms of the immune system will synergize to provide protection even if T-cell responses are diminished.", [["immune system", "ANATOMY", 42, 55], ["T-cell", "ANATOMY", 101, 107], ["T-cell", "CELL", 101, 107], ["diminished", "PROBLEM", 122, 132], ["diminished", "OBSERVATION_MODIFIER", 122, 132]]], ["Thus, for a TCE to impact pathogen resistance, T-cells have to provide primary and nonredundant protection against that pathogen, the pathogen should have few, rather than many, immunodominant and protective epitopes and frequency of T-cells specific for these epitopes should be low.", [["T-cells", "ANATOMY", 47, 54], ["T-cells", "ANATOMY", 234, 241], ["TCE", "CHEMICAL", 12, 15], ["TCE", "CHEMICAL", 12, 15], ["T-cells", "CELL", 47, 54], ["T-cells", "CELL", 234, 241], ["T-cells", "CELL_TYPE", 47, 54], ["T-cells", "CELL_TYPE", 234, 241], ["epitopes", "PROTEIN", 261, 269], ["pathogen resistance", "PROBLEM", 26, 45], ["pathogen", "PROBLEM", 120, 128], ["the pathogen", "PROBLEM", 130, 142], ["immunodominant and protective epitopes", "PROBLEM", 178, 216], ["T-cells", "PROBLEM", 234, 241], ["these epitopes", "PROBLEM", 255, 269]]], ["In the one case where the impact of TCE upon immune defense was tested ), most, if not all, of the above conditions were met.", [["TCE", "CHEMICAL", 36, 39], ["TCE", "CHEMICAL", 36, 39], ["TCE", "SIMPLE_CHEMICAL", 36, 39]]], ["In that study, resistance to herpes simplex virus (HSV-1) was studied in B6 mice, where an octamer derived from the glycoprotein B accounts for > 90% of the total CD8 T-cell response Messaoudi 2001 Wallace et al. 1999 ) .", [["CD8 T-cell", "ANATOMY", 163, 173], ["herpes simplex virus", "DISEASE", 29, 49], ["herpes simplex virus", "ORGANISM", 29, 49], ["HSV-1", "ORGANISM", 51, 56], ["B6 mice", "ORGANISM", 73, 80], ["glycoprotein B", "GENE_OR_GENE_PRODUCT", 116, 130], ["CD8", "GENE_OR_GENE_PRODUCT", 163, 166], ["octamer", "DNA", 91, 98], ["glycoprotein B", "PROTEIN", 116, 130], ["CD8", "PROTEIN", 163, 166], ["herpes simplex virus", "SPECIES", 29, 49], ["HSV-1", "SPECIES", 51, 56], ["mice", "SPECIES", 76, 80], ["herpes simplex virus", "SPECIES", 29, 49], ["HSV-1", "SPECIES", 51, 56], ["mice", "SPECIES", 76, 80], ["that study", "TEST", 3, 13], ["herpes simplex virus", "PROBLEM", 29, 49], ["HSV", "TEST", 51, 54]]], ["Moreover, the response itself is highly restricted with regard to TCRV region utilization (with V\u03b210 and 8 contributing >80% of the response (Cose et al. 1995 ) ).", [["TCRV region", "DNA", 66, 77]]], ["Old animals with and without TCE were challenged with HSV and magnitude and functional characteristics of the response measured.", [["TCE", "CHEMICAL", 29, 32], ["TCE", "CHEMICAL", 29, 32], ["animals", "ORGANISM", 4, 11], ["HSV", "ORGANISM", 54, 57], ["HSV", "SPECIES", 54, 57], ["TCE", "PROBLEM", 29, 32], ["HSV", "PROBLEM", 54, 57]]], ["It was found that TCE could impair the generation of productive responses in a selective manner.", [["TCE", "CHEMICAL", 18, 21], ["TCE", "CHEMICAL", 18, 21], ["TCE", "SIMPLE_CHEMICAL", 18, 21]]], ["So, when an animal contained a large TCE which expressed V\u03b210 and 8, it was unable to mount a response to HSV gB, whereas TCE expressing other TCR V\u03b2 segments did not impair responsiveness beyond the reduction seen due to age in a littermate control group ).", [["TCE", "CHEMICAL", 37, 40], ["TCE", "CHEMICAL", 122, 125], ["TCR", "CHEMICAL", 143, 146], ["TCE", "CHEMICAL", 37, 40], ["TCE", "CHEMICAL", 122, 125], ["V\u03b210", "GENE_OR_GENE_PRODUCT", 57, 61], ["HSV", "ORGANISM", 106, 109], ["gB", "ORGANISM", 110, 112], ["V\u03b2", "PROTEIN", 57, 59], ["HSV gB", "PROTEIN", 106, 112], ["TCR", "PROTEIN", 143, 146], ["V\u03b2 segments", "PROTEIN", 147, 158], ["HSV", "SPECIES", 106, 109], ["a large TCE", "PROBLEM", 29, 40], ["HSV gB", "TEST", 106, 112], ["impair responsiveness", "PROBLEM", 167, 188], ["a littermate control group", "TREATMENT", 229, 255], ["large", "OBSERVATION_MODIFIER", 31, 36], ["TCE", "OBSERVATION", 37, 40]]], ["These results were somewhat puzzling and suggested that TCE preferentially competed out against the T-cells bearing the same TCRV\u03b2 segment.", [["T-cells", "ANATOMY", 100, 107], ["TCE", "CHEMICAL", 56, 59], ["TCE", "CHEMICAL", 56, 59], ["TCE", "SIMPLE_CHEMICAL", 56, 59], ["T-cells", "CELL", 100, 107], ["T-cells", "CELL_TYPE", 100, 107], ["TCRV\u03b2 segment", "DNA", 125, 138], ["TCE", "TEST", 56, 59], ["segment", "ANATOMY_MODIFIER", 131, 138]]], ["This could be explained, for example, if TCRV\u03b2 residues conserved within the V\u03b2 family but differing between V\u03b2 families (e.g. CDR1 & 2 and \"framework\" parts of CDR3) were important in contacting self-pMHC complexes in the course of trophic interactions needed for T-cell maintenance, so that a TCE would compete out na\u00efve T-cells of the same TCRV\u03b2 family.", [["T-cell", "ANATOMY", 265, 271], ["T-cells", "ANATOMY", 323, 330], ["TCE", "CHEMICAL", 295, 298], ["TCE", "CHEMICAL", 295, 298], ["TCRV\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 77, 79], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 109, 111], ["CDR1 & 2", "GENE_OR_GENE_PRODUCT", 127, 135], ["CDR3", "GENE_OR_GENE_PRODUCT", 161, 165], ["pMHC", "GENE_OR_GENE_PRODUCT", 201, 205], ["T-cell", "CELL", 265, 271], ["TCE", "SIMPLE_CHEMICAL", 295, 298], ["T-cells", "CELL", 323, 330], ["TCRV\u03b2", "GENE_OR_GENE_PRODUCT", 343, 348], ["TCRV\u03b2 residues", "PROTEIN", 41, 55], ["V\u03b2 family", "PROTEIN", 77, 86], ["V\u03b2 families", "PROTEIN", 109, 120], ["CDR1", "PROTEIN", 127, 131], ["CDR3", "PROTEIN", 161, 165], ["pMHC complexes", "PROTEIN", 201, 215], ["na\u00efve T-cells", "CELL_TYPE", 317, 330], ["TCRV\u03b2 family", "PROTEIN", 343, 355], ["TCRV\u03b2 residues", "PROBLEM", 41, 55], ["trophic interactions", "TREATMENT", 233, 253], ["T-cell maintenance", "TREATMENT", 265, 283], ["a TCE", "TEST", 293, 298]]], ["Nevertheless, the above study ) does show that TCE can potentially impair protective immunity.Impact of TCE on Pathogen Resistance-the Mouse ModelWhile the above experiments were performed with spontaneously arising TCE, which were most likely AI-TCE, there is no reason to believe that a similar situation may not exist with AR-TCE as well.", [["TCE", "CHEMICAL", 47, 50], ["TCE", "CHEMICAL", 104, 107], ["TCE", "CHEMICAL", 216, 219], ["TCE", "CHEMICAL", 247, 250], ["TCE", "CHEMICAL", 329, 332], ["TCE", "CHEMICAL", 47, 50], ["TCE", "CHEMICAL", 104, 107], ["TCE", "CHEMICAL", 216, 219], ["TCE", "CHEMICAL", 247, 250], ["TCE", "CHEMICAL", 329, 332], ["TCE", "SIMPLE_CHEMICAL", 47, 50], ["Mouse", "ORGANISM", 135, 140], ["AR", "GENE_OR_GENE_PRODUCT", 326, 328], ["AR", "PROTEIN", 326, 328], ["Mouse", "SPECIES", 135, 140], ["the above study", "TEST", 14, 29], ["Pathogen Resistance", "TEST", 111, 130], ["AR", "PROBLEM", 326, 328], ["TCE", "OBSERVATION_MODIFIER", 104, 107], ["Pathogen Resistance", "OBSERVATION", 111, 130], ["most likely", "UNCERTAINTY", 232, 243], ["no reason to", "UNCERTAINTY", 261, 273]]], ["Another unaddressed question relates to the impact of TCE upon memory responses.", [["TCE", "CHEMICAL", 54, 57], ["TCE", "CHEMICAL", 54, 57], ["TCE", "SIMPLE_CHEMICAL", 54, 57]]], ["Memory T-cells are more difficult to compete out than na\u00efve T-cells, possibly due to their ability for self-renewal and relative resistance to apoptosis.", [["Memory T-cells", "ANATOMY", 0, 14], ["T-cells", "ANATOMY", 60, 67], ["Memory T-cells", "CELL", 0, 14], ["T-cells", "CELL", 60, 67], ["Memory T-cells", "CELL_TYPE", 0, 14], ["na\u00efve T-cells", "CELL_TYPE", 54, 67], ["apoptosis", "PROBLEM", 143, 152]]], ["Perhaps the most pertinent question is whether TCE can affect the response to latent and/or chronic persistent pathogens, where a large fraction of the immune system is periodically or continuously stimulated by these pathogens.", [["immune system", "ANATOMY", 152, 165], ["TCE", "CHEMICAL", 47, 50], ["TCE", "CHEMICAL", 47, 50], ["TCE", "SIMPLE_CHEMICAL", 47, 50], ["chronic persistent pathogens", "PROBLEM", 92, 120], ["these pathogens", "PROBLEM", 212, 227], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["persistent", "OBSERVATION_MODIFIER", 100, 110], ["pathogens", "OBSERVATION", 111, 120], ["large", "OBSERVATION_MODIFIER", 130, 135], ["fraction", "OBSERVATION_MODIFIER", 136, 144], ["immune system", "OBSERVATION", 152, 165], ["pathogens", "OBSERVATION", 218, 227]]], ["At the present, this issue remains unresolved.Impact of TCE on Pathogen Resistance-Evidence from HumansIn reviewing the known impact of TCEs on pathogen resistance, one needs to distinguish between two parameters: 1) correlation of presence of TCE with presence of other immunological factors known to impair immune responses, and 2) direct evidence for impact of TCE on pathogen resistance.", [["TCE", "CHEMICAL", 56, 59], ["TCEs", "CHEMICAL", 136, 140], ["TCE", "CHEMICAL", 244, 247], ["TCE", "CHEMICAL", 364, 367], ["TCE", "CHEMICAL", 56, 59], ["TCE", "CHEMICAL", 244, 247], ["TCE", "CHEMICAL", 364, 367], ["TCEs", "SIMPLE_CHEMICAL", 136, 140], ["TCE", "SIMPLE_CHEMICAL", 364, 367], ["immunological factors", "PROTEIN", 271, 292], ["pathogen resistance", "PROBLEM", 144, 163], ["other immunological factors", "PROBLEM", 265, 292], ["pathogen resistance", "PROBLEM", 371, 390], ["Pathogen Resistance", "OBSERVATION", 63, 82], ["pathogen resistance", "OBSERVATION", 371, 390]]], ["The occurrence of TCEs has been well documented in patients and in a variety of animal models, so we shall first review that scenario.", [["TCEs", "DISEASE", 18, 22], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["One should bear in mind, however, that it is often difficult to distinguish the specific effect of TCE from the effects of old age-associated defects in antipathogen immunity, since in most cases TCEs are detected only in advanced age.", [["TCE", "CHEMICAL", 99, 102], ["TCE", "CHEMICAL", 99, 102], ["TCE", "SIMPLE_CHEMICAL", 99, 102], ["TCEs", "CANCER", 196, 200], ["associated defects in antipathogen immunity", "PROBLEM", 131, 174], ["defects", "OBSERVATION", 142, 149]]], ["It is therefore most appropriate to evaluate TCE as a superimposing, possibly aggravating factor that may, or may not, further impair protective immunity in an already suboptimal setting of an old organism.", [["TCE", "CHEMICAL", 45, 48], ["TCE", "CHEMICAL", 45, 48], ["aggravating factor", "PROBLEM", 78, 96], ["an old organism", "PROBLEM", 190, 205], ["possibly", "UNCERTAINTY", 69, 77]]], ["Some TCEs have known antigenic specificity.", [["TCEs", "CANCER", 5, 9]]], ["Two types of conclusions on the effects of these TCEs on pathogen resistance can be drawn: 1) effect upon resistance to the pathogen the TCE is specific for, and 2) effect upon resistance to unrelated pathogens.", [["TCEs", "CHEMICAL", 49, 53], ["TCE", "CHEMICAL", 137, 140], ["TCE", "CHEMICAL", 137, 140], ["TCEs", "SIMPLE_CHEMICAL", 49, 53], ["pathogen resistance", "TEST", 57, 76], ["unrelated pathogens", "PROBLEM", 191, 210]]], ["In humans, the most commonly documented cases of TCEs of known specificity involve memory CD8 T-cells specific for CMV (rev. in ) and, to a lesser extent, EBV (Ouyang et al. 2003b ) .", [["memory CD8 T-cells", "ANATOMY", 83, 101], ["humans", "ORGANISM", 3, 9], ["TCEs", "CANCER", 49, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["CMV", "ORGANISM", 115, 118], ["EBV", "ORGANISM", 155, 158], ["memory CD8 T-cells", "CELL_TYPE", 83, 101], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["CMV", "SPECIES", 115, 118], ["CMV", "PROBLEM", 115, 118], ["lesser extent", "OBSERVATION_MODIFIER", 140, 153]]], ["Original studies documented the presence of CD28 -CD8 + TCEs in elderly patients (Hingorani et al. 1993b ; Posnett et al. 1994 ) .", [["CD28", "GENE_OR_GENE_PRODUCT", 44, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["patients", "ORGANISM", 72, 80], ["CD28", "PROTEIN", 44, 48], ["CD8", "PROTEIN", 50, 53], ["patients", "SPECIES", 72, 80], ["Original studies", "TEST", 0, 16], ["CD28", "TEST", 44, 48]]], ["With the advent of tetramers and intracellular cytokine staining techniques that allowed enumeration of Ag-specific T-cells, it was shown that the CD28-CD8 T-cell expansions were frequently specific for CMV and were clonal or oligoclonal in nature (Ouyang et al. 2002 ) .", [["intracellular", "ANATOMY", 33, 46], ["T-cells", "ANATOMY", 116, 123], ["CD28-CD8 T-cell", "ANATOMY", 147, 162], ["Ag", "CHEMICAL", 104, 106], ["Ag", "CHEMICAL", 104, 106], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["Ag", "GENE_OR_GENE_PRODUCT", 104, 106], ["T-cells", "CELL", 116, 123], ["CD28", "GENE_OR_GENE_PRODUCT", 147, 151], ["CD8", "GENE_OR_GENE_PRODUCT", 152, 155], ["CMV", "ORGANISM", 203, 206], ["tetramers", "PROTEIN", 19, 28], ["Ag", "PROTEIN", 104, 106], ["T-cells", "CELL_TYPE", 116, 123], ["CD28", "PROTEIN", 147, 151], ["CD8", "PROTEIN", 152, 155], ["CMV", "SPECIES", 203, 206], ["the advent of tetramers", "TREATMENT", 5, 28], ["intracellular cytokine staining techniques", "TREATMENT", 33, 75], ["Ag", "TEST", 104, 106], ["the CD28", "TEST", 143, 151], ["CMV", "PROBLEM", 203, 206], ["clonal", "OBSERVATION_MODIFIER", 216, 222], ["oligoclonal", "OBSERVATION_MODIFIER", 226, 237]]], ["Moreover, longitudinal studies in the Swedish elderly cohorts concluded that CMV seropositivity, together with an array of additional immune characteristics such as the inverted CD4:CD8 ratio and poor proliferative responses of T-cells to mitogens, constitute an immune risk phenotype (IRP, discussed in detail elsewhere in this book) (Wikby et al. 2005 ) , which predicted mortality within 2 years in octogenerians of the Swedish cohort (Hadrup et al. 2006 ).", [["T-cells", "ANATOMY", 228, 235], ["CMV", "ORGANISM", 77, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 178, 181], ["CD8", "GENE_OR_GENE_PRODUCT", 182, 185], ["T-cells", "CELL", 228, 235], ["CD4", "PROTEIN", 178, 181], ["CD8", "PROTEIN", 182, 185], ["T-cells", "CELL_TYPE", 228, 235], ["mitogens", "PROTEIN", 239, 247], ["IRP", "PROTEIN", 286, 289], ["CMV", "SPECIES", 77, 80], ["longitudinal studies", "TEST", 10, 30], ["CMV seropositivity", "PROBLEM", 77, 95], ["the inverted CD4", "TEST", 165, 181], ["CD8 ratio", "TEST", 182, 191], ["mitogens", "TEST", 239, 247], ["an immune risk phenotype", "PROBLEM", 260, 284], ["poor proliferative", "OBSERVATION_MODIFIER", 196, 214]]], ["Moreover, it is not clear exactly how the presence of CMV-specific TCE might affect pathogen resistance, in isolation from the other IRP-associated defects, highlighting one of the problems inherent to the otherwise highly informative human longitudinal studies.Impact of TCE on Pathogen Resistance-Evidence from HumansAt the present, there is some evidence that CMV-specific T-cells may themselves be compromised as a direct result of development of TCE.", [["T-cells", "ANATOMY", 376, 383], ["TCE", "CHEMICAL", 67, 70], ["TCE", "CHEMICAL", 272, 275], ["TCE", "CHEMICAL", 451, 454], ["TCE", "CHEMICAL", 67, 70], ["TCE", "CHEMICAL", 272, 275], ["TCE", "CHEMICAL", 451, 454], ["CMV", "ORGANISM", 54, 57], ["TCE", "SIMPLE_CHEMICAL", 67, 70], ["IRP", "GENE_OR_GENE_PRODUCT", 133, 136], ["human", "ORGANISM", 235, 240], ["CMV", "ORGANISM", 363, 366], ["T-cells", "CELL", 376, 383], ["IRP", "PROTEIN", 133, 136], ["T-cells", "CELL_TYPE", 376, 383], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 235, 240], ["CMV", "SPECIES", 363, 366], ["CMV", "PROBLEM", 54, 57], ["pathogen resistance", "PROBLEM", 84, 103], ["the other IRP-associated defects", "PROBLEM", 123, 155], ["Pathogen Resistance", "TEST", 279, 298], ["CMV", "TEST", 363, 366], ["CMV", "OBSERVATION", 54, 57], ["pathogen resistance", "OBSERVATION", 84, 103], ["defects", "OBSERVATION", 148, 155], ["TCE", "OBSERVATION_MODIFIER", 272, 275], ["Pathogen Resistance", "OBSERVATION", 279, 298], ["CMV", "OBSERVATION", 363, 366]]], ["Several studies demonstrated accumulation of dysfunctional CMV-specific memory CD8 T-cells in the elderly (Ouyang et al. 2003a ; Ouyang et al. 2003c ; Ouyang et al. 2004 ).", [["memory CD8 T-cells", "ANATOMY", 72, 90], ["CMV", "ORGANISM", 59, 62], ["memory CD8 T-cells", "CELL_TYPE", 72, 90], ["Several studies", "TEST", 0, 15], ["dysfunctional CMV", "PROBLEM", 45, 62], ["accumulation", "OBSERVATION_MODIFIER", 29, 41], ["dysfunctional CMV", "OBSERVATION", 45, 62]]], ["In addition, the large CMV-specific memory cell population expressed a marker of replicative senescence, KLRG-1, and its expression correlated with decreased production of IFN\u03b3 upon antigenic stimulation (Ouyang et al. 2004 ) .", [["memory cell", "ANATOMY", 36, 47], ["CMV", "ORGANISM", 23, 26], ["memory cell", "CELL", 36, 47], ["KLRG-1", "GENE_OR_GENE_PRODUCT", 105, 111], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 172, 176], ["memory cell population", "CELL_TYPE", 36, 58], ["KLRG", "PROTEIN", 105, 109], ["IFN\u03b3", "PROTEIN", 172, 176], ["the large CMV", "PROBLEM", 13, 26], ["KLRG", "TEST", 105, 109], ["decreased production of IFN", "PROBLEM", 148, 175], ["antigenic stimulation", "TREATMENT", 182, 203], ["large", "OBSERVATION_MODIFIER", 17, 22], ["CMV", "OBSERVATION", 23, 26], ["memory cell population", "OBSERVATION", 36, 58], ["decreased", "OBSERVATION_MODIFIER", 148, 157]]], ["The key question is whether this leads to inability to mount an adequate functional response to viral reactivation, permitting viral replication above the subclinical level normally associated with CMV seropositivity.", [["CMV", "ORGANISM", 198, 201], ["CMV", "SPECIES", 198, 201], ["viral reactivation", "PROBLEM", 96, 114], ["permitting viral replication", "PROBLEM", 116, 144], ["CMV seropositivity", "PROBLEM", 198, 216], ["viral reactivation", "OBSERVATION", 96, 114], ["associated with", "UNCERTAINTY", 182, 197], ["CMV seropositivity", "OBSERVATION", 198, 216]]], ["In that regard, one study (Stowe et al. 2007 ) demonstrated the presence of CMV and EBV DNA in urine (CMV) and blood (EBV) of elderly patients, as opposed to the seropositive adults, implying some loss of control of viral reactivation in the elderly.", [["urine", "ANATOMY", 95, 100], ["blood", "ANATOMY", 111, 116], ["CMV", "ORGANISM", 76, 79], ["EBV", "ORGANISM", 84, 87], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["urine", "ORGANISM_SUBSTANCE", 95, 100], ["CMV", "ORGANISM", 102, 105], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["EBV", "ORGANISM", 118, 121], ["patients", "ORGANISM", 134, 142], ["adults", "ORGANISM", 175, 181], ["patients", "SPECIES", 134, 142], ["CMV", "SPECIES", 76, 79], ["EBV", "SPECIES", 84, 87], ["CMV", "SPECIES", 102, 105], ["EBV", "SPECIES", 118, 121], ["one study", "TEST", 16, 25], ["CMV", "PROBLEM", 76, 79], ["EBV DNA in urine", "PROBLEM", 84, 100], ["CMV", "TEST", 102, 105], ["blood (EBV", "TEST", 111, 121], ["viral reactivation", "PROBLEM", 216, 234], ["CMV", "OBSERVATION", 76, 79], ["EBV DNA", "OBSERVATION", 84, 91], ["loss", "OBSERVATION_MODIFIER", 197, 201], ["viral reactivation", "OBSERVATION", 216, 234]]], ["Consistent with that explanation, these authors also found elevated expression of lytic and latent EBV genes in blood of elderly but not adult seropositive patients (Stowe et al. 2007 ) .", [["blood", "ANATOMY", 112, 117], ["EBV", "ORGANISM", 99, 102], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["patients", "ORGANISM", 156, 164], ["lytic and latent EBV genes", "DNA", 82, 108], ["patients", "SPECIES", 156, 164], ["elevated expression of lytic and latent EBV genes in blood of elderly", "PROBLEM", 59, 128], ["lytic", "OBSERVATION_MODIFIER", 82, 87], ["latent", "OBSERVATION_MODIFIER", 92, 98], ["EBV genes", "OBSERVATION", 99, 108]]], ["It is possible that accumulation of dysfunctional CMV-or EBV-specific TCE, which were unable to control the virus, may be the reason for increase in viral reactivation in aging.", [["TCE", "CHEMICAL", 70, 73], ["CMV", "ORGANISM", 50, 53], ["EBV", "ORGANISM", 57, 60], ["TCE", "GENE_OR_GENE_PRODUCT", 70, 73], ["dysfunctional CMV", "PROBLEM", 36, 53], ["EBV", "PROBLEM", 57, 60], ["specific TCE", "PROBLEM", 61, 73], ["the virus", "PROBLEM", 104, 113], ["viral reactivation", "PROBLEM", 149, 167], ["accumulation", "OBSERVATION_MODIFIER", 20, 32], ["dysfunctional", "OBSERVATION_MODIFIER", 36, 49], ["CMV", "OBSERVATION", 50, 53], ["viral reactivation", "OBSERVATION", 149, 167]]], ["However, in that study, the elderly actually had an elevated frequency of IFN\u03b3-producing CMVand EBV-specific memory CD8 T-cells, making the hypothesis unlikely.", [["memory CD8 T-cells", "ANATOMY", 109, 127], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 74, 78], ["CMVand", "ORGANISM", 89, 95], ["EBV", "ORGANISM", 96, 99], ["memory CD8 T-cells", "CELL", 109, 127], ["IFN\u03b3", "PROTEIN", 74, 78], ["CMVand EBV-specific memory CD8 T-cells", "CELL_TYPE", 89, 127], ["that study", "TEST", 12, 22], ["an elevated frequency of IFN\u03b3", "PROBLEM", 49, 78], ["CMVand EBV", "PROBLEM", 89, 99], ["elevated", "OBSERVATION", 52, 60], ["hypothesis unlikely", "UNCERTAINTY", 140, 159]]], ["Moreover, CMV-mediated disease does not seem to be associated with aging in the absence of iatrogenic or acquired immune suppression, suggesting that a manifest loss of CMV control does not occur in the elderly.", [["CMV", "ORGANISM", 10, 13], ["CMV", "ORGANISM", 169, 172], ["CMV-mediated disease", "PROBLEM", 10, 30], ["iatrogenic", "PROBLEM", 91, 101], ["acquired immune suppression", "PROBLEM", 105, 132], ["CMV control", "TREATMENT", 169, 180], ["CMV", "OBSERVATION", 10, 13], ["disease", "OBSERVATION", 23, 30], ["iatrogenic", "OBSERVATION", 91, 101], ["CMV", "OBSERVATION", 169, 172]]], ["Further studies are needed to decisively address the role of accumulation of dysfunctional CMV-specific TCEs on the persistent latent Herpes virus control in old age.Impact of TCE on Pathogen Resistance-Evidence from HumansA separate issue is whether CMV-specific TCE affect immunity to other infections in humans, and how.", [["latent Herpes virus", "DISEASE", 127, 146], ["TCE", "CHEMICAL", 176, 179], ["TCE", "CHEMICAL", 264, 267], ["infections", "DISEASE", 293, 303], ["TCE", "CHEMICAL", 176, 179], ["TCE", "CHEMICAL", 264, 267], ["CMV", "ORGANISM", 91, 94], ["TCEs", "GENE_OR_GENE_PRODUCT", 104, 108], ["Herpes virus", "ORGANISM", 134, 146], ["CMV", "ORGANISM", 251, 254], ["TCE", "SIMPLE_CHEMICAL", 264, 267], ["humans", "ORGANISM", 307, 313], ["humans", "SPECIES", 307, 313], ["Herpes virus", "SPECIES", 134, 146], ["humans", "SPECIES", 307, 313], ["Further studies", "TEST", 0, 15], ["dysfunctional CMV", "PROBLEM", 77, 94], ["the persistent latent Herpes virus control", "TREATMENT", 112, 154], ["Pathogen Resistance", "TEST", 183, 202], ["CMV", "PROBLEM", 251, 254], ["dysfunctional CMV", "OBSERVATION", 77, 94], ["persistent", "OBSERVATION_MODIFIER", 116, 126], ["latent", "OBSERVATION_MODIFIER", 127, 133], ["Herpes virus", "OBSERVATION", 134, 146], ["TCE", "OBSERVATION", 176, 179], ["Pathogen Resistance", "OBSERVATION", 183, 202]]], ["There is some evidence that presence of CMV-specific TCE is associated with lower frequency of memory CD8 T-cells specific for coresident EBV infection (Khan et al. 2004 ).", [["memory CD8 T-cells", "ANATOMY", 95, 113], ["TCE", "CHEMICAL", 53, 56], ["EBV infection", "DISEASE", 138, 151], ["TCE", "CHEMICAL", 53, 56], ["CMV", "ORGANISM", 40, 43], ["CD8", "GENE_OR_GENE_PRODUCT", 102, 105], ["EBV", "ORGANISM", 138, 141], ["memory CD8 T-cells", "CELL_TYPE", 95, 113], ["CMV", "SPECIES", 40, 43], ["EBV", "SPECIES", 138, 141], ["CMV", "PROBLEM", 40, 43], ["specific TCE", "PROBLEM", 44, 56], ["coresident EBV infection", "PROBLEM", 127, 151], ["CMV", "OBSERVATION", 40, 43]]], ["This study did not examine whether control of latent EBV in patients with large CMV-specific TCE is impaired.", [["TCE", "CHEMICAL", 93, 96], ["TCE", "CHEMICAL", 93, 96], ["EBV", "ORGANISM", 53, 56], ["patients", "ORGANISM", 60, 68], ["CMV", "ORGANISM", 80, 83], ["patients", "SPECIES", 60, 68], ["EBV", "SPECIES", 53, 56], ["This study", "TEST", 0, 10], ["latent EBV", "PROBLEM", 46, 56], ["large CMV", "PROBLEM", 74, 83], ["latent", "OBSERVATION_MODIFIER", 46, 52], ["EBV", "OBSERVATION", 53, 56], ["large", "OBSERVATION_MODIFIER", 74, 79], ["CMV", "OBSERVATION", 80, 83], ["impaired", "OBSERVATION", 100, 108]]], ["While one could speculate that the T-cell response, and therefore immunity to EBV will be compromised in patients with large CMV-specific TCE similar to the results seen in mice with the effect of spontaneous TCE upon HSV immunity , the mechanism by which these TCE affect the size of the EBV memory CD8 T-cell pool is currently unknown.Impact of TCE on Pathogen Resistance-Evidence from HumansSince many of the TCEs identified in humans are specific for CMV, it was proposed that CMV is the main driver behind generation of TCEs .", [["T-cell", "ANATOMY", 35, 41], ["memory CD8 T-cell", "ANATOMY", 293, 310], ["TCE", "CHEMICAL", 138, 141], ["TCE", "CHEMICAL", 209, 212], ["TCE", "CHEMICAL", 262, 265], ["TCE", "CHEMICAL", 347, 350], ["TCE", "CHEMICAL", 209, 212], ["TCE", "CHEMICAL", 262, 265], ["TCE", "CHEMICAL", 347, 350], ["T-cell", "CELL", 35, 41], ["EBV", "ORGANISM", 78, 81], ["patients", "ORGANISM", 105, 113], ["CMV", "ORGANISM", 125, 128], ["mice", "ORGANISM", 173, 177], ["HSV", "ORGANISM", 218, 221], ["TCE", "SIMPLE_CHEMICAL", 262, 265], ["EBV", "ORGANISM", 289, 292], ["CD8", "GENE_OR_GENE_PRODUCT", 300, 303], ["TCEs", "CANCER", 412, 416], ["humans", "ORGANISM", 431, 437], ["CMV", "ORGANISM", 455, 458], ["CMV", "ORGANISM", 481, 484], ["TCEs", "GENE_OR_GENE_PRODUCT", 525, 529], ["EBV memory CD8 T-cell pool", "CELL_TYPE", 289, 315], ["patients", "SPECIES", 105, 113], ["mice", "SPECIES", 173, 177], ["humans", "SPECIES", 431, 437], ["EBV", "SPECIES", 78, 81], ["CMV", "SPECIES", 125, 128], ["mice", "SPECIES", 173, 177], ["HSV", "SPECIES", 218, 221], ["humans", "SPECIES", 431, 437], ["CMV", "SPECIES", 455, 458], ["CMV", "SPECIES", 481, 484], ["EBV", "TEST", 78, 81], ["large CMV", "PROBLEM", 119, 128], ["spontaneous TCE", "PROBLEM", 197, 212], ["HSV immunity", "TREATMENT", 218, 230], ["the EBV memory", "TEST", 285, 299], ["Pathogen Resistance", "TEST", 354, 373], ["HumansSince", "TREATMENT", 388, 399], ["CMV", "PROBLEM", 455, 458], ["CMV", "PROBLEM", 481, 484], ["CMV", "OBSERVATION", 125, 128], ["size", "OBSERVATION_MODIFIER", 277, 281], ["TCE", "OBSERVATION", 347, 350], ["Pathogen Resistance", "OBSERVATION", 354, 373], ["CMV", "OBSERVATION", 481, 484]]], ["While this may be the case, evidence from murine studies suggests that virus-specific TCE can also develop independently from ongoing antigenic stimulation.", [["TCE", "CHEMICAL", 86, 89], ["TCE", "CHEMICAL", 86, 89], ["murine", "ORGANISM", 42, 48], ["TCE", "SIMPLE_CHEMICAL", 86, 89], ["murine", "SPECIES", 42, 48], ["murine studies", "TEST", 42, 56], ["virus", "PROBLEM", 71, 76], ["ongoing antigenic stimulation", "TREATMENT", 126, 155], ["antigenic stimulation", "OBSERVATION", 134, 155]]], ["Ely et al. (Ely et al. 2007 ) detected presence of TCE specific for Sendai virus and flu in old mice that had been infected as adults.", [["TCE", "CHEMICAL", 51, 54], ["TCE", "CHEMICAL", 51, 54], ["TCE", "SIMPLE_CHEMICAL", 51, 54], ["Sendai virus", "ORGANISM", 68, 80], ["mice", "ORGANISM", 96, 100], ["Sendai virus", "SPECIES", 68, 80], ["mice", "SPECIES", 96, 100], ["Sendai virus", "SPECIES", 68, 80], ["mice", "SPECIES", 96, 100], ["Sendai virus", "PROBLEM", 68, 80], ["flu", "PROBLEM", 85, 88], ["infected", "OBSERVATION", 115, 123]]], ["Similarly, we have found that old mice infected with WNV at a young age developed expansions of virusspecific memory CD8 T-cells in old age (A Lang et al. submitted) .", [["virusspecific memory CD8 T-cells", "ANATOMY", 96, 128], ["WNV", "DISEASE", 53, 56], ["mice", "ORGANISM", 34, 38], ["WNV", "ORGANISM", 53, 56], ["CD8 T-cells", "CELL", 117, 128], ["virusspecific memory CD8 T-cells", "CELL_TYPE", 96, 128], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38], ["WNV", "SPECIES", 53, 56], ["WNV", "PROBLEM", 53, 56], ["expansions", "PROBLEM", 82, 92], ["infected", "OBSERVATION", 39, 47], ["virusspecific memory CD8", "OBSERVATION", 96, 120]]], ["In a different infection model, we found that following localized (ocular) HSV-1 infection, mice develop expansions of HSV-specific memory CD8 T-cells once they reach old age.", [["ocular", "ANATOMY", 67, 73], ["memory CD8 T-cells", "ANATOMY", 132, 150], ["infection", "DISEASE", 15, 24], ["infection", "DISEASE", 81, 90], ["HSV-1", "ORGANISM", 75, 80], ["mice", "ORGANISM", 92, 96], ["HSV", "ORGANISM", 119, 122], ["HSV-specific memory CD8 T-cells", "CELL_TYPE", 119, 150], ["HSV-1", "SPECIES", 75, 80], ["mice", "SPECIES", 92, 96], ["HSV-1", "SPECIES", 75, 80], ["mice", "SPECIES", 92, 96], ["HSV", "SPECIES", 119, 122], ["localized (ocular) HSV-1 infection", "PROBLEM", 56, 90], ["HSV", "PROBLEM", 119, 122], ["infection", "OBSERVATION", 15, 24], ["ocular", "ANATOMY", 67, 73]]], ["This process was unlikely to be caused by viral reactivation, as mice treated continuously with antiviral drugs also developed these age-associated T-cell expansions.", [["T-cell", "ANATOMY", 148, 154], ["mice", "ORGANISM", 65, 69], ["T-cell", "CELL", 148, 154], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["viral reactivation", "PROBLEM", 42, 60], ["antiviral drugs", "TREATMENT", 96, 111], ["associated T-cell expansions", "PROBLEM", 137, 165], ["unlikely to be caused", "UNCERTAINTY", 17, 38], ["viral reactivation", "OBSERVATION", 42, 60], ["cell expansions", "OBSERVATION", 150, 165]]], ["At present, only a small number of these antigen-independent age-associated expansions were confirmed to be clonal, with oligoclonality being seen more often (A Lang et al. submitted) .", [["antigen", "GENE_OR_GENE_PRODUCT", 41, 48], ["these antigen", "TEST", 35, 48], ["associated expansions", "PROBLEM", 65, 86], ["oligoclonality", "PROBLEM", 121, 135], ["small", "OBSERVATION_MODIFIER", 19, 24], ["number", "OBSERVATION_MODIFIER", 25, 31]]], ["Unlike is the case with CMV-specific TCEs, the T-cell expansions that developed independently from ongoing antigenic stimulation were fully functional, showing excellent correlation of percentage of tetramer + and IFN\u03b3 + cells (A Lang et al. submitted) .", [["T-cell", "ANATOMY", 47, 53], ["IFN\u03b3 + cells", "ANATOMY", 214, 226], ["CMV", "ORGANISM", 24, 27], ["TCEs", "GENE_OR_GENE_PRODUCT", 37, 41], ["T-cell", "CELL", 47, 53], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 214, 218], ["tetramer", "PROTEIN", 199, 207], ["IFN\u03b3", "PROTEIN", 214, 218], ["CMV", "SPECIES", 24, 27], ["CMV", "TEST", 24, 27], ["the T-cell expansions", "PROBLEM", 43, 64], ["ongoing antigenic stimulation", "PROBLEM", 99, 128], ["tetramer", "TEST", 199, 207], ["IFN\u03b3 + cells", "PROBLEM", 214, 226]]], ["Therefore, it is not likely that development of TCEs by this mechanism will affect immunity to the cognate pathogen.", [["TCEs", "GENE_OR_GENE_PRODUCT", 48, 52], ["development of TCEs", "PROBLEM", 33, 52], ["not likely", "UNCERTAINTY", 17, 27]]], ["Additional studies will be required to determine whether TCEs can develop from preexisting memory CD8 T-cells specific for nonpersisting pathogens in elderly humans, as they do in old mice.Impact of TCE on Pathogen Resistance-Evidence from HumansAre these TCE impairing productive immunity in humans?", [["memory CD8 T-cells", "ANATOMY", 91, 109], ["TCE", "CHEMICAL", 199, 202], ["TCE", "CHEMICAL", 256, 259], ["TCE", "CHEMICAL", 199, 202], ["TCE", "CHEMICAL", 256, 259], ["TCEs", "SIMPLE_CHEMICAL", 57, 61], ["CD8 T-cells", "CELL", 98, 109], ["humans", "ORGANISM", 158, 164], ["mice", "ORGANISM", 184, 188], ["Humans", "ORGANISM", 240, 246], ["humans", "ORGANISM", 293, 299], ["memory CD8 T-cells", "CELL_TYPE", 91, 109], ["humans", "SPECIES", 158, 164], ["mice", "SPECIES", 184, 188], ["humans", "SPECIES", 293, 299], ["humans", "SPECIES", 158, 164], ["mice", "SPECIES", 184, 188], ["humans", "SPECIES", 293, 299], ["Additional studies", "TEST", 0, 18], ["nonpersisting pathogens in elderly humans", "PROBLEM", 123, 164], ["Pathogen Resistance", "TEST", 206, 225], ["TCE", "OBSERVATION", 199, 202], ["Pathogen Resistance", "OBSERVATION", 206, 225], ["productive", "OBSERVATION_MODIFIER", 270, 280], ["immunity", "OBSERVATION", 281, 289]]], ["Of interest, the number of influenza-specific memory CD8 T-cells was shown to decline with age in humans (Goronzy et al. 2001 ).", [["memory CD8 T-cells", "ANATOMY", 46, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 53, 56], ["humans", "ORGANISM", 98, 104], ["influenza-specific memory CD8 T-cells", "CELL_TYPE", 27, 64], ["humans", "SPECIES", 98, 104], ["humans", "SPECIES", 98, 104]]], ["This phenomenon was independent of the patients' CMV status.", [["patients", "ORGANISM", 39, 47], ["CMV", "ORGANISM", 49, 52], ["patients", "SPECIES", 39, 47]]], ["In another study of success of flu vaccination in CMV-seropositive patients, CMV seropositivity correlated with impaired response to vaccination (Saurwein-Teissl et al. 2002 ) .", [["CMV-seropositive", "DISEASE", 50, 66], ["CMV", "ORGANISM", 50, 53], ["patients", "ORGANISM", 67, 75], ["CMV", "ORGANISM", 77, 80], ["patients", "SPECIES", 67, 75], ["CMV", "SPECIES", 50, 53], ["CMV", "SPECIES", 77, 80], ["flu vaccination", "TREATMENT", 31, 46], ["CMV", "TEST", 50, 53], ["CMV seropositivity", "PROBLEM", 77, 95], ["vaccination", "TREATMENT", 133, 144]]], ["However, the authors did not delineate whether this correlates best to the presence of TCE, to the overall decrease in number of na\u00efve cells or to proliferative/replicative senescence, and, as with most clinical studies, the mechanism responsible for this outcome has not been resolved.", [["cells", "ANATOMY", 135, 140], ["TCE", "CHEMICAL", 87, 90], ["cells", "CELL", 135, 140], ["na\u00efve cells", "CELL_TYPE", 129, 140], ["na\u00efve cells", "PROBLEM", 129, 140], ["proliferative/replicative senescence", "PROBLEM", 147, 183], ["clinical studies", "TEST", 203, 219], ["decrease", "OBSERVATION_MODIFIER", 107, 115], ["na\u00efve cells", "OBSERVATION", 129, 140], ["replicative senescence", "OBSERVATION", 161, 183]]], ["Therefore, the presence of TCE could be one of the useful biomarkers predicting poor outcome of flu vaccination (Goronzy et al. 2001 ; Saurwein-Teissl et al. 2002 ) , or perhaps even general immunological vulnerability, but that requires further and rigorous verification in larger and heterogeneous populations of human subjects.Concluding Remarks, Challenges and QuestionsIt follows from the above discussion that much remains to be learned about the biology of TCE and their precise impact upon resistance to infectious diseases.", [["TCE", "CHEMICAL", 27, 30], ["flu", "DISEASE", 96, 99], ["TCE", "CHEMICAL", 464, 467], ["infectious diseases", "DISEASE", 512, 531], ["TCE", "CHEMICAL", 27, 30], ["TCE", "CHEMICAL", 464, 467], ["TCE", "SIMPLE_CHEMICAL", 27, 30], ["human", "ORGANISM", 315, 320], ["TCE", "SIMPLE_CHEMICAL", 464, 467], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 315, 320], ["flu vaccination", "TREATMENT", 96, 111], ["rigorous verification", "TEST", 250, 271], ["infectious diseases", "PROBLEM", 512, 531], ["larger", "OBSERVATION_MODIFIER", 275, 281], ["heterogeneous", "OBSERVATION_MODIFIER", 286, 299], ["populations", "OBSERVATION", 300, 311], ["infectious", "OBSERVATION", 512, 522]]], ["Drawing generalized conclusions about the impact of TCEs on pathogen resistance from the available data is often difficult, since they come from a number of different experimental models.", [["TCEs", "CHEMICAL", 52, 56], ["TCEs", "SIMPLE_CHEMICAL", 52, 56], ["pathogen resistance", "PROBLEM", 60, 79], ["pathogen resistance", "OBSERVATION", 60, 79]]], ["At present we do not know how closely the mechanisms of generation of TCEs and their subsequent effects on pathogen resistance compare between them.", [["TCEs", "GENE_OR_GENE_PRODUCT", 70, 74], ["generation of TCEs", "PROBLEM", 56, 74], ["pathogen resistance", "TREATMENT", 107, 126]]], ["However, the models and the reagents that are currently available provide good tools to systematically address the questions that still remain regarding the impact of TCEs on immunity.", [["TCEs", "SIMPLE_CHEMICAL", 167, 171]]], ["In particular, new quantitative tools are becoming available allowing us to precisely dissect the breadth and the reserve of T-cell receptor repertoire and the size of precursor populations specific for immunodominant epitopes of various pathogens, and that should allow us to quantitatively evaluate to what extent is TCR repertoire constricted by different types of TCE, and to determine what type of intervention (many of which are now in clinical trials (Zuniga-Pflucker, van den Brink 2007 )) could be applied in individual situations.Concluding Remarks, Challenges and QuestionsOverall, the most important practical issues related to TCE and the infectious diseases of the elderly are:Concluding Remarks, Challenges and Questions1.", [["T-cell", "ANATOMY", 125, 131], ["TCE", "CHEMICAL", 368, 371], ["TCE", "CHEMICAL", 640, 643], ["TCE", "CHEMICAL", 368, 371], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 125, 140], ["precursor populations", "CELL", 168, 189], ["TCR", "GENE_OR_GENE_PRODUCT", 319, 322], ["T-cell receptor repertoire", "PROTEIN", 125, 151], ["precursor populations", "CELL_TYPE", 168, 189], ["immunodominant epitopes", "PROTEIN", 203, 226], ["TCR repertoire", "PROTEIN", 319, 333], ["new quantitative tools", "PROBLEM", 15, 37], ["T-cell receptor repertoire", "TREATMENT", 125, 151], ["precursor populations", "PROBLEM", 168, 189], ["immunodominant epitopes of various pathogens", "PROBLEM", 203, 247], ["intervention", "TREATMENT", 403, 415], ["Zuniga", "TREATMENT", 459, 465], ["new", "OBSERVATION_MODIFIER", 15, 18], ["size", "OBSERVATION_MODIFIER", 160, 164], ["infectious", "OBSERVATION", 652, 662]]], ["Which groups of elderly are at an increased risk of infection and which are not?Concluding Remarks, Challenges and QuestionsAre TCE a risk factor in that regard? 2.", [["infection", "DISEASE", 52, 61], ["TCE", "CHEMICAL", 128, 131], ["infection", "PROBLEM", 52, 61], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["infection", "OBSERVATION", 52, 61]]], ["For those groups that are at risk, can they be helped with the existing vaccines or do they need alternate ways of immunostimulation?", [["the existing vaccines", "TREATMENT", 59, 80], ["immunostimulation", "TREATMENT", 115, 132]]], ["Can TCE be removed or shrunken? 3.", [["TCE", "CHEMICAL", 4, 7], ["TCE", "CHEMICAL", 4, 7], ["TCE", "SIMPLE_CHEMICAL", 4, 7], ["removed", "OBSERVATION", 11, 18], ["shrunken", "OBSERVATION", 22, 30]]], ["If immunostimulation is to be attempted in a targeted manner, which modes of immunostimulation are the most efficacious?", [["immunostimulation", "TREATMENT", 3, 20], ["immunostimulation", "TREATMENT", 77, 94]]], ["Different vaccination regimens, additional costimulation or cytokine treatments? 4.", [["cytokine", "PROTEIN", 60, 68], ["Different vaccination regimens", "TREATMENT", 0, 30], ["additional costimulation", "TREATMENT", 32, 56], ["cytokine treatments", "TREATMENT", 60, 79]]], ["For those where immunostimulation may be insufficient, is T-cell rejuvenation the best option?Concluding Remarks, Challenges and QuestionsAnswering these questions will undoubtedly be rewarding for scientists and physicians, as well as to the growing populations of elderly around the world.", [["T-cell", "ANATOMY", 58, 64], ["T-cell", "CELL", 58, 64], ["immunostimulation", "TREATMENT", 16, 33], ["T-cell rejuvenation", "TREATMENT", 58, 77]]]], "44f4de1539c12006a4f950f53d0810ef3598d8ac": [["Indeed, daily practice may be altered in response to the sudden outbreak of COVID-19 as we did in cardiology.", [["COVID-19", "CHEMICAL", 76, 84]]], ["We proposed previously a modified workflow for managing STEMI patients which had undergone repeated discussions as to achieve optimal benefits over risks.", [["STEMI", "DISEASE", 56, 61], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["managing STEMI", "TREATMENT", 47, 61]]], ["1 However, we have to admit that 1 the workflow renewed is not a universal guideline but rather a local guidance which is the result of experiences from Chinese cardiologists at the forefront of the COVID-19 pandemic 2 ; there is currently no evidence to support or oppose the rationality of this altered reperfusion strategy, and we believe it will surely change over time with changes in the pandemic.", [["the COVID", "TEST", 195, 204], ["this altered reperfusion strategy", "PROBLEM", 292, 325], ["no evidence to", "UNCERTAINTY", 240, 254], ["reperfusion", "OBSERVATION", 305, 316]]]], "4795899d85d00776b6ea5510bd5bff3f6f63d54b": [["It is 110 estimated that the global economic burden of asthma is between 1.5 and 3 billion euros 111 annually, and higher costs are associated with greater disease severity (5).112Severe asthma affects 3.9% of asthmatic patients (5).", [["asthma", "DISEASE", 55, 61], ["asthma", "DISEASE", 187, 193], ["asthmatic", "DISEASE", 210, 219], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["asthma", "PROBLEM", 55, 61], ["greater disease severity", "PROBLEM", 148, 172], ["Severe asthma affects", "PROBLEM", 180, 201], ["asthmatic patients", "PROBLEM", 210, 228], ["global", "OBSERVATION_MODIFIER", 29, 35], ["economic", "OBSERVATION_MODIFIER", 36, 44], ["burden", "OBSERVATION_MODIFIER", 45, 51], ["asthma", "OBSERVATION", 55, 61], ["higher", "OBSERVATION_MODIFIER", 115, 121], ["costs", "OBSERVATION", 122, 127], ["greater", "OBSERVATION_MODIFIER", 148, 155], ["disease", "OBSERVATION", 156, 163], ["Severe", "OBSERVATION_MODIFIER", 180, 186], ["asthma", "OBSERVATION", 187, 193]]], ["It is defined as an inflammatory 113 chronic respiratory disease that remains uncontrolled despite optimal therapy and 114 treatment of contributing factors, or which worsens when high-dose treatment is 115 decreased (6).", [["respiratory", "ANATOMY", 45, 56], ["respiratory disease", "DISEASE", 45, 64], ["an inflammatory 113 chronic respiratory disease", "PROBLEM", 17, 64], ["optimal therapy", "TREATMENT", 99, 114], ["contributing factors", "PROBLEM", 136, 156], ["high-dose treatment", "TREATMENT", 180, 199], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32], ["chronic", "OBSERVATION_MODIFIER", 37, 44], ["respiratory disease", "OBSERVATION", 45, 64]]], ["Around 50% of patients with severe asthma experience uncontrolled or 116 partially controlled symptoms despite maximal treatment (5).", [["asthma", "DISEASE", 35, 41], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["severe asthma", "PROBLEM", 28, 41], ["partially controlled symptoms", "PROBLEM", 73, 102], ["maximal treatment", "TREATMENT", 111, 128], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["asthma", "OBSERVATION", 35, 41]]], ["These patients pose a 117 special challenge for care providers because of the extensive diagnostic testing and care 118 resources they require.119The aim of this study is to determine the prevalence and characterization of COVID-19 120 infection among patients with severe asthma according to ERS/ATS criteria who 121 presented to our allergy department during the COVID-19 pandemic.", [["COVID-19 120", "CHEMICAL", 223, 235], ["infection", "DISEASE", 236, 245], ["asthma", "DISEASE", 273, 279], ["allergy", "DISEASE", 335, 342], ["patients", "ORGANISM", 6, 14], ["COVID-19 120", "ORGANISM", 223, 235], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 252, 260], ["COVID-19 120", "SPECIES", 223, 235], ["the extensive diagnostic testing", "TEST", 74, 106], ["this study", "TEST", 157, 167], ["COVID", "TEST", 223, 228], ["severe asthma", "PROBLEM", 266, 279], ["the COVID", "TEST", 361, 370], ["pandemic", "PROBLEM", 374, 382], ["severe", "OBSERVATION_MODIFIER", 266, 272], ["asthma", "OBSERVATION", 273, 279]]]], "PMC3388012": [["BackgroundTuberculosis is still a major killer worldwide, causing an estimated 2-3 million deaths per year [1].", [["BackgroundTuberculosis", "CHEMICAL", 0, 22], ["deaths", "DISEASE", 91, 97]]], ["The sequence of the pathogen Mycobacterium tuberculosis (Mtb) strain H37Rv has been available for a decade [2,3], but the biology of the pathogen remains poorly understood.", [["Mycobacterium tuberculosis", "DISEASE", 29, 55], ["pathogen", "ORGANISM", 20, 28], ["Mycobacterium tuberculosis", "ORGANISM", 29, 55], ["Mtb) strain H37Rv", "ORGANISM", 57, 74], ["Mycobacterium tuberculosis", "SPECIES", 29, 55], ["Mycobacterium tuberculosis", "SPECIES", 29, 55], ["H37Rv", "SPECIES", 69, 74], ["the pathogen Mycobacterium tuberculosis (Mtb) strain H37Rv", "PROBLEM", 16, 74], ["Mycobacterium tuberculosis", "OBSERVATION", 29, 55]]], ["Available genome sequences from Mtb strains and other closely related Mycobacteria present an opportunity to bring the power of comparative genomics to the study of Mtb.BackgroundWe report here the results of a comparative analysis of 31 publicly available genomes (http://www.tbdb.org, Figure 1, Table 1).", [["Mtb strains", "ORGANISM", 32, 43], ["Mtb", "GENE_OR_GENE_PRODUCT", 165, 168], ["Available genome sequences", "TEST", 0, 26], ["Mtb strains", "PROBLEM", 32, 43], ["the study", "TEST", 152, 161], ["Mtb", "PROBLEM", 165, 168], ["a comparative analysis", "TEST", 209, 231], ["Mycobacteria", "OBSERVATION", 70, 82]]], ["These include eight closely related members of the Mtb complex that can cause tuberculosis disease, (two M. bovis strains and six Mtb strains).", [["tuberculosis disease", "DISEASE", 78, 98], ["Mtb", "GENE_OR_GENE_PRODUCT", 51, 54], ["M. bovis", "ORGANISM", 105, 113], ["Mtb complex", "PROTEIN", 51, 62], ["M. bovis", "SPECIES", 105, 113], ["M. bovis", "SPECIES", 105, 113], ["the Mtb complex", "PROBLEM", 47, 62], ["tuberculosis disease", "PROBLEM", 78, 98], ["two M. bovis strains", "PROBLEM", 101, 121], ["six Mtb strains", "PROBLEM", 126, 141], ["tuberculosis", "OBSERVATION", 78, 90]]], ["Another 11 additional Mycobacteria range from obligate parasites to free-living soil bacteria: M. leprae and M. avium subsp.", [["M. leprae", "ORGANISM", 95, 104], ["M. avium", "ORGANISM", 109, 117], ["subsp", "ORGANISM", 118, 123], ["M. leprae", "SPECIES", 95, 104], ["M. avium", "SPECIES", 109, 117], ["subsp", "SPECIES", 118, 123], ["M. leprae", "SPECIES", 95, 104], ["M. avium", "SPECIES", 109, 117], ["Another 11 additional Mycobacteria range", "PROBLEM", 0, 40], ["obligate parasites", "PROBLEM", 46, 64], ["Mycobacteria", "OBSERVATION", 22, 34], ["M. leprae", "OBSERVATION", 95, 104]]], ["Paratuberculosis K10, the causative agents of leprosy and paratuberculosis respectively, are pathogenic and require hosts to survive; M. ulcerans, M. marinum, M. avium 104, and M. abscessus have the potential to be pathogenic but can survive outside the confines of a host; M. vanbaalenii, M. sp.", [["leprosy", "DISEASE", 46, 53], ["Paratuberculosis K10", "ORGANISM", 0, 20], ["M. ulcerans", "ORGANISM", 134, 145], ["M. marinum", "ORGANISM", 147, 157], ["M. avium 104", "ORGANISM", 159, 171], ["M. abscessus", "ORGANISM", 177, 189], ["M. vanbaalenii", "ORGANISM", 274, 288], ["M. sp", "ORGANISM", 290, 295], ["paratuberculosis", "SPECIES", 58, 74], ["M. ulcerans", "SPECIES", 134, 145], ["M. marinum", "SPECIES", 147, 157], ["M. avium", "SPECIES", 159, 167], ["M. abscessus", "SPECIES", 177, 189], ["M. vanbaalenii", "SPECIES", 274, 288], ["paratuberculosis", "SPECIES", 58, 74], ["M. ulcerans", "SPECIES", 134, 145], ["M. marinum", "SPECIES", 147, 157], ["M. avium", "SPECIES", 159, 167], ["M. abscessus", "SPECIES", 177, 189], ["M. vanbaalenii", "SPECIES", 274, 288], ["Paratuberculosis K10", "PROBLEM", 0, 20], ["leprosy", "PROBLEM", 46, 53], ["paratuberculosis", "PROBLEM", 58, 74], ["pathogenic", "PROBLEM", 93, 103], ["M. avium", "TEST", 159, 167], ["M. abscessus", "PROBLEM", 177, 189], ["pathogenic", "PROBLEM", 215, 225], ["leprosy", "OBSERVATION", 46, 53], ["paratuberculosis", "OBSERVATION", 58, 74], ["ulcerans", "OBSERVATION", 137, 145], ["marinum", "ANATOMY", 150, 157], ["abscessus", "OBSERVATION", 180, 189]]], ["KMS, M. sp.", [["M. sp", "ORGANISM", 5, 10]]], ["MCS, and M. gilvum are free-living soil bacteria which are known to degrade a variety of compounds including polycyclic aromatic hydrocarbons (PAH), and are useful in bioremediation efforts.", [["polycyclic aromatic hydrocarbons", "CHEMICAL", 109, 141], ["PAH", "CHEMICAL", 143, 146], ["polycyclic aromatic hydrocarbons", "CHEMICAL", 109, 141], ["PAH", "CHEMICAL", 143, 146], ["M. gilvum", "ORGANISM", 9, 18], ["polycyclic aromatic hydrocarbons", "SIMPLE_CHEMICAL", 109, 141], ["PAH", "SIMPLE_CHEMICAL", 143, 146], ["M. gilvum", "SPECIES", 9, 18], ["M. gilvum", "SPECIES", 9, 18], ["MCS", "TEST", 0, 3], ["living soil bacteria", "PROBLEM", 28, 48], ["gilvum", "ANATOMY", 12, 18]]], ["Thus, the Mycobacteria included in our dataset span an ecological range from host-dependent pathogens to soil bacteria, allowing us to study multiple evolutionary transitions.BackgroundTo gain further insight into the Mycobacterium cluster, we also included a related Rhodococcus (also involved in bioremediation), a pathogenic Nocardia, four Corynebacteria (two pathogens and two that are commercially useful in amino acid production), two Streptomyces (antibiotic-producing soil bacteria), Acidothermus cellulolyticus (a thermophilic actinobacteria from the hot springs of Yellowstone), Propionibacterium acnes (causative agent of common acne), and Bifidobacterium longum (a digestive track commensal often found in yogurt).", [["digestive", "ANATOMY", 677, 686], ["Nocardia", "DISEASE", 328, 336], ["Corynebacteria", "CHEMICAL", 343, 357], ["amino acid", "CHEMICAL", 413, 423], ["Propionibacterium acnes", "DISEASE", 589, 612], ["acne", "DISEASE", 640, 644], ["amino acid", "CHEMICAL", 413, 423], ["amino acid", "AMINO_ACID", 413, 423], ["Acidothermus cellulolyticus", "ORGANISM", 492, 519], ["Propionibacterium acnes", "ORGANISM", 589, 612], ["Bifidobacterium longum", "ORGANISM", 651, 673], ["digestive", "ORGAN", 677, 686], ["yogurt", "ORGANISM_SUBDIVISION", 718, 724], ["Acidothermus cellulolyticus", "SPECIES", 492, 519], ["Propionibacterium acnes", "SPECIES", 589, 612], ["Bifidobacterium longum", "SPECIES", 651, 673], ["Acidothermus cellulolyticus", "SPECIES", 492, 519], ["Propionibacterium acnes", "SPECIES", 589, 612], ["Bifidobacterium longum", "SPECIES", 651, 673], ["the Mycobacteria", "TEST", 6, 22], ["host-dependent pathogens", "PROBLEM", 77, 101], ["soil bacteria", "PROBLEM", 105, 118], ["the Mycobacterium cluster", "PROBLEM", 214, 239], ["a related Rhodococcus", "PROBLEM", 258, 279], ["a pathogenic Nocardia", "PROBLEM", 315, 336], ["four Corynebacteria (two pathogens", "PROBLEM", 338, 372], ["amino acid production", "TREATMENT", 413, 434], ["two Streptomyces", "TREATMENT", 437, 453], ["antibiotic", "TREATMENT", 455, 465], ["soil bacteria", "PROBLEM", 476, 489], ["Acidothermus cellulolyticus", "PROBLEM", 492, 519], ["a thermophilic actinobacteria", "PROBLEM", 521, 550], ["Propionibacterium acnes", "PROBLEM", 589, 612], ["Bifidobacterium longum", "PROBLEM", 651, 673], ["Mycobacteria", "OBSERVATION", 10, 22], ["host-dependent", "OBSERVATION_MODIFIER", 77, 91], ["soil bacteria", "OBSERVATION", 105, 118], ["Mycobacterium", "OBSERVATION", 218, 231], ["thermophilic actinobacteria", "OBSERVATION", 523, 550], ["Bifidobacterium longum", "ANATOMY", 651, 673]]], ["We extend this comparative analysis to other more distantly related Actinobacteria to yield additional insight into evolutionary trends.BackgroundWe examined protein evolution across these 31 organisms, both at the nucleotide level and at the level of protein families, including studying gene families associated with the transition from nonpathogenic soil-dwelling bacteria to obligate pathogens.", [["nucleotide", "CHEMICAL", 215, 225], ["protein families", "PROTEIN", 252, 268], ["this comparative analysis", "TEST", 10, 35], ["Actinobacteria", "PROBLEM", 68, 82], ["protein evolution", "TEST", 158, 175], ["the nucleotide level", "TEST", 211, 231], ["the transition", "PROBLEM", 319, 333], ["nonpathogenic soil", "PROBLEM", 339, 357], ["dwelling bacteria", "PROBLEM", 358, 375], ["obligate pathogens", "PROBLEM", 379, 397]]], ["Our results highlight the importance of lipid metabolism and its regulation, and reveal differences in the evolutionary profiles for genes implicated in saturated and unsaturated fatty acid metabolism.", [["fatty acid", "CHEMICAL", 179, 189], ["saturated and unsaturated fatty acid", "CHEMICAL", 153, 189], ["lipid", "SIMPLE_CHEMICAL", 40, 45], ["saturated", "SIMPLE_CHEMICAL", 153, 162], ["fatty acid", "SIMPLE_CHEMICAL", 179, 189], ["lipid metabolism", "TEST", 40, 56], ["unsaturated fatty acid metabolism", "PROBLEM", 167, 200], ["fatty acid", "OBSERVATION", 179, 189]]], ["Our analysis also suggests that DNA repair and molybdopterin cofactors are expanded in pathogenic Mycobacteria and Mtb.BackgroundWe also identified highly conserved elements within noncoding regions using whole-genome multiple alignments and gene expression data.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["molybdopterin", "GENE_OR_GENE_PRODUCT", 47, 60], ["Mtb", "GENE_OR_GENE_PRODUCT", 115, 118], ["molybdopterin cofactors", "PROTEIN", 47, 70], ["noncoding regions", "DNA", 181, 198], ["Our analysis", "TEST", 0, 12], ["DNA repair", "TREATMENT", 32, 42], ["molybdopterin cofactors", "PROBLEM", 47, 70], ["pathogenic Mycobacteria", "PROBLEM", 87, 110], ["Mtb", "PROBLEM", 115, 118], ["gene expression data", "TEST", 242, 262], ["DNA repair", "OBSERVATION", 32, 42], ["molybdopterin cofactors", "OBSERVATION", 47, 70], ["pathogenic", "OBSERVATION_MODIFIER", 87, 97], ["Mycobacteria", "OBSERVATION", 98, 110]]], ["These conserved elements include 37 predicted conserved promoter regulatory motifs, of which 14 correspond to previously reported motifs.", [["conserved elements", "DNA", 6, 24], ["conserved promoter regulatory motifs", "DNA", 46, 82]]], ["They also include approximately 50 predicted novel noncoding RNAs.", [["novel noncoding RNAs", "RNA", 45, 65], ["noncoding RNAs", "OBSERVATION", 51, 65]]], ["Guided by our computational analysis, we tested and experimentally confirmed the expression of 4 novel small RNAs in Mtb.BackgroundThe results of our analyses are available on our website, and provide a foundation for understanding the genome and biology of Mtb in a comparative context.An orthogroup catalogue for Mycobacteria ::: Results and discussionWe used SYNERGY [27,28] to reconstruct the phylogeny of proteins across all 31 organisms, define sets of orthologs (\"orthogroups\"), and construct a phylogenetic tree of the genomes (Figure 1).", [["Mtb", "GENE_OR_GENE_PRODUCT", 117, 120], ["Mtb", "GENE_OR_GENE_PRODUCT", 258, 261], ["4 novel small RNAs", "RNA", 95, 113], ["our computational analysis", "TEST", 10, 36], ["4 novel small RNAs in Mtb", "PROBLEM", 95, 120], ["our analyses", "TEST", 146, 158], ["small RNAs", "OBSERVATION", 103, 113]]], ["An orthogroup is defined as the set of genes descended from a single common ancestral gene in the last common ancestor of the species under consideration [28], containing both orthologs and possibly paralogs (Methods).", [["possibly", "UNCERTAINTY", 190, 198]]], ["At each node in the phylogenetic tree, we tabulated orthogroup appearances, duplications, and losses (Figure 2).", [["node", "ANATOMY", 8, 12], ["duplications", "PROBLEM", 76, 88], ["node", "OBSERVATION", 8, 12], ["phylogenetic", "ANATOMY_MODIFIER", 20, 32], ["tree", "ANATOMY_MODIFIER", 33, 37]]], ["Full listings of the events tabulated in Figure 2, as well as additional information about each orthogroup, can be found on the Supplementary Information website:Tracing the evolution of biological processes ::: Results and discussionTo examine the evolution of entire pathways and gene families, we categorized orthogroups according to GO (Gene Ontology) and GO Slim terms [29], PFAM domains [30], metabolic pathways, predicted regulons (sets of genes predicted to be regulated by a common regulatory protein), and groups of genes upregulated under certain lipids (Methods).", [["PFAM domains", "DNA", 380, 392], ["regulons", "DNA", 429, 437], ["common regulatory protein", "PROTEIN", 484, 509], ["PFAM domains", "TEST", 380, 392]]], ["We also looked for orthogroups undergoing positive selection by calculating the ratio of nonsynonymous to synonymous mutations (the dN/dS ratio).", [["synonymous mutations", "PROBLEM", 106, 126], ["the dN/dS ratio", "TREATMENT", 128, 143], ["synonymous mutations", "OBSERVATION", 106, 126]]], ["Tables 2 and 3 show the PFAM and GO categories most expanded (with the most orthogroup members) in the Mtb clade relative to the non-pathogenic Mycobacteria, and Tables 4 and 5 show those most expanded in the Mycobacteria relative to the non-Mycobacteria.Substantial expansion of known pathogenicity and lipid metabolism genes ::: Results and discussionDespite the smaller genome sizes present in the pathogenic Mycobacteria, and the resulting background of orthogroup loss in the evolution towards pathogens, we observe significant expansions in certain gene families in the pathogenic Mycobacteria and the Mtb complex relative to non-pathogenic relatives.", [["Mycobacteria", "DISEASE", 412, 424], ["orthogroup loss", "DISEASE", 458, 473], ["lipid", "SIMPLE_CHEMICAL", 304, 309], ["Mycobacteria", "CANCER", 587, 599], ["Mtb", "GENE_OR_GENE_PRODUCT", 608, 611], ["PFAM", "PROTEIN", 24, 28], ["lipid metabolism genes", "DNA", 304, 326], ["Mtb complex", "PROTEIN", 608, 619], ["the PFAM", "TEST", 20, 28], ["the Mtb clade", "PROBLEM", 99, 112], ["the non-pathogenic Mycobacteria", "TEST", 125, 156], ["Tables", "TEST", 162, 168], ["the Mycobacteria", "TEST", 205, 221], ["known pathogenicity", "PROBLEM", 280, 299], ["the smaller genome sizes", "PROBLEM", 361, 385], ["the pathogenic Mycobacteria", "PROBLEM", 397, 424], ["orthogroup loss", "PROBLEM", 458, 473], ["pathogens", "PROBLEM", 499, 508], ["significant expansions", "PROBLEM", 521, 543], ["the pathogenic Mycobacteria", "PROBLEM", 572, 599], ["non-pathogenic", "OBSERVATION_MODIFIER", 129, 143], ["Mycobacteria", "OBSERVATION", 144, 156], ["Mycobacteria", "OBSERVATION", 209, 221], ["expansion", "OBSERVATION_MODIFIER", 267, 276], ["pathogenicity", "OBSERVATION", 286, 299], ["lipid metabolism genes", "OBSERVATION", 304, 326], ["smaller", "OBSERVATION_MODIFIER", 365, 372], ["genome", "OBSERVATION_MODIFIER", 373, 379], ["sizes", "OBSERVATION_MODIFIER", 380, 385], ["pathogenic", "OBSERVATION_MODIFIER", 401, 411], ["Mycobacteria", "OBSERVATION", 412, 424], ["orthogroup loss", "OBSERVATION", 458, 473], ["significant", "OBSERVATION_MODIFIER", 521, 532], ["expansions", "OBSERVATION", 533, 543], ["pathogenic", "OBSERVATION_MODIFIER", 576, 586], ["Mycobacteria", "OBSERVATION", 587, 599]]], ["We also observe evidence for selection in certain families on branches leading to the pathogenic Mycobacteria, the Mtb complex, and the soil-dwelling Mycobacteria.Substantial expansion of known pathogenicity and lipid metabolism genes ::: Results and discussionAs expected, many genes known to be related to pathogenicity or antigenic variability are among the groups most expanded in the Mtb clade relative to soil dwelling Mycobacteria as well as being among the categories with the most variability in copy number in their category-level profiles overall, including toxin-antitoxin genes, genes containing PE (Pro-Glu) and PPE (Pro-Pro-Glu) domains, MCE (Mammalian Cell Entry) genes, genes involved in the synthesis of the mycolic acid coat, Esx genes, and gene involved in antibiotic resistance.", [["Cell", "ANATOMY", 668, 672], ["Glu", "CHEMICAL", 617, 620], ["mycolic acid", "CHEMICAL", 726, 738], ["Glu", "CHEMICAL", 617, 620], ["Pro-Pro-Glu", "CHEMICAL", 631, 642], ["mycolic acid", "CHEMICAL", 726, 738], ["Mtb", "GENE_OR_GENE_PRODUCT", 115, 118], ["lipid", "SIMPLE_CHEMICAL", 212, 217], ["toxin-antitoxin", "GENE_OR_GENE_PRODUCT", 569, 584], ["PE (Pro-Glu", "GENE_OR_GENE_PRODUCT", 609, 620], ["PPE", "GENE_OR_GENE_PRODUCT", 626, 629], ["Esx", "GENE_OR_GENE_PRODUCT", 745, 748], ["Mtb complex", "PROTEIN", 115, 126], ["lipid metabolism genes", "DNA", 212, 234], ["toxin-antitoxin genes", "DNA", 569, 590], ["PE (Pro-Glu) and PPE (Pro-Pro-Glu) domains", "DNA", 609, 651], ["MCE", "DNA", 653, 656], ["Mammalian Cell Entry) genes", "DNA", 658, 685], ["mycolic acid coat, Esx genes", "DNA", 726, 754], ["selection in certain families on branches", "PROBLEM", 29, 70], ["the pathogenic Mycobacteria", "PROBLEM", 82, 109], ["the Mtb complex", "PROBLEM", 111, 126], ["the soil-dwelling Mycobacteria", "PROBLEM", 132, 162], ["known pathogenicity", "PROBLEM", 188, 207], ["pathogenicity", "PROBLEM", 308, 321], ["antigenic variability", "PROBLEM", 325, 346], ["the Mtb clade", "PROBLEM", 385, 398], ["soil dwelling Mycobacteria", "PROBLEM", 411, 437], ["toxin", "TEST", 569, 574], ["antitoxin genes", "PROBLEM", 575, 590], ["genes containing PE", "PROBLEM", 592, 611], ["Pro-Glu", "TEST", 613, 620], ["PPE", "TEST", 626, 629], ["Pro", "TEST", 631, 634], ["MCE", "TEST", 653, 656], ["the mycolic acid coat", "TREATMENT", 722, 743], ["antibiotic resistance", "TREATMENT", 777, 798], ["observe evidence for", "UNCERTAINTY", 8, 28], ["pathogenic", "OBSERVATION_MODIFIER", 86, 96], ["Mycobacteria", "OBSERVATION", 97, 109], ["expansion", "OBSERVATION_MODIFIER", 175, 184], ["pathogenicity", "OBSERVATION", 194, 207], ["lipid metabolism genes", "OBSERVATION", 212, 234], ["PE", "OBSERVATION", 609, 611], ["antibiotic resistance", "OBSERVATION", 777, 798]]], ["Below we focus on specific additional families showing noteworthy expansions and trends.Substantial expansion of known pathogenicity and lipid metabolism genes ::: Results and discussionThe single most significant trend in our analysis of protein family evolution is that genes related to lipid metabolism are greatly expanded across all Mycobacteria and related organisms, consistent with previous observations [2,31] (Table 5).", [["lipid", "SIMPLE_CHEMICAL", 137, 142], ["lipid", "SIMPLE_CHEMICAL", 289, 294], ["lipid metabolism genes", "DNA", 137, 159], ["noteworthy expansions", "PROBLEM", 55, 76], ["known pathogenicity", "PROBLEM", 113, 132], ["lipid metabolism", "PROBLEM", 289, 305], ["all Mycobacteria", "PROBLEM", 334, 350], ["related organisms", "PROBLEM", 355, 372], ["expansion", "OBSERVATION_MODIFIER", 100, 109], ["pathogenicity", "OBSERVATION", 119, 132], ["lipid metabolism genes", "OBSERVATION", 137, 159], ["significant", "OBSERVATION_MODIFIER", 202, 213], ["trend", "OBSERVATION_MODIFIER", 214, 219], ["Mycobacteria", "OBSERVATION", 338, 350], ["consistent with", "UNCERTAINTY", 374, 389]]], ["Our analysis extends these previous observations by identifying the emergence of this expansion in lipid metabolism genes as occurring at the root node of the Mycobacteria and Rhodococcus (Figure 3).Particular expansion of saturated fatty acid metabolism and lipid synthesis genes in pathogenic Mycobacteria ::: Results and discussionGenes predicted to be involved in the metabolism of saturated fatty acids are more expanded than those involved in the metabolism of unsaturated fatty acids.", [["root node", "ANATOMY", 142, 151], ["fatty acid", "CHEMICAL", 233, 243], ["fatty acids", "CHEMICAL", 396, 407], ["unsaturated fatty acids", "CHEMICAL", 467, 490], ["fatty acid", "CHEMICAL", 233, 243], ["saturated fatty acids", "CHEMICAL", 386, 407], ["unsaturated fatty acids", "CHEMICAL", 467, 490], ["lipid", "SIMPLE_CHEMICAL", 99, 104], ["root node", "MULTI-TISSUE_STRUCTURE", 142, 151], ["fatty acid", "SIMPLE_CHEMICAL", 233, 243], ["lipid", "SIMPLE_CHEMICAL", 259, 264], ["saturated fatty acids", "SIMPLE_CHEMICAL", 386, 407], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 467, 490], ["lipid metabolism genes", "DNA", 99, 121], ["Our analysis", "TEST", 0, 12], ["this expansion in lipid metabolism genes", "PROBLEM", 81, 121], ["the Mycobacteria", "PROBLEM", 155, 171], ["Particular expansion of saturated fatty acid metabolism", "PROBLEM", 199, 254], ["lipid synthesis genes", "PROBLEM", 259, 280], ["saturated fatty acids", "PROBLEM", 386, 407], ["metabolism genes", "OBSERVATION", 105, 121], ["root node", "ANATOMY", 142, 151], ["Mycobacteria", "OBSERVATION", 159, 171], ["saturated", "OBSERVATION_MODIFIER", 223, 232], ["fatty acid metabolism", "OBSERVATION", 233, 254], ["lipid synthesis genes", "OBSERVATION", 259, 280], ["pathogenic Mycobacteria", "OBSERVATION", 284, 307]]], ["Using a compendium of microarray expression experiments (Methods), we compiled a list of genes upregulated in the presence of different fatty acid sources.", [["fatty acid", "CHEMICAL", 136, 146], ["fatty acid", "CHEMICAL", 136, 146], ["fatty acid", "SIMPLE_CHEMICAL", 136, 146], ["microarray expression experiments", "TREATMENT", 22, 55], ["different fatty acid sources", "PROBLEM", 126, 154], ["fatty acid", "OBSERVATION", 136, 146]]], ["We found that genes upregulated under unsaturated conditions have more uniform phylogenetic profiles, while those upregulated under saturated conditions, cholesterol or ceramide have expanded through duplications in pathogenic Mycobacteria (Figure 4).", [["cholesterol", "CHEMICAL", 154, 165], ["ceramide", "CHEMICAL", 169, 177], ["cholesterol", "CHEMICAL", 154, 165], ["ceramide", "CHEMICAL", 169, 177], ["cholesterol", "SIMPLE_CHEMICAL", 154, 165], ["ceramide", "SIMPLE_CHEMICAL", 169, 177], ["cholesterol or ceramide", "TREATMENT", 154, 177], ["duplications in pathogenic Mycobacteria", "PROBLEM", 200, 239], ["more uniform", "OBSERVATION_MODIFIER", 66, 78], ["phylogenetic profiles", "OBSERVATION", 79, 100], ["pathogenic Mycobacteria", "OBSERVATION", 216, 239]]], ["Saturated fatty acids and cholesterol are more prevalent in an animal host than in the soil, which contains mostly unsaturated fatty acid from plant inputs.", [["fatty acids", "CHEMICAL", 10, 21], ["cholesterol", "CHEMICAL", 26, 37], ["fatty acid", "CHEMICAL", 127, 137], ["Saturated fatty acids", "CHEMICAL", 0, 21], ["cholesterol", "CHEMICAL", 26, 37], ["unsaturated fatty acid", "CHEMICAL", 115, 137], ["Saturated fatty acids", "SIMPLE_CHEMICAL", 0, 21], ["cholesterol", "SIMPLE_CHEMICAL", 26, 37], ["unsaturated fatty acid", "SIMPLE_CHEMICAL", 115, 137], ["Saturated fatty acids", "TEST", 0, 21], ["cholesterol", "TEST", 26, 37], ["cholesterol", "OBSERVATION_MODIFIER", 26, 37], ["more prevalent", "OBSERVATION_MODIFIER", 42, 56], ["animal host", "OBSERVATION_MODIFIER", 63, 74], ["mostly", "OBSERVATION_MODIFIER", 108, 114], ["unsaturated", "OBSERVATION_MODIFIER", 115, 126], ["fatty acid", "OBSERVATION", 127, 137]]], ["Since it is believed that Mtb uses cholesterol as a carbon source within the host [32], this could reflect an adaptation to the host environment.", [["cholesterol", "CHEMICAL", 35, 46], ["cholesterol", "CHEMICAL", 35, 46], ["carbon", "CHEMICAL", 52, 58], ["Mtb", "GENE_OR_GENE_PRODUCT", 26, 29], ["cholesterol", "SIMPLE_CHEMICAL", 35, 46], ["Mtb", "OBSERVATION", 26, 29]]], ["Consistent with our observations in host-adapted Mycobacteria, Desulfovibrio desulfuricans intestinal strains contain a higher ratio of saturated to unsaturated fatty acids than soil strains of Desulfovibrio desulfuricans [33].Particular expansion of saturated fatty acid metabolism and lipid synthesis genes in pathogenic Mycobacteria ::: Results and discussionOur analysis also reveals differences in evolutionary profiles between genes predicted to be involved in catabolism and anabolism of lipids.", [["intestinal strains", "ANATOMY", 91, 109], ["unsaturated fatty acids", "CHEMICAL", 149, 172], ["fatty acid", "CHEMICAL", 261, 271], ["unsaturated fatty acids", "CHEMICAL", 149, 172], ["fatty acid", "CHEMICAL", 261, 271], ["Mycobacteria", "ORGANISM", 49, 61], ["Desulfovibrio desulfuricans intestinal strains", "ORGANISM", 63, 109], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 149, 172], ["Desulfovibrio desulfuricans", "ORGANISM", 194, 221], ["fatty acid", "SIMPLE_CHEMICAL", 261, 271], ["lipid", "SIMPLE_CHEMICAL", 287, 292], ["lipids", "SIMPLE_CHEMICAL", 495, 501], ["Desulfovibrio desulfuricans", "SPECIES", 63, 90], ["Desulfovibrio desulfuricans", "SPECIES", 194, 221], ["Desulfovibrio desulfuricans", "SPECIES", 63, 90], ["Desulfovibrio desulfuricans", "SPECIES", 194, 221], ["Mycobacteria", "PROBLEM", 49, 61], ["Desulfovibrio desulfuricans intestinal strains", "PROBLEM", 63, 109], ["unsaturated fatty acids", "PROBLEM", 149, 172], ["Desulfovibrio desulfuricans", "PROBLEM", 194, 221], ["Particular expansion of saturated fatty acid metabolism", "PROBLEM", 227, 282], ["lipid synthesis genes", "PROBLEM", 287, 308], ["discussionOur analysis", "TEST", 352, 374], ["anabolism of lipids", "TREATMENT", 482, 501], ["saturated", "OBSERVATION_MODIFIER", 251, 260], ["fatty acid metabolism", "OBSERVATION", 261, 282], ["lipid synthesis genes", "OBSERVATION", 287, 308], ["pathogenic Mycobacteria", "OBSERVATION", 312, 335]]], ["Both sets of genes are expanded in soil-dwelling and pathogenic Mycobacteria, but lipid synthesis genes are additionally expanded in pathogens relative to soil dwellers.", [["lipid", "SIMPLE_CHEMICAL", 82, 87], ["lipid synthesis genes", "DNA", 82, 103], ["pathogenic Mycobacteria", "PROBLEM", 53, 76], ["lipid synthesis genes", "PROBLEM", 82, 103], ["pathogens", "PROBLEM", 133, 142], ["genes", "ANATOMY", 13, 18], ["expanded", "OBSERVATION_MODIFIER", 23, 31], ["pathogenic", "OBSERVATION_MODIFIER", 53, 63], ["Mycobacteria", "OBSERVATION", 64, 76]]], ["General lipid synthesis genes are expanded across the Mycobacteria, but certain groups of lipid synthesis genes, including those related to cell wall synthesis, are further expanded in the Mtb complex (see Supplementary Information).", [["cell wall", "ANATOMY", 140, 149], ["lipid", "SIMPLE_CHEMICAL", 8, 13], ["lipid", "SIMPLE_CHEMICAL", 90, 95], ["cell wall", "CELLULAR_COMPONENT", 140, 149], ["lipid synthesis genes", "DNA", 90, 111], ["Mtb complex", "PROTEIN", 189, 200], ["General lipid synthesis genes", "PROBLEM", 0, 29], ["the Mycobacteria", "PROBLEM", 50, 66], ["lipid synthesis genes", "PROBLEM", 90, 111], ["cell wall synthesis", "PROBLEM", 140, 159], ["lipid", "OBSERVATION", 8, 13], ["synthesis genes", "OBSERVATION", 14, 29], ["Mycobacteria", "OBSERVATION", 54, 66], ["lipid synthesis genes", "OBSERVATION", 90, 111], ["wall", "ANATOMY_MODIFIER", 145, 149], ["synthesis", "OBSERVATION", 150, 159]]], ["In pathogenic Mycobacteria, the waxy mycolic acid coat helps evade the host immune system [34].", [["Mycobacteria", "DISEASE", 14, 26], ["waxy mycolic acid", "CHEMICAL", 32, 49], ["mycolic acid", "CHEMICAL", 37, 49], ["pathogenic Mycobacteria", "PROBLEM", 3, 26], ["the waxy mycolic acid coat", "TEST", 28, 54], ["pathogenic", "OBSERVATION_MODIFIER", 3, 13], ["Mycobacteria", "OBSERVATION", 14, 26]]], ["Consistent with this, we see categories related to mycolic acid synthesis showing up among the most non-uniform categories, highly expanded in the Mtb complex (see Supplementary Information).Particular expansion of saturated fatty acid metabolism and lipid synthesis genes in pathogenic Mycobacteria ::: Results and discussionIn contrast, some lipid degradation gene families are more expanded in the soil-dwelling Mycobacteria than in the pathogens (Supplementary Data).", [["mycolic acid", "CHEMICAL", 51, 63], ["fatty acid", "CHEMICAL", 225, 235], ["mycolic acid", "CHEMICAL", 51, 63], ["fatty acid", "CHEMICAL", 225, 235], ["mycolic acid", "SIMPLE_CHEMICAL", 51, 63], ["fatty acid", "SIMPLE_CHEMICAL", 225, 235], ["lipid", "SIMPLE_CHEMICAL", 251, 256], ["Mtb complex", "PROTEIN", 147, 158], ["mycolic acid synthesis", "TEST", 51, 73], ["Particular expansion of saturated fatty acid metabolism", "PROBLEM", 191, 246], ["lipid synthesis genes", "PROBLEM", 251, 272], ["some lipid degradation gene families", "PROBLEM", 339, 375], ["dwelling Mycobacteria", "PROBLEM", 406, 427], ["most non-uniform", "OBSERVATION_MODIFIER", 95, 111], ["highly", "OBSERVATION_MODIFIER", 124, 130], ["expanded", "OBSERVATION_MODIFIER", 131, 139], ["saturated", "OBSERVATION_MODIFIER", 215, 224], ["fatty acid metabolism", "OBSERVATION", 225, 246], ["lipid synthesis genes", "OBSERVATION", 251, 272], ["pathogenic Mycobacteria", "OBSERVATION", 276, 299]]], ["The soil-dwellers have the unusual ability to degrade a vast array of compounds, including diverse lipids.Positive selection of lipid metabolism genes ::: Results and discussionIn addition to gene family expansions, we observe evidence for selection on the coding sequence of lipid metabolism genes.", [["lipid", "SIMPLE_CHEMICAL", 128, 133], ["lipid", "SIMPLE_CHEMICAL", 276, 281], ["lipid metabolism genes", "DNA", 128, 150], ["lipid metabolism genes", "DNA", 276, 298], ["diverse lipids", "TREATMENT", 91, 105], ["gene family expansions", "PROBLEM", 192, 214], ["lipid metabolism genes", "OBSERVATION", 128, 150]]], ["In our dN/dS calculations, we observe enrichment for positive selection in lipid degradation genes on the branch leading to the pathogenic Mycobacteria (Additional file 1: Table S2).", [["lipid degradation genes", "DNA", 75, 98], ["positive selection in lipid degradation genes", "PROBLEM", 53, 98], ["the pathogenic Mycobacteria", "PROBLEM", 124, 151], ["pathogenic", "OBSERVATION_MODIFIER", 128, 138], ["Mycobacteria", "OBSERVATION", 139, 151]]], ["For example, Rv2524c, the multifunctional FAS-I polypeptide utilized during de novo fatty synthesis [35], has the second highest dN/dS value on this branch.", [["Rv2524c", "GENE_OR_GENE_PRODUCT", 13, 20], ["FAS-I", "GENE_OR_GENE_PRODUCT", 42, 47], ["Rv2524c", "PROTEIN", 13, 20], ["FAS", "PROTEIN", 42, 45], ["I polypeptide", "PROTEIN", 46, 59], ["the multifunctional FAS-I polypeptide", "TREATMENT", 22, 59], ["branch", "ANATOMY_MODIFIER", 149, 155]]], ["Additional lipid metabolism genes with elevated dN/dS values include 15 genes predicted to be involved in the \u03b2-oxidation pathway of fatty acid degradation: seven fadE (acyl coA dehydrogenase) genes, three fadD (fatty acid CoA ligase) genes, two fadB (NADPH quinone oxidoreductase/3-hydroxybutyryl-CoA dehydrogenase) genes, one fadA (acetyl-CoA acyltransferase) gene, and two echA (enoyl-CoA hydratase) genes.", [["fatty acid", "CHEMICAL", 133, 143], ["fatty acid", "CHEMICAL", 212, 222], ["NADPH", "CHEMICAL", 252, 257], ["acetyl", "CHEMICAL", 334, 340], ["fatty acid", "CHEMICAL", 133, 143], ["acyl", "CHEMICAL", 169, 173], ["fatty acid CoA", "CHEMICAL", 212, 226], ["NADPH", "CHEMICAL", 252, 257], ["quinone", "CHEMICAL", 258, 265], ["3-hydroxybutyryl-CoA", "CHEMICAL", 281, 301], ["acetyl-CoA", "CHEMICAL", 334, 344], ["enoyl-CoA", "CHEMICAL", 382, 391], ["lipid", "SIMPLE_CHEMICAL", 11, 16], ["fatty acid", "SIMPLE_CHEMICAL", 133, 143], ["acyl coA dehydrogenase", "GENE_OR_GENE_PRODUCT", 169, 191], ["fadD", "GENE_OR_GENE_PRODUCT", 206, 210], ["fatty acid CoA ligase", "GENE_OR_GENE_PRODUCT", 212, 233], ["fadB", "GENE_OR_GENE_PRODUCT", 246, 250], ["NADPH quinone oxidoreductase", "GENE_OR_GENE_PRODUCT", 252, 280], ["3-hydroxybutyryl-CoA dehydrogenase", "GENE_OR_GENE_PRODUCT", 281, 315], ["fadA", "SIMPLE_CHEMICAL", 328, 332], ["acetyl-CoA acyltransferase", "GENE_OR_GENE_PRODUCT", 334, 360], ["echA", "GENE_OR_GENE_PRODUCT", 376, 380], ["enoyl-CoA hydratase", "GENE_OR_GENE_PRODUCT", 382, 401], ["lipid metabolism genes", "DNA", 11, 33], ["dN", "DNA", 48, 50], ["fadE (acyl coA dehydrogenase) genes", "DNA", 163, 198], ["fadD (fatty acid CoA ligase) genes", "DNA", 206, 240], ["fadB", "DNA", 246, 250], ["NADPH quinone oxidoreductase/3-hydroxybutyryl-CoA dehydrogenase) genes", "DNA", 252, 322], ["fadA (acetyl-CoA acyltransferase) gene", "DNA", 328, 366], ["echA (enoyl-CoA hydratase) genes", "DNA", 376, 408], ["Additional lipid metabolism genes", "TEST", 0, 33], ["elevated dN/dS values", "PROBLEM", 39, 60], ["fatty acid degradation", "PROBLEM", 133, 155], ["three fadD (fatty acid CoA ligase)", "TREATMENT", 200, 234], ["NADPH quinone oxidoreductase", "TREATMENT", 252, 280], ["hydroxybutyryl", "TREATMENT", 283, 297], ["acetyl", "TREATMENT", 334, 340], ["metabolism genes", "OBSERVATION", 17, 33]]], ["Hence, we observe expansions of lipid biosynthesis genes, as well as observing evidence for positive selection acting on genes within the \u03b2-oxidation pathway.", [["lipid", "SIMPLE_CHEMICAL", 32, 37], ["lipid biosynthesis genes", "DNA", 32, 56], ["expansions of lipid biosynthesis genes", "PROBLEM", 18, 56], ["positive selection", "PROBLEM", 92, 110], ["lipid biosynthesis genes", "OBSERVATION", 32, 56]]], ["Both the lipid biosynthesis and lipid degradation pathways are specialized within the pathogenic Mycobacteria.", [["lipid", "SIMPLE_CHEMICAL", 9, 14], ["lipid", "SIMPLE_CHEMICAL", 32, 37], ["the lipid biosynthesis", "TREATMENT", 5, 27], ["lipid degradation pathways", "TREATMENT", 32, 58], ["the pathogenic Mycobacteria", "PROBLEM", 82, 109], ["lipid biosynthesis", "OBSERVATION", 9, 27], ["pathogenic", "OBSERVATION_MODIFIER", 86, 96], ["Mycobacteria", "OBSERVATION", 97, 109]]], ["This expansion could possibly benefit the pathogen in a manner to accommodate production and modification of cell wall lipids involved in manipulation of host immune response.", [["cell wall", "ANATOMY", 109, 118], ["cell wall lipids", "CELLULAR_COMPONENT", 109, 125], ["the pathogen", "PROBLEM", 38, 50], ["modification of cell wall lipids", "TREATMENT", 93, 125], ["host immune response", "OBSERVATION", 154, 174]]], ["The lipid degradation is particularly beneficial for the long term survival of the pathogen metabolizing host lipids encountered during infection.Coordinated evolution of lipid metabolism genes and the regulator KstR ::: Results and discussionKstR is a transcription factor known to be involved in lipid and cholesterol degradation [36,37].", [["infection", "DISEASE", 136, 145], ["cholesterol", "CHEMICAL", 308, 319], ["cholesterol", "CHEMICAL", 308, 319], ["lipid", "SIMPLE_CHEMICAL", 4, 9], ["lipid", "SIMPLE_CHEMICAL", 171, 176], ["lipid", "SIMPLE_CHEMICAL", 298, 303], ["cholesterol", "SIMPLE_CHEMICAL", 308, 319], ["lipid metabolism genes", "DNA", 171, 193], ["KstR", "PROTEIN", 212, 216], ["discussionKstR", "PROTEIN", 233, 247], ["transcription factor", "PROTEIN", 253, 273], ["The lipid degradation", "PROBLEM", 0, 21], ["the long term survival", "TREATMENT", 53, 75], ["the pathogen metabolizing host lipids", "TREATMENT", 79, 116], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145], ["lipid metabolism genes", "OBSERVATION", 171, 193]]], ["It has been recently shown that Mtb uses cholesterol as a carbon source within the host [32].", [["cholesterol", "CHEMICAL", 41, 52], ["cholesterol", "CHEMICAL", 41, 52], ["carbon", "CHEMICAL", 58, 64], ["Mtb", "GENE_OR_GENE_PRODUCT", 32, 35], ["cholesterol", "SIMPLE_CHEMICAL", 41, 52], ["Mtb", "OBSERVATION", 32, 35]]], ["Strikingly, KstR exhibits an evolutionary history that parallels the expansion of lipid metabolism genes in the Mycobacteria, and displays a singular conservation in its regulatory binding sites.Coordinated evolution of lipid metabolism genes and the regulator KstR ::: Results and discussionKstR appears to have evolved at the last common ancestor of the Mycobacteria and Rhodococcus.", [["KstR", "GENE_OR_GENE_PRODUCT", 12, 16], ["lipid", "SIMPLE_CHEMICAL", 82, 87], ["lipid", "SIMPLE_CHEMICAL", 220, 225], ["KstR", "PROTEIN", 12, 16], ["lipid metabolism genes", "DNA", 82, 104], ["regulatory binding sites", "DNA", 170, 194], ["lipid metabolism genes", "DNA", 220, 242], ["KstR", "PROTEIN", 261, 265], ["discussionKstR", "PROTEIN", 282, 296], ["lipid metabolism genes in the Mycobacteria", "PROBLEM", 82, 124], ["the Mycobacteria", "PROBLEM", 352, 368], ["Rhodococcus", "PROBLEM", 373, 384], ["expansion", "OBSERVATION_MODIFIER", 69, 78], ["lipid metabolism genes", "OBSERVATION", 82, 104], ["Mycobacteria", "OBSERVATION", 112, 124], ["singular", "OBSERVATION_MODIFIER", 141, 149], ["conservation", "OBSERVATION", 150, 162], ["binding sites", "OBSERVATION", 181, 194], ["lipid metabolism genes", "OBSERVATION", 220, 242], ["Mycobacteria", "OBSERVATION", 356, 368]]], ["In all Mycobacteria analyzed (except M. leprae), Rhodococcus, and Nocardia there is one highly conserved ortholog of the KstR gene.", [["M. leprae", "ORGANISM", 37, 46], ["KstR", "GENE_OR_GENE_PRODUCT", 121, 125], ["KstR gene", "DNA", 121, 130], ["M. leprae", "SPECIES", 37, 46], ["M. leprae", "SPECIES", 37, 46], ["all Mycobacteria", "TEST", 3, 19], ["Rhodococcus", "PROBLEM", 49, 60], ["Nocardia", "PROBLEM", 66, 74], ["Mycobacteria", "OBSERVATION", 7, 19], ["Nocardia", "OBSERVATION", 66, 74]]], ["However, in organisms more distantly related to Mtb, the KstR gene is not present in a single copy.", [["Mtb", "GENE_OR_GENE_PRODUCT", 48, 51], ["KstR", "GENE_OR_GENE_PRODUCT", 57, 61], ["KstR gene", "DNA", 57, 66], ["Mtb", "PROBLEM", 48, 51], ["Mtb", "OBSERVATION", 48, 51]]], ["Rather, 2-3 paralogs of KstR are present in these more distantly related organisms, as well as the environmental Mycobacteria, including M. ulcerans, M. avium 104, M. sp.", [["2-3", "GENE_OR_GENE_PRODUCT", 8, 11], ["KstR", "GENE_OR_GENE_PRODUCT", 24, 28], ["M. ulcerans", "ORGANISM", 137, 148], ["M. avium 104", "ORGANISM", 150, 162], ["M. sp", "ORGANISM", 164, 169], ["KstR", "PROTEIN", 24, 28], ["M. ulcerans", "SPECIES", 137, 148], ["M. avium", "SPECIES", 150, 158], ["M. ulcerans", "SPECIES", 137, 148], ["M. avium", "SPECIES", 150, 158], ["the environmental Mycobacteria", "TEST", 95, 125], ["M. ulcerans", "PROBLEM", 137, 148], ["M. avium", "TEST", 150, 158], ["Mycobacteria", "OBSERVATION", 113, 125], ["ulcerans", "OBSERVATION", 140, 148]]], ["KMS, and M. vanbaalenii (Additional file 2: Figure S1).", [["M. vanbaalenii", "SPECIES", 9, 23], ["M. vanbaalenii", "SPECIES", 9, 23], ["KMS", "TEST", 0, 3]]], ["Remarkably, these paralogs of KstR are all absent in the pathogenic Mycobacteria.", [["KstR", "GENE_OR_GENE_PRODUCT", 30, 34], ["KstR", "PROTEIN", 30, 34], ["these paralogs of KstR", "PROBLEM", 12, 34], ["the pathogenic Mycobacteria", "PROBLEM", 53, 80], ["pathogenic", "OBSERVATION_MODIFIER", 57, 67], ["Mycobacteria", "OBSERVATION", 68, 80]]], ["Thus, coincident with the expansion in lipid metabolism genes described above, the KstR gene appears to have emerged through gene duplication within the existing gene family of tetR-like transcriptional regulators at the last common ancestor of Mycobacteria and Rhodococcus.", [["lipid", "SIMPLE_CHEMICAL", 39, 44], ["KstR", "GENE_OR_GENE_PRODUCT", 83, 87], ["tetR", "GENE_OR_GENE_PRODUCT", 177, 181], ["lipid metabolism genes", "DNA", 39, 61], ["KstR gene", "DNA", 83, 92], ["tetR", "PROTEIN", 177, 181], ["transcriptional regulators", "PROTEIN", 187, 213], ["the expansion in lipid metabolism genes", "PROBLEM", 22, 61], ["gene duplication", "PROBLEM", 125, 141], ["Mycobacteria", "PROBLEM", 245, 257], ["Rhodococcus", "PROBLEM", 262, 273], ["expansion", "OBSERVATION_MODIFIER", 26, 35], ["lipid", "OBSERVATION", 39, 44], ["metabolism genes", "OBSERVATION", 45, 61], ["Mycobacteria", "OBSERVATION", 245, 257]]], ["All other members of this gene family were subsequently lost in the Mtb complex, while the KstR protein was maintained and underwent limited sequence divergence.Coordinated evolution of lipid metabolism genes and the regulator KstR ::: Results and discussionThere is another homolog to KstR found in Mtb H37Rv (Rv3557c) that has previously been reported to also be involved in cholesterol metabolism, named KstR2 [38].", [["cholesterol", "CHEMICAL", 377, 388], ["cholesterol", "CHEMICAL", 377, 388], ["Mtb", "GENE_OR_GENE_PRODUCT", 68, 71], ["KstR", "GENE_OR_GENE_PRODUCT", 91, 95], ["lipid", "SIMPLE_CHEMICAL", 186, 191], ["KstR", "GENE_OR_GENE_PRODUCT", 286, 290], ["Mtb H37Rv", "GENE_OR_GENE_PRODUCT", 300, 309], ["Rv3557c", "AMINO_ACID", 311, 318], ["cholesterol", "SIMPLE_CHEMICAL", 377, 388], ["Mtb complex", "PROTEIN", 68, 79], ["KstR protein", "PROTEIN", 91, 103], ["lipid metabolism genes", "DNA", 186, 208], ["KstR", "PROTEIN", 227, 231], ["KstR", "PROTEIN", 286, 290], ["Mtb H37Rv", "PROTEIN", 300, 309], ["Rv3557c", "PROTEIN", 311, 318], ["the KstR protein", "TREATMENT", 87, 103], ["lipid metabolism genes", "OBSERVATION", 186, 208]]], ["However, KstR is much more similar to the other members of the Mycobacterial tetR family discussed above than it is to KstR2.", [["KstR", "GENE_OR_GENE_PRODUCT", 9, 13], ["tetR", "GENE_OR_GENE_PRODUCT", 77, 81], ["KstR2", "GENE_OR_GENE_PRODUCT", 119, 124], ["KstR", "PROTEIN", 9, 13], ["Mycobacterial tetR family", "PROTEIN", 63, 88], ["KstR2", "PROTEIN", 119, 124]]], ["KstR2 is categorized into a separate orthogroup (orthogroup 32655) and is more distantly related to KstR.Coordinated evolution of lipid metabolism genes and the regulator KstR ::: Results and discussionThe high sequence conservation of the KstR transcription factor is mirrored in the conservation of KstR binding sites across numerous promoters.", [["KstR2", "GENE_OR_GENE_PRODUCT", 0, 5], ["KstR", "GENE_OR_GENE_PRODUCT", 100, 104], ["lipid", "SIMPLE_CHEMICAL", 130, 135], ["KstR", "GENE_OR_GENE_PRODUCT", 240, 244], ["KstR", "GENE_OR_GENE_PRODUCT", 301, 305], ["KstR2", "PROTEIN", 0, 5], ["KstR", "PROTEIN", 100, 104], ["lipid metabolism genes", "DNA", 130, 152], ["KstR", "PROTEIN", 171, 175], ["KstR transcription factor", "PROTEIN", 240, 265], ["KstR binding sites", "DNA", 301, 319], ["promoters", "DNA", 336, 345], ["the KstR transcription factor", "TREATMENT", 236, 265], ["KstR binding sites", "TREATMENT", 301, 319], ["lipid metabolism genes", "OBSERVATION", 130, 152]]], ["KstR binding sites are known to be highly conserved across the Mycobacteria, out to Rhodococcus and Nocardia [36].", [["KstR", "GENE_OR_GENE_PRODUCT", 0, 4], ["KstR binding sites", "DNA", 0, 18], ["KstR binding sites", "PROBLEM", 0, 18], ["the Mycobacteria", "TEST", 59, 75], ["Rhodococcus", "PROBLEM", 84, 95], ["Nocardia", "PROBLEM", 100, 108], ["Mycobacteria", "OBSERVATION", 63, 75]]], ["These sites are conserved in both sequence and position within their respective promoters.", [["promoters", "DNA", 80, 89]]], ["In our analysis, both in searches using known transcription factor binding motifs, as well as in our de novo motif searches, a subset of KstR binding sites are the most conserved transcription factor motifs observed.", [["KstR", "GENE_OR_GENE_PRODUCT", 137, 141], ["transcription factor binding motifs", "DNA", 46, 81], ["KstR binding sites", "DNA", 137, 155], ["transcription factor motifs", "DNA", 179, 206], ["our analysis", "TEST", 3, 15], ["KstR binding sites", "PROBLEM", 137, 155]]], ["They are also among the most conserved of any noncoding sequence we identified.", [["noncoding sequence", "DNA", 46, 64]]], ["The conservation of the KstR gene and binding sites, the emergence of KstR at the ancestor of Rhodococcus and the Mycobacteria, and the loss of KstR paralogs within the pathogenic Mycobacteria, suggests that this transcription factor and its evolving regulon have played an important role in the expansion of lipid metabolism and its adaptation to pathogenicity in Mtb.Positive selection of DNA repair genes ::: Results and discussionMtb, as well as non-tuberculous Mycobacteria, differ from other bacteria in several key respects of DNA repair [39-42].", [["KstR", "GENE_OR_GENE_PRODUCT", 24, 28], ["KstR", "GENE_OR_GENE_PRODUCT", 70, 74], ["KstR", "GENE_OR_GENE_PRODUCT", 144, 148], ["lipid", "SIMPLE_CHEMICAL", 309, 314], ["Mtb", "GENE_OR_GENE_PRODUCT", 365, 368], ["DNA", "CELLULAR_COMPONENT", 391, 394], ["DNA", "CELLULAR_COMPONENT", 534, 537], ["KstR gene", "DNA", 24, 33], ["binding sites", "DNA", 38, 51], ["KstR", "PROTEIN", 70, 74], ["KstR paralogs", "PROTEIN", 144, 157], ["transcription factor", "PROTEIN", 213, 233], ["DNA repair genes", "DNA", 391, 407], ["the KstR gene", "TREATMENT", 20, 33], ["binding sites", "PROBLEM", 38, 51], ["KstR", "TREATMENT", 70, 74], ["Rhodococcus", "PROBLEM", 94, 105], ["the Mycobacteria", "TEST", 110, 126], ["the loss of KstR paralogs", "PROBLEM", 132, 157], ["the pathogenic Mycobacteria", "PROBLEM", 165, 192], ["this transcription factor", "PROBLEM", 208, 233], ["lipid metabolism", "PROBLEM", 309, 325], ["DNA repair", "TREATMENT", 391, 401], ["Mtb", "TEST", 434, 437], ["non-tuberculous Mycobacteria", "PROBLEM", 450, 478], ["other bacteria", "PROBLEM", 492, 506], ["DNA repair", "TREATMENT", 534, 544], ["Mycobacteria", "OBSERVATION", 114, 126], ["pathogenic Mycobacteria", "OBSERVATION", 169, 192], ["lipid metabolism", "OBSERVATION", 309, 325], ["DNA repair", "OBSERVATION", 391, 401], ["non-tuberculous Mycobacteria", "OBSERVATION", 450, 478], ["DNA repair", "OBSERVATION", 534, 544]]], ["Within the host, Mtb must combat damage to its DNA from macrophage-generated reactive oxygen and nitrogen intermediates.", [["macrophage", "ANATOMY", 56, 66], ["oxygen", "CHEMICAL", 86, 92], ["nitrogen", "CHEMICAL", 97, 105], ["oxygen", "CHEMICAL", 86, 92], ["nitrogen", "CHEMICAL", 97, 105], ["Mtb", "GENE_OR_GENE_PRODUCT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["macrophage", "CELL", 56, 66], ["reactive", "SIMPLE_CHEMICAL", 77, 85], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["nitrogen intermediates", "SIMPLE_CHEMICAL", 97, 119], ["Mtb", "PROBLEM", 17, 20], ["reactive oxygen", "TREATMENT", 77, 92], ["nitrogen intermediates", "TREATMENT", 97, 119], ["Mtb", "OBSERVATION", 17, 20], ["reactive oxygen", "OBSERVATION", 77, 92]]], ["Although genes implicated in DNA repair have not expanded in the Mtb lineage, we note that the set of genes showing positive selection on the Mtb lineage in our dN/dS analysis is enriched for genes involved in the COG category for DNA replication, recombination, and repair (Additional file 1: Table S2).", [["DNA", "CELLULAR_COMPONENT", 29, 32], ["DNA", "CELLULAR_COMPONENT", 231, 234], ["Mtb lineage", "CELL_TYPE", 65, 76], ["Mtb lineage", "CELL_TYPE", 142, 153], ["DNA repair", "TREATMENT", 29, 39], ["positive selection", "PROBLEM", 116, 134], ["dS analysis", "TEST", 164, 175], ["DNA replication", "TREATMENT", 231, 246], ["repair", "TREATMENT", 267, 273], ["DNA repair", "OBSERVATION", 29, 39], ["positive selection", "OBSERVATION", 116, 134]]], ["Several of the genes in this set with highest dN/dS values are known DNA repair genes (including recA, recB, and dnaE2), and several additional genes are helicases (dnaB, helZ, and gyrB).Positive selection of DNA repair genes ::: Results and discussionInterestingly, we observe that recA has the highest dN/dS score of all the genes in Mtb on the branch leading to the Mtb complex, and recB also has a very high score.", [["DNA", "CELLULAR_COMPONENT", 69, 72], ["recA", "GENE_OR_GENE_PRODUCT", 97, 101], ["recB", "GENE_OR_GENE_PRODUCT", 103, 107], ["dnaE2", "GENE_OR_GENE_PRODUCT", 113, 118], ["dnaB", "GENE_OR_GENE_PRODUCT", 165, 169], ["helZ", "GENE_OR_GENE_PRODUCT", 171, 175], ["gyrB", "GENE_OR_GENE_PRODUCT", 181, 185], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["recA", "GENE_OR_GENE_PRODUCT", 283, 287], ["Mtb", "GENE_OR_GENE_PRODUCT", 336, 339], ["Mtb", "GENE_OR_GENE_PRODUCT", 369, 372], ["recB", "GENE_OR_GENE_PRODUCT", 386, 390], ["dN", "DNA", 46, 48], ["DNA repair genes", "DNA", 69, 85], ["recA", "DNA", 97, 101], ["recB", "DNA", 103, 107], ["dnaE2", "DNA", 113, 118], ["helicases", "DNA", 154, 163], ["dnaB", "DNA", 165, 169], ["helZ", "DNA", 171, 175], ["gyrB", "DNA", 181, 185], ["DNA repair genes", "DNA", 209, 225], ["recA", "DNA", 283, 287], ["Mtb", "PROTEIN", 336, 339], ["Mtb complex", "PROTEIN", 369, 380], ["recB", "PROTEIN", 386, 390], ["dS values", "PROBLEM", 49, 58], ["DNA repair genes", "TREATMENT", 69, 85], ["recA, recB", "TREATMENT", 97, 107], ["DNA repair", "TREATMENT", 209, 219], ["DNA repair", "OBSERVATION", 209, 219], ["Mtb", "OBSERVATION", 336, 339], ["branch", "ANATOMY_MODIFIER", 347, 353], ["Mtb", "OBSERVATION", 369, 372]]], ["Mycobacteria lack a mutSL-based mismatch repair (MMR) system [42], and it is believed that recA may be involved in compensating pathways. dnaE2 (DNA polymerase III) also has one of the highest dN/dS values on the branch leading to Mtb, and both dnaE1 (DNA polymerase III) and dnaE2 show evidence of selection on the branch leading to the pathogenic Mycobacteria.", [["Mycobacteria", "DISEASE", 349, 361], ["recA", "GENE_OR_GENE_PRODUCT", 91, 95], ["dnaE2", "GENE_OR_GENE_PRODUCT", 138, 143], ["DNA polymerase III", "GENE_OR_GENE_PRODUCT", 145, 163], ["Mtb", "GENE_OR_GENE_PRODUCT", 231, 234], ["dnaE1", "GENE_OR_GENE_PRODUCT", 245, 250], ["DNA polymerase III", "GENE_OR_GENE_PRODUCT", 252, 270], ["dnaE2", "GENE_OR_GENE_PRODUCT", 276, 281], ["mutSL", "PROTEIN", 20, 25], ["recA", "DNA", 91, 95], ["dnaE2", "PROTEIN", 138, 143], ["DNA polymerase III", "PROTEIN", 145, 163], ["Mtb", "PROTEIN", 231, 234], ["dnaE1", "PROTEIN", 245, 250], ["DNA polymerase III", "PROTEIN", 252, 270], ["dnaE2", "PROTEIN", 276, 281], ["Mycobacteria", "PROBLEM", 0, 12], ["a mutSL-based mismatch repair", "TREATMENT", 18, 47], ["dS values", "PROBLEM", 196, 205], ["Mtb", "PROBLEM", 231, 234], ["selection on the branch", "PROBLEM", 299, 322], ["the pathogenic Mycobacteria", "PROBLEM", 334, 361], ["mismatch repair", "OBSERVATION", 32, 47], ["branch", "ANATOMY_MODIFIER", 213, 219], ["Mtb", "OBSERVATION", 231, 234], ["evidence of", "UNCERTAINTY", 287, 298], ["selection", "OBSERVATION", 299, 308], ["branch", "ANATOMY_MODIFIER", 316, 322], ["pathogenic", "OBSERVATION_MODIFIER", 338, 348], ["Mycobacteria", "OBSERVATION", 349, 361]]], ["In Mtb, damage-induced base-substitution mutagenesis is dependent on dnaE2.", [["dnaE2", "GENE_OR_GENE_PRODUCT", 69, 74], ["dnaE2", "PROTEIN", 69, 74], ["damage", "PROBLEM", 8, 14], ["base-substitution mutagenesis", "TREATMENT", 23, 52], ["dependent on dnaE2", "PROBLEM", 56, 74], ["Mtb", "OBSERVATION", 3, 6], ["base", "ANATOMY_MODIFIER", 23, 27], ["substitution mutagenesis", "OBSERVATION", 28, 52], ["dependent", "OBSERVATION_MODIFIER", 56, 65]]], ["Loss of dnaE2 activity renders Mtb hypersensitive to DNA damage, eliminates induced mutagenesis, attenuates virulence, and reduces the frequency of drug resistance in vivo [39,45]. dnaE1 provides essential, high-fidelity replicative polymerase function [39], and is expressed in response to DNA damage, along with dnaE2 and recA [39,45].Positive selection of DNA repair genes ::: Results and discussionWe also observe positive selection for dinX (DNA polymerase IV) on the branch leading to the pathogenic Mycobacteria (branch-site model) in our dN/dS analysis (see Supplementary Information website).", [["dnaE1", "CHEMICAL", 181, 186], ["dnaE2", "GENE_OR_GENE_PRODUCT", 8, 13], ["Mtb", "GENE_OR_GENE_PRODUCT", 31, 34], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["dnaE1", "GENE_OR_GENE_PRODUCT", 181, 186], ["DNA", "CELLULAR_COMPONENT", 291, 294], ["dnaE2", "GENE_OR_GENE_PRODUCT", 314, 319], ["recA", "GENE_OR_GENE_PRODUCT", 324, 328], ["DNA", "CELLULAR_COMPONENT", 359, 362], ["dinX", "GENE_OR_GENE_PRODUCT", 441, 445], ["DNA polymerase IV", "GENE_OR_GENE_PRODUCT", 447, 464], ["dnaE2", "PROTEIN", 8, 13], ["dnaE1", "PROTEIN", 181, 186], ["dnaE2", "PROTEIN", 314, 319], ["recA", "DNA", 324, 328], ["DNA repair genes", "DNA", 359, 375], ["dinX", "PROTEIN", 441, 445], ["DNA polymerase IV", "PROTEIN", 447, 464], ["Loss of dnaE2 activity", "PROBLEM", 0, 22], ["Mtb", "PROBLEM", 31, 34], ["DNA damage", "PROBLEM", 53, 63], ["induced mutagenesis", "PROBLEM", 76, 95], ["attenuates virulence", "PROBLEM", 97, 117], ["DNA damage", "PROBLEM", 291, 301], ["DNA repair", "TREATMENT", 359, 369], ["dinX (DNA polymerase IV", "TREATMENT", 441, 464], ["the pathogenic Mycobacteria", "PROBLEM", 491, 518], ["dS analysis", "TEST", 549, 560], ["DNA repair", "OBSERVATION", 359, 369], ["pathogenic", "OBSERVATION_MODIFIER", 495, 505], ["Mycobacteria", "OBSERVATION", 506, 518]]], ["Most organisms use specialized DNA polymerases that are able to catalyze translesion synthesis (TLS) across sites of damage, including the dinB group of Y family polymerases.", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["Y family polymerases", "GENE_OR_GENE_PRODUCT", 153, 173], ["DNA polymerases", "PROTEIN", 31, 46], ["dinB group", "PROTEIN", 139, 149], ["Y family polymerases", "PROTEIN", 153, 173], ["specialized DNA polymerases", "TREATMENT", 19, 46], ["damage", "PROBLEM", 117, 123], ["damage", "OBSERVATION", 117, 123]]], ["There are two dinB-family polymerases in Mtb (dinX and dinP).", [["dinB", "GENE_OR_GENE_PRODUCT", 14, 18], ["Mtb", "GENE_OR_GENE_PRODUCT", 41, 44], ["dinX", "GENE_OR_GENE_PRODUCT", 46, 50], ["dinP", "GENE_OR_GENE_PRODUCT", 55, 59], ["dinB-family polymerases", "PROTEIN", 14, 37], ["Mtb", "PROTEIN", 41, 44], ["dinX", "PROTEIN", 46, 50], ["dinP", "PROTEIN", 55, 59]]], ["Unlike in other bacteria, dinX and dinP expression are not dependent on recA, the SOS response, or the presence of DNA damage, and could therefore serve a novel yet uncharacterized role in Mtb [46-49].Expansion of pterin cofactors ::: Results and discussionGenes involved in the first steps of pterin cofactor (a component of the molybdenum cofactor) biosynthesis are known to be expanded in the Mtb complex [50].", [["pterin", "CHEMICAL", 214, 220], ["pterin", "CHEMICAL", 294, 300], ["molybdenum", "CHEMICAL", 330, 340], ["pterin", "CHEMICAL", 214, 220], ["pterin", "CHEMICAL", 294, 300], ["molybdenum", "CHEMICAL", 330, 340], ["dinX", "GENE_OR_GENE_PRODUCT", 26, 30], ["dinP", "GENE_OR_GENE_PRODUCT", 35, 39], ["recA", "GENE_OR_GENE_PRODUCT", 72, 76], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["pterin", "SIMPLE_CHEMICAL", 214, 220], ["pterin cofactor", "GENE_OR_GENE_PRODUCT", 294, 309], ["molybdenum", "SIMPLE_CHEMICAL", 330, 340], ["dinX", "PROTEIN", 26, 30], ["dinP", "PROTEIN", 35, 39], ["recA", "DNA", 72, 76], ["pterin cofactors", "PROTEIN", 214, 230], ["pterin cofactor", "PROTEIN", 294, 309], ["molybdenum cofactor", "PROTEIN", 330, 349], ["Mtb complex", "PROTEIN", 396, 407], ["other bacteria", "PROBLEM", 10, 24], ["dinP expression", "PROBLEM", 35, 50], ["DNA damage", "PROBLEM", 115, 125], ["pterin cofactor", "PROBLEM", 294, 309], ["the molybdenum cofactor", "TREATMENT", 326, 349], ["bacteria", "OBSERVATION", 16, 24], ["pterin cofactors", "OBSERVATION", 214, 230]]], ["Molybdenum cofactor-requiring enzymes (such as xanthine oxidase and aldehyde oxidase) could have physiological functions in the metabolism of reactive oxygen species during stress response [51].", [["Molybdenum", "CHEMICAL", 0, 10], ["xanthine", "CHEMICAL", 47, 55], ["aldehyde", "CHEMICAL", 68, 76], ["oxygen", "CHEMICAL", 151, 157], ["Molybdenum", "CHEMICAL", 0, 10], ["xanthine", "CHEMICAL", 47, 55], ["aldehyde", "CHEMICAL", 68, 76], ["oxygen", "CHEMICAL", 151, 157], ["Molybdenum", "SIMPLE_CHEMICAL", 0, 10], ["xanthine oxidase", "GENE_OR_GENE_PRODUCT", 47, 63], ["aldehyde oxidase", "GENE_OR_GENE_PRODUCT", 68, 84], ["reactive oxygen species", "SIMPLE_CHEMICAL", 142, 165], ["Molybdenum cofactor-requiring enzymes", "PROTEIN", 0, 37], ["xanthine oxidase", "PROTEIN", 47, 63], ["aldehyde oxidase", "PROTEIN", 68, 84], ["Molybdenum cofactor", "PROBLEM", 0, 19], ["enzymes", "TREATMENT", 30, 37], ["xanthine oxidase", "TREATMENT", 47, 63], ["aldehyde oxidase", "TREATMENT", 68, 84], ["physiological functions", "PROBLEM", 97, 120], ["reactive oxygen species", "PROBLEM", 142, 165], ["cofactor", "OBSERVATION", 11, 19], ["reactive", "OBSERVATION_MODIFIER", 142, 150], ["oxygen species", "OBSERVATION", 151, 165]]], ["Molybdenum cofactor is an efficient catalyst in oxygen-transfer reactions, can be used in anaerobic respiration, and can catalyze redox reactions in carbon, nitrogen, and sulfur metabolism.", [["Molybdenum", "CHEMICAL", 0, 10], ["oxygen", "CHEMICAL", 48, 54], ["carbon, nitrogen", "CHEMICAL", 149, 165], ["sulfur", "CHEMICAL", 171, 177], ["Molybdenum", "CHEMICAL", 0, 10], ["oxygen", "CHEMICAL", 48, 54], ["carbon", "CHEMICAL", 149, 155], ["nitrogen", "CHEMICAL", 157, 165], ["sulfur", "CHEMICAL", 171, 177], ["Molybdenum", "SIMPLE_CHEMICAL", 0, 10], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["carbon", "SIMPLE_CHEMICAL", 149, 155], ["nitrogen", "SIMPLE_CHEMICAL", 157, 165], ["sulfur", "SIMPLE_CHEMICAL", 171, 177], ["Molybdenum cofactor", "PROBLEM", 0, 19], ["anaerobic respiration", "TEST", 90, 111], ["carbon, nitrogen", "TREATMENT", 149, 165], ["cofactor", "OBSERVATION", 11, 19], ["efficient", "OBSERVATION_MODIFIER", 26, 35], ["catalyst", "OBSERVATION_MODIFIER", 36, 44]]], ["Recently, genes related to molybdenum cofactor protein synthesis have been shown to be upregulated under conditions of stress in Mtb [52].", [["molybdenum", "CHEMICAL", 27, 37], ["molybdenum", "CHEMICAL", 27, 37], ["molybdenum cofactor", "GENE_OR_GENE_PRODUCT", 27, 46], ["molybdenum cofactor", "PROTEIN", 27, 46], ["molybdenum cofactor protein synthesis", "PROBLEM", 27, 64]]], ["Molybdenum cofactor biosynthesis has been previously linked to pathogenesis.", [["Molybdenum", "CHEMICAL", 0, 10], ["Molybdenum", "CHEMICAL", 0, 10], ["Molybdenum", "SIMPLE_CHEMICAL", 0, 10], ["Molybdenum cofactor biosynthesis", "PROBLEM", 0, 32], ["pathogenesis", "PROBLEM", 63, 75], ["cofactor biosynthesis", "OBSERVATION", 11, 32]]], ["The regulator of the moa1 locus, MoaR1, was identified as having a SNP in M. bovis BCG, but not in virulent M. bovis or Mtb [53].", [["SNP", "CHEMICAL", 67, 70], ["moa1", "GENE_OR_GENE_PRODUCT", 21, 25], ["MoaR1", "GENE_OR_GENE_PRODUCT", 33, 38], ["M. bovis BCG", "ORGANISM", 74, 86], ["M. bovis", "ORGANISM", 108, 116], ["Mtb [53", "ORGANISM", 120, 127], ["moa1 locus", "DNA", 21, 31], ["MoaR1", "DNA", 33, 38], ["M. bovis BCG", "SPECIES", 74, 86], ["M. bovis", "SPECIES", 108, 116], ["M. bovis", "SPECIES", 74, 82], ["M. bovis", "SPECIES", 108, 116], ["a SNP in M. bovis BCG", "TREATMENT", 65, 86], ["bovis BCG", "OBSERVATION", 77, 86]]], ["In addition, moa3 is present with varying frequency in the RD1 region, which is absent in M. bovis BCG, of pathogenic strains [54].Expansion of pterin cofactors ::: Results and discussionIn agreement with previous observations of expansions of molybdopterin biosynthesis genes, we observe five protein domains related to pterin cofactor biosynthesis among the top protein domains expanded in the Mtb complex compared to the non-pathogenic Mycobacteria (Table 2, -\"d\").", [["pterin", "CHEMICAL", 144, 150], ["molybdopterin", "CHEMICAL", 244, 257], ["pterin", "CHEMICAL", 321, 327], ["pterin", "CHEMICAL", 144, 150], ["molybdopterin", "CHEMICAL", 244, 257], ["pterin", "CHEMICAL", 321, 327], ["moa3", "GENE_OR_GENE_PRODUCT", 13, 17], ["RD1", "GENE_OR_GENE_PRODUCT", 59, 62], ["M. bovis BCG", "ORGANISM", 90, 102], ["pterin", "SIMPLE_CHEMICAL", 144, 150], ["molybdopterin", "GENE_OR_GENE_PRODUCT", 244, 257], ["pterin", "SIMPLE_CHEMICAL", 321, 327], ["Mtb", "GENE_OR_GENE_PRODUCT", 396, 399], ["moa3", "PROTEIN", 13, 17], ["RD1 region", "DNA", 59, 69], ["pterin cofactors", "PROTEIN", 144, 160], ["molybdopterin biosynthesis genes", "DNA", 244, 276], ["protein domains", "PROTEIN", 294, 309], ["pterin cofactor", "PROTEIN", 321, 336], ["top protein domains", "PROTEIN", 360, 379], ["Mtb complex", "PROTEIN", 396, 407], ["M. bovis", "SPECIES", 90, 98], ["M. bovis", "SPECIES", 90, 98], ["varying frequency in the RD1 region", "PROBLEM", 34, 69], ["pathogenic strains", "PROBLEM", 107, 125], ["molybdopterin biosynthesis genes", "PROBLEM", 244, 276], ["five protein domains", "PROBLEM", 289, 309], ["pterin cofactor biosynthesis", "TREATMENT", 321, 349], ["the top protein domains", "PROBLEM", 356, 379], ["the Mtb complex", "PROBLEM", 392, 407], ["the non-pathogenic Mycobacteria", "TEST", 420, 451], ["varying", "OBSERVATION_MODIFIER", 34, 41], ["frequency", "OBSERVATION_MODIFIER", 42, 51], ["RD1", "ANATOMY", 59, 62], ["region", "ANATOMY_MODIFIER", 63, 69], ["pterin cofactors", "OBSERVATION", 144, 160], ["cofactor biosynthesis", "OBSERVATION", 328, 349], ["Mycobacteria", "OBSERVATION", 439, 451]]], ["Among the top GO terms expanded in the Mtb clade relative to the soil dwellers (Table 3), there are also several groups involved in pterin and molybdopterin biosynthesis.", [["pterin", "CHEMICAL", 132, 138], ["molybdopterin", "CHEMICAL", 143, 156], ["pterin", "CHEMICAL", 132, 138], ["molybdopterin", "CHEMICAL", 143, 156], ["pterin", "SIMPLE_CHEMICAL", 132, 138], ["molybdopterin", "SIMPLE_CHEMICAL", 143, 156], ["pterin and molybdopterin biosynthesis", "TREATMENT", 132, 169], ["Mtb clade", "OBSERVATION", 39, 48], ["molybdopterin biosynthesis", "OBSERVATION", 143, 169]]], ["Some of these gene copies (the moa1 locus) are believed to have been acquired by lateral gene transfer on the branch leading to the Mtb complex [10,50].Expansion of pterin cofactors ::: Results and discussionWe also observe evidence for selection on molybdenum-related genes in our dN/dS data.", [["pterin", "CHEMICAL", 165, 171], ["molybdenum", "CHEMICAL", 250, 260], ["pterin", "CHEMICAL", 165, 171], ["molybdenum", "CHEMICAL", 250, 260], ["moa1", "GENE_OR_GENE_PRODUCT", 31, 35], ["Mtb", "GENE_OR_GENE_PRODUCT", 132, 135], ["pterin", "SIMPLE_CHEMICAL", 165, 171], ["molybdenum", "SIMPLE_CHEMICAL", 250, 260], ["moa1 locus", "DNA", 31, 41], ["Mtb complex", "PROTEIN", 132, 143], ["pterin cofactors", "PROTEIN", 165, 181], ["molybdenum-related genes", "DNA", 250, 274], ["selection on molybdenum", "PROBLEM", 237, 260], ["pterin cofactors", "OBSERVATION", 165, 181]]], ["On the branch leading to the pathogenic Mycobacteria, several orthogroups with high log likelihood scores when testing for selection are related to molybdenum (see Supplementary Information website).", [["molybdenum", "CHEMICAL", 148, 158], ["molybdenum", "CHEMICAL", 148, 158], ["molybdenum", "SIMPLE_CHEMICAL", 148, 158], ["the pathogenic Mycobacteria", "PROBLEM", 25, 52], ["testing", "TEST", 111, 118], ["branch", "ANATOMY_MODIFIER", 7, 13], ["pathogenic", "OBSERVATION_MODIFIER", 29, 39], ["Mycobacteria", "OBSERVATION", 40, 52]]], ["The orthogroup containing BisC (biotin sulfoxide reductase, a molybdoenzyme), as well as the orthogroup containing ModA (an ABC-family molybdate transporter), are among those with the highest dN/dS values on the branch leading to the pathogens.", [["BisC", "CHEMICAL", 26, 30], ["biotin sulfoxide", "CHEMICAL", 32, 48], ["molybdate", "CHEMICAL", 135, 144], ["BisC", "CHEMICAL", 26, 30], ["biotin sulfoxide", "CHEMICAL", 32, 48], ["molybdate", "CHEMICAL", 135, 144], ["BisC", "SIMPLE_CHEMICAL", 26, 30], ["biotin sulfoxide reductase", "GENE_OR_GENE_PRODUCT", 32, 58], ["molybdoenzyme", "SIMPLE_CHEMICAL", 62, 75], ["ModA", "GENE_OR_GENE_PRODUCT", 115, 119], ["ABC", "GENE_OR_GENE_PRODUCT", 124, 127], ["BisC", "PROTEIN", 26, 30], ["biotin sulfoxide reductase", "PROTEIN", 32, 58], ["molybdoenzyme", "PROTEIN", 62, 75], ["orthogroup", "PROTEIN", 93, 103], ["ModA", "PROTEIN", 115, 119], ["ABC-family molybdate transporter", "PROTEIN", 124, 156], ["The orthogroup", "TREATMENT", 0, 14], ["BisC (biotin sulfoxide reductase", "TREATMENT", 26, 58], ["a molybdoenzyme)", "TREATMENT", 60, 76], ["the pathogens", "PROBLEM", 230, 243], ["pathogens", "OBSERVATION", 234, 243]]], ["MoaB2 is one of the highest-scoring genes on all three branches tested.Expansions of genes of unknown function in Mtb clade ::: Results and discussionThere are also many categories of unknown function that are greatly expanded in the Mtb clade relative to the non-pathogenic Mycobacteria (Tables 2 and 3, red).", [["MoaB2", "GENE_OR_GENE_PRODUCT", 0, 5], ["MoaB2", "DNA", 0, 5], ["the Mtb clade", "PROBLEM", 230, 243], ["the non-pathogenic Mycobacteria", "PROBLEM", 256, 287], ["branches", "ANATOMY_MODIFIER", 55, 63], ["greatly", "OBSERVATION_MODIFIER", 210, 217], ["expanded", "OBSERVATION_MODIFIER", 218, 226], ["Mtb clade", "OBSERVATION", 234, 243], ["non-pathogenic", "OBSERVATION_MODIFIER", 260, 274], ["Mycobacteria", "OBSERVATION", 275, 287]]], ["For example, Rv0918 (in the Pfam group of unknown function PF08681) was found in a genetic screen that facilitates isolation of mutants defective in arresting the maturation of phagosomes [55], helping Mtb to survive within host cells.", [["phagosomes", "ANATOMY", 177, 187], ["cells", "ANATOMY", 229, 234], ["Rv0918", "CHEMICAL", 13, 19], ["Rv0918", "GENE_OR_GENE_PRODUCT", 13, 19], ["phagosomes", "CELLULAR_COMPONENT", 177, 187], ["Mtb", "GENE_OR_GENE_PRODUCT", 202, 205], ["host cells", "CELL", 224, 234], ["Rv0918", "PROTEIN", 13, 19], ["Pfam group", "PROTEIN", 28, 38], ["host cells", "CELL_TYPE", 224, 234], ["a genetic screen", "TEST", 81, 97], ["mutants defective", "PROBLEM", 128, 145]]], ["PF07161 contains four lipoproteins (LprF, LprG, LprA, LppX).", [["PF07161", "CHEMICAL", 0, 7], ["PF07161", "SIMPLE_CHEMICAL", 0, 7], ["LprF", "GENE_OR_GENE_PRODUCT", 36, 40], ["LprG", "GENE_OR_GENE_PRODUCT", 42, 46], ["LprA", "GENE_OR_GENE_PRODUCT", 48, 52], ["LppX", "GENE_OR_GENE_PRODUCT", 54, 58], ["lipoproteins", "PROTEIN", 22, 34], ["LprF", "PROTEIN", 36, 40], ["LprG", "PROTEIN", 42, 46], ["LprA", "PROTEIN", 48, 52], ["LppX", "PROTEIN", 54, 58], ["four lipoproteins", "TREATMENT", 17, 34], ["LprF", "TREATMENT", 36, 40], ["LprG", "TREATMENT", 42, 46], ["LprA", "TREATMENT", 48, 52], ["four", "OBSERVATION_MODIFIER", 17, 21], ["lipoproteins", "OBSERVATION_MODIFIER", 22, 34]]], ["LprG and LppX were found to be in vivo essential genes by TraSH analysis [56].Detection of conserved noncoding sequences ::: Results and discussionSequence conservation - or phylogenetic footprinting - provides a powerful approach for identifying potential functional noncoding sequences, and has been used in a variety of eukaryotic and prokaryotic organisms to identify protein coding genes, noncoding RNAs, and regulatory elements [57,58].", [["LprG", "GENE_OR_GENE_PRODUCT", 0, 4], ["LppX", "GENE_OR_GENE_PRODUCT", 9, 13], ["LprG", "PROTEIN", 0, 4], ["LppX", "PROTEIN", 9, 13], ["conserved noncoding sequences", "DNA", 91, 120], ["noncoding sequences", "DNA", 268, 287], ["protein coding genes", "DNA", 372, 392], ["noncoding RNAs", "RNA", 394, 408], ["regulatory elements", "DNA", 414, 433], ["LppX", "TREATMENT", 9, 13], ["TraSH analysis", "TEST", 58, 72], ["Sequence conservation", "TEST", 147, 168], ["phylogenetic footprinting", "PROBLEM", 174, 199], ["prokaryotic organisms", "TREATMENT", 338, 359], ["protein coding genes", "PROBLEM", 372, 392], ["noncoding RNAs", "PROBLEM", 394, 408]]], ["For optimal power, the organisms being analyzed must be sufficiently distant such that non-functional elements have diverged, but not so distant such that functional elements have evolved or re-arranged.", [["non-functional elements", "DNA", 87, 110], ["the organisms", "PROBLEM", 19, 32]]], ["Organisms within the Mtb complex are all highly similar at the sequence level, and thus by themselves do not allow for effective phylogenetic footprinting.", [["Mtb", "GENE_OR_GENE_PRODUCT", 21, 24], ["Mtb complex", "PROTEIN", 21, 32], ["Organisms within the Mtb complex", "PROBLEM", 0, 32], ["effective phylogenetic footprinting", "PROBLEM", 119, 154], ["Mtb complex", "OBSERVATION", 21, 32], ["footprinting", "OBSERVATION", 142, 154]]], ["By leveraging the evolutionary similarity of the most distantly related Mycobacteria and Actinomycetes, we gained additional power to allow us to detect functional sequences under purifying selection, albeit only those shared by at least a majority of Mycobacteria.", [["Mycobacteria", "DISEASE", 252, 264], ["Mycobacteria and Actinomycetes", "PROBLEM", 72, 102], ["purifying selection", "TREATMENT", 180, 199], ["Mycobacteria", "PROBLEM", 252, 264], ["Mycobacteria", "OBSERVATION", 72, 84], ["Mycobacteria", "OBSERVATION", 252, 264]]], ["We used this approach to predict two classes of conserved noncoding sequences: small noncoding RNAs and transcription factor binding motifs.Novel putative conserved small noncoding RNAs in Mycobacteria ::: Results and discussionSmall noncoding RNAs (sRNAs) have been shown to play a role in regulating gene expression in numerous bacterial species [59], including Streptococcus [60,61].", [["conserved noncoding sequences", "DNA", 48, 77], ["small noncoding RNAs", "RNA", 79, 99], ["transcription factor binding motifs", "DNA", 104, 139], ["small noncoding RNAs", "RNA", 165, 185], ["Small noncoding RNAs", "RNA", 228, 248], ["sRNAs", "DNA", 250, 255], ["this approach", "TREATMENT", 8, 21], ["small noncoding RNAs", "PROBLEM", 79, 99], ["Small noncoding RNAs (sRNAs", "PROBLEM", 228, 255], ["numerous bacterial species", "PROBLEM", 321, 347], ["Streptococcus", "PROBLEM", 364, 377], ["small", "OBSERVATION_MODIFIER", 79, 84], ["noncoding RNAs", "OBSERVATION", 85, 99], ["small", "OBSERVATION_MODIFIER", 165, 170], ["noncoding RNAs", "OBSERVATION", 171, 185]]], ["Yet only recently were sRNAs reported in Mycobacteria [60,62].", [["Mycobacteria", "TEST", 41, 53], ["Mycobacteria", "OBSERVATION", 41, 53]]], ["Using a combination of direct isolation of small RNAs, and validation by Northern blotting and 5' and 3' RACE transcript mapping, Arnvig and Young [62] first described nine sRNAs in Mtb.", [["Mtb", "GENE_OR_GENE_PRODUCT", 182, 185], ["small RNAs", "RNA", 43, 53], ["sRNAs", "DNA", 173, 178], ["direct isolation of small RNAs", "TREATMENT", 23, 53], ["3' RACE transcript mapping", "TREATMENT", 102, 128], ["small RNAs", "OBSERVATION", 43, 53]]], ["Subsequently, DiChiara et al. [63] describe 34 small RNAs in M. bovis BCG, of which many were conserved in both Mtb and M. smegmatis.Novel putative conserved small noncoding RNAs in Mycobacteria ::: Results and discussionTo build on these results, we used a combination of comparative genomics, RNA-seq, and experimental validation by Northern blotting to identify additional sRNAs conserved among the Mycobacteria (Methods).", [["M. bovis BCG", "ORGANISM", 61, 73], ["Mtb", "GENE_OR_GENE_PRODUCT", 112, 115], ["M. smegmatis", "ORGANISM", 120, 132], ["small noncoding RNAs", "RNA", 158, 178], ["sRNAs", "DNA", 376, 381], ["M. bovis", "SPECIES", 61, 69], ["BCG", "SPECIES", 70, 73], ["M. smegmatis", "SPECIES", 120, 132], ["M. bovis", "SPECIES", 61, 69], ["M. smegmatis", "SPECIES", 120, 132], ["small RNAs", "PROBLEM", 47, 57], ["M. bovis BCG", "TEST", 61, 73], ["experimental validation", "TEST", 308, 331], ["additional sRNAs", "PROBLEM", 365, 381], ["Mtb", "OBSERVATION", 112, 115], ["M. smegmatis", "OBSERVATION", 120, 132], ["small", "OBSERVATION_MODIFIER", 158, 163], ["noncoding RNAs", "OBSERVATION", 164, 178], ["Mycobacteria", "OBSERVATION", 402, 414]]], ["Our computational results provide evidence for 50 conserved small RNAs in Mtb that have not been previously reported.", [["Mtb", "GENE_OR_GENE_PRODUCT", 74, 77], ["50 conserved small RNAs", "RNA", 47, 70], ["Mtb", "PROTEIN", 74, 77], ["small RNAs in Mtb", "PROBLEM", 60, 77], ["small", "OBSERVATION_MODIFIER", 60, 65], ["RNAs", "OBSERVATION", 66, 70]]], ["It is likely that additional conserved regions are expressed under other diverse conditions.", [["is likely", "UNCERTAINTY", 3, 12]]], ["Figure 5a shows the expression and conservation map for one of our predicted RNAs in the GenomeView Browser [64].", [["conservation map", "TEST", 35, 51]]], ["Table 6 shows a listing of the top 12 candidate RNAs.", [["top 12 candidate RNAs", "RNA", 31, 52]]], ["To verify a subset of these candidate small RNAs, we used Northern blot analysis on four of the top predicted regions (Methods).", [["candidate small RNAs", "RNA", 28, 48], ["small RNAs", "PROBLEM", 38, 48], ["Northern blot analysis", "TEST", 58, 80], ["small RNAs", "OBSERVATION", 38, 48]]], ["The results (Figure 5b) show signals corresponding to small RNAs from each of four candidates (Table 6, labeled 1, 2, 3, and 9).", [["3", "GENE_OR_GENE_PRODUCT", 118, 119], ["small RNAs", "RNA", 54, 64], ["small RNAs", "PROBLEM", 54, 64], ["small RNAs", "OBSERVATION", 54, 64]]], ["All transcripts were near the expected size, or slightly larger.", [["expected", "OBSERVATION_MODIFIER", 30, 38], ["size", "OBSERVATION_MODIFIER", 39, 43], ["slightly", "OBSERVATION_MODIFIER", 48, 56], ["larger", "OBSERVATION_MODIFIER", 57, 63]]], ["Consistent with previous work, the majority of small RNAs were seen as more than one size transcript [62].", [["small RNAs", "RNA", 47, 57], ["small RNAs", "PROBLEM", 47, 57], ["small RNAs", "OBSERVATION", 47, 57]]], ["This suggests that small RNAs might be generated by processing of larger transcripts.", [["small RNAs", "RNA", 19, 29], ["small RNAs", "PROBLEM", 19, 29], ["small RNAs", "OBSERVATION", 19, 29], ["larger transcripts", "OBSERVATION", 66, 84]]], ["In the RNA-seq data, there are longer \"tails\" extending outside of the main peak that corresponds to the RNA prediction--different length RNAs could be responsible for the additional bands of higher mass.Conserved cis-regulatory motifs in Mycobacteria ::: Results and discussionFew transcription factor binding motifs have been identified in Mtb.", [["Mtb", "GENE_OR_GENE_PRODUCT", 342, 345], ["length RNAs", "RNA", 131, 142], ["Conserved cis-regulatory motifs", "DNA", 204, 235], ["transcription factor binding motifs", "DNA", 282, 317], ["longer \"tails", "PROBLEM", 31, 44], ["the RNA prediction", "PROBLEM", 101, 119], ["different length RNAs", "PROBLEM", 121, 142], ["the additional bands of higher mass", "PROBLEM", 168, 203], ["Few transcription factor binding motifs", "PROBLEM", 278, 317], ["main", "OBSERVATION_MODIFIER", 71, 75], ["peak", "OBSERVATION", 76, 80], ["length", "OBSERVATION_MODIFIER", 131, 137], ["could be responsible for", "UNCERTAINTY", 143, 167], ["bands", "OBSERVATION_MODIFIER", 183, 188], ["higher", "OBSERVATION_MODIFIER", 192, 198], ["mass", "OBSERVATION", 199, 203], ["cis-regulatory motifs", "OBSERVATION", 214, 235], ["Mycobacteria", "OBSERVATION", 239, 251]]], ["Transcription factors for which binding motifs have been identified include KstR [36], DosR [67], IdeR [68], ZurB [69], Crp [70], CsoR [71], FurA [72], MprAB [73], and Acr [74].", [["KstR [36]", "GENE_OR_GENE_PRODUCT", 76, 85], ["DosR [67]", "GENE_OR_GENE_PRODUCT", 87, 96], ["IdeR [68]", "GENE_OR_GENE_PRODUCT", 98, 107], ["ZurB", "GENE_OR_GENE_PRODUCT", 109, 113], ["Crp [70", "GENE_OR_GENE_PRODUCT", 120, 127], ["CsoR", "GENE_OR_GENE_PRODUCT", 130, 134], ["Transcription factors", "PROTEIN", 0, 21], ["KstR", "PROTEIN", 76, 80], ["Transcription factors", "PROBLEM", 0, 21], ["KstR", "TEST", 76, 80], ["ZurB", "TEST", 109, 113], ["Crp", "TEST", 120, 123], ["CsoR", "TEST", 130, 134], ["FurA", "TEST", 141, 145], ["MprAB", "TEST", 152, 157], ["Acr", "TEST", 168, 171]]], ["Because of the limited knowledge of transcriptional regulation in Mtb, we searched for additional motifs computationally.", [["Mtb", "GENE_OR_GENE_PRODUCT", 66, 69], ["Mtb", "PROTEIN", 66, 69]]], ["We combined comparative sequence analysis with microarray data to identify a large number of motifs conserved in Mycobacteria.Conserved cis-regulatory motifs in Mycobacteria ::: Results and discussionWe clustered microarray data contained in the TB database [75] and searched for upstream regulatory motifs shared in the upstream regions of the resulting clusters using AlignACE (Methods).", [["Conserved cis-regulatory motifs", "DNA", 126, 157], ["upstream regulatory motifs", "DNA", 280, 306], ["upstream regions", "DNA", 321, 337], ["AlignACE", "DNA", 370, 378], ["comparative sequence analysis", "TEST", 12, 41], ["microarray data", "TEST", 47, 62], ["a large number of motifs", "PROBLEM", 75, 99], ["Mycobacteria", "PROBLEM", 113, 125], ["microarray data", "TEST", 213, 228], ["upstream regulatory motifs", "PROBLEM", 280, 306], ["AlignACE (Methods", "TREATMENT", 370, 387], ["large", "OBSERVATION_MODIFIER", 77, 82], ["Mycobacteria", "OBSERVATION", 113, 125], ["cis-regulatory motifs", "OBSERVATION", 136, 157], ["Mycobacteria", "OBSERVATION", 161, 173]]], ["Because of significant noise in the results, we used a set of stringent filters, including a requirement that candidate motifs be highly conserved.", [["significant noise", "PROBLEM", 11, 28], ["stringent filters", "TREATMENT", 62, 79], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["noise", "OBSERVATION", 23, 28]]], ["37 motif instances passed our stringent filters (Table 7, Methods).", [["our stringent filters", "TREATMENT", 26, 47]]], ["14 of the top 37 (38%) motif instances correspond to cases of known Mtb motifs (several known Mtb motifs were found more than once, in different clusters, or in clusters with different size parameters).", [["Mtb", "GENE_OR_GENE_PRODUCT", 68, 71], ["Mtb motifs", "PROTEIN", 68, 78], ["Mtb motifs", "PROTEIN", 94, 104], ["motif instances", "TEST", 23, 38], ["known Mtb motifs", "PROBLEM", 62, 78], ["several known Mtb motifs", "PROBLEM", 80, 104], ["size", "OBSERVATION_MODIFIER", 185, 189]]], ["In contrast, none of the top motifs showed similarity only to known E. coli or Corynebacteria motifs.", [["E. coli", "ORGANISM", 68, 75], ["top motifs", "DNA", 25, 35], ["E. coli or Corynebacteria motifs", "DNA", 68, 100], ["E. coli", "SPECIES", 68, 75], ["E. coli", "SPECIES", 68, 75], ["the top motifs", "TEST", 21, 35], ["known E. coli", "PROBLEM", 62, 75], ["Corynebacteria motifs", "PROBLEM", 79, 100], ["E. coli", "OBSERVATION", 68, 75], ["Corynebacteria motifs", "OBSERVATION", 79, 100]]], ["Within these top motifs, we were able to identify four of the nine known Mtb motifs (DosR, IdeR, KstR, and ZurB).Conserved cis-regulatory motifs in Mycobacteria ::: Results and discussionAs described above, the KstR motif shows a much stronger signal, in terms of both conservation and information content, than any of the other motifs (top of the ranked conservation list, Table 7).", [["Mtb", "GENE_OR_GENE_PRODUCT", 73, 76], ["DosR", "GENE_OR_GENE_PRODUCT", 85, 89], ["IdeR", "GENE_OR_GENE_PRODUCT", 91, 95], ["KstR", "GENE_OR_GENE_PRODUCT", 97, 101], ["ZurB", "GENE_OR_GENE_PRODUCT", 107, 111], ["KstR", "GENE_OR_GENE_PRODUCT", 211, 215], ["Mtb motifs", "PROTEIN", 73, 83], ["DosR", "PROTEIN", 85, 89], ["IdeR", "PROTEIN", 91, 95], ["KstR", "PROTEIN", 97, 101], ["ZurB", "PROTEIN", 107, 111], ["Conserved cis-regulatory motifs", "DNA", 113, 144], ["KstR motif", "DNA", 211, 221], ["KstR", "TREATMENT", 97, 101], ["the KstR motif", "TEST", 207, 221], ["Mtb", "OBSERVATION", 73, 76], ["cis-regulatory motifs", "OBSERVATION", 123, 144], ["Mycobacteria", "OBSERVATION", 148, 160]]], ["Based on the distribution of highly conserved predicted motif instances for KstR across the genome, we predict a more general role for KstR in lipid metabolism.", [["KstR", "GENE_OR_GENE_PRODUCT", 76, 80], ["KstR", "GENE_OR_GENE_PRODUCT", 135, 139], ["lipid", "SIMPLE_CHEMICAL", 143, 148], ["KstR", "PROTEIN", 76, 80], ["KstR", "PROTEIN", 135, 139], ["KstR across the genome", "PROBLEM", 76, 98], ["KstR in lipid metabolism", "TREATMENT", 135, 159]]], ["We see KstR motif instances near many other lipid genes not related to cholesterol degradation, in support of the view that KstR is a more general lipid regulator controlling a large regulon [36].Conserved cis-regulatory motifs in Mycobacteria ::: Results and discussionOne of the most interesting new motif candidates that shows up in our analysis is a conserved palindromic motif, consisting of a highly conserved TAC...", [["cholesterol", "CHEMICAL", 71, 82], ["cholesterol", "CHEMICAL", 71, 82], ["TAC", "CHEMICAL", 416, 419], ["KstR", "GENE_OR_GENE_PRODUCT", 7, 11], ["cholesterol", "SIMPLE_CHEMICAL", 71, 82], ["KstR", "GENE_OR_GENE_PRODUCT", 124, 128], ["KstR motif", "DNA", 7, 17], ["lipid genes", "DNA", 44, 55], ["KstR", "PROTEIN", 124, 128], ["Conserved cis-regulatory motifs", "DNA", 196, 227], ["conserved palindromic motif", "DNA", 354, 381], ["cholesterol degradation", "PROBLEM", 71, 94], ["a more general lipid regulator", "TREATMENT", 132, 162], ["a conserved palindromic motif", "PROBLEM", 352, 381], ["cis-regulatory motifs", "OBSERVATION", 206, 227], ["Mycobacteria", "OBSERVATION", 231, 243]]], ["GTA separated by 6 bp of less well conserved sequence (marked with an X in Table 7) that is found in clusters of 2-3 closely spaced sites upstream of several genes related to fatty acid metabolism (Figure 6).", [["fatty acid", "CHEMICAL", 175, 185], ["fatty acid", "CHEMICAL", 175, 185], ["X in Table 7", "GENE_OR_GENE_PRODUCT", 70, 82], ["fatty acid", "SIMPLE_CHEMICAL", 175, 185], ["X in Table 7", "DNA", 70, 82], ["2-3 closely spaced sites", "DNA", 113, 137], ["fatty acid metabolism", "PROBLEM", 175, 196]]], ["There is a cluster of 3 evenly spaced sites upstream of Rv3229c (linoeyl-coA desaturase), a cluster of 2 sites upstream of the adjacent Rv3230c (oxidoreductase), and a cluster of 3 sites upstream of Rv2524c (fatty acid synthase).", [["fatty acid", "CHEMICAL", 208, 218], ["linoeyl", "CHEMICAL", 65, 72], ["fatty acid", "CHEMICAL", 208, 218], ["Rv3229c", "GENE_OR_GENE_PRODUCT", 56, 63], ["linoeyl-coA desaturase", "GENE_OR_GENE_PRODUCT", 65, 87], ["Rv3230c", "GENE_OR_GENE_PRODUCT", 136, 143], ["oxidoreductase", "GENE_OR_GENE_PRODUCT", 145, 159], ["Rv2524c", "GENE_OR_GENE_PRODUCT", 199, 206], ["fatty acid synthase", "GENE_OR_GENE_PRODUCT", 208, 227], ["Rv3229c", "PROTEIN", 56, 63], ["linoeyl", "DNA", 65, 72], ["coA desaturase", "PROTEIN", 73, 87], ["Rv3230c", "DNA", 136, 143], ["oxidoreductase", "PROTEIN", 145, 159], ["Rv2524c", "PROTEIN", 199, 206], ["fatty acid synthase", "PROTEIN", 208, 227], ["a cluster of 3 evenly spaced sites", "PROBLEM", 9, 43], ["Rv2524c (fatty acid synthase", "TREATMENT", 199, 227], ["cluster", "OBSERVATION_MODIFIER", 11, 18], ["evenly", "OBSERVATION_MODIFIER", 24, 30], ["spaced", "OBSERVATION_MODIFIER", 31, 37], ["sites", "OBSERVATION_MODIFIER", 38, 43], ["upstream", "OBSERVATION_MODIFIER", 44, 52]]], ["This motif shows up as one of the top motifs associated with the clusters of genes upregulated under saturated fatty acid conditions (specifically palmitate).ConclusionTo better understand Mtb, we performed a comparative analysis of 31 organisms from the Tuberculosis Database.", [["fatty acid", "CHEMICAL", 111, 121], ["palmitate", "CHEMICAL", 147, 156], ["Tuberculosis", "DISEASE", 255, 267], ["fatty acid", "CHEMICAL", 111, 121], ["palmitate", "CHEMICAL", 147, 156], ["saturated fatty acid", "SIMPLE_CHEMICAL", 101, 121], ["palmitate", "SIMPLE_CHEMICAL", 147, 156], ["a comparative analysis", "TEST", 207, 229], ["31 organisms", "PROBLEM", 233, 245], ["the Tuberculosis Database", "PROBLEM", 251, 276], ["Tuberculosis", "OBSERVATION", 255, 267]]], ["We studied the evolution of protein families and metabolic pathways, looked for proteins with evidence of selection, and searched for new noncoding RNAs and transcription factor binding site motifs.ConclusionThe most striking features of our analysis are related to lipid metabolism and its regulation.", [["lipid", "SIMPLE_CHEMICAL", 266, 271], ["protein families", "PROTEIN", 28, 44], ["noncoding RNAs", "RNA", 138, 152], ["transcription factor binding site motifs", "DNA", 157, 197], ["new noncoding RNAs", "TREATMENT", 134, 152], ["transcription factor binding site motifs", "PROBLEM", 157, 197], ["our analysis", "TEST", 238, 250], ["lipid metabolism", "PROBLEM", 266, 282], ["most striking", "OBSERVATION_MODIFIER", 212, 225], ["lipid metabolism", "OBSERVATION", 266, 282]]], ["In addition to observing a general expansion of lipid metabolism genes in the Mycobacteria and Rhodococcus, we observe increased expansions of genes related to saturated fatty acid metabolism in the pathogenic Mycobacteria compared to the soil-dwelling Mycobacteria.", [["fatty acid", "CHEMICAL", 170, 180], ["fatty acid", "CHEMICAL", 170, 180], ["lipid", "SIMPLE_CHEMICAL", 48, 53], ["fatty acid", "SIMPLE_CHEMICAL", 170, 180], ["lipid metabolism genes", "DNA", 48, 70], ["lipid metabolism genes", "PROBLEM", 48, 70], ["the Mycobacteria", "PROBLEM", 74, 90], ["Rhodococcus", "PROBLEM", 95, 106], ["increased expansions of genes", "PROBLEM", 119, 148], ["saturated fatty acid metabolism", "PROBLEM", 160, 191], ["the pathogenic Mycobacteria", "PROBLEM", 195, 222], ["the soil", "TEST", 235, 243], ["Mycobacteria", "PROBLEM", 253, 265], ["lipid metabolism genes", "OBSERVATION", 48, 70], ["Mycobacteria", "OBSERVATION", 78, 90], ["pathogenic Mycobacteria", "OBSERVATION", 199, 222]]], ["We also note differences in evolutionary profiles for catabolic and anabolic lipid metabolism genes, and evidence for positive selection in lipid metabolism genes.", [["lipid", "SIMPLE_CHEMICAL", 77, 82], ["lipid", "SIMPLE_CHEMICAL", 140, 145], ["lipid metabolism genes", "DNA", 140, 162], ["catabolic and anabolic lipid metabolism genes", "PROBLEM", 54, 99], ["positive selection in lipid metabolism genes", "PROBLEM", 118, 162], ["anabolic lipid", "OBSERVATION", 68, 82], ["metabolism genes", "OBSERVATION", 83, 99], ["lipid metabolism genes", "OBSERVATION", 140, 162]]], ["The cis-regulatory elements bound by the KstR protein, a known regulator of lipid/cholesterol metabolism, are among the strongest, most highly conserved noncoding signals across the Mycobacteria.", [["cholesterol", "CHEMICAL", 82, 93], ["cholesterol", "CHEMICAL", 82, 93], ["KstR", "GENE_OR_GENE_PRODUCT", 41, 45], ["lipid", "SIMPLE_CHEMICAL", 76, 81], ["cholesterol", "SIMPLE_CHEMICAL", 82, 93], ["cis-regulatory elements", "DNA", 4, 27], ["KstR protein", "PROTEIN", 41, 53], ["the KstR protein", "TEST", 37, 53], ["lipid/cholesterol metabolism", "PROBLEM", 76, 104], ["cholesterol metabolism", "OBSERVATION", 82, 104], ["Mycobacteria", "OBSERVATION", 182, 194]]], ["Both KstR and its binding sites are highly conserved, appearing at the last common ancestor between Rhodococcus and the Mycobacteria.ConclusionWithin our set of organisms, we examine the evolution of pathogenicity, moving from the soil-dwelling Mycobacteria up to the intracellular parasites of the Mtb complex.", [["intracellular", "ANATOMY", 268, 281], ["KstR", "GENE_OR_GENE_PRODUCT", 5, 9], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 268, 281], ["Mtb", "GENE_OR_GENE_PRODUCT", 299, 302], ["KstR", "PROTEIN", 5, 9], ["binding sites", "DNA", 18, 31], ["Mtb complex", "PROTEIN", 299, 310], ["its binding sites", "PROBLEM", 14, 31], ["the Mycobacteria", "PROBLEM", 116, 132], ["pathogenicity", "PROBLEM", 200, 213], ["the soil-dwelling Mycobacteria", "TEST", 227, 257], ["binding sites", "OBSERVATION", 18, 31], ["Mycobacteria", "OBSERVATION", 120, 132], ["pathogenicity", "OBSERVATION", 200, 213], ["intracellular parasites", "OBSERVATION", 268, 291], ["Mtb complex", "OBSERVATION", 299, 310]]], ["We see expansions of many known gene families related to pathogenicity (PE/PPE genes, antibiotic resistance genes, genes involved in the synthesis of the mycolic acid coat, MCE genes, and Esx genes).", [["mycolic acid", "CHEMICAL", 154, 166], ["mycolic acid", "CHEMICAL", 154, 166], ["PPE", "GENE_OR_GENE_PRODUCT", 75, 78], ["Esx", "GENE_OR_GENE_PRODUCT", 188, 191], ["PE/PPE genes", "DNA", 72, 84], ["antibiotic resistance genes", "DNA", 86, 113], ["mycolic acid coat, MCE genes", "DNA", 154, 182], ["Esx genes", "DNA", 188, 197], ["pathogenicity (PE/PPE genes", "PROBLEM", 57, 84], ["antibiotic resistance genes", "TREATMENT", 86, 113], ["the mycolic acid coat", "TEST", 150, 171], ["PE", "OBSERVATION", 72, 74]]], ["By similarity of phylogenetic profiles, we can predict likely candidates for novel gene families related to pathogenicity.", [["pathogenicity", "PROBLEM", 108, 121]]], ["For example, we see similar expansions in gene families related to biosynthesis of molybdopterin.", [["molybdopterin", "CHEMICAL", 83, 96], ["molybdopterin", "CHEMICAL", 83, 96], ["molybdopterin", "SIMPLE_CHEMICAL", 83, 96], ["molybdopterin", "PROTEIN", 83, 96], ["biosynthesis of molybdopterin", "TREATMENT", 67, 96]]], ["We further observe evidence of positive selection on molybdenum-related genes, providing further support for the importance of molybdenum in these pathogens.", [["molybdenum", "CHEMICAL", 53, 63], ["molybdenum", "CHEMICAL", 127, 137], ["molybdenum", "CHEMICAL", 53, 63], ["molybdenum", "CHEMICAL", 127, 137], ["molybdenum", "SIMPLE_CHEMICAL", 53, 63], ["molybdenum", "SIMPLE_CHEMICAL", 127, 137], ["molybdenum-related genes", "DNA", 53, 77], ["positive selection on molybdenum", "PROBLEM", 31, 63], ["further support", "TREATMENT", 89, 104], ["these pathogens", "PROBLEM", 141, 156], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["selection", "OBSERVATION", 40, 49], ["pathogens", "OBSERVATION", 147, 156]]], ["On the branch leading to the pathogenic Mycobacteria, we also observe evidence for positive selection in genes related to replication, recombination, and repair.", [["the pathogenic Mycobacteria", "PROBLEM", 25, 52], ["positive selection in genes", "PROBLEM", 83, 110], ["repair", "TREATMENT", 154, 160], ["branch", "ANATOMY_MODIFIER", 7, 13], ["pathogenic", "OBSERVATION_MODIFIER", 29, 39], ["Mycobacteria", "OBSERVATION", 40, 52]]], ["It is possible that these DNA repair-related processes give the pathogenic Mycobacteria an advantage when dealing with the assault on its DNA by macrophage-generated reactive oxygen and nitrogen intermediates.ConclusionOur whole-genome alignments, coupled with RNA-seq and microarray data, allowed us to predict novel noncoding features, including small RNAs (four of which we have validated experimentally), and potential transcription factor binding sites.ConclusionThe main forces driving genome evolution in prokaryotes include gene genesis, lateral gene transfer, and gene loss.", [["oxygen", "CHEMICAL", 175, 181], ["nitrogen", "CHEMICAL", 186, 194], ["oxygen", "CHEMICAL", 175, 181], ["nitrogen", "CHEMICAL", 186, 194], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["macrophage", "CELL", 145, 155], ["reactive", "SIMPLE_CHEMICAL", 166, 174], ["oxygen", "SIMPLE_CHEMICAL", 175, 181], ["nitrogen intermediates", "SIMPLE_CHEMICAL", 186, 208], ["small RNAs", "RNA", 348, 358], ["transcription factor binding sites", "DNA", 423, 457], ["these DNA repair", "TREATMENT", 20, 36], ["the pathogenic Mycobacteria", "PROBLEM", 60, 87], ["reactive oxygen", "TREATMENT", 166, 181], ["nitrogen intermediates", "TREATMENT", 186, 208], ["RNA", "TEST", 261, 264], ["microarray data", "TEST", 273, 288], ["novel noncoding features", "PROBLEM", 312, 336], ["small RNAs", "PROBLEM", 348, 358], ["potential transcription factor binding sites", "PROBLEM", 413, 457], ["gene genesis", "PROBLEM", 532, 544], ["lateral gene transfer", "TREATMENT", 546, 567], ["gene loss", "PROBLEM", 573, 582], ["pathogenic", "OBSERVATION_MODIFIER", 64, 74], ["Mycobacteria", "OBSERVATION", 75, 87], ["reactive oxygen", "OBSERVATION", 166, 181], ["small RNAs", "OBSERVATION", 348, 358], ["main", "OBSERVATION_MODIFIER", 472, 476], ["forces", "OBSERVATION_MODIFIER", 477, 483]]], ["Our analysis of protein evolution using SYNERGY does not examine whether orthogroups appearing have arisen by lateral gene transfer or by gene genesis involving duplication and divergence from other orthogroups.", [["SYNERGY", "PROTEIN", 40, 47], ["Our analysis", "TEST", 0, 12]]], ["A detailed comparison to categorize these orthogroup appearances according to lateral or vertical gene transfer is beyond the scope of this study, but other studies indicate that lateral gene transfer has played a significant role in Mycobacterial evolution and the evolution of pathogenesis [79-83].ConclusionA recent paper suggests that the Mycobacterial genome has been shaped by a biphasic process involving gene acquisition (including lateral gene transfer) and duplications followed by gene loss [79].", [["Mycobacterial genome", "DNA", 343, 363], ["this study", "TEST", 135, 145], ["other studies", "TEST", 151, 164], ["pathogenesis", "PROBLEM", 279, 291], ["the Mycobacterial genome", "PROBLEM", 339, 363], ["a biphasic process", "PROBLEM", 383, 401], ["lateral gene transfer", "TREATMENT", 440, 461], ["duplications", "PROBLEM", 467, 479], ["gene loss", "PROBLEM", 492, 501], ["Mycobacterial", "OBSERVATION", 234, 247], ["Mycobacterial genome", "OBSERVATION", 343, 363]]], ["Other studies report numerous genes, including a large number involved in lipid metabolism, that have been acquired by horizontal gene transfer at different phylogenetic strata and have led to the emergence of pathogenesis in Mtb [80,81].", [["lipid", "SIMPLE_CHEMICAL", 74, 79], ["Other studies", "TEST", 0, 13], ["large", "OBSERVATION_MODIFIER", 49, 54], ["lipid metabolism", "OBSERVATION", 74, 90]]], ["Previous studies indicate a possible more ancient lateral gene transfer of fatty acid biosynthesis genes from \u03b1-proteobacteria to actinobacteria [84].", [["fatty acid", "CHEMICAL", 75, 85], ["fatty acid", "CHEMICAL", 75, 85], ["fatty acid", "SIMPLE_CHEMICAL", 75, 85], ["\u03b1-proteobacteria", "SIMPLE_CHEMICAL", 110, 126], ["fatty acid biosynthesis genes", "DNA", 75, 104], ["Previous studies", "TEST", 0, 16], ["fatty acid biosynthesis genes", "PROBLEM", 75, 104], ["\u03b1-proteobacteria to actinobacteria", "PROBLEM", 110, 144]]], ["However, genetic studies show that the Mtb complex and pathogenic Mycobacteria do not exchange genetic material frequently [85,86], so there is limited lateral gene transfer within the Mtb complex.ConclusionWe are currently performing high-throughput Chromatin Immunoprecipitation (ChIP)-Seq experiments in several different Mycobacteria, including Mtb, M. smegmatis, and M. vanbaalenii[87].", [["Mtb", "GENE_OR_GENE_PRODUCT", 39, 42], ["Mtb", "GENE_OR_GENE_PRODUCT", 185, 188], ["Mtb", "GENE_OR_GENE_PRODUCT", 349, 352], ["M. smegmatis", "ORGANISM", 354, 366], ["M. vanbaalenii", "ORGANISM", 372, 386], ["Mtb complex", "PROTEIN", 39, 50], ["Mtb complex", "PROTEIN", 185, 196], ["M. smegmatis", "SPECIES", 354, 366], ["M. vanbaalenii", "SPECIES", 372, 386], ["M. smegmatis", "SPECIES", 354, 366], ["M. vanbaalenii", "SPECIES", 372, 386], ["genetic studies", "TEST", 9, 24], ["the Mtb complex", "PROBLEM", 35, 50], ["pathogenic Mycobacteria", "PROBLEM", 55, 78], ["high-throughput Chromatin Immunoprecipitation", "TREATMENT", 235, 280], ["several different Mycobacteria", "PROBLEM", 307, 337], ["Mtb", "PROBLEM", 349, 352], ["Mycobacteria", "OBSERVATION", 66, 78], ["several different", "OBSERVATION_MODIFIER", 307, 324], ["Mycobacteria", "OBSERVATION", 325, 337], ["M. smegmatis", "OBSERVATION", 354, 366]]], ["We plan to integrate the information obtained from our comparative analysis with data coming from these high-throughput experiments, as well as other 'omic datasets, using a systems biology approach.", [["our comparative analysis", "TEST", 51, 75], ["a systems biology approach", "TREATMENT", 172, 198]]], ["This will enable construction of gene regulatory networks for Mtb, and examination of their evolution across species.Genome sequences ::: MethodsThe 31 organisms used in our analysis are described in Table 1.", [["Mtb", "GENE_OR_GENE_PRODUCT", 62, 65], ["gene regulatory networks", "TREATMENT", 33, 57], ["Mtb", "PROBLEM", 62, 65], ["examination", "TEST", 71, 82], ["our analysis", "TEST", 170, 182]]], ["These genome sequences are all contained in the TB database (TBDB) [75].", [["genome sequences", "DNA", 6, 22], ["These genome sequences", "TEST", 0, 22]]], ["The three unpublished sequences generated at the Broad Institute (M. tuberculosis F11, M. tuberculosis Haarlem, and M. tuberculosis C) are high-quality genome sequences.", [["M. tuberculosis F11", "ORGANISM", 66, 85], ["M. tuberculosis Haarlem", "ORGANISM", 87, 110], ["M. tuberculosis C", "ORGANISM", 116, 133], ["high-quality genome sequences", "DNA", 139, 168], ["M. tuberculosis", "SPECIES", 66, 81], ["M. tuberculosis", "SPECIES", 87, 102], ["M. tuberculosis", "SPECIES", 116, 131], ["M. tuberculosis", "SPECIES", 66, 81], ["M. tuberculosis", "SPECIES", 87, 102], ["M. tuberculosis", "SPECIES", 116, 131], ["The three unpublished sequences", "TEST", 0, 31], ["Haarlem", "TEST", 103, 110]]], ["M. tuberculosis F11 and M. tuberculosis Haarlem are finished, and M. tuberculosis C has 6.7\u00d7 coverage and 4 scaffolds.", [["M. tuberculosis F11", "ORGANISM", 0, 19], ["M. tuberculosis Haarlem", "ORGANISM", 24, 47], ["M. tuberculosis C", "ORGANISM", 66, 83], ["M. tuberculosis", "SPECIES", 0, 15], ["M. tuberculosis", "SPECIES", 24, 39], ["M. tuberculosis", "SPECIES", 66, 81], ["M. tuberculosis", "SPECIES", 0, 15], ["M. tuberculosis", "SPECIES", 24, 39], ["M. tuberculosis", "SPECIES", 66, 81], ["M. tuberculosis F11", "PROBLEM", 0, 19], ["6.7\u00d7 coverage and 4 scaffolds", "TREATMENT", 88, 117], ["tuberculosis", "OBSERVATION", 3, 15], ["tuberculosis", "OBSERVATION", 27, 39], ["tuberculosis", "OBSERVATION", 69, 81]]], ["The Broad Institute sequencing read pipeline interacts with the sample management system to ensure the read is associated with the correct sample.", [["the sample management system", "TREATMENT", 60, 88]]], ["Vector identification, length checks and quality clipping were performed on all reads.", [["Vector identification", "TEST", 0, 21], ["length checks", "TEST", 23, 36], ["quality clipping", "TREATMENT", 41, 57]]], ["Contamination checks and organism checks were also performed using a kmer-based algorithm that can compare sequence to a profile from any organism.Defining protein families and constructing phylogenetic trees ::: MethodsThe SYNERGY algorithm [27,28] was applied to the 31 genomes in Table 1.", [["Contamination checks", "TEST", 0, 20], ["organism checks", "TEST", 25, 40], ["a kmer-based algorithm", "TREATMENT", 67, 89], ["any organism", "PROBLEM", 134, 146]]], ["SYNERGY organizes groups of genes across organisms into orthogroups, or groups of orthologs and paralogs, which consist of all the genes descended from a single ancestral gene in the species' last common ancestor.", [["SYNERGY", "DNA", 0, 7], ["orthogroups", "DNA", 56, 67], ["orthologs", "DNA", 82, 91], ["paralogs", "DNA", 96, 104], ["orthologs and paralogs", "PROBLEM", 82, 104]]], ["SYNERGY also associates orthogroups with a gene tree, from which we can derive an \"extended phylogenetic profile\", showing the gene copy number in each extant organism and at each ancestral node.", [["node", "ANATOMY", 190, 194], ["ancestral node", "MULTI-TISSUE_STRUCTURE", 180, 194], ["SYNERGY", "DNA", 0, 7], ["node", "OBSERVATION", 190, 194]]], ["Importantly, by reconciling an organism tree with each gene tree, SYNERGY provides an evolutionary scenario for each gene tree predicting where all losses, gains, and duplications occurred in its evolution.", [["SYNERGY", "DNA", 66, 73], ["duplications", "PROBLEM", 167, 179]]], ["These lists of losses, gains, and duplications contain actual evolutionary events, as well as artifacts caused by genes that could not be properly categorized by SYNERGY.", [["SYNERGY", "PROTEIN", 162, 169], ["duplications", "PROBLEM", 34, 46], ["actual evolutionary events", "PROBLEM", 55, 81], ["artifacts", "PROBLEM", 94, 103]]], ["However, we observe that SYNERGY is effective at properly categorizing genes into orthogroups, and the SYNERGY orthogroups were very useful in our analysis.", [["SYNERGY", "CHEMICAL", 25, 32], ["SYNERGY", "GENE_OR_GENE_PRODUCT", 25, 32], ["SYNERGY", "GENE_OR_GENE_PRODUCT", 103, 110], ["SYNERGY", "DNA", 25, 32], ["orthogroups", "DNA", 82, 93], ["SYNERGY orthogroups", "DNA", 103, 122], ["the SYNERGY orthogroups", "TEST", 99, 122], ["our analysis", "TEST", 143, 155]]], ["Analysis of the 31 genomes resulted in a total of 32,505 orthogroups, including those containing single genes from only a single genome (below).", [["31 genomes", "DNA", 16, 26], ["Analysis", "TEST", 0, 8]]], ["There were 177 \"uniform\" (1:1:1:1...) orthogroups representative of some of the most conserved and indispensible housekeeping genes.", [["housekeeping genes", "DNA", 113, 131], ["housekeeping genes", "OBSERVATION", 113, 131]]], ["Additional file 4: Figure S3 summarizes the SYNERGY orthogroups.Defining protein families and constructing phylogenetic trees ::: MethodsWe started running SYNERGY using an initial phylogenetic tree generated using orthologs based on bidirectional best BLAST hits.", [["SYNERGY orthogroups", "DNA", 44, 63], ["SYNERGY", "DNA", 156, 163], ["bidirectional best BLAST hits", "DNA", 234, 263], ["MethodsWe", "TREATMENT", 130, 139], ["running SYNERGY", "TREATMENT", 148, 163], ["BLAST hits", "OBSERVATION", 253, 263]]], ["The list of uniform orthogroups from the first SYNERGY run was used to construct a refined phylogenetic tree.", [["orthogroups", "CANCER", 20, 31], ["SYNERGY", "DNA", 47, 54], ["phylogenetic tree", "OBSERVATION", 91, 108]]], ["SYNERGY was then re-run using the refined phylogenetic trees.", [["SYNERGY", "DNA", 0, 7]]], ["To generate our final phylogenetic tree, the final set of 177 31-way orthologs (31-way uniform orthogroups from the SYNERGY analysis) were aligned according to their nucleotide sequences with CLUSTALW [88] and concatenated, distances were computed with Phylip's DNADIST algorithm [89], and Phylip's FITCH algorithm was used to create the tree.Defining protein families and constructing phylogenetic trees ::: MethodsBecause of the similarity of the genomes within the Mtb complex, we were not able to resolve the phylogeny using only these 177 proteins that are uniform across all 31 organisms.", [["nucleotide", "CHEMICAL", 166, 176], ["Mtb", "GENE_OR_GENE_PRODUCT", 468, 471], ["177 31-way orthologs", "DNA", 58, 78], ["SYNERGY", "DNA", 116, 123], ["nucleotide sequences", "DNA", 166, 186], ["Phylip's FITCH algorithm", "DNA", 290, 314], ["Mtb complex", "PROTEIN", 468, 479], ["177 proteins", "PROTEIN", 540, 552], ["orthologs", "TEST", 69, 78], ["the SYNERGY analysis", "TEST", 112, 132], ["their nucleotide sequences", "TEST", 160, 186], ["CLUSTALW", "TEST", 192, 200], ["Phylip's FITCH algorithm", "TREATMENT", 290, 314], ["tree", "OBSERVATION_MODIFIER", 35, 39], ["tree", "ANATOMY_MODIFIER", 338, 342]]], ["In order to better resolve the tree within the Mtb cluster, we computed a separate tree using 1747 orthogroups that are uniform across the Mtb cluster and M. ulcerans, which we used as an outgroup.", [["Mtb", "GENE_OR_GENE_PRODUCT", 139, 142], ["M. ulcerans", "ORGANISM", 155, 166], ["M. ulcerans", "SPECIES", 155, 166], ["M. ulcerans", "SPECIES", 155, 166], ["M. ulcerans", "PROBLEM", 155, 166], ["tree", "ANATOMY_MODIFIER", 31, 35], ["Mtb cluster", "OBSERVATION", 47, 58], ["Mtb cluster", "OBSERVATION", 139, 150], ["ulcerans", "OBSERVATION", 158, 166]]], ["Using this expanded gene set, we were able to resolve the tree for the Mtb cluster.Defining protein families and constructing phylogenetic trees ::: MethodsBootstrap analysis was performed to validate tree topologies.", [["Mtb", "GENE_OR_GENE_PRODUCT", 71, 74], ["this expanded gene set", "TREATMENT", 6, 28], ["MethodsBootstrap analysis", "TEST", 149, 174], ["Mtb cluster", "OBSERVATION", 71, 82]]], ["Phylip's SEQBOOT was used to create 1000 bootstrap input replicates for each tree.", [["SEQBOOT", "DNA", 9, 16], ["Phylip's SEQBOOT", "TREATMENT", 0, 16]]], ["Phylip's CONSENSE was used to obtain a bootstrap tree (Additional file 5: Figure S4)Metabolic pathways and functional groups ::: MethodsEFICAZ [90] was used to assign EC numbers for proteins in all 31 organisms.", [["EC", "ANATOMY", 167, 169], ["EC", "CELL", 167, 169], ["EC", "CELL_TYPE", 167, 169], ["Phylip's", "TREATMENT", 0, 8], ["a bootstrap tree", "TREATMENT", 37, 53], ["MethodsEFICAZ", "TREATMENT", 129, 142], ["proteins", "TEST", 182, 190]]], ["Metabolic pathways were constructed in Biocyc [91,92].", [["Metabolic pathways", "TEST", 0, 18]]], ["An orthogroup was considered to be part of a metabolic pathway if any of its component genes had been identified as part of that pathway using this pipeline.Metabolic pathways and functional groups ::: MethodsWe obtained the Gene Ontology (GO) [29] and GO Slim terms for each of the 31 organisms using BLAST2GO [93].", [["this pipeline", "TREATMENT", 143, 156]]], ["PFAM assignments [30] were taken from http://www.tbdb.org[75].", [["PFAM assignments", "TEST", 0, 16]]], ["An orthogroup was associated with a GO, GO Slim, or PFAM descriptor if greater than half of its protein members were associated with that descriptor.Metabolic pathways and functional groups ::: MethodsFor each node in the phylogenetic tree, we tabulated orthogroups lost, gained, or duplicated.", [["node", "ANATOMY", 210, 214], ["protein members", "PROTEIN", 96, 111], ["PFAM descriptor", "TEST", 52, 67], ["Methods", "TREATMENT", 194, 201], ["node", "OBSERVATION", 210, 214], ["phylogenetic", "ANATOMY_MODIFIER", 222, 234], ["tree", "ANATOMY_MODIFIER", 235, 239]]], ["Using GO terms, GO Slim terms, and PFAM domain groupings with less than 500 members, we calculated over-representations within losses, gains, and duplications each of these groupings at each node using the hypergeometric test.", [["node", "ANATOMY", 191, 195], ["node", "MULTI-TISSUE_STRUCTURE", 191, 195], ["the hypergeometric test", "TEST", 202, 225], ["node", "OBSERVATION", 191, 195]]], ["A complete summary of gains, losses, and duplications for all nodes in the phylogenetic tree is available on our supplementary information website.Phylogenetic profiles ::: MethodsExtended phylogenetic profiles for each category (metabolic pathways, GO terms, GO Slim terms and PFAM categories) were obtained from SYNERGY output by summing the phylogenetic profiles from their component orthogroups.", [["duplications", "TREATMENT", 41, 53], ["all nodes in the phylogenetic tree", "PROBLEM", 58, 92], ["PFAM categories", "TEST", 278, 293], ["SYNERGY output", "TEST", 314, 328], ["nodes", "OBSERVATION", 62, 67], ["phylogenetic tree", "OBSERVATION", 75, 92]]], ["Categories with the most similar profiles were obtained by calculating Euclidean distances to all other profiles.Phylogenetic profiles ::: MethodsInstances of expanded or missing pathways across the 31 organisms will have non-uniform pathway-level phylogenetic profiles.", [["missing pathways", "PROBLEM", 171, 187], ["non-uniform pathway", "TEST", 222, 241], ["level phylogenetic profiles", "PROBLEM", 242, 269]]], ["Thus we tabulated the number of genes in each genome for each category, and automatically searched for gene categories whose copy number (normalized for genome size) had the most non-uniform distribution across the 31 organisms in order to identify the most significant examples of expansions or losses.", [["expansions or losses", "PROBLEM", 282, 302], ["expansions", "OBSERVATION", 282, 292]]], ["To identify categories with bimodal properties (such as a categories with a loss or a large expansion on only certain branches of the phylogenetic tree), we clustered each profile into two groups and looked for the pathways with the greatest separation between the two clusters.", [["bimodal properties", "TREATMENT", 28, 46], ["a loss", "PROBLEM", 74, 80], ["a large expansion", "PROBLEM", 84, 101], ["bimodal properties", "OBSERVATION", 28, 46], ["large", "OBSERVATION_MODIFIER", 86, 91], ["expansion", "OBSERVATION", 92, 101], ["phylogenetic tree", "ANATOMY", 134, 151], ["greatest", "OBSERVATION_MODIFIER", 233, 241]]], ["We used k-means (k = 2) to cluster the profile vectors, and compared the intra- and inter-cluster point-to-centroid distances to find the clusters with the greatest separation.", [["clusters", "OBSERVATION_MODIFIER", 138, 146], ["greatest", "OBSERVATION_MODIFIER", 156, 164], ["separation", "OBSERVATION_MODIFIER", 165, 175]]], ["We further select those that have at least five organisms in the smallest of the two clusters, and an average of at least five genes per genome.", [["five", "OBSERVATION_MODIFIER", 43, 47], ["organisms", "OBSERVATION", 48, 57], ["smallest", "OBSERVATION_MODIFIER", 65, 73], ["two", "OBSERVATION_MODIFIER", 81, 84], ["clusters", "OBSERVATION_MODIFIER", 85, 93], ["average", "OBSERVATION_MODIFIER", 102, 109]]], ["P-values are calculated from a T-test between the values for the two groups, with Bonferroni correction applied.", [["P", "DNA", 0, 1], ["a T-test", "TEST", 29, 37], ["Bonferroni correction", "TREATMENT", 82, 103]]], ["When we select the metabolic pathways, PFAM domains, and GO terms with the most non-uniform category-level phylogenetic profiles overall, we find that many of the top categories are lipid metabolism-related categories expanded in the Mycobacteria.Phylogenetic profiles ::: MethodsWe also measured the similarity between evolutionary profiles to find the PFAM categories and GO terms with the biggest difference between pre-defined sets of organisms.", [["lipid", "SIMPLE_CHEMICAL", 182, 187], ["PFAM domains", "PROTEIN", 39, 51], ["PFAM domains", "TEST", 39, 51], ["lipid metabolism", "PROBLEM", 182, 198], ["the Mycobacteria", "PROBLEM", 230, 246], ["the PFAM categories", "TEST", 350, 369], ["Mycobacteria", "OBSERVATION", 234, 246]]], ["For example, we compared both the Mtb complex and a group consisting of other pathogenic Mycobacteria to the set of soil-dwelling Mycobacteria in order to examine the evolution of soil-dwelling, free-living Mycobacteria into more pathogenic Mycobacteria that require a host to survive.", [["Mtb complex", "PROTEIN", 34, 45], ["other pathogenic Mycobacteria", "PROBLEM", 72, 101], ["dwelling Mycobacteria", "PROBLEM", 121, 142], ["soil-dwelling", "PROBLEM", 180, 193], ["living Mycobacteria", "PROBLEM", 200, 219], ["pathogenic Mycobacteria", "PROBLEM", 230, 253], ["Mycobacteria", "OBSERVATION", 89, 101], ["pathogenic Mycobacteria", "OBSERVATION", 230, 253]]], ["We used the following categories:Phylogenetic profiles ::: Methods1.", [["Methods1", "TREATMENT", 59, 67]]], ["All Mycobacteria (excluding M. leprae because of its massive gene loss).Phylogenetic profiles ::: Methods2.", [["M. leprae", "ORGANISM", 28, 37], ["M. leprae", "SPECIES", 28, 37], ["M. leprae", "SPECIES", 28, 37], ["All Mycobacteria", "PROBLEM", 0, 16], ["its massive gene loss)", "PROBLEM", 49, 71], ["Methods2", "PROBLEM", 98, 106], ["Mycobacteria", "OBSERVATION", 4, 16], ["massive", "OBSERVATION_MODIFIER", 53, 60], ["gene loss", "OBSERVATION", 61, 70]]], ["All non-Mycobacteria in our set (excluding Nocardia and Rhodococcus because of their similarity to Mycobacteria)Phylogenetic profiles ::: Methods3.", [["Nocardia", "DISEASE", 43, 51], ["All non-Mycobacteria", "TEST", 0, 20], ["Nocardia", "PROBLEM", 43, 51], ["Rhodococcus", "PROBLEM", 56, 67], ["Methods3", "PROBLEM", 138, 146]]], ["Mtb complex (8 organisms)Phylogenetic profiles ::: Methods4.", [["Mtb complex", "PROTEIN", 0, 11], ["Mtb complex", "PROBLEM", 0, 11], ["Phylogenetic profiles", "TEST", 25, 46], ["Methods4", "TEST", 51, 59]]], ["Other pathogenic Mycobacteria (M. ulcerans, M. avium 104, M. avium K10, M. marinum).Phylogenetic profiles ::: Methods5.", [["M. ulcerans", "ORGANISM", 31, 42], ["M. avium 104", "ORGANISM", 44, 56], ["M. avium K10", "ORGANISM", 58, 70], ["M. marinum", "ORGANISM", 72, 82], ["M. ulcerans", "SPECIES", 31, 42], ["M. avium", "SPECIES", 44, 52], ["M. avium", "SPECIES", 58, 66], ["M. marinum", "SPECIES", 72, 82], ["M. ulcerans", "SPECIES", 31, 42], ["M. avium", "SPECIES", 44, 52], ["M. avium", "SPECIES", 58, 66], ["M. marinum", "SPECIES", 72, 82], ["Other pathogenic Mycobacteria (M. ulcerans", "PROBLEM", 0, 42], ["M. avium", "TEST", 44, 52], ["M. avium K10", "TEST", 58, 70], ["Methods5", "TREATMENT", 110, 118], ["pathogenic", "OBSERVATION_MODIFIER", 6, 16], ["Mycobacteria", "OBSERVATION", 17, 29], ["M. ulcerans", "OBSERVATION", 31, 42]]], ["Soil-dwelling Mycobacteria that do not require a host (M. sp.", [["M. sp", "ORGANISM", 55, 60], ["dwelling Mycobacteria", "PROBLEM", 5, 26], ["dwelling Mycobacteria", "OBSERVATION", 5, 26]]], ["KMS, M. smegmatis, M. vanbaalenii, M. abscessus, M. gilvum).Phylogenetic profiles ::: Methods6.", [["M. smegmatis", "ORGANISM", 5, 17], ["M. vanbaalenii", "ORGANISM", 19, 33], ["M. abscessus", "ORGANISM", 35, 47], ["M. gilvum", "ORGANISM", 49, 58], ["M. smegmatis", "SPECIES", 5, 17], ["M. vanbaalenii", "SPECIES", 19, 33], ["M. abscessus", "SPECIES", 35, 47], ["M. gilvum", "SPECIES", 49, 58], ["M. smegmatis", "SPECIES", 5, 17], ["M. vanbaalenii", "SPECIES", 19, 33], ["M. abscessus", "SPECIES", 35, 47], ["M. gilvum", "SPECIES", 49, 58], ["Methods6", "TREATMENT", 86, 94], ["M. smegmatis", "OBSERVATION", 5, 17], ["abscessus", "OBSERVATION", 38, 47]]], ["R. jostii RHA1 and N. farciniaPhylogenetic profiles ::: MethodsWe calculated differences between two sets of organisms exactly as we calculated distances between clusters (above).", [["R. jostii RHA1", "ORGANISM", 0, 14], ["R. jostii", "SPECIES", 0, 9], ["R. jostii", "SPECIES", 0, 9], ["MethodsWe calculated differences", "PROBLEM", 56, 88], ["N. farciniaPhylogenetic", "OBSERVATION", 19, 42]]], ["However, rather than using different clusters of organisms determined by k-means clustering, we used these pre-defined clusters of organisms.", [["organisms", "PROBLEM", 49, 58]]], ["We looked at distances between the following sets of organisms: 1-2, 3-4, 3-5, 3-6, 4-5, 4-6, 5-6.", [["1-2, 3-4, 3-5, 3-6, 4-5, 4-6, 5-6", "DNA", 64, 97]]], ["For each PFAM domain or GO term represented in at least two organisms in these pairings, we calculated p-values for the differences between the profile values by T-test (Bonferroni-corrected by the number of PFAM domains represented in that set of organisms) and computed inter-and intra-centroid distances (as described in the above paragraph).", [["PFAM domain", "PROTEIN", 9, 20], ["PFAM domains", "PROTEIN", 208, 220], ["each PFAM domain", "PROBLEM", 4, 20], ["Bonferroni", "TEST", 170, 180], ["PFAM domains", "TEST", 208, 220]]], ["Many potentially interesting expansions do not make the overly conservative Bonferroni-corrected p-value cutoff [95,96].Motif discovery ::: MethodsUsing a compendium of 946 microarray experiments from the TB database [75], we used several different clustering methods to generate predicted regulons.", [["the TB database", "TEST", 201, 216]]], ["We searched the upstream regions of these regulons for shared transcriptional regulatory motifs.", [["upstream regions", "DNA", 16, 32], ["transcriptional regulatory motifs", "DNA", 62, 95]]], ["Because real regulons can be of varying sizes, we performed k-means with k = 50, 100, 200, and 250, then used all the resulting clusters for further analysis.", [["k", "TEST", 73, 74], ["further analysis", "TEST", 141, 157]]], ["We found that the clusters obtained from hierarchical clustering were not very useful because their size distribution did not approximate that of real regulons as well as those from k-means; therefore we did not analyze clusters from hierarchical clustering further.Motif discovery ::: MethodsWe used AlignACE [97] to search the upstream regions of the genes in these clusters for motifs.", [["upstream regions", "DNA", 329, 345], ["size", "OBSERVATION_MODIFIER", 100, 104]]], ["We used the methods for operon prediction, selecting upstream regions, and applying AlignACE to prokaryotic genomes as described in McGuire et al. [77].", [["upstream regions", "DNA", 53, 69], ["AlignACE", "DNA", 84, 92], ["prokaryotic genomes", "DNA", 96, 115], ["the methods", "TREATMENT", 8, 19], ["operon prediction", "TREATMENT", 24, 41], ["selecting upstream regions", "TREATMENT", 43, 69]]], ["Briefly, because of the presence of operons in prokaryotes, we must choose the upstream region of the operon head rather than the region immediately upstream of the gene of interest.", [["head", "ANATOMY", 109, 113], ["head", "ORGAN", 109, 113], ["operons", "DNA", 36, 43], ["upstream region", "DNA", 79, 94], ["operon head", "DNA", 102, 113], ["head", "ANATOMY", 109, 113]]], ["Since it is more important to include the correct region than to erroneously include extra incorrect regions, we use a loose operon definition and include sequences for several different possibilities if there is any ambiguity.", [["a loose operon definition", "TREATMENT", 117, 142]]], ["We look upstream of our gene of interest and select all intergenic sequences until we encounter either a divergent intergenic region or an intergenic region longer than 300 bp.Motif discovery ::: MethodsMotifs of interest were selected by applying a set of filters: specificity score [77], quality of alignment (AlignACE MAP score) [97], palindromicity [77], and conservation.", [["intergenic sequences", "DNA", 56, 76], ["divergent intergenic region", "DNA", 105, 132], ["intergenic region", "DNA", 139, 156], ["a divergent intergenic region", "PROBLEM", 103, 132], ["specificity score", "TEST", 266, 283], ["alignment (AlignACE MAP score", "TEST", 301, 330]]], ["To determine the degree of conservation, a search matrix was constructed for each motif.", [["matrix", "CELLULAR_COMPONENT", 50, 56], ["a search matrix", "TREATMENT", 41, 56]]], ["Each of the other genomes was searched with this search matrix using CompareACE, and N-way conserved sites were identified.", [["matrix", "CELLULAR_COMPONENT", 56, 62], ["CompareACE, and N-way conserved sites", "DNA", 69, 106], ["CompareACE", "TREATMENT", 69, 79]]], ["N-way conserved hits are hits identified upstream of orthologous genes in N genomes, where orthology is defined by membership in the same SYNERGY orthogroup.", [["SYNERGY", "GENE_OR_GENE_PRODUCT", 138, 145], ["N-way conserved hits", "DNA", 0, 20], ["orthologous genes", "DNA", 53, 70], ["N genomes", "DNA", 74, 83], ["SYNERGY orthogroup", "DNA", 138, 156]]], ["To select interesting motifs we required specificity score < 1e-10, palindromicity > 0.7, MAP score > 5, and at least 8 sites conserved in 8 genomes.Motif discovery ::: MethodsMotifs were compared to a library of search matrices for 9 known Mtb motifs (Acr, Crp, CsoR, DosR, FurA, IdeR, KstR, MprAB, and ZurB), as well as a library of 55 E. coli motifs [98] and 22 Corynebacterial motifs [99].", [["Acr", "GENE_OR_GENE_PRODUCT", 253, 256], ["Crp", "GENE_OR_GENE_PRODUCT", 258, 261], ["CsoR", "GENE_OR_GENE_PRODUCT", 263, 267], ["DosR", "GENE_OR_GENE_PRODUCT", 269, 273], ["FurA", "GENE_OR_GENE_PRODUCT", 275, 279], ["IdeR", "GENE_OR_GENE_PRODUCT", 281, 285], ["KstR", "GENE_OR_GENE_PRODUCT", 287, 291], ["MprAB", "GENE_OR_GENE_PRODUCT", 293, 298], ["ZurB", "GENE_OR_GENE_PRODUCT", 304, 308], ["E. coli", "ORGANISM", 338, 345], ["Mtb motifs", "PROTEIN", 241, 251], ["Acr", "PROTEIN", 253, 256], ["Crp", "PROTEIN", 258, 261], ["CsoR", "PROTEIN", 263, 267], ["DosR", "PROTEIN", 269, 273], ["FurA", "PROTEIN", 275, 279], ["IdeR", "PROTEIN", 281, 285], ["KstR", "PROTEIN", 287, 291], ["MprAB", "PROTEIN", 293, 298], ["ZurB", "PROTEIN", 304, 308], ["E. coli", "SPECIES", 338, 345], ["E. coli", "SPECIES", 338, 345], ["specificity score", "TEST", 41, 58], ["palindromicity", "TEST", 68, 82], ["MAP score", "TEST", 90, 99], ["MethodsMotifs", "TREATMENT", 169, 182], ["Acr", "TEST", 253, 256], ["Crp", "TEST", 258, 261], ["CsoR", "TEST", 263, 267], ["MprAB", "TREATMENT", 293, 298], ["Corynebacterial motifs", "TEST", 365, 387]]], ["Comparison of motifs was done using CompareACE [76].Defining groups based on expression under different lipids ::: MethodsWe separated the experiments in our compendium of Mtb H37Rv microarray experiments into separate conditions based on what nutrients were present in their growth conditions (focusing on different lipid conditions, because of the observed importance of lipid metabolism in these organisms).", [["lipid", "SIMPLE_CHEMICAL", 373, 378], ["H37Rv", "SPECIES", 176, 181], ["Mtb H37Rv microarray experiments", "TREATMENT", 172, 204], ["different lipid conditions", "TREATMENT", 307, 333], ["lipid metabolism", "PROBLEM", 373, 389]]], ["The following categories were used (the number of experiments in each category is shown in parentheses): Palmitic acid (168), Oleic acid (102), Arachidonic and Eicosatetraynoic acids (76), Linoleic acid (41), Eicosatetraynoic acid (13), Ceramide (4), Nordihydroguaiaretic (3), Cholesterol (2), Glucose (1), KstR knockout (1), KstR knockout with cholesterol added (1).Defining groups based on expression under different lipids ::: MethodsWithin each experiment, we extracted a list of genes upregulated 1.5 and 2 standard deviations above the mean.", [["Palmitic acid", "CHEMICAL", 105, 118], ["Oleic acid", "CHEMICAL", 126, 136], ["Arachidonic", "CHEMICAL", 144, 155], ["Eicosatetraynoic acids", "CHEMICAL", 160, 182], ["Linoleic acid", "CHEMICAL", 189, 202], ["Eicosatetraynoic acid", "CHEMICAL", 209, 230], ["Ceramide", "CHEMICAL", 237, 245], ["Nordihydroguaiaretic", "CHEMICAL", 251, 271], ["Cholesterol", "CHEMICAL", 277, 288], ["Glucose", "CHEMICAL", 294, 301], ["cholesterol", "CHEMICAL", 345, 356], ["Palmitic acid", "CHEMICAL", 105, 118], ["Oleic acid", "CHEMICAL", 126, 136], ["Arachidonic and Eicosatetraynoic acids", "CHEMICAL", 144, 182], ["Linoleic acid", "CHEMICAL", 189, 202], ["Eicosatetraynoic acid", "CHEMICAL", 209, 230], ["Ceramide", "CHEMICAL", 237, 245], ["Nordihydroguaiaretic", "CHEMICAL", 251, 271], ["Cholesterol", "CHEMICAL", 277, 288], ["Glucose", "CHEMICAL", 294, 301], ["cholesterol", "CHEMICAL", 345, 356], ["Palmitic acid", "SIMPLE_CHEMICAL", 105, 118], ["Oleic acid", "SIMPLE_CHEMICAL", 126, 136], ["Arachidonic", "SIMPLE_CHEMICAL", 144, 155], ["Eicosatetraynoic acids", "SIMPLE_CHEMICAL", 160, 182], ["Linoleic acid", "SIMPLE_CHEMICAL", 189, 202], ["Eicosatetraynoic acid", "SIMPLE_CHEMICAL", 209, 230], ["Ceramide", "SIMPLE_CHEMICAL", 237, 245], ["Nordihydroguaiaretic", "SIMPLE_CHEMICAL", 251, 271], ["Cholesterol", "SIMPLE_CHEMICAL", 277, 288], ["Glucose", "SIMPLE_CHEMICAL", 294, 301], ["KstR", "SIMPLE_CHEMICAL", 307, 311], ["KstR", "GENE_OR_GENE_PRODUCT", 326, 330], ["cholesterol", "SIMPLE_CHEMICAL", 345, 356], ["Palmitic acid", "TEST", 105, 118], ["Oleic acid", "TEST", 126, 136], ["Arachidonic and Eicosatetraynoic acids", "TREATMENT", 144, 182], ["Linoleic acid", "TEST", 189, 202], ["Eicosatetraynoic acid", "TREATMENT", 209, 230], ["Ceramide", "TREATMENT", 237, 245], ["Nordihydroguaiaretic", "TREATMENT", 251, 271], ["Cholesterol", "TEST", 277, 288], ["Glucose", "TEST", 294, 301], ["KstR knockout", "TREATMENT", 307, 320], ["KstR knockout with cholesterol", "TREATMENT", 326, 356]]], ["We then searched for genes that were only upregulated under certain conditions or sets of conditions.Defining groups based on expression under different lipids ::: MethodsWe looked at the evolution of these sets of Mtb H37Rv genes by taking the other members of their orthogroups across all 31 other organisms.", [["Mtb H37Rv", "GENE_OR_GENE_PRODUCT", 215, 224], ["Mtb H37Rv genes", "DNA", 215, 230], ["H37Rv", "SPECIES", 219, 224]]], ["Evolution of these groups can be visualized in our supplementary information http://www.broadinstitute.org/ftp/pub/seq/msc/pub/SYNERGY/index.html.dN/dS Analysis ::: MethodsWe used PAML to calculate dN/dS values according to several different evolutionary models [100,101].", [["dN/dS values", "TEST", 198, 210]]], ["Since orthogroups contain paralogs as well as orthologs, we used the gene trees output from SYNERGY when running PAML.", [["SYNERGY", "DNA", 92, 99], ["paralogs", "OBSERVATION", 26, 34]]], ["Some orthogroups may contain single-copy orthologs in only two closely related organisms, whereas others could contain paralogs in all 31 organisms.dN/dS Analysis ::: MethodsFor the basic model, we used the following parameters: model = 0 and getSE = 1 (to calculate standard errors).", [["single-copy orthologs", "TEST", 29, 50]]], ["This simple evolutionary model gives one value of dN/dS for each orthogroup, averaged over all lineages as well as all positions in the gene [102].", [["dN", "DNA", 50, 52], ["dN/dS", "PROBLEM", 50, 55]]], ["While this model does not reflect the evolutionary history that has taken place, it is nevertheless a very blunt yet efficient tool for observing selection.dN/dS Analysis ::: MethodsTo gain insight into the evolution of the three major clades of the phylogenetic tree we also used a \"branch model\" where a different dN/dS value is allowed on a \"foreground\" branch (but dN/dS is averaged along positions in the protein) [103,104].", [["dN", "DNA", 316, 318], ["a very blunt", "PROBLEM", 100, 112], ["Methods", "TREATMENT", 175, 182], ["a different dN/dS value", "PROBLEM", 304, 327], ["dN/dS", "PROBLEM", 369, 374], ["does not reflect", "UNCERTAINTY", 17, 33], ["phylogenetic tree", "OBSERVATION", 250, 267], ["branch", "ANATOMY_MODIFIER", 357, 363]]], ["For each of the three foreground branches, we used a Bonferroni correction equal to the number of orthogroups present at the branch.", [["a Bonferroni correction", "TREATMENT", 51, 74], ["branches", "OBSERVATION_MODIFIER", 33, 41], ["branch", "ANATOMY_MODIFIER", 125, 131]]], ["We ran this separately for three different \"foreground\" branches on the phylogenetic tree (labeled in Figure 1): A) The branch leading to the Mtb complex; B) The branch leading to pathogenic Mycobacteria; and C) The branch leading to soil-dwelling, non-pathogenic Mycobacteria.", [["Mycobacteria", "DISEASE", 264, 276], ["Mtb complex", "PROTEIN", 142, 153], ["B", "PROTEIN", 155, 156], ["the Mtb complex", "PROBLEM", 138, 153], ["pathogenic Mycobacteria", "PROBLEM", 180, 203], ["non-pathogenic Mycobacteria", "PROBLEM", 249, 276], ["branches", "ANATOMY_MODIFIER", 56, 64], ["tree", "ANATOMY_MODIFIER", 85, 89], ["branch", "ANATOMY_MODIFIER", 120, 126], ["branch", "ANATOMY_MODIFIER", 162, 168], ["pathogenic", "OBSERVATION_MODIFIER", 180, 190], ["Mycobacteria", "OBSERVATION", 191, 203], ["branch", "ANATOMY_MODIFIER", 216, 222], ["non-pathogenic", "OBSERVATION_MODIFIER", 249, 263], ["Mycobacteria", "OBSERVATION", 264, 276]]], ["The log-likelihood model that we use here compares this branch model to the simple model with a single value of dN/dS described above, and tests whether the model allowing dN/dS to differ on the foreground branch fits the data better than the basic model.dN/dS Analysis ::: MethodsBranch-site models allow dN/dS to vary across branches of the tree and among sites in the protein.", [["dN", "DNA", 172, 174], ["Branch-site models", "DNA", 281, 299], ["dN/dS", "DNA", 306, 311], ["dN/dS", "PROBLEM", 112, 117], ["dN/dS", "TREATMENT", 172, 177], ["MethodsBranch", "TREATMENT", 274, 287], ["dN/dS", "TREATMENT", 306, 311], ["branches", "ANATOMY_MODIFIER", 327, 335], ["tree", "ANATOMY_MODIFIER", 343, 347]]], ["We also used the branch-site model of Zhang and Nielsen [100] using Model = 2, NSsites = 2, and fix_blength = 2.", [["Zhang and Nielsen", "TREATMENT", 38, 55], ["NSsites", "TREATMENT", 79, 86], ["fix_blength", "TREATMENT", 96, 107], ["branch", "ANATOMY_MODIFIER", 17, 23]]], ["We used the model = 0 calculations to determine branch lengths for the branch-site model calculations to save computational time.", [["the model = 0 calculations", "TREATMENT", 8, 34], ["the branch-site model calculations", "TREATMENT", 67, 101], ["branch", "ANATOMY_MODIFIER", 71, 77]]], ["We chose the same three sets of branches (A-C) that we used for the branch model described above.", [["A-C)", "TREATMENT", 42, 46], ["branches", "ANATOMY_MODIFIER", 32, 40], ["branch", "ANATOMY_MODIFIER", 68, 74]]], ["For each of the three foreground branches, we used a Bonferroni correction equal to the number of orthogroups present at the branch.", [["a Bonferroni correction", "TREATMENT", 51, 74], ["branches", "OBSERVATION_MODIFIER", 33, 41], ["branch", "ANATOMY_MODIFIER", 125, 131]]], ["The branch-site model was the most informative.dN/dS Analysis ::: MethodsWe calculated the functional group over-representations separately for each functional group dataset.", [["branch", "ANATOMY_MODIFIER", 4, 10], ["site model", "OBSERVATION", 11, 21]]], ["These datasets included 21 COG categories, 168 KEGG categories, 749 metabolic pathways, and 7 additional Mycobacteria-specific groupings (PE genes, PPE genes, toxin-antitoxin genes, DosR regulon, esx genes, Rv0474 regulon, and the KstR regulon).", [["PE", "GENE_OR_GENE_PRODUCT", 138, 140], ["PPE", "GENE_OR_GENE_PRODUCT", 148, 151], ["toxin-antitoxin", "GENE_OR_GENE_PRODUCT", 159, 174], ["DosR", "GENE_OR_GENE_PRODUCT", 182, 186], ["esx", "GENE_OR_GENE_PRODUCT", 196, 199], ["Rv0474", "GENE_OR_GENE_PRODUCT", 207, 213], ["KstR", "GENE_OR_GENE_PRODUCT", 231, 235], ["PE genes", "DNA", 138, 146], ["PPE genes", "DNA", 148, 157], ["toxin-antitoxin genes", "DNA", 159, 180], ["DosR regulon", "DNA", 182, 194], ["esx genes", "DNA", 196, 205], ["Rv0474 regulon", "DNA", 207, 221], ["KstR regulon", "DNA", 231, 243], ["These datasets", "TEST", 0, 14], ["COG categories", "TEST", 27, 41], ["KEGG categories", "TEST", 47, 62], ["metabolic pathways", "TEST", 68, 86], ["additional Mycobacteria", "TEST", 94, 117], ["PE genes", "PROBLEM", 138, 146], ["PPE genes", "TEST", 148, 157], ["toxin", "TEST", 159, 164], ["antitoxin genes", "TREATMENT", 165, 180], ["DosR regulon", "TREATMENT", 182, 194], ["the KstR regulon", "TREATMENT", 227, 243], ["Mycobacteria", "OBSERVATION", 105, 117], ["PE", "OBSERVATION", 138, 140]]], ["We multiplied the hypergeometric p-values by a Bonferroni correction equal to the number of categories or tests performed.Generating multi-genome alignments ::: MethodsWe constructed whole-genome alignments of all 31 organisms, as well as subsets including only Mycobacterial organisms, and organisms within the Mtb complex.", [["Mtb", "GENE_OR_GENE_PRODUCT", 312, 315], ["multi-genome alignments", "DNA", 133, 156], ["Mtb complex", "PROTEIN", 312, 323], ["a Bonferroni correction", "TREATMENT", 45, 68], ["tests", "TEST", 106, 111], ["all 31 organisms", "TEST", 210, 226], ["Mycobacterial organisms", "TEST", 262, 285], ["organisms within the Mtb complex", "PROBLEM", 291, 323], ["Mycobacterial organisms", "OBSERVATION", 262, 285], ["Mtb complex", "OBSERVATION", 312, 323]]], ["Our whole genome multiple alignments reveal unannotated stretches of conservation in noncoding regions including transcription factor binding sites in promoter regions, noncoding RNAs, and mis-annotated proteins.Generating multi-genome alignments ::: MethodsTo generate whole-genome multiple alignments, we first aligned the reference genome to each target genome in a pairwise manner.", [["noncoding regions", "DNA", 85, 102], ["transcription factor binding sites", "DNA", 113, 147], ["promoter regions", "DNA", 151, 167], ["noncoding RNAs", "RNA", 169, 183], ["mis-annotated proteins", "PROTEIN", 189, 211], ["multi-genome alignments", "DNA", 223, 246], ["reference genome", "DNA", 325, 341], ["target genome", "DNA", 350, 363], ["conservation in noncoding regions", "TREATMENT", 69, 102], ["transcription factor binding sites", "PROBLEM", 113, 147], ["noncoding RNAs", "PROBLEM", 169, 183], ["Methods", "TREATMENT", 251, 258], ["stretches", "OBSERVATION_MODIFIER", 56, 65], ["binding sites", "OBSERVATION", 134, 147], ["noncoding RNAs", "OBSERVATION", 169, 183], ["multiple alignments", "OBSERVATION", 283, 302]]], ["The process of pairwise whole-genome alignment consists of using PatternHunter [105] to identify anchors of local alignment, grouping collinear anchors separated by a limited distance into chains, filtering out smaller chains that shadow larger ones, and finally using LAGAN [106] to globally align the entire chain.", [["local alignment", "OBSERVATION", 108, 123], ["smaller", "OBSERVATION_MODIFIER", 211, 218], ["chains", "OBSERVATION_MODIFIER", 219, 225], ["shadow", "OBSERVATION_MODIFIER", 231, 237], ["larger", "OBSERVATION_MODIFIER", 238, 244], ["entire", "OBSERVATION_MODIFIER", 303, 309], ["chain", "OBSERVATION_MODIFIER", 310, 315]]], ["Once all genomes have been aligned to the reference, we then identified intervals of the reference that map tightly to a single interval of some or all of the target genomes, and we consider these the endpoints of blocks of multiple alignment.", [["target genomes", "DNA", 159, 173], ["multiple", "OBSERVATION_MODIFIER", 224, 232], ["alignment", "OBSERVATION_MODIFIER", 233, 242]]], ["These blocks are generally smaller than any precursor pairwise alignment, because a rearrangement or loss of detectable similarity in any genome will truncate the block for all member genomes.", [["member genomes", "DNA", 177, 191], ["These blocks", "PROBLEM", 0, 12], ["generally", "OBSERVATION_MODIFIER", 17, 26], ["smaller", "OBSERVATION_MODIFIER", 27, 34], ["pairwise alignment", "OBSERVATION", 54, 72]]], ["We then ran the multiple aligner MLAGAN on each block.", [["multiple aligner MLAGAN", "DNA", 16, 39], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["aligner", "OBSERVATION", 25, 32]]], ["Finally, to facilitate searches for constrained regions of the reference, we projected the blocks onto the reference genome, effectively unwinding all genome rearrangements in the target genomes relative to the reference.", [["reference genome", "DNA", 107, 123], ["genome rearrangements", "DNA", 151, 172], ["target genomes", "DNA", 180, 194]]], ["We visualized the alignments in the GenomeView browser [64].Selecting conserved regions within the alignments ::: MethodsWe used Gumby [65] to select conserved regions in our multiple alignments using a value of p < 0.5.", [["a value", "TEST", 201, 208]]], ["In a multiple alignment of all 19 Mycobacterial genomes, we identified 4697 regions of conservation overlapping coding genes in the reference annotation, and 394 regions in intergenic regions.Selecting conserved regions within the alignments ::: MethodsWe also used the method of Ruzzo and Tompa [107] to identify conserved regions.", [["Mycobacterial genomes", "DNA", 34, 55], ["4697 regions", "DNA", 71, 83], ["394 regions", "DNA", 158, 169], ["intergenic regions", "DNA", 173, 191], ["multiple", "OBSERVATION_MODIFIER", 5, 13], ["alignment", "OBSERVATION_MODIFIER", 14, 23], ["Mycobacterial genomes", "OBSERVATION", 34, 55], ["intergenic", "ANATOMY_MODIFIER", 173, 183], ["regions", "ANATOMY_MODIFIER", 184, 191]]], ["Scores were normalized to the background inferred from the 3 rd-base frequencies.", [["Scores", "TEST", 0, 6], ["base", "ANATOMY_MODIFIER", 64, 68]]], ["For all H37Rv coding sequences, all bases in the third position were extracted from the 31-way multiple alignment.", [["H37Rv coding sequences", "DNA", 8, 30], ["H37Rv", "SPECIES", 8, 13], ["all H37Rv coding sequences", "TEST", 4, 30], ["bases", "ANATOMY_MODIFIER", 36, 41], ["multiple", "OBSERVATION_MODIFIER", 95, 103], ["alignment", "OBSERVATION_MODIFIER", 104, 113]]], ["These were concatenated in a new multiple alignment only containing third bases.", [["new", "OBSERVATION_MODIFIER", 29, 32], ["multiple", "OBSERVATION_MODIFIER", 33, 41], ["alignment", "OBSERVATION", 42, 51], ["third", "ANATOMY_MODIFIER", 68, 73], ["bases", "ANATOMY_MODIFIER", 74, 79]]], ["From this new multiple alignment we calculated the baseline conservation which is used to normalize the conservation scores for the regular alignment.", [["the baseline conservation", "TREATMENT", 47, 72], ["new", "OBSERVATION_MODIFIER", 10, 13], ["multiple", "OBSERVATION_MODIFIER", 14, 22], ["alignment", "OBSERVATION_MODIFIER", 23, 32]]], ["Both sets of highly conserved regions can be viewed as alignment tracks for the GenomeView browser [64], downloadable on our website.Predicting RNAs ::: MethodsWe predicted regions likely to form RNAs within the conserved intergenic regions of our multiple alignment of 19 Mycobacteria, using Evofold [66].", [["RNAs", "RNA", 144, 148], ["conserved intergenic regions", "DNA", 212, 240], ["MethodsWe predicted regions", "PROBLEM", 153, 180], ["intergenic", "OBSERVATION_MODIFIER", 222, 232], ["multiple", "OBSERVATION_MODIFIER", 248, 256], ["alignment", "OBSERVATION_MODIFIER", 257, 266]]], ["We divided the intergenic region into 240-bp segments, tiled by 80 bp, to run Evofold.", [["intergenic region", "DNA", 15, 32], ["240-bp segments", "DNA", 38, 53], ["bp", "TEST", 67, 69], ["intergenic", "OBSERVATION_MODIFIER", 15, 25]]], ["Looking within intergenic regions, we identified 536 regions with Evofold (regions greater than 5 bp in length with length-normalized folding potential score > 0.2).Predicting RNAs ::: MethodsWe examined these 536 regions, as well as the 394 conserved intergenic regions found by Gumby, to see if any of these showed significant expression in our log-phase Mtb RNA-seq data.", [["intergenic regions", "DNA", 15, 33], ["536 regions", "DNA", 49, 60], ["Evofold", "DNA", 66, 73], ["RNAs", "RNA", 176, 180], ["536 regions", "DNA", 210, 221], ["394 conserved intergenic regions", "DNA", 238, 270], ["Evofold (regions", "PROBLEM", 66, 82], ["bp", "TEST", 98, 100], ["length", "TEST", 104, 110], ["length", "TEST", 116, 122], ["score", "TEST", 152, 157], ["Methods", "TREATMENT", 185, 192]]], ["We calculated RPKM [108] values for each of these regions.", [["RPKM", "TEST", 14, 18]]], ["We examined the regions with RPKM value \u2265200 and a number of RNA-seq reads \u2265 20.", [["RPKM value", "TEST", 29, 39], ["RNA", "TEST", 61, 64]]], ["We eliminated an additional 35 regions which corresponded to known RNAs from the Mtb annotation, or RNAs similar to those found in M. bovis and Streptococcus [60-63], including 26 tRNAs, 2 riboswitches, and 3 found in other organisms.Predicting RNAs ::: MethodsTo select intergenic regions with high levels of expression that do not correspond to UTRs, we also calculated RPKM values for the 100 bp regions of the flanking genes closest to the intergenic regions.", [["Mtb", "GENE_OR_GENE_PRODUCT", 81, 84], ["M. bovis", "ORGANISM", 131, 139], ["Streptococcus", "ORGANISM", 144, 157], ["RNAs", "RNA", 67, 71], ["RNAs", "RNA", 245, 249], ["intergenic regions", "DNA", 271, 289], ["UTRs", "DNA", 347, 351], ["100 bp regions", "DNA", 392, 406], ["flanking genes", "DNA", 414, 428], ["intergenic regions", "DNA", 444, 462], ["M. bovis", "SPECIES", 131, 139], ["M. bovis", "SPECIES", 131, 139], ["known RNAs", "PROBLEM", 61, 71], ["the Mtb annotation", "TEST", 77, 95], ["RNAs", "PROBLEM", 100, 104], ["M. bovis", "TEST", 131, 139], ["Streptococcus", "TEST", 144, 157], ["26 tRNAs, 2 riboswitches", "PROBLEM", 177, 201], ["Methods", "TREATMENT", 254, 261], ["RPKM values", "TEST", 372, 383], ["high levels", "OBSERVATION_MODIFIER", 295, 306], ["flanking genes", "OBSERVATION", 414, 428], ["intergenic", "ANATOMY_MODIFIER", 444, 454], ["regions", "ANATOMY_MODIFIER", 455, 462]]], ["We selected those intergenic regions with the highest ratio of the RPKM value of the region of interest (within the intergenic region) to the RPKM of the start/stop of the flanking genes.", [["intergenic regions", "DNA", 18, 36], ["intergenic region", "DNA", 116, 133], ["RPKM", "DNA", 142, 146], ["start/stop", "DNA", 154, 164], ["flanking genes", "DNA", 172, 186], ["intergenic", "OBSERVATION_MODIFIER", 18, 28], ["highest", "OBSERVATION_MODIFIER", 46, 53], ["region", "ANATOMY_MODIFIER", 85, 91], ["intergenic", "OBSERVATION_MODIFIER", 116, 126], ["flanking genes", "OBSERVATION", 172, 186]]], ["We also looked for regions with a gap in expression between the gene and the region of interest.", [["gap", "OBSERVATION", 34, 37]]], ["This will eliminate many regions that merely correspond to UTRs, and select for regions that are disproportionately expressed within the intergenic region only.", [["UTRs", "DNA", 59, 63], ["intergenic region", "DNA", 137, 154], ["UTRs", "TEST", 59, 63], ["disproportionately", "OBSERVATION_MODIFIER", 97, 115], ["intergenic", "ANATOMY_MODIFIER", 137, 147], ["region", "ANATOMY_MODIFIER", 148, 154]]], ["We found this method to be most useful for selecting regions of interest, and successfully enriched our top hits for previously known small RNAs.", [["small RNAs", "RNA", 134, 144], ["previously known small RNAs", "PROBLEM", 117, 144], ["small RNAs", "OBSERVATION", 134, 144]]], ["The top 50 predicted RNAs can be viewed as a track in the GenomeView browser (see Supplementary Information).Predicting RNAs ::: MethodsWe further examined log-phase RNA-seq data from M. smegmatis to confirm that many of the orthologous regions also show expression in M. smegmatis.Strain, media, and culture conditions for RNA-seq ::: MethodsMycobacterium tuberculosis H37Rv and M. smegmatis were grown at 37\u00b0c in 7H9 media supplemented with 10% ADC (Becton Dickinson), 0.2% glycerol and 0.05% Tween 80.", [["glycerol", "CHEMICAL", 476, 484], ["glycerol", "CHEMICAL", 476, 484], ["Tween 80", "CHEMICAL", 495, 503], ["M. smegmatis", "GENE_OR_GENE_PRODUCT", 184, 196], ["M. smegmatis", "ORGANISM", 269, 281], ["MethodsMycobacterium tuberculosis H37Rv", "ORGANISM", 336, 375], ["M. smegmatis", "ORGANISM", 380, 392], ["glycerol", "SIMPLE_CHEMICAL", 476, 484], ["GenomeView browser", "DNA", 58, 76], ["RNAs", "RNA", 120, 124], ["orthologous regions", "DNA", 225, 244], ["M. smegmatis", "SPECIES", 184, 196], ["M. smegmatis", "SPECIES", 269, 281], ["MethodsMycobacterium tuberculosis H37Rv", "SPECIES", 336, 375], ["M. smegmatis", "SPECIES", 380, 392], ["M. smegmatis", "SPECIES", 184, 196], ["M. smegmatis", "SPECIES", 269, 281], ["MethodsMycobacterium tuberculosis H37Rv", "SPECIES", 336, 375], ["M. smegmatis", "SPECIES", 380, 392], ["The top 50 predicted RNAs", "TREATMENT", 0, 25], ["M. smegmatis", "TEST", 184, 196], ["expression in M. smegmatis", "PROBLEM", 255, 281], ["Strain", "PROBLEM", 282, 288], ["culture conditions", "TEST", 301, 319], ["RNA", "TEST", 324, 327], ["MethodsMycobacterium tuberculosis H37Rv", "PROBLEM", 336, 375], ["M. smegmatis", "PROBLEM", 380, 392], ["10% ADC (Becton Dickinson)", "TREATMENT", 443, 469], ["0.2% glycerol", "TREATMENT", 471, 484], ["M. smegmatis", "OBSERVATION", 269, 281]]], ["For log phase, cells were grown to OD540 0.2.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20]]], ["Roller bottles were used for culturing M. tuberculosis, and shaker flasks for M. smegmatis.RNA isolation from in vitro cultures for RNA-seq ::: MethodsBacterial pellet from log-phase cultures of M. tuberculosis and M. smegmatis were resuspended in TRIzol reagent (Invitrogen) and immediately transferred to 2 ml screw-cap tubes containing 0.1 mm zirconia/silica beads (BioSpec Products).", [["tuberculosis", "DISEASE", 198, 210], ["zirconia/silica", "CHEMICAL", 346, 361], ["zirconia", "CHEMICAL", 346, 354], ["silica", "CHEMICAL", 355, 361], ["M. tuberculosis", "ORGANISM", 39, 54], ["M. smegmatis", "ORGANISM", 78, 90], ["M. tuberculosis", "ORGANISM", 195, 210], ["M. smegmatis", "ORGANISM", 215, 227], ["silica beads", "SIMPLE_CHEMICAL", 355, 367], ["M. tuberculosis", "SPECIES", 39, 54], ["M. smegmatis", "SPECIES", 78, 90], ["M. tuberculosis", "SPECIES", 195, 210], ["M. smegmatis", "SPECIES", 215, 227], ["M. tuberculosis", "SPECIES", 39, 54], ["M. smegmatis", "SPECIES", 78, 90], ["M. tuberculosis", "SPECIES", 195, 210], ["M. smegmatis", "SPECIES", 215, 227], ["Roller bottles", "TREATMENT", 0, 14], ["culturing M. tuberculosis", "PROBLEM", 29, 54], ["M. smegmatis", "PROBLEM", 78, 90], ["RNA isolation", "TEST", 91, 104], ["vitro cultures", "TEST", 113, 127], ["MethodsBacterial pellet", "TREATMENT", 144, 167], ["log-phase cultures", "TEST", 173, 191], ["M. tuberculosis", "PROBLEM", 195, 210], ["M. smegmatis", "PROBLEM", 215, 227], ["TRIzol reagent", "TREATMENT", 248, 262], ["2 ml screw-cap tubes", "TREATMENT", 307, 327], ["0.1 mm zirconia/silica beads (BioSpec Products", "TREATMENT", 339, 385], ["tuberculosis", "OBSERVATION", 42, 54], ["tuberculosis", "OBSERVATION", 198, 210], ["cap tubes", "OBSERVATION", 318, 327], ["silica beads", "OBSERVATION", 355, 367]]], ["M. tuberculosis cells were lysed using a FastPrep-24 bead-beater (MP Biomedicals) 3 times for 30 seconds each at speed 6.", [["cells", "ANATOMY", 16, 21], ["tuberculosis", "DISEASE", 3, 15], ["M. tuberculosis cells", "CELL", 0, 21], ["M. tuberculosis", "SPECIES", 0, 15], ["M. tuberculosis", "SPECIES", 0, 15], ["M. tuberculosis cells", "PROBLEM", 0, 21], ["a FastPrep", "TEST", 39, 49], ["bead-beater (MP Biomedicals)", "TREATMENT", 53, 81], ["tuberculosis cells", "OBSERVATION", 3, 21]]], ["M. smegmatis cells were lysed using MagNalyser (Roche).", [["cells", "ANATOMY", 13, 18], ["M. smegmatis cells", "CELL", 0, 18], ["M. smegmatis", "SPECIES", 0, 12], ["M. smegmatis", "SPECIES", 0, 12], ["M. smegmatis cells", "PROBLEM", 0, 18], ["smegmatis cells", "OBSERVATION", 3, 18]]], ["Samples were kept on ice for 1 min between pulses.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["The TRIzol extracted RNA was treated twice with DNAse and further purified using RNAeasy kit (Qiagen).Directional mRNA-seq libraries for RNA-seq ::: MethodsWe generated mRNA-seq libraries for sequencing on Illumina's GA Sequencer (San Diego, CA).", [["DNAse", "GENE_OR_GENE_PRODUCT", 48, 53], ["DNAse", "PROTEIN", 48, 53], ["The TRIzol extracted RNA", "TREATMENT", 0, 24], ["DNAse", "TREATMENT", 48, 53], ["RNAeasy kit (Qiagen)", "TREATMENT", 81, 101], ["Directional mRNA", "TEST", 102, 118], ["Illumina's GA Sequencer", "TEST", 206, 229]]], ["2 \u03bcg purified RNA was depleted of ribosomal RNA using Ambion's MICROBExpress Kit (Austin, TX) as per manufacture's recommended protocol.", [["ribosomal", "ANATOMY", 34, 43], ["ribosomal", "CELLULAR_COMPONENT", 34, 43], ["2 \u03bcg purified RNA", "RNA", 0, 17], ["ribosomal RNA", "RNA", 34, 47], ["2 \u03bcg purified RNA", "TREATMENT", 0, 17], ["ribosomal RNA", "TREATMENT", 34, 47], ["Ambion", "TREATMENT", 54, 60], ["ribosomal RNA", "OBSERVATION", 34, 47]]], ["The enriched mRNA was used to prepare libraries using Illumina's Directional mRNA-seq Library Prep v1.0 protocol.", [["enriched mRNA", "RNA", 4, 17], ["The enriched mRNA", "TREATMENT", 0, 17], ["Illumina's Directional mRNA", "TREATMENT", 54, 81]]], ["Briefly, 100 ng mRNA was fragmented with cations and heat, end-repaired, adapted by sequential ligation of unique 5-prime and 3-prime adapters, reverse transcribed, PCR amplified, and purified using Agencourt's AMPure Beads (Beverly, MA).", [["cations", "SIMPLE_CHEMICAL", 41, 48], ["100 ng mRNA", "RNA", 9, 20], ["5-prime and 3-prime adapters", "DNA", 114, 142], ["cations and heat", "TREATMENT", 41, 57], ["PCR", "TEST", 165, 168], ["Agencourt's AMPure Beads", "TREATMENT", 199, 223]]], ["The libraries were visualized on an Agilent 2100 Bioanalyzer (Santa Clara, CA) and found to have the expected average fragment length of ~250 bp.RNA isolation and Northern Blotting ::: MethodsTotal RNA was isolated from Mtb as described previously [109] with minor modifications.", [["Mtb", "GENE_OR_GENE_PRODUCT", 220, 223], ["MethodsTotal RNA", "RNA", 185, 201], ["bp", "TEST", 142, 144], ["MethodsTotal RNA", "PROBLEM", 185, 201], ["Mtb", "PROBLEM", 220, 223], ["average", "OBSERVATION_MODIFIER", 110, 117], ["fragment", "OBSERVATION_MODIFIER", 118, 126], ["length", "OBSERVATION_MODIFIER", 127, 133]]], ["Briefly, log-phase cells were pelleted, resuspended in TRIzol (Invitrogen), and transferred to Lysing Matrix B tube (QBiogene).", [["log-phase cells", "ANATOMY", 9, 24], ["cells", "CELL", 19, 24], ["log-phase cells", "CELL_LINE", 9, 24], ["log-phase cells", "TREATMENT", 9, 24], ["TRIzol", "TREATMENT", 55, 61], ["Lysing Matrix B tube (QBiogene)", "TREATMENT", 95, 126], ["tube", "OBSERVATION", 111, 115]]], ["The cells were lysed using MagNalyser (Roche), and RNA extracted with Trizol reagent as instructed by the manufacturer.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["MagNalyser", "PROTEIN", 27, 37], ["MagNalyser (Roche)", "TREATMENT", 27, 45], ["Trizol reagent", "TREATMENT", 70, 84]]], ["RNA was treated with Turbo DNase (Ambion) for 30 minutes at 37\u00b0C twice and purified further using TRIzol solution and 100% Ethanol.RNA isolation and Northern Blotting ::: MethodsTotal RNA was separated on 10% TBE-Urea acrylamide gels (Bio-Rad) and electroblotted onto Hybond N + membranes (GE Healthcare).", [["Ethanol", "CHEMICAL", 123, 130], ["Urea acrylamide", "CHEMICAL", 213, 228], ["Ethanol", "CHEMICAL", 123, 130], ["Urea acrylamide", "CHEMICAL", 213, 228], ["Hybond", "CHEMICAL", 268, 274], ["DNase", "GENE_OR_GENE_PRODUCT", 27, 32], ["Ambion", "ORGANISM_SUBSTANCE", 34, 40], ["Ethanol", "SIMPLE_CHEMICAL", 123, 130], ["TBE-Urea acrylamide", "SIMPLE_CHEMICAL", 209, 228], ["RNA", "RNA", 0, 3], ["Turbo DNase", "PROTEIN", 21, 32], ["Turbo DNase (Ambion", "TREATMENT", 21, 40], ["TRIzol solution", "TREATMENT", 98, 113], ["RNA isolation", "TREATMENT", 131, 144], ["MethodsTotal RNA", "TREATMENT", 171, 187], ["TBE", "TEST", 209, 212], ["Urea acrylamide gels", "TREATMENT", 213, 233]]], ["After UV cross-linking the membranes were pre-hybridized and hybridized with labeled probes at 48\u00b0C as per the DIG manual (Roche).", [["membranes", "ANATOMY", 27, 36], ["membranes", "CELLULAR_COMPONENT", 27, 36]]], ["Probe sequences are CGATGGTCGAAAAGGAACTCGATACGGCTATGCGGTTCT (RNA1), AGTTCACGAAACGAAGAAAGAAGCTAAGAAGACATAGGTT (RNA2), GACTGCCAGCAGGCGCCGCGCAATGCGCTTGCAGGACTTC (RNA3), and GGGTGACATGGCTCAGGGAAGCCCGGGCGGGCTGGGACGT (RNA9).", [["AGTTCACGAAACGAAGAAAGAAGCTAAGAAGACATAGGTT (RNA2)", "GENE_OR_GENE_PRODUCT", 68, 115], ["GACTGCCAGCAGGCGCCGCGCAATGCGCTTGCAGGACTTC (RNA3)", "GENE_OR_GENE_PRODUCT", 117, 164], ["GGGTGACATGGCTCAGGGAAGCCCGGGCGGGCTGGGACGT", "GENE_OR_GENE_PRODUCT", 170, 210], ["Probe sequences", "DNA", 0, 15], ["RNA1", "DNA", 61, 65], ["RNA9", "PROTEIN", 212, 216]]], ["After hybridization the membranes were washed twice using a low stringency buffer (2\u00d7 SSC, 0.1% SDS), and a high stringency buffer (0.1\u00d7 SSC, 0.1% SDS), for 15 and 5 minutes at 48\u00b0C, respectively.", [["membranes", "ANATOMY", 24, 33], ["membranes", "CELLULAR_COMPONENT", 24, 33], ["a low stringency buffer", "TREATMENT", 58, 81], ["a high stringency buffer", "TREATMENT", 106, 130]]], ["The membranes were processed with DIG detection system (Roche) and exposed to X-ray film.AbbreviationsMtb: Mycobacterium tuberculosis; PAH: Polycyclic aromatic hydrocarbons; GO: Gene Ontology; MMR: Mismatch repair.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsAMM performed the analysis and drafted and finalized the manuscript.", [["membranes", "ANATOMY", 4, 13], ["Mycobacterium tuberculosis", "DISEASE", 107, 133], ["PAH", "CHEMICAL", 135, 138], ["Polycyclic aromatic hydrocarbons", "CHEMICAL", 140, 172], ["PAH", "CHEMICAL", 135, 138], ["Polycyclic aromatic hydrocarbons", "CHEMICAL", 140, 172], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["DIG", "SIMPLE_CHEMICAL", 34, 37], ["Mycobacterium tuberculosis", "ORGANISM", 107, 133], ["Polycyclic aromatic hydrocarbons", "SIMPLE_CHEMICAL", 140, 172], ["Mycobacterium tuberculosis", "SPECIES", 107, 133], ["Mycobacterium tuberculosis", "SPECIES", 107, 133], ["X-ray film", "TEST", 78, 88], ["Mycobacterium tuberculosis", "PROBLEM", 107, 133], ["Polycyclic aromatic hydrocarbons", "PROBLEM", 140, 172], ["Mismatch repair", "TREATMENT", 198, 213], ["the analysis", "TEST", 327, 339], ["Mycobacterium tuberculosis", "OBSERVATION", 107, 133], ["Mismatch repair", "OBSERVATION", 198, 213]]], ["BW and RR were involved in many aspects of the comparative analysis.", [["BW", "TEST", 0, 2], ["RR", "TEST", 7, 9], ["the comparative analysis", "TEST", 43, 67]]], ["STP and SR performed the experimental validation.", [["STP", "PROTEIN", 0, 3]]], ["IW and AR performed the SYNERGY analysis.", [["AR", "PROTEIN", 7, 9], ["SYNERGY", "DNA", 24, 31], ["the SYNERGY analysis", "TEST", 20, 40]]], ["GD, GKS, RTY, MIM, MJK, and A. Maer provided the M. tuberculosis RNA-seq data.", [["M. tuberculosis", "SPECIES", 49, 64], ["A. Maer", "SPECIES", 28, 35], ["M. tuberculosis", "SPECIES", 49, 64], ["tuberculosis", "OBSERVATION", 52, 64]]], ["TA provided the GenomeView browser.", [["GenomeView browser", "DNA", 16, 34]]], ["JW, PS, and MK constructed multiple alignments.", [["multiple alignments", "OBSERVATION", 27, 46]]], ["MP worked on motif discovery and network reconstruction.", [["MP", "DISEASE", 0, 2], ["MP", "GENE_OR_GENE_PRODUCT", 0, 2], ["motif discovery", "TREATMENT", 13, 28], ["network reconstruction", "TREATMENT", 33, 55]]], ["JEG initiated and supervised the study, and revised the manuscript.", [["the study", "TEST", 29, 38]]]], "405118050d7e9b739468a6f243409f49e85570aa": [["INTRODUCTIONComplementation is a naturally occurring genetic mechanism that enables the functional rescue of defective or mutant genomes.", [["mutant genomes", "DNA", 122, 136], ["defective or mutant genomes", "PROBLEM", 109, 136]]], ["This phenomenon can be used for in vitro assays.", [["vitro assays", "TEST", 35, 47]]], ["In conventional complementation experiments, a defective genome or protein is rescued by a wild-type (wt) copy (Fig. 1 ).", [["genome", "CELLULAR_COMPONENT", 57, 63], ["defective genome", "DNA", 47, 63], ["a defective genome or protein", "PROBLEM", 45, 74], ["defective genome", "OBSERVATION", 47, 63]]], ["In virology, complementation is a genomic tool used to investigate protein functions and viral particle assembly or establish whether genome replication occurs preferentially through a cis-acting mechanism.", [["genome", "CELLULAR_COMPONENT", 134, 140], ["a genomic tool", "PROBLEM", 32, 46], ["protein functions", "PROBLEM", 67, 84], ["viral particle", "PROBLEM", 89, 103], ["genome replication", "PROBLEM", 134, 152], ["viral particle", "OBSERVATION", 89, 103]]], ["Moreover, this model can also be used to produce defective viruses for various purposes.INTRODUCTIONFlaviviridae are positive-strand RNA viruses and replicate their genomes in virus-induced vesicular compartments.", [["vesicular compartments", "ANATOMY", 190, 212], ["vesicular compartments", "MULTI-TISSUE_STRUCTURE", 190, 212], ["defective viruses", "PROBLEM", 49, 66], ["INTRODUCTIONFlaviviridae", "TREATMENT", 88, 112], ["positive", "PROBLEM", 117, 125], ["strand RNA viruses", "PROBLEM", 126, 144], ["viruses", "OBSERVATION", 59, 66], ["positive", "OBSERVATION", 117, 125], ["strand RNA viruses", "OBSERVATION", 126, 144], ["vesicular", "ANATOMY_MODIFIER", 190, 199], ["compartments", "ANATOMY_MODIFIER", 200, 212]]], ["These membranous complexes are rather enclosed structures, which tends to limit to exchange of viral RNA and proteins by trans-complementation [1] .", [["membranous complexes", "ANATOMY", 6, 26], ["membranous complexes", "PROTEIN", 6, 26], ["viral RNA", "RNA", 95, 104], ["viral RNA", "PROBLEM", 95, 104], ["membranous", "OBSERVATION_MODIFIER", 6, 16], ["complexes", "OBSERVATION", 17, 26]]], ["Moreover, for a number of plus-strand RNA viruses from a range of virus families (such as the Picornaviridae (poliovirus), Alphaviridae (Sindbis virus, Semliki Forest virus, and Venezuelan equine encephalitis virus), Coronaviridae (human coronavirus E229) and Flaviviridae (tick-borne encephalitis virus, Kunjin virus, West Nile virus, and yellow fever virus)), assembly of progeny viruses can be achieved when structural proteins are expressed in trans independently of the RNA molecule that encodes the replicase proteins [2] [3] [4] [5] [6] [7] .", [["Sindbis virus", "DISEASE", 137, 150], ["Venezuelan equine encephalitis", "DISEASE", 178, 208], ["human coronavirus E229) and Flaviviridae", "DISEASE", 232, 272], ["tick-borne encephalitis", "DISEASE", 274, 297], ["yellow fever", "DISEASE", 340, 352], ["Picornaviridae", "ORGANISM", 94, 108], ["poliovirus)", "ORGANISM", 110, 121], ["Alphaviridae (", "ORGANISM", 123, 137], ["Sindbis virus", "ORGANISM", 137, 150], ["Semliki Forest virus", "ORGANISM", 152, 172], ["Venezuelan equine encephalitis virus", "ORGANISM", 178, 214], ["human coronavirus E229", "ORGANISM", 232, 254], ["Flaviviridae (", "ORGANISM", 260, 274], ["tick-borne encephalitis virus", "ORGANISM", 274, 303], ["Kunjin virus", "ORGANISM", 305, 317], ["West Nile virus", "ORGANISM", 319, 334], ["yellow fever virus", "ORGANISM", 340, 358], ["[2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 524, 547], ["structural proteins", "PROTEIN", 411, 430], ["RNA molecule", "PROTEIN", 475, 487], ["replicase proteins", "PROTEIN", 505, 523], ["Sindbis virus", "SPECIES", 137, 150], ["Semliki Forest virus", "SPECIES", 152, 172], ["Venezuelan", "SPECIES", 178, 188], ["equine encephalitis virus", "SPECIES", 189, 214], ["human", "SPECIES", 232, 237], ["coronavirus E229", "SPECIES", 238, 254], ["tick-borne encephalitis virus", "SPECIES", 274, 303], ["Kunjin virus", "SPECIES", 305, 317], ["West Nile virus", "SPECIES", 319, 334], ["yellow fever virus", "SPECIES", 340, 358], ["Sindbis virus", "SPECIES", 137, 150], ["Semliki Forest virus", "SPECIES", 152, 172], ["Venezuelan equine encephalitis virus", "SPECIES", 178, 214], ["human coronavirus E229", "SPECIES", 232, 254], ["tick-borne encephalitis virus", "SPECIES", 274, 303], ["Kunjin virus", "SPECIES", 305, 317], ["West Nile virus", "SPECIES", 319, 334], ["yellow fever virus", "SPECIES", 340, 358], ["plus-strand RNA viruses", "PROBLEM", 26, 49], ["virus families", "TREATMENT", 66, 80], ["the Picornaviridae (poliovirus)", "TREATMENT", 90, 121], ["Alphaviridae (Sindbis virus", "TREATMENT", 123, 150], ["Semliki Forest virus", "TREATMENT", 152, 172], ["Venezuelan equine encephalitis virus", "TREATMENT", 178, 214], ["Coronaviridae (human coronavirus E229)", "TREATMENT", 217, 255], ["Flaviviridae (tick-borne encephalitis virus", "TREATMENT", 260, 303], ["Kunjin virus", "PROBLEM", 305, 317], ["West Nile virus", "PROBLEM", 319, 334], ["yellow fever virus", "PROBLEM", 340, 358], ["progeny viruses", "PROBLEM", 374, 389], ["the replicase proteins", "TEST", 501, 523], ["RNA viruses", "OBSERVATION", 38, 49]]], ["The particles are infectious but are only capable of a single round of infection.", [["infection", "DISEASE", 71, 80], ["infectious", "PROBLEM", 18, 28], ["infection", "PROBLEM", 71, 80], ["particles", "OBSERVATION_MODIFIER", 4, 13], ["infectious", "OBSERVATION", 18, 28], ["infection", "OBSERVATION", 71, 80]]], ["These viral transencapsidation systems may also be useful vaccine delivery systems [8] [9] [10] .INTRODUCTIONConcerning HCV, some researchers have reported the presence of natural HCV subgenomic RNAs in the serum and liver tissue of infected patients.", [["serum", "ANATOMY", 207, 212], ["liver tissue", "ANATOMY", 217, 229], ["HCV", "ORGANISM", 120, 123], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["liver tissue", "TISSUE", 217, 229], ["patients", "ORGANISM", 242, 250], ["natural HCV subgenomic RNAs", "RNA", 172, 199], ["patients", "SPECIES", 242, 250], ["HCV", "SPECIES", 120, 123], ["HCV", "SPECIES", 180, 183], ["These viral transencapsidation systems", "TREATMENT", 0, 38], ["vaccine delivery systems", "TREATMENT", 58, 82], ["HCV", "PROBLEM", 120, 123], ["natural HCV subgenomic RNAs", "PROBLEM", 172, 199], ["natural", "OBSERVATION_MODIFIER", 172, 179], ["HCV", "OBSERVATION", 180, 183], ["subgenomic RNAs", "OBSERVATION", 184, 199], ["liver", "ANATOMY", 217, 222], ["infected", "OBSERVATION", 233, 241]]], ["Most of these subgenomic RNAs contain large, in-frame deletions (from E1 up to NS2) and are always found together with the full-length wt RNAs [11] [12] [13] [14] .", [["subgenomic RNAs", "RNA", 14, 29], ["E1", "DNA", 70, 72], ["NS2", "DNA", 79, 82], ["large, in-frame deletions", "PROBLEM", 38, 63], ["subgenomic RNAs", "OBSERVATION", 14, 29], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["The mutant viral genomes persist for at least 2 years and sequence analysis suggests that subgenomic and full-length HCV RNAs evolve independently [14] .", [["HCV", "ORGANISM", 117, 120], ["mutant viral genomes", "DNA", 4, 24], ["HCV RNAs", "RNA", 117, 125], ["HCV", "SPECIES", 117, 120], ["The mutant viral genomes", "PROBLEM", 0, 24], ["sequence analysis", "TEST", 58, 75], ["subgenomic and full-length HCV RNAs", "PROBLEM", 90, 125], ["viral genomes", "OBSERVATION", 11, 24], ["subgenomic", "OBSERVATION", 90, 100]]], ["The relative abundance and persistence of these subgenomic RNAs in vivo suggests that they are capable of autonomous replication and can be packaged and secreted as infectious viral particles.INTRODUCTIONThe first HCV trans-complementation studies concerned the replication complex.", [["subgenomic RNAs", "RNA", 48, 63], ["replication complex", "PROTEIN", 262, 281], ["HCV", "SPECIES", 214, 217], ["these subgenomic RNAs", "PROBLEM", 42, 63], ["autonomous replication", "TREATMENT", 106, 128], ["infectious viral particles", "PROBLEM", 165, 191], ["complementation studies", "TEST", 224, 247], ["abundance", "OBSERVATION_MODIFIER", 13, 22], ["persistence", "OBSERVATION_MODIFIER", 27, 38], ["subgenomic RNAs", "OBSERVATION", 48, 63], ["autonomous replication", "OBSERVATION", 106, 128]]], ["Next, the development of cell-culture-grown hepatitis C virus (HCVcc) systems that can assemble and release of infectious viral particles has made it possible to the study structural regions using trans-complementation systems.", [["cell", "ANATOMY", 25, 29], ["hepatitis C", "DISEASE", 44, 55], ["cell", "CELL", 25, 29], ["hepatitis C virus", "ORGANISM", 44, 61], ["HCVcc", "ORGANISM", 63, 68], ["hepatitis C virus", "SPECIES", 44, 61], ["hepatitis C virus", "SPECIES", 44, 61], ["cell-culture", "TEST", 25, 37], ["hepatitis C virus (HCVcc) systems", "PROBLEM", 44, 77], ["infectious viral particles", "PROBLEM", 111, 137], ["cell", "ANATOMY", 25, 29], ["infectious", "OBSERVATION_MODIFIER", 111, 121]]], ["Furthermore, various trans-packaging systems for HCV subgenomic replicon RNAs have been developed.Trans-complementation of HCV replication by NS5AThe first trans-complementation studies were performed in 2005 by Appel et al. by using subgenomic replicons, such as Con-1 (HCV type 1b, EMBL accession number AJ238799) [15] .", [["HCV", "ORGANISM", 49, 52], ["HCV", "ORGANISM", 123, 126], ["NS5", "ORGANISM", 142, 145], ["Con-1", "GENE_OR_GENE_PRODUCT", 264, 269], ["HCV type 1b", "ORGANISM", 271, 282], ["HCV subgenomic replicon RNAs", "RNA", 49, 77], ["NS5", "PROTEIN", 142, 145], ["subgenomic replicons", "DNA", 234, 254], ["Con-1", "DNA", 264, 269], ["HCV", "SPECIES", 49, 52], ["HCV", "SPECIES", 123, 126], ["various trans-packaging systems", "TREATMENT", 13, 44], ["HCV subgenomic replicon RNAs", "TREATMENT", 49, 77], ["HCV replication", "TREATMENT", 123, 138], ["complementation studies", "TEST", 162, 185], ["subgenomic replicons", "TREATMENT", 234, 254], ["replicon RNAs", "OBSERVATION", 64, 77], ["subgenomic replicons", "OBSERVATION", 234, 254]]], ["The researchers looked at whether lethal mutations in non-structural (NS) HCV genes could be rescued by trans-complementation [1] .", [["non-structural (NS) HCV", "GENE_OR_GENE_PRODUCT", 54, 77], ["non-structural (NS) HCV genes", "DNA", 54, 83], ["HCV", "SPECIES", 74, 77], ["lethal mutations", "PROBLEM", 34, 50], ["non-structural (NS) HCV genes", "TREATMENT", 54, 83]]], ["A series of replicon RNAs carrying mutations (in the NS3, NS4B, NS5A and NS5B regions) that abolished replication were transfected into Huh-7 hepatoma cells harbouring autonomous replicating HCV helper RNAs.", [["Huh-7 hepatoma cells", "ANATOMY", 136, 156], ["NS5A", "GENE_OR_GENE_PRODUCT", 64, 68], ["Huh-7 hepatoma cells", "CELL", 136, 156], ["HCV", "ORGANISM", 191, 194], ["NS3, NS4B, NS5A and NS5B regions", "DNA", 53, 85], ["Huh-7 hepatoma cells", "CELL_LINE", 136, 156], ["HCV helper RNAs", "RNA", 191, 206], ["Huh-7", "SPECIES", 136, 141], ["HCV", "SPECIES", 191, 194], ["replicon RNAs carrying mutations", "TREATMENT", 12, 44], ["the NS3", "TREATMENT", 49, 56], ["NS4B, NS5A and NS5B regions", "TREATMENT", 58, 85], ["Huh", "TEST", 136, 139], ["hepatoma cells", "PROBLEM", 142, 156], ["NS5A", "ANATOMY", 64, 68]]], ["In this context, only NS5A mutations in the low complexity sequence I (LCS I) domain have been efficiently rescued ( Table 1 ).", [["NS5A", "GENE_OR_GENE_PRODUCT", 22, 26], ["NS5A", "PROTEIN", 22, 26], ["LCS I) domain", "PROTEIN", 71, 84], ["NS5A mutations", "PROBLEM", 22, 36], ["NS5A", "OBSERVATION", 22, 26]]], ["The required proteins for complementation were NS3-NS5A, whereas NS5A expressed alone did not restore RNA replication.", [["NS3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS5A", "GENE_OR_GENE_PRODUCT", 51, 55], ["NS5A", "GENE_OR_GENE_PRODUCT", 65, 69], ["NS3", "PROTEIN", 47, 50], ["NS5A", "PROTEIN", 51, 55], ["NS5A", "PROTEIN", 65, 69], ["complementation", "TREATMENT", 26, 41], ["NS3", "TREATMENT", 47, 50], ["NS5A", "TREATMENT", 51, 55], ["NS5A", "TREATMENT", 65, 69], ["RNA replication", "TREATMENT", 102, 117]]], ["These findings strongly suggested that other NS HCV proteins specifically act in cis on HCV RNA and, indeed, the hypothesis was confirmed in 2006 by Tong and Malcom [16] .", [["NS HCV", "ORGANISM", 45, 51], ["HCV", "ORGANISM", 88, 91], ["NS HCV proteins", "PROTEIN", 45, 60], ["HCV RNA", "RNA", 88, 95], ["HCV", "SPECIES", 48, 51], ["HCV", "SPECIES", 88, 91], ["other NS HCV proteins", "PROBLEM", 39, 60], ["HCV RNA", "PROBLEM", 88, 95], ["HCV", "OBSERVATION", 48, 51]]], ["Nevertheless, trans-acting function of NS5A likely would require protein hyperphosphorylation [17] .Trans-complementation of HCV replication by NS5AIn 2008, additional studies showed that deletion of NS5A domain III from the Jc1 genome (HCV chimeric type 2a/2a) [18] does not abolish replication but that pseudoinfectious particles are not produced [19] .", [["NS5A", "GENE_OR_GENE_PRODUCT", 39, 43], ["HCV", "ORGANISM", 125, 128], ["NS5A domain III", "GENE_OR_GENE_PRODUCT", 200, 215], ["Jc1", "GENE_OR_GENE_PRODUCT", 225, 228], ["HCV chimeric type 2a/2a", "ORGANISM", 237, 260], ["NS5A", "PROTEIN", 39, 43], ["NS5A domain III", "PROTEIN", 200, 215], ["Jc1 genome", "DNA", 225, 235], ["HCV", "SPECIES", 125, 128], ["NS5A", "TREATMENT", 39, 43], ["protein hyperphosphorylation", "TREATMENT", 65, 93], ["HCV replication", "TREATMENT", 125, 140], ["additional studies", "TEST", 157, 175], ["deletion of NS5A domain III", "PROBLEM", 188, 215], ["the Jc1 genome", "PROBLEM", 221, 235], ["pseudoinfectious particles", "PROBLEM", 305, 331], ["NS5A", "OBSERVATION", 200, 204]]], ["Therefore, cotransfection of deleted Jc1 with a JFH1 NS3-NS5B replicon rescues HCV particle production (Table 1) .", [["Jc1", "GENE_OR_GENE_PRODUCT", 37, 40], ["JFH1 NS3", "ORGANISM", 48, 56], ["HCV", "ORGANISM", 79, 82], ["Jc1", "DNA", 37, 40], ["JFH1 NS3-NS5B replicon", "DNA", 48, 70], ["HCV", "SPECIES", 79, 82], ["cotransfection of deleted Jc1", "TREATMENT", 11, 40], ["a JFH1 NS3", "TREATMENT", 46, 56], ["NS5B replicon", "TREATMENT", 57, 70]]], ["Taken as a whole, these results have elucidated the key role of NS5A domain III in the HCV assembly process.Trans-complementation of HCV replication by NS4BIn 2009, Jones et al. [20] performed the firstly NS4B transcomplementation using various replicon RNAs carrying various replication-abolishing mutations in the NS4B C-terminal domain.", [["C", "CHEMICAL", 321, 322], ["NS5A domain III", "GENE_OR_GENE_PRODUCT", 64, 79], ["HCV", "ORGANISM", 133, 136], ["NS5A domain III", "PROTEIN", 64, 79], ["NS4B", "PROTEIN", 205, 209], ["NS4B C-terminal domain", "PROTEIN", 316, 338], ["HCV", "SPECIES", 87, 90], ["HCV", "SPECIES", 133, 136], ["NS5A domain III", "TREATMENT", 64, 79], ["HCV replication", "TREATMENT", 133, 148], ["NS4B transcomplementation", "TREATMENT", 205, 230], ["various replicon RNAs", "TREATMENT", 237, 258], ["various replication", "TREATMENT", 268, 287], ["abolishing mutations", "PROBLEM", 288, 308], ["HCV", "OBSERVATION", 87, 90]]], ["The RNAs rescued replication of two G196A and E226A mutants (Table 1) .", [["G196A", "GENE_OR_GENE_PRODUCT", 36, 41]]], ["Nevertheless, the complementation efficiency was lowabout 1%, vs 24% for the NS5A S232A mutant.", [["NS5A", "GENE_OR_GENE_PRODUCT", 77, 81], ["NS5A S232A mutant", "PROTEIN", 77, 94], ["the complementation efficiency", "PROBLEM", 14, 44]]], ["Both G196 and E226 are highly conserved amino acids that are predicted to lie within unstructured regions flanking helix 1.", [["amino acids", "CHEMICAL", 40, 51], ["amino acids", "CHEMICAL", 40, 51], ["G196", "GENE_OR_GENE_PRODUCT", 5, 9], ["E226", "GENE_OR_GENE_PRODUCT", 14, 18], ["amino acids", "AMINO_ACID", 40, 51], ["G196", "DNA", 5, 9], ["E226", "DNA", 14, 18], ["helix 1", "PROTEIN", 115, 122], ["amino acids", "TREATMENT", 40, 51], ["amino acids", "OBSERVATION", 40, 51]]], ["The researchers concluded that NS4B complementation was limited.Trans-complementation of HCV replication by NS2Trans-complementation assays have also been used to study the role of NS2 in viral particle assembly [21] .", [["NS4B", "GENE_OR_GENE_PRODUCT", 31, 35], ["HCV", "ORGANISM", 89, 92], ["NS2Trans", "GENE_OR_GENE_PRODUCT", 108, 116], ["NS2", "GENE_OR_GENE_PRODUCT", 181, 184], ["NS4B", "PROTEIN", 31, 35], ["NS2Trans", "PROTEIN", 108, 116], ["NS2", "PROTEIN", 181, 184], ["HCV", "SPECIES", 89, 92], ["NS4B complementation", "TREATMENT", 31, 51], ["HCV replication", "TREATMENT", 89, 104], ["complementation assays", "TEST", 117, 139]]], ["A number of different deletions within trans-membrane segments (TMS1-3) or the protease domain of the Jc1 (J6/ JFH1) chimera genome have been examined (Table 1) .", [["membrane", "ANATOMY", 45, 53], ["TMS1-3", "GENE_OR_GENE_PRODUCT", 64, 70], ["Jc1", "GENE_OR_GENE_PRODUCT", 102, 105], ["trans-membrane segments", "PROTEIN", 39, 62], ["TMS1", "PROTEIN", 64, 68], ["protease domain", "PROTEIN", 79, 94], ["Jc1 (J6/ JFH1) chimera genome", "DNA", 102, 131], ["different deletions", "PROBLEM", 12, 31], ["TMS1", "TEST", 64, 68], ["the protease domain", "PROBLEM", 75, 94], ["the Jc1 (J6/ JFH1) chimera genome", "TREATMENT", 98, 131], ["number", "OBSERVATION_MODIFIER", 2, 8], ["different", "OBSERVATION_MODIFIER", 12, 21], ["deletions", "OBSERVATION", 22, 31], ["trans", "ANATOMY_MODIFIER", 39, 44], ["-membrane", "ANATOMY_MODIFIER", 44, 53], ["segments", "ANATOMY_MODIFIER", 54, 62]]], ["Again, replication was seen in the absence of pseudo-infectious particle production.", [["replication", "PROBLEM", 7, 18], ["pseudo-infectious particle production", "PROBLEM", 46, 83], ["pseudo", "OBSERVATION", 46, 52], ["infectious", "OBSERVATION_MODIFIER", 53, 63], ["particle production", "OBSERVATION", 64, 83]]], ["Three bicistronic helper RNAs (spE2-p7-NS2, spp7-NS2 and spNS2) were built by combining the JFH1 replicase module (UTRs and the NS3-NS5B coding region) and a 5\u2032-terminal expression module under control of the poliovirus internal ribosomal entry site (IRES).", [["ribosomal", "ANATOMY", 229, 238], ["spE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["NS2", "GENE_OR_GENE_PRODUCT", 39, 42], ["spp7-NS2", "GENE_OR_GENE_PRODUCT", 44, 52], ["spNS2", "GENE_OR_GENE_PRODUCT", 57, 62], ["bicistronic helper RNAs", "DNA", 6, 29], ["spE2", "PROTEIN", 31, 35], ["p7", "DNA", 36, 38], ["NS2", "DNA", 39, 42], ["spp7", "DNA", 44, 48], ["NS2", "DNA", 49, 52], ["spNS2", "DNA", 57, 62], ["JFH1 replicase module", "DNA", 92, 113], ["UTRs", "DNA", 115, 119], ["NS3-NS5B coding region", "DNA", 128, 150], ["5\u2032-terminal expression module", "DNA", 158, 187], ["poliovirus internal ribosomal entry site", "DNA", 209, 249], ["IRES", "DNA", 251, 255], ["spE2", "TEST", 31, 35], ["p7", "TEST", 36, 38], ["NS2", "TEST", 39, 42], ["spp7", "TEST", 44, 48], ["NS2", "PROBLEM", 49, 52], ["spNS2", "TEST", 57, 62], ["the JFH1 replicase module", "PROBLEM", 88, 113], ["UTRs", "TEST", 115, 119], ["the NS3-NS5B coding region", "TREATMENT", 124, 150], ["a 5\u2032-terminal expression module", "TREATMENT", 156, 187], ["helper RNAs", "OBSERVATION", 18, 29], ["terminal", "OBSERVATION_MODIFIER", 161, 169], ["expression module", "OBSERVATION", 170, 187], ["poliovirus", "OBSERVATION", 209, 219], ["ribosomal entry", "OBSERVATION", 229, 244]]], ["Various cotransfections between Jc1 NS2 mutants and bicistronic helper RNAs were performed in Huh-7.5 cells.", [["Huh-7.5 cells", "ANATOMY", 94, 107], ["Jc1 NS2", "GENE_OR_GENE_PRODUCT", 32, 39], ["Huh-7.5 cells", "CELL", 94, 107], ["Jc1 NS2 mutants", "PROTEIN", 32, 47], ["bicistronic helper RNAs", "RNA", 52, 75], ["Huh-7.5 cells", "CELL_LINE", 94, 107], ["Various cotransfections between Jc1 NS2 mutants", "PROBLEM", 0, 47], ["bicistronic helper RNAs", "TREATMENT", 52, 75], ["Huh", "TEST", 94, 97]]], ["All three NS2 mutants could be rescued by transcomplementation.", [["NS2", "GENE_OR_GENE_PRODUCT", 10, 13], ["NS2 mutants", "PROTEIN", 10, 21], ["NS2 mutants", "OBSERVATION", 10, 21]]], ["Infectivity titres obtained in rescue experiments were about 10-fold lower than in the Jc1 wt.Trans-complementation of HCV replication by NS2At the same time, Yi et al. [22] studied the role of the NS2 serine amino acid (aa) at position 168 (Ser-168) in the viral assembly and maturation process.", [["amino acid", "CHEMICAL", 209, 219], ["Ser-168", "CHEMICAL", 242, 249], ["serine amino acid", "CHEMICAL", 202, 219], ["Ser", "CHEMICAL", 242, 245], ["HCV", "ORGANISM", 119, 122], ["serine", "AMINO_ACID", 202, 208], ["amino acid", "AMINO_ACID", 209, 219], ["aa", "AMINO_ACID", 221, 223], ["position 168", "AMINO_ACID", 228, 240], ["Ser-168", "AMINO_ACID", 242, 249], ["HCV", "SPECIES", 119, 122], ["Infectivity titres", "TEST", 0, 18], ["rescue experiments", "TEST", 31, 49], ["HCV replication", "TREATMENT", 119, 134], ["the NS2 serine amino acid", "TREATMENT", 194, 219], ["HCV", "OBSERVATION", 119, 122]]], ["They found that substitution of Ser-168 by an alanine or glycine aa abolished infectious virus production but not polyprotein processing or genome replication (Table 1 ).", [["Ser-168", "CHEMICAL", 32, 39], ["alanine", "CHEMICAL", 46, 53], ["glycine", "CHEMICAL", 57, 64], ["Ser", "CHEMICAL", 32, 35], ["alanine", "CHEMICAL", 46, 53], ["glycine", "CHEMICAL", 57, 64], ["Ser-168", "AMINO_ACID", 32, 39], ["alanine", "AMINO_ACID", 46, 53], ["glycine", "AMINO_ACID", 57, 64], ["aa", "AMINO_ACID", 65, 67], ["infectious virus", "ORGANISM", 78, 94], ["Ser", "TEST", 32, 35], ["an alanine or glycine aa", "TREATMENT", 43, 67], ["infectious virus production", "PROBLEM", 78, 105], ["polyprotein processing", "TREATMENT", 114, 136]]], ["However, transfection of Ser-168 mutant replicon RNA into a cell line expressing wt NS2 rescued the production of infectious virus.", [["cell line", "ANATOMY", 60, 69], ["Ser-168", "CHEMICAL", 25, 32], ["infectious virus", "DISEASE", 114, 130], ["Ser", "CHEMICAL", 25, 28], ["Ser-168", "GENE_OR_GENE_PRODUCT", 25, 32], ["cell line", "CELL", 60, 69], ["wt NS2", "ORGANISM", 81, 87], ["infectious virus", "ORGANISM", 114, 130], ["cell line", "CELL_LINE", 60, 69], ["NS2", "PROTEIN", 84, 87], ["Ser-168 mutant replicon RNA", "TREATMENT", 25, 52], ["a cell line", "TREATMENT", 58, 69], ["infectious virus", "PROBLEM", 114, 130], ["infectious virus", "OBSERVATION", 114, 130]]], ["In contrast, transfection into a wt H77 (type 1a) NS2-expressing cell line was unable to rescue virus production.", [["cell line", "ANATOMY", 65, 74], ["wt H77 (type 1a", "ORGANISM", 33, 48], ["NS2", "GENE_OR_GENE_PRODUCT", 50, 53], ["cell line", "CELL", 65, 74], ["wt H77 (type 1a) NS2-expressing cell line", "CELL_LINE", 33, 74], ["a wt H77", "TEST", 31, 39], ["NS2", "PROBLEM", 50, 53], ["expressing cell line", "PROBLEM", 54, 74], ["rescue virus production", "PROBLEM", 89, 112], ["cell line", "OBSERVATION", 65, 74]]], ["Although H77 and JFH1 NS2-expressing cells could rescue viral production in the H77-JFH1 chimera Ser-168 mutant, this rescue was only partial with wt JFH1 NS2expressing cells.", [["H77", "ANATOMY", 9, 12], ["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 169, 174], ["Ser", "CHEMICAL", 97, 100], ["H77", "CELL", 9, 12], ["JFH1 NS2", "ORGANISM", 17, 25], ["cells", "CELL", 37, 42], ["H77-JFH1", "ORGANISM", 80, 88], ["Ser-168", "AMINO_ACID", 97, 104], ["cells", "CELL", 169, 174], ["H77 and JFH1 NS2-expressing cells", "CELL_LINE", 9, 42], ["H77", "PROTEIN", 80, 83], ["wt JFH1 NS2expressing cells", "CELL_LINE", 147, 174], ["JFH1", "SPECIES", 17, 21], ["JFH1", "SPECIES", 150, 154], ["H77", "TEST", 9, 12], ["expressing cells", "PROBLEM", 26, 42], ["viral production", "PROBLEM", 56, 72], ["wt JFH1 NS2expressing cells", "TREATMENT", 147, 174]]], ["The same experiment was performed in a cell line expressing NS2 carrying a 71-aa deletion in the Cterminal domain.", [["cell line", "ANATOMY", 39, 48], ["cell line", "CELL", 39, 48], ["NS2", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS2", "PROTEIN", 60, 63], ["71-aa deletion", "DNA", 75, 89], ["Cterminal domain", "PROTEIN", 97, 113], ["a cell line", "TREATMENT", 37, 48], ["a 71-aa deletion in the Cterminal domain", "PROBLEM", 73, 113]]], ["Infectious particle production was not obtained, indicating that NS2's C-terminal domain is a major determinant of HCV production.", [["C", "CHEMICAL", 71, 72], ["NS2", "GENE_OR_GENE_PRODUCT", 65, 68], ["HCV", "ORGANISM", 115, 118], ["NS2", "PROTEIN", 65, 68], ["C-terminal domain", "PROTEIN", 71, 88], ["HCV", "SPECIES", 115, 118], ["Infectious particle production", "PROBLEM", 0, 30], ["NS2's C-terminal domain", "PROBLEM", 65, 88], ["HCV production", "PROBLEM", 115, 129], ["HCV", "OBSERVATION", 115, 118]]], ["All these results indicate that wt NS2 expression is able to trans-complement NS2-defective constructs and is genotype-and straindependent.", [["NS2", "GENE_OR_GENE_PRODUCT", 35, 38], ["NS2", "GENE_OR_GENE_PRODUCT", 78, 81], ["NS2", "PROTEIN", 35, 38], ["NS2", "PROTEIN", 78, 81], ["defective constructs", "DNA", 82, 102], ["wt NS2 expression", "PROBLEM", 32, 49], ["defective constructs", "PROBLEM", 82, 102]]], ["Mutant or defective genomes can be rescued by a wild-type copy that allows the production of infectious particles capable of a single round of infection.Trans-complementation of HCV replication by NS2Appel et al. [19] Jc1-NS5AD2328-2435Trans-complementation of HCV replication by NS2Jones et al. [20] Luc-JFH1-E226ATrans-complementation of HCV replication by NS2Yi et al. [22] JFH1-NS2-S168G HJ3-5-NS2-S168G In conclusion, trans-complementation based on NS regions has shown that (i) NS5A region carrying mutations in the LCS1 domain or deletions in domain III can be complemented by the minimal sequence NS3-NS5A, (ii) NS2 can be efficiency trans-complemented by wt NS2 and (iii) NS4B trans-complementation exists for mutations in unstructured regions but is weak.Trans-complementation of HCV multiplication by coreThe use of the HCVcc system to produce infectious viral particles has enabled investigation of the core protein's role in the assembly process.", [["infection", "DISEASE", 143, 152], ["HCV", "ORGANISM", 178, 181], ["[19] Jc1", "SIMPLE_CHEMICAL", 213, 221], ["HCV", "ORGANISM", 261, 264], ["[20] Luc-JFH1", "SIMPLE_CHEMICAL", 296, 309], ["E226ATrans", "GENE_OR_GENE_PRODUCT", 310, 320], ["HCV", "ORGANISM", 340, 343], ["HCV", "ORGANISM", 790, 793], ["HCVcc", "ORGANISM", 831, 836], ["E226ATrans", "PROTEIN", 310, 320], ["NS2", "PROTEIN", 382, 385], ["NS2", "PROTEIN", 398, 401], ["NS regions", "DNA", 454, 464], ["NS5A region", "PROTEIN", 484, 495], ["LCS1 domain", "PROTEIN", 522, 533], ["domain III", "PROTEIN", 550, 560], ["NS3", "PROTEIN", 605, 608], ["NS5A", "PROTEIN", 609, 613], ["NS2", "PROTEIN", 620, 623], ["NS2", "PROTEIN", 667, 670], ["NS4B", "PROTEIN", 681, 685], ["HCV", "SPECIES", 178, 181], ["HCV", "SPECIES", 261, 264], ["HCV", "SPECIES", 340, 343], ["HCV", "SPECIES", 790, 793], ["Mutant or defective genomes", "PROBLEM", 0, 27], ["infectious particles", "PROBLEM", 93, 113], ["infection", "PROBLEM", 143, 152], ["HCV replication", "TREATMENT", 178, 193], ["Jc1", "TEST", 218, 221], ["HCV replication", "TREATMENT", 261, 276], ["Luc-JFH1", "TREATMENT", 301, 309], ["HCV replication", "TREATMENT", 340, 355], ["JFH1", "TEST", 377, 381], ["NS2", "TEST", 382, 385], ["HJ3", "TEST", 392, 395], ["NS2", "TEST", 398, 401], ["NS regions", "TREATMENT", 454, 464], ["NS5A region carrying mutations", "PROBLEM", 484, 514], ["deletions in domain III", "PROBLEM", 537, 560], ["the minimal sequence NS3", "TREATMENT", 584, 608], ["NS5A, (ii) NS2", "TREATMENT", 609, 623], ["NS4B trans-complementation", "TREATMENT", 681, 707], ["mutations in unstructured regions", "PROBLEM", 719, 752], ["HCV multiplication", "PROBLEM", 790, 808], ["the HCVcc system", "TREATMENT", 827, 843], ["infectious viral particles", "PROBLEM", 855, 881], ["defective genomes", "OBSERVATION", 10, 27], ["infectious", "OBSERVATION", 93, 103], ["infection", "OBSERVATION", 143, 152], ["HCV", "OBSERVATION", 178, 181], ["weak", "OBSERVATION", 760, 764], ["HCV", "OBSERVATION", 790, 793], ["infectious", "OBSERVATION", 855, 865]]], ["It has been shown that Core and 60-90% of the NS proteins were localized within lipid droplets (LDs) [23] .", [["lipid droplets", "ANATOMY", 80, 94], ["LDs", "ANATOMY", 96, 99], ["lipid droplets", "CELLULAR_COMPONENT", 80, 94], ["NS proteins", "PROTEIN", 46, 57], ["Core", "TEST", 23, 27], ["the NS proteins", "TREATMENT", 42, 57], ["lipid droplets", "TEST", 80, 94], ["Core", "OBSERVATION_MODIFIER", 23, 27]]], ["Conversely, the lack of core expression in replicating JFH1 cells (JFH1dC) was associated with a diffuse distribution of NS proteins on the endoplasmic reticulum (ER) and the absence of concentration around the LDs.", [["JFH1 cells", "ANATOMY", 55, 65], ["endoplasmic reticulum", "ANATOMY", 140, 161], ["ER", "ANATOMY", 163, 165], ["LDs", "ANATOMY", 211, 214], ["JFH1 cells", "CELL", 55, 65], ["JFH1dC", "CELL", 67, 73], ["NS proteins", "GENE_OR_GENE_PRODUCT", 121, 132], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 140, 161], ["ER", "GENE_OR_GENE_PRODUCT", 163, 165], ["LDs", "CELLULAR_COMPONENT", 211, 214], ["JFH1 cells", "CELL_LINE", 55, 65], ["JFH1dC", "CELL_LINE", 67, 73], ["NS proteins", "PROTEIN", 121, 132], ["ER", "PROTEIN", 163, 165], ["replicating JFH1 cells", "PROBLEM", 43, 65], ["NS proteins on the endoplasmic reticulum", "PROBLEM", 121, 161], ["JFH1 cells", "OBSERVATION", 55, 65], ["diffuse", "OBSERVATION_MODIFIER", 97, 104], ["distribution", "OBSERVATION_MODIFIER", 105, 117], ["NS proteins", "OBSERVATION", 121, 132], ["endoplasmic reticulum", "OBSERVATION", 140, 161]]], ["Moreover, LD levels were lower in JFH1dC replicating cells than in wt JFH1 replicating cells.", [["cells", "ANATOMY", 53, 58], ["cells", "ANATOMY", 87, 92], ["cells", "CELL", 53, 58], ["JFH1", "ORGANISM", 70, 74], ["cells", "CELL", 87, 92], ["LD", "PROTEIN", 10, 12], ["JFH1dC replicating cells", "CELL_LINE", 34, 58], ["wt JFH1 replicating cells", "CELL_LINE", 67, 92], ["JFH1", "SPECIES", 70, 74], ["LD levels", "TEST", 10, 19], ["replicating cells", "OBSERVATION", 41, 58], ["replicating cells", "OBSERVATION", 75, 92]]], ["Interestingly, NS proteins again accumulated around LDs when JFH1dC replicating cells were transfected with a plasmid expressing wt Core.", [["LDs", "ANATOMY", 52, 55], ["cells", "ANATOMY", 80, 85], ["plasmid", "ANATOMY", 110, 117], ["LDs", "CELLULAR_COMPONENT", 52, 55], ["cells", "CELL", 80, 85], ["NS proteins", "PROTEIN", 15, 26], ["JFH1dC replicating cells", "CELL_LINE", 61, 85], ["plasmid", "DNA", 110, 117], ["NS proteins", "TREATMENT", 15, 26], ["JFH1dC replicating cells", "TREATMENT", 61, 85]]], ["These results showed that LD-associated Core recruits NS proteins from the ER to the LDs.", [["ER", "ANATOMY", 75, 77], ["LDs", "ANATOMY", 85, 88], ["ER", "GENE_OR_GENE_PRODUCT", 75, 77], ["LDs", "CELLULAR_COMPONENT", 85, 88], ["LD", "PROTEIN", 26, 28], ["NS proteins", "PROTEIN", 54, 65], ["ER", "PROTEIN", 75, 77], ["NS proteins", "TREATMENT", 54, 65]]], ["Moreover, Core activity could be restored by trans-complementation.Trans-complementation of HCV multiplication by coreIn parallel, Kopp et al. [24] used trans-complementation assays to investigate the role of the core C-terminal region and to identify the essential residues involved in infectious particle production.", [["C", "CHEMICAL", 218, 219], ["HCV", "ORGANISM", 92, 95], ["core C-terminal region", "DNA", 213, 235], ["HCV", "SPECIES", 92, 95], ["HCV multiplication", "TREATMENT", 92, 110], ["trans-complementation assays", "TEST", 153, 181], ["infectious particle production", "PROBLEM", 287, 317], ["HCV", "OBSERVATION", 92, 95], ["terminal", "ANATOMY_MODIFIER", 220, 228], ["residues", "OBSERVATION", 266, 274], ["infectious", "OBSERVATION_MODIFIER", 287, 297]]], ["It was found that mutations at positions 170 and 174-177 abrogated pseudo-infectious particle production, despite the presence of wild-type replication levels.", [["170 and 174-177", "CHEMICAL", 41, 56], ["mutations at positions", "PROBLEM", 18, 40], ["pseudo-infectious particle production", "PROBLEM", 67, 104], ["infectious particle", "OBSERVATION", 74, 93]]], ["In contrast, cotransfection of the J6/JFH1 replicon (containing a large deletion in the sequence coding for Core protein, that is residues 57-160) with a fulllength HCV core protein plasmid led to significant levels of pseudo-infectious particle release.", [["J6", "GENE_OR_GENE_PRODUCT", 35, 37], ["JFH1 replicon", "ORGANISM", 38, 51], ["J6/JFH1 replicon", "DNA", 35, 51], ["Core protein", "PROTEIN", 108, 120], ["fulllength HCV core protein plasmid", "DNA", 154, 189], ["HCV", "SPECIES", 165, 168], ["cotransfection of the J6/JFH1 replicon", "TREATMENT", 13, 51], ["a large deletion", "PROBLEM", 64, 80], ["Core protein", "TEST", 108, 120], ["a fulllength HCV core protein plasmid", "TREATMENT", 152, 189], ["pseudo-infectious particle release", "PROBLEM", 219, 253], ["large", "OBSERVATION_MODIFIER", 66, 71], ["deletion", "OBSERVATION", 72, 80], ["infectious particle", "OBSERVATION", 226, 245]]], ["No pseudo-infectious particles were obtained when using Core 170 and 174-177 mutants plasmids.", [["plasmids", "ANATOMY", 85, 93], ["Core 170 and 174-177 mutants plasmids", "DNA", 56, 93], ["pseudo-infectious particles", "PROBLEM", 3, 30], ["mutants plasmids", "TREATMENT", 77, 93], ["pseudo", "OBSERVATION", 3, 9], ["infectious", "OBSERVATION", 10, 20]]], ["In this context, trans-complementation systems have highlighted the importance of these residues in pseudo-infectious particle production.Trans-complementation of HCV multiplication by p7Brohm et al. [25] developed a complementation system for investigating key determinants that are essential for the optimal function of p7 in HCV infectious particle production.", [["HCV", "ORGANISM", 163, 166], ["p7", "GENE_OR_GENE_PRODUCT", 322, 324], ["HCV", "ORGANISM", 328, 331], ["p7", "PROTEIN", 322, 324], ["HCV", "SPECIES", 163, 166], ["HCV", "SPECIES", 328, 331], ["these residues", "PROBLEM", 82, 96], ["pseudo-infectious particle production", "PROBLEM", 100, 137], ["HCV multiplication", "PROBLEM", 163, 181], ["a complementation system", "TEST", 215, 239], ["HCV infectious particle production", "PROBLEM", 328, 362], ["infectious particle", "OBSERVATION", 107, 126], ["HCV", "OBSERVATION_MODIFIER", 328, 331], ["infectious", "OBSERVATION", 332, 342]]], ["Three Jc1 replicons were constructed: one with a deletion of the entire p7 coding region (Jc1Dp7 full ), a second lacking residues 1-32 of p7 (Jc1Dp7 half ) and a third carrying a dual mutation of the highly conserved basic residues KR33/35 to QQ (Jc1-KR33.35QQ) ( Table 1 ).", [["Jc1", "GENE_OR_GENE_PRODUCT", 6, 9], ["Jc1 replicons", "DNA", 6, 19], ["p7 coding region", "DNA", 72, 88], ["Jc1Dp7 full", "DNA", 90, 101], ["residues 1-32", "DNA", 122, 135], ["p7", "DNA", 139, 141], ["Jc1Dp7 half", "DNA", 143, 154], ["QQ", "DNA", 244, 246], ["Jc1", "DNA", 248, 251], ["KR33.35QQ", "DNA", 252, 261], ["Three Jc1 replicons", "TREATMENT", 0, 19], ["a second lacking residues", "TREATMENT", 105, 130], ["Jc1", "TEST", 248, 251]]], ["The replicons Jc1Dp7 full and Jc1Dp7 half were unable to generate infectious particles.", [["Jc1Dp7", "GENE_OR_GENE_PRODUCT", 14, 20], ["replicons Jc1Dp7 full and Jc1Dp7 half", "DNA", 4, 41], ["The replicons Jc1Dp7 full and Jc1Dp7 half", "TREATMENT", 0, 41], ["infectious", "OBSERVATION", 66, 76]]], ["With the Jc1-KR33.35QQ replicon, 100-fold fewer infectious particles were released than with the parent Jc1 genome.", [["Jc1", "GENE_OR_GENE_PRODUCT", 9, 12], ["Jc1", "GENE_OR_GENE_PRODUCT", 104, 107], ["Jc1", "DNA", 9, 12], ["Jc1 genome", "DNA", 104, 114], ["the Jc1", "TEST", 5, 12], ["QQ replicon", "TREATMENT", 20, 31], ["infectious particles", "PROBLEM", 48, 68], ["infectious", "OBSERVATION", 48, 58], ["Jc1 genome", "OBSERVATION", 104, 114]]], ["These defective HCV p7 replicons were then cotransfected with bicistronic JFH1-derived helper replicons expressing either p7 alone, p7-NS2, E2-p7, E2 alone or E2-p7-NS2 in the first cistron and JFH1 NS proteins in the second.", [["E2", "CHEMICAL", 147, 149], ["E2", "CHEMICAL", 159, 161], ["HCV", "ORGANISM", 16, 19], ["JFH1", "ORGANISM", 74, 78], ["p7", "GENE_OR_GENE_PRODUCT", 122, 124], ["p7-NS2", "GENE_OR_GENE_PRODUCT", 132, 138], ["E2-p7", "GENE_OR_GENE_PRODUCT", 140, 145], ["E2", "GENE_OR_GENE_PRODUCT", 147, 149], ["E2", "GENE_OR_GENE_PRODUCT", 159, 161], ["HCV p7 replicons", "DNA", 16, 32], ["p7", "PROTEIN", 122, 124], ["p7", "PROTEIN", 132, 134], ["NS2", "PROTEIN", 135, 138], ["E2", "PROTEIN", 140, 142], ["p7", "PROTEIN", 143, 145], ["E2", "PROTEIN", 147, 149], ["E2", "PROTEIN", 159, 161], ["p7", "PROTEIN", 162, 164], ["NS2", "PROTEIN", 165, 168], ["cistron", "DNA", 182, 189], ["JFH1 NS proteins", "PROTEIN", 194, 210], ["HCV", "SPECIES", 16, 19], ["These defective HCV p7 replicons", "TREATMENT", 0, 32], ["bicistronic JFH1", "TREATMENT", 62, 78], ["helper replicons", "TREATMENT", 87, 103], ["E2", "TEST", 140, 142], ["E2", "TREATMENT", 147, 149], ["E2", "TEST", 159, 161], ["NS2", "TREATMENT", 165, 168], ["JFH1 NS proteins", "TREATMENT", 194, 210], ["defective", "OBSERVATION_MODIFIER", 6, 15], ["HCV", "OBSERVATION", 16, 19]]], ["Jc1Dp7 half infectivity was rescued by all helper RNAs expressing p7, whereas the E2 signal sequence had no influence.", [["E2", "CHEMICAL", 82, 84], ["Jc1Dp7", "GENE_OR_GENE_PRODUCT", 0, 6], ["p7", "GENE_OR_GENE_PRODUCT", 66, 68], ["E2", "GENE_OR_GENE_PRODUCT", 82, 84], ["helper RNAs", "RNA", 43, 54], ["p7", "PROTEIN", 66, 68], ["E2 signal sequence", "DNA", 82, 100], ["the E2 signal sequence", "TEST", 78, 100], ["infectivity", "OBSERVATION", 12, 23]]], ["However, cotransfection of E2-p7 and E2-p7-NS2 helper RNAs yielded higher virus titres.", [["E2", "CHEMICAL", 27, 29], ["E2", "CHEMICAL", 37, 39], ["E2-p7", "GENE_OR_GENE_PRODUCT", 27, 32], ["E2", "GENE_OR_GENE_PRODUCT", 37, 39], ["E2-p7 and E2-p7-NS2 helper RNAs", "DNA", 27, 58], ["cotransfection", "TEST", 9, 23], ["E2", "TEST", 27, 29], ["E2", "TEST", 37, 39], ["NS2 helper RNAs", "TREATMENT", 43, 58], ["higher virus titres", "PROBLEM", 67, 86], ["higher virus titres", "OBSERVATION", 67, 86]]], ["In the case of the Jc1Dp7 full replicon, complementation was achieved only by the co-expression of E2-p7-NS2.", [["E2", "CHEMICAL", 99, 101], ["Jc1Dp7", "GENE_OR_GENE_PRODUCT", 19, 25], ["E2", "GENE_OR_GENE_PRODUCT", 99, 101], ["Jc1Dp7 full replicon", "DNA", 19, 39], ["E2", "PROTEIN", 99, 101], ["p7", "PROTEIN", 102, 104], ["NS2", "PROTEIN", 105, 108], ["the Jc1Dp7 full replicon", "TREATMENT", 15, 39], ["E2", "TEST", 99, 101]]], ["Jc1-KR33.35QQ infectivity was rescued by all helper RNAs, although pseudo-infectious particle production was only increased in the presence of E2-p7 and E2-p7-NS2 helper RNAs.", [["E2", "CHEMICAL", 143, 145], ["E2", "CHEMICAL", 153, 155], ["Jc1", "GENE_OR_GENE_PRODUCT", 0, 3], ["KR33.35", "GENE_OR_GENE_PRODUCT", 4, 11], ["E2-p7", "GENE_OR_GENE_PRODUCT", 143, 148], ["E2", "GENE_OR_GENE_PRODUCT", 153, 155], ["helper RNAs", "RNA", 45, 56], ["E2-p7 and E2-p7-NS2 helper RNAs", "RNA", 143, 174], ["Jc1", "TEST", 0, 3], ["QQ infectivity", "PROBLEM", 11, 25], ["pseudo-infectious particle production", "PROBLEM", 67, 104], ["E2", "TEST", 143, 145], ["E2", "TEST", 153, 155], ["infectious", "OBSERVATION", 74, 84], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["helper RNAs", "OBSERVATION", 163, 174]]], ["Lastly, no production of infectious particles was seen with the Con1-p7 (HCV type 1b) helper replicon, which indicated genotype specificity.", [["Con1-p7", "GENE_OR_GENE_PRODUCT", 64, 71], ["HCV type 1b", "ORGANISM", 73, 84], ["Con1-p7 (HCV type 1b) helper replicon", "DNA", 64, 101], ["production of infectious particles", "PROBLEM", 11, 45], ["the Con1", "TEST", 60, 68], ["helper replicon", "TREATMENT", 86, 101], ["genotype specificity", "TEST", 119, 139], ["no", "UNCERTAINTY", 8, 10], ["production", "OBSERVATION_MODIFIER", 11, 21], ["infectious", "OBSERVATION", 25, 35]]], ["These results indicate that a p7 protein-deficient replicon could only be rescued by E2-p7-NS2 expression and not by p7 protein alone.Trans-complementation of HCV multiplication by p7In conclusion, trans-complementation of the structural region has shown that Core can be trans-complemented by wt Core and p7 can be trans-complemented by the E2-p7-NS2 sequence and not by p7 expressed alone.Trans-complementation of HCV multiplication by p7HCV TRANS-ENCAPSIDATION SYSTEMS The first trans-encapsidation systems were described for packaging replicons for flavivirus, including Kunjin virus [2, 3] , yellow fever virus [4] , tick-borne encephalitis virus [5] and West Nile virus [6, 7] .", [["E2", "CHEMICAL", 85, 87], ["E2", "CHEMICAL", 342, 344], ["flavivirus", "DISEASE", 553, 563], ["yellow fever", "DISEASE", 597, 609], ["tick-borne encephalitis", "DISEASE", 622, 645], ["p7", "GENE_OR_GENE_PRODUCT", 30, 32], ["E2-p7", "GENE_OR_GENE_PRODUCT", 85, 90], ["p7", "GENE_OR_GENE_PRODUCT", 117, 119], ["HCV", "ORGANISM", 159, 162], ["p7In", "GENE_OR_GENE_PRODUCT", 181, 185], ["Core", "GENE_OR_GENE_PRODUCT", 297, 301], ["p7", "GENE_OR_GENE_PRODUCT", 306, 308], ["E2", "GENE_OR_GENE_PRODUCT", 342, 344], ["HCV", "ORGANISM", 416, 419], ["Kunjin virus", "ORGANISM", 575, 587], ["yellow fever virus", "ORGANISM", 597, 615], ["tick-borne encephalitis virus", "ORGANISM", 622, 651], ["West Nile virus", "ORGANISM", 660, 675], ["p7 protein", "PROTEIN", 30, 40], ["p7", "PROTEIN", 88, 90], ["NS2", "PROTEIN", 91, 94], ["p7 protein", "PROTEIN", 117, 127], ["p7In", "PROTEIN", 181, 185], ["p7", "PROTEIN", 306, 308], ["E2-p7-NS2 sequence", "DNA", 342, 360], ["p7", "PROTEIN", 372, 374], ["Kunjin virus", "SPECIES", 575, 587], ["yellow fever virus", "SPECIES", 597, 615], ["tick-borne encephalitis virus", "SPECIES", 622, 651], ["West Nile virus", "SPECIES", 660, 675], ["HCV", "SPECIES", 159, 162], ["HCV", "SPECIES", 416, 419], ["p7HCV", "SPECIES", 438, 443], ["Kunjin virus", "SPECIES", 575, 587], ["yellow fever virus", "SPECIES", 597, 615], ["tick-borne encephalitis virus", "SPECIES", 622, 651], ["West Nile virus", "SPECIES", 660, 675], ["a p7 protein-deficient replicon", "TREATMENT", 28, 59], ["HCV multiplication", "PROBLEM", 159, 177], ["HCV multiplication", "PROBLEM", 416, 434], ["The first trans-encapsidation systems", "TREATMENT", 472, 509], ["packaging replicons", "TREATMENT", 529, 548], ["flavivirus", "PROBLEM", 553, 563], ["Kunjin virus", "PROBLEM", 575, 587], ["yellow fever virus", "PROBLEM", 597, 615], ["tick-borne encephalitis virus", "PROBLEM", 622, 651], ["West Nile virus", "PROBLEM", 660, 675], ["HCV", "OBSERVATION", 416, 419]]], ["These virus-like-particle-generating systems enabled the development of vaccine models and the analysis of some aspects of viral assembly and entry [6] .", [["These virus", "TEST", 0, 11], ["vaccine models", "TREATMENT", 72, 86], ["the analysis", "TEST", 91, 103]]], ["Based on these studies, various systems for packaging HCV replicons have been created.Packaging repliconsTwo types of constructs have been used in trans-encapsidation systems: a minimal replicase complex and the fulllength genome carrying deletions in envelope-encoding genes ( Table 2 ).Packaging repliconsThe first studies used JFH1-NS3-NS5B replicons associated either with a resistance gene (such as neomycin in SGR-JFH1) [26] [27] [28] [29] or a reporter gene (such as Renilla luciferase in Luc-NS3-NS5B) [30] .", [["neomycin", "CHEMICAL", 404, 412], ["neomycin", "CHEMICAL", 404, 412], ["HCV", "ORGANISM", 54, 57], ["JFH1-NS3", "ORGANISM", 330, 338], ["neomycin", "SIMPLE_CHEMICAL", 404, 412], ["luciferase", "GENE_OR_GENE_PRODUCT", 482, 492], ["Luc-NS3", "GENE_OR_GENE_PRODUCT", 496, 503], ["packaging HCV replicons", "DNA", 44, 67], ["minimal replicase complex", "PROTEIN", 178, 203], ["fulllength genome", "DNA", 212, 229], ["envelope-encoding genes", "DNA", 252, 275], ["JFH1-NS3-NS5B replicons", "DNA", 330, 353], ["resistance gene", "DNA", 379, 394], ["neomycin", "DNA", 404, 412], ["reporter gene", "DNA", 451, 464], ["Renilla luciferase", "DNA", 474, 492], ["Luc", "PROTEIN", 496, 499], ["NS3", "PROTEIN", 500, 503], ["NS5B", "PROTEIN", 504, 508], ["HCV", "SPECIES", 54, 57], ["these studies", "TEST", 9, 22], ["packaging HCV replicons", "TREATMENT", 44, 67], ["Packaging replicons", "TREATMENT", 86, 105], ["a minimal replicase complex", "PROBLEM", 176, 203], ["Packaging replicons", "TREATMENT", 288, 307], ["The first studies", "TEST", 307, 324], ["JFH1", "TREATMENT", 330, 334], ["NS3", "TREATMENT", 335, 338], ["NS5B replicons", "TREATMENT", 339, 353], ["a resistance gene", "PROBLEM", 377, 394], ["neomycin", "TEST", 404, 412], ["Renilla luciferase", "TEST", 474, 492], ["Luc", "TEST", 496, 499], ["NS3", "TEST", 500, 503], ["replicons", "OBSERVATION_MODIFIER", 96, 105], ["replicons", "OBSERVATION_MODIFIER", 298, 307]]], ["The SGR-JFH1 replicon enabled the establishment of stable cell lines [26] , the titration of colony-forming units (CFU/mL) [26, 27] and the selection of efficiently replicating cell clones [28] .", [["cell lines", "ANATOMY", 58, 68], ["colony", "ANATOMY", 93, 99], ["cell clones", "ANATOMY", 177, 188], ["cell lines", "CELL", 58, 68], ["cell clones", "CELL", 177, 188], ["SGR-JFH1 replicon", "DNA", 4, 21], ["stable cell lines", "CELL_LINE", 51, 68], ["replicating cell clones", "CELL_LINE", 165, 188], ["The SGR-JFH1 replicon", "TREATMENT", 0, 21], ["stable cell lines", "TREATMENT", 51, 68], ["the titration of colony", "TREATMENT", 76, 99], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["cell lines", "OBSERVATION", 58, 68], ["cell clones", "OBSERVATION", 177, 188]]], ["Rapid infectious particle assays [30] could been performed with the Luc-NS3-NS5B replicon.", [["Luc", "GENE_OR_GENE_PRODUCT", 68, 71], ["Luc-NS3-NS5B replicon", "DNA", 68, 89], ["Rapid infectious particle assays", "TEST", 0, 32], ["the Luc", "TEST", 64, 71], ["NS3", "TREATMENT", 72, 75], ["NS5B replicon", "TREATMENT", 76, 89], ["NS5B replicon", "OBSERVATION", 76, 89]]], ["The SGR-JFH1 NS2-NS5B construct was used by Adair et al. [26] to study NS2's role in the particle assembly process and has yielded the highest infectious titres.", [["JFH1", "ORGANISM", 8, 12], ["NS2", "GENE_OR_GENE_PRODUCT", 71, 74], ["SGR-JFH1 NS2-NS5B construct", "DNA", 4, 31], ["NS2", "PROTEIN", 71, 74], ["The SGR", "TEST", 0, 7], ["NS5B construct", "TREATMENT", 17, 31], ["the highest infectious titres", "PROBLEM", 131, 160], ["highest", "OBSERVATION_MODIFIER", 135, 142], ["infectious", "OBSERVATION", 143, 153]]], ["Masaki et al. and Suzuki et al. chose to use a JFH-1 cDNA clone plasmid containing the Pol I promoter, terminator sequences and luciferase gene reporter sequences for directly transfecting cells without the need for a transcription step [31, 32] (Table 1) .Packaging repliconsAnother approach was adopted by Pacini and Sugiyama, using replicons based on the defective genomes found in both serum and liver tissue from chronically HCV-infected patients.", [["cells", "ANATOMY", 189, 194], ["serum", "ANATOMY", 390, 395], ["liver tissue", "ANATOMY", 400, 412], ["HCV-infected", "DISEASE", 430, 442], ["Pol I", "GENE_OR_GENE_PRODUCT", 87, 92], ["luciferase", "GENE_OR_GENE_PRODUCT", 128, 138], ["cells", "CELL", 189, 194], ["serum", "ORGANISM_SUBSTANCE", 390, 395], ["liver tissue", "TISSUE", 400, 412], ["chronically HCV", "ORGANISM", 418, 433], ["patients", "ORGANISM", 443, 451], ["JFH-1 cDNA clone plasmid", "DNA", 47, 71], ["Pol I promoter", "DNA", 87, 101], ["terminator sequences", "DNA", 103, 123], ["luciferase gene reporter sequences", "DNA", 128, 162], ["patients", "SPECIES", 443, 451], ["HCV", "SPECIES", 430, 433], ["a JFH-1 cDNA clone plasmid", "TREATMENT", 45, 71], ["the Pol I promoter", "TREATMENT", 83, 101], ["luciferase gene reporter sequences", "TREATMENT", 128, 162], ["a transcription step", "TEST", 216, 236], ["Packaging replicons", "TREATMENT", 257, 276], ["Sugiyama", "TREATMENT", 319, 327], ["replicons", "TREATMENT", 335, 344], ["the defective genomes", "PROBLEM", 354, 375], ["chronically HCV", "PROBLEM", 418, 433], ["replicons", "OBSERVATION_MODIFIER", 267, 276], ["defective genomes", "OBSERVATION", 358, 375], ["liver", "ANATOMY", 400, 405], ["chronically", "OBSERVATION_MODIFIER", 418, 429], ["HCV", "OBSERVATION", 430, 433], ["infected", "OBSERVATION", 434, 442]]], ["Sugiyama et al. generated a 1b/JFH1-2a chimera based on defective 1b patient isolate and that carried deletions in the genes coding for the envelope, p7 and NS2 proteins [33] .", [["JFH1-2a", "ORGANISM", 31, 38], ["patient", "ORGANISM", 69, 76], ["p7", "GENE_OR_GENE_PRODUCT", 150, 152], ["envelope, p7 and NS2 proteins", "PROTEIN", 140, 169], ["patient", "SPECIES", 69, 76], ["a 1b/JFH1-2a chimera", "TREATMENT", 26, 46], ["defective 1b patient isolate", "TREATMENT", 56, 84]]], ["Likewise, Pacini et al. used a J6/JFH1 chimera to build constructs with various deletions in the E1-E2 glycoprotein region (448 aa) and the E1 to NS2 (674 aa), E2 to p7, core to p7 and E2 to NS2 regions, respectively (Table 2) .Packaging repliconsLastly, several research groups have studied replicons carrying deletions (351 aa) in the envelope gene (JFH1DE1E2 or J6/JFH1-DE1E2) [29, 30, 34, 35] (Table 2) .Structural protein expression systemsEncapsidation of subgenomic replicons with partially or totally deleted structural regions has been performed in various systems expressing structural proteins in trans (Table 3) in the presence or absence of p7 and NS2 proteins.", [["E2", "CHEMICAL", 100, 102], ["JFH1", "ORGANISM", 34, 38], ["E1-E2 glycoprotein", "GENE_OR_GENE_PRODUCT", 97, 115], ["E2", "GENE_OR_GENE_PRODUCT", 160, 162], ["p7", "GENE_OR_GENE_PRODUCT", 166, 168], ["E2", "GENE_OR_GENE_PRODUCT", 185, 187], ["trans (Table 3", "GENE_OR_GENE_PRODUCT", 608, 622], ["p7", "GENE_OR_GENE_PRODUCT", 654, 656], ["NS2", "GENE_OR_GENE_PRODUCT", 661, 664], ["J6", "PROTEIN", 31, 33], ["E1-E2 glycoprotein region", "DNA", 97, 122], ["E1", "DNA", 140, 142], ["NS2", "PROTEIN", 146, 149], ["E2 to p7, core to p7 and E2 to NS2 regions", "DNA", 160, 202], ["envelope gene", "DNA", 337, 350], ["JFH1DE1E2", "DNA", 352, 361], ["J6", "DNA", 365, 367], ["DE1E2", "DNA", 373, 378], ["subgenomic replicons", "DNA", 462, 482], ["structural proteins", "PROTEIN", 585, 604], ["p7", "PROTEIN", 654, 656], ["NS2 proteins", "PROTEIN", 661, 673], ["a J6/JFH1 chimera", "TREATMENT", 29, 46], ["various deletions", "PROBLEM", 72, 89], ["E2", "TEST", 160, 162], ["Structural protein expression systems", "PROBLEM", 408, 445], ["subgenomic replicons", "PROBLEM", 462, 482], ["partially or totally deleted structural regions", "PROBLEM", 488, 535], ["absence of p7 and NS2 proteins", "PROBLEM", 643, 673], ["various deletions", "OBSERVATION", 72, 89], ["protein expression", "OBSERVATION", 419, 437], ["subgenomic replicons", "OBSERVATION", 462, 482], ["partially", "OBSERVATION_MODIFIER", 488, 497], ["structural proteins", "OBSERVATION", 585, 604]]], ["Some researchers have focused on replicons, helper viruses [29, 30] and direct expression vectors [29, 31] , whereas others have established stable cell lines [27, 30, 33] and baculovirus or lentivirus delivery systems [26, 28] .", [["cell lines", "ANATOMY", 148, 158], ["cell lines", "CELL", 148, 158], ["baculovirus", "ORGANISM", 176, 187], ["lentivirus", "ORGANISM", 191, 201], ["stable cell lines", "CELL_LINE", 141, 158], ["baculovirus", "SPECIES", 176, 187], ["lentivirus", "SPECIES", 191, 201], ["replicons", "TREATMENT", 33, 42], ["baculovirus or lentivirus delivery systems", "TREATMENT", 176, 218], ["stable", "OBSERVATION_MODIFIER", 141, 147], ["cell lines", "OBSERVATION", 148, 158]]], ["Luc-coreD212-NS2Structural protein expression systemsLuc-nocore-NS2Structural protein expression systemsLuc-coreD212-NS3Structural protein expression systemsPacini et al. [29] Pacini et al. [29] Pacini et al.", [["Luc-coreD212-NS2Structural protein expression systemsLuc-nocore-NS2Structural protein", "PROTEIN", 0, 85], ["systemsLuc", "PROTEIN", 97, 107], ["coreD212", "PROTEIN", 108, 116], ["Luc-", "TEST", 0, 4], ["systemsLuc", "TEST", 46, 56], ["nocore", "TEST", 57, 63], ["systemsLuc", "TEST", 97, 107], ["NS3Structural protein expression systems", "PROBLEM", 117, 157]]], ["[ The first trans-encapsidation assays were performed in Huh7.5 cells via transient transfection with replicons or helper viruses, allowed reproducing in vitro natural transencapsidation mechanism in vivo [29] .", [["Huh7.5 cells", "ANATOMY", 57, 69], ["Huh7.5 cells", "CELL", 57, 69], ["Huh7.5 cells", "CELL_LINE", 57, 69], ["encapsidation assays", "TEST", 18, 38], ["transient transfection with replicons", "TREATMENT", 74, 111], ["helper viruses", "TREATMENT", 115, 129]]], ["Similar experiments with heterologous helper viruses (such as Con1/C3 and Jc1 [30] ) have been attempted.", [["Con1/C3", "GENE_OR_GENE_PRODUCT", 62, 69], ["Con1", "PROTEIN", 62, 66], ["C3", "PROTEIN", 67, 69], ["heterologous helper viruses", "PROBLEM", 25, 52], ["Con1/C3 and Jc1", "TREATMENT", 62, 77]]], ["However, given the competition between defective replicons and helper viruses, it has been difficult to obtain equal replication and high trans-encapsidation efficiencies.", [["defective replicons and helper viruses", "PROBLEM", 39, 77], ["helper viruses", "OBSERVATION", 63, 77], ["encapsidation efficiencies", "OBSERVATION", 144, 170]]], ["Moreover, two different markers must been introduced to identify the two encapsidated replicons.Structural protein expression systemsOther researchers have chosen structural proteins expressing plasmids (in the presence or absence of p7 and NS2) to perform trans-encapsidation and determine the minimal sequence required for efficient encapsidation.", [["plasmids", "ANATOMY", 194, 202], ["p7", "GENE_OR_GENE_PRODUCT", 234, 236], ["NS2", "GENE_OR_GENE_PRODUCT", 241, 244], ["structural proteins", "PROTEIN", 163, 182], ["plasmids", "DNA", 194, 202], ["p7", "PROTEIN", 234, 236], ["NS2", "PROTEIN", 241, 244], ["Structural protein expression systems", "PROBLEM", 96, 133], ["trans-encapsidation", "TREATMENT", 257, 276], ["encapsidated replicons", "OBSERVATION", 73, 95], ["protein expression", "OBSERVATION", 107, 125], ["encapsidation", "OBSERVATION", 335, 348]]], ["Various plasmid constructs have been used, such as the pEF6 plasmid (encoding C-NS2, C-p7, C-E2, E1-NS2, E1-p7 or E1-E2 from J6/JFH1 chimeras [29] ), the pCAGC plasmid (expressing C-p7 and C-NS2 regions [31, 32] ), pCDNA-E1-p7 [34] and pcDNA3-JFH1-E1/E2 [35] (Table 2) .Structural protein expression systemsIn parallel, the use of stable cell lines has improved the yield of pseudo-infectious particles.", [["plasmid", "ANATOMY", 8, 15], ["plasmid", "ANATOMY", 160, 167], ["cell lines", "ANATOMY", 338, 348], ["pEF6", "GENE_OR_GENE_PRODUCT", 55, 59], ["C-NS2", "GENE_OR_GENE_PRODUCT", 78, 83], ["C-p7", "GENE_OR_GENE_PRODUCT", 85, 89], ["C-E2", "GENE_OR_GENE_PRODUCT", 91, 95], ["E1-NS2", "GENE_OR_GENE_PRODUCT", 97, 103], ["E1-p7", "GENE_OR_GENE_PRODUCT", 105, 110], ["E1-E2", "GENE_OR_GENE_PRODUCT", 114, 119], ["pCAGC", "GENE_OR_GENE_PRODUCT", 154, 159], ["C-p7", "GENE_OR_GENE_PRODUCT", 180, 184], ["C-NS2", "GENE_OR_GENE_PRODUCT", 189, 194], ["pCDNA-E1", "GENE_OR_GENE_PRODUCT", 215, 223], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 236, 242], ["cell lines", "CELL", 338, 348], ["plasmid constructs", "DNA", 8, 26], ["pEF6 plasmid", "DNA", 55, 67], ["NS2", "PROTEIN", 80, 83], ["C", "PROTEIN", 85, 86], ["p7", "PROTEIN", 87, 89], ["C", "PROTEIN", 91, 92], ["E2", "PROTEIN", 93, 95], ["E1", "PROTEIN", 97, 99], ["NS2", "PROTEIN", 100, 103], ["E1", "PROTEIN", 105, 107], ["p7", "PROTEIN", 108, 110], ["E1", "PROTEIN", 114, 116], ["E2", "PROTEIN", 117, 119], ["J6", "PROTEIN", 125, 127], ["pCAGC plasmid", "DNA", 154, 167], ["C-p7 and C-NS2 regions", "DNA", 180, 202], ["pCDNA", "PROTEIN", 215, 220], ["E1", "DNA", 221, 223], ["pcDNA3", "DNA", 236, 242], ["stable cell lines", "CELL_LINE", 331, 348], ["Various plasmid constructs", "TREATMENT", 0, 26], ["the pEF6 plasmid", "TEST", 51, 67], ["C", "TEST", 78, 79], ["NS2", "TEST", 80, 83], ["C", "TEST", 85, 86], ["p7", "TEST", 87, 89], ["C", "TEST", 91, 92], ["E1", "TEST", 97, 99], ["E1", "TEST", 105, 107], ["E1", "TEST", 114, 116], ["J6", "TEST", 125, 127], ["chimeras", "TEST", 133, 141], ["the pCAGC plasmid", "TEST", 150, 167], ["C", "TEST", 180, 181], ["pCDNA", "TEST", 215, 220], ["E1", "TEST", 221, 223], ["pcDNA3", "TEST", 236, 242], ["JFH1", "TEST", 243, 247], ["Structural protein expression systems", "PROBLEM", 270, 307], ["stable cell lines", "TREATMENT", 331, 348], ["pseudo-infectious particles", "PROBLEM", 375, 402], ["plasmid constructs", "OBSERVATION", 8, 26], ["protein expression", "OBSERVATION", 281, 299], ["parallel", "OBSERVATION_MODIFIER", 310, 318], ["stable", "OBSERVATION_MODIFIER", 331, 337], ["cell lines", "OBSERVATION", 338, 348], ["infectious particles", "OBSERVATION", 382, 402]]], ["With a pEF4 plasmid, Ishii et al. [27] established stable cell lines expressing JFH1 Core-p7 and Core-NS2 proteins, respectively.", [["cell lines", "ANATOMY", 58, 68], ["cell lines", "CELL", 58, 68], ["JFH1", "ORGANISM", 80, 84], ["Core-p7", "GENE_OR_GENE_PRODUCT", 85, 92], ["Core-NS2", "GENE_OR_GENE_PRODUCT", 97, 105], ["pEF4 plasmid", "DNA", 7, 19], ["stable cell lines", "CELL_LINE", 51, 68], ["JFH1 Core-p7 and Core-NS2 proteins", "PROTEIN", 80, 114], ["a pEF4 plasmid", "TREATMENT", 5, 19], ["Core-NS2 proteins", "TEST", 97, 114], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["cell lines", "OBSERVATION", 58, 68]]], ["Steinmann et al. [30] cotransfected lentiviral vectors expressing Jc1 Core-E1 and E2-NS2 proteins into Huh7.5 and Huh7-lunet cells, respectively, and obtained high levels of structural protein expression.", [["Huh7.5", "ANATOMY", 103, 109], ["Huh7-lunet cells", "ANATOMY", 114, 130], ["lentiviral", "ORGANISM", 36, 46], ["Jc1 Core-E1", "GENE_OR_GENE_PRODUCT", 66, 77], ["E2-NS2", "GENE_OR_GENE_PRODUCT", 82, 88], ["Huh7.5", "CELL", 103, 109], ["Huh7-lunet cells", "CELL", 114, 130], ["Jc1 Core-E1 and E2-NS2 proteins", "PROTEIN", 66, 97], ["Huh7.5 and Huh7-lunet cells", "CELL_LINE", 103, 130], ["cotransfected lentiviral vectors", "TREATMENT", 22, 54], ["E2", "TEST", 82, 84], ["NS2 proteins", "TEST", 85, 97], ["Huh7", "TEST", 114, 118], ["structural protein expression", "PROBLEM", 174, 203], ["lunet cells", "ANATOMY", 119, 130], ["structural protein expression", "OBSERVATION", 174, 203]]], ["Conversely, stable cell lines based on defective replicons with resistant genes (such as SGR-JFH1) can be used to select more efficient cell clones and achieve high levels of replication.Structural protein expression systemsThe latter models to have been developed for the expression of complementing structural proteins are baculovirus systems expressing JFH1 Core to p7 or Core to NS2 proteins [26] and lentivirus systems expressing Core to NS2 [28] .Trans-packaging particle productionAlthough trans-encapsidation assays have preferentially been performed in human liver-derived cell lines (i.e. Huh7 and subclones), murine hepatic cell line have also been studied [28] .", [["cell lines", "ANATOMY", 19, 29], ["cell clones", "ANATOMY", 136, 147], ["liver-derived cell lines", "ANATOMY", 568, 592], ["Huh7", "ANATOMY", 599, 603], ["subclones", "ANATOMY", 608, 617], ["hepatic cell line", "ANATOMY", 627, 644], ["cell lines", "CELL", 19, 29], ["cell clones", "CELL", 136, 147], ["baculovirus", "ORGANISM", 325, 336], ["JFH1 Core", "ORGANISM", 356, 365], ["p7", "GENE_OR_GENE_PRODUCT", 369, 371], ["lentivirus", "ORGANISM", 405, 415], ["human", "ORGANISM", 562, 567], ["liver-derived cell lines", "CELL", 568, 592], ["Huh7", "CELL", 599, 603], ["subclones", "CELL", 608, 617], ["murine", "ORGANISM", 620, 626], ["hepatic cell line", "CELL", 627, 644], ["stable cell lines", "CELL_LINE", 12, 29], ["resistant genes", "DNA", 64, 79], ["SGR", "DNA", 89, 92], ["cell clones", "CELL_LINE", 136, 147], ["structural proteins", "PROTEIN", 301, 320], ["p7", "PROTEIN", 369, 371], ["NS2 proteins", "PROTEIN", 383, 395], ["NS2", "PROTEIN", 443, 446], ["human liver-derived cell lines", "CELL_LINE", 562, 592], ["Huh7", "CELL_LINE", 599, 603], ["murine hepatic cell line", "CELL_LINE", 620, 644], ["human", "SPECIES", 562, 567], ["murine", "SPECIES", 620, 626], ["baculovirus", "SPECIES", 325, 336], ["human", "SPECIES", 562, 567], ["stable cell lines", "TREATMENT", 12, 29], ["defective replicons", "TREATMENT", 39, 58], ["resistant genes", "PROBLEM", 64, 79], ["Structural protein expression systems", "PROBLEM", 187, 224], ["complementing structural proteins", "PROBLEM", 287, 320], ["baculovirus systems", "TREATMENT", 325, 344], ["NS2 proteins", "TEST", 383, 395], ["encapsidation assays", "TEST", 503, 523], ["cell lines", "TREATMENT", 582, 592], ["Huh7 and subclones", "TREATMENT", 599, 617], ["murine hepatic cell line", "TREATMENT", 620, 644], ["stable", "OBSERVATION_MODIFIER", 12, 18], ["cell lines", "OBSERVATION", 19, 29], ["cell clones", "OBSERVATION", 136, 147], ["protein expression", "OBSERVATION", 198, 216], ["particle production", "OBSERVATION", 469, 488], ["liver", "ANATOMY", 568, 573], ["cell lines", "OBSERVATION", 582, 592], ["hepatic", "ANATOMY", 627, 634], ["cell line", "OBSERVATION", 635, 644]]], ["In a two-step development process, deleted replicons and helper replicons are first validated in transient experiments and then adapted to stable cell lines for standardizing and improving the system.", [["cell lines", "ANATOMY", 146, 156], ["cell lines", "CELL", 146, 156], ["helper replicons", "DNA", 57, 73], ["stable cell lines", "CELL_LINE", 139, 156], ["deleted replicons", "TREATMENT", 35, 52], ["helper replicons", "TREATMENT", 57, 73], ["stable cell lines", "TREATMENT", 139, 156], ["cell lines", "OBSERVATION", 146, 156]]], ["Various researchers have thus shown that trans-packaging systems are functional (Table 3) .Trans-packaging particle productionIt has been proven that the NS3-NS5B replicon can be packaged by Core-NS2 or Core-NS3 proteins expressed in trans but not by Core-p7 [26] [27] [28] 30, 31] .", [["NS3", "GENE_OR_GENE_PRODUCT", 154, 157], ["Core-NS2", "GENE_OR_GENE_PRODUCT", 191, 199], ["NS3-NS5B replicon", "DNA", 154, 171], ["Core-NS2 or Core-NS3 proteins", "PROTEIN", 191, 220], ["the NS3-NS5B replicon", "TREATMENT", 150, 171], ["Core-NS3 proteins", "TREATMENT", 203, 220], ["particle production", "OBSERVATION", 107, 126]]], ["Therefore, NS2 protein is essential for infectious particle production.", [["NS2", "GENE_OR_GENE_PRODUCT", 11, 14], ["NS2 protein", "PROTEIN", 11, 22], ["NS2 protein", "TEST", 11, 22], ["infectious particle production", "PROBLEM", 40, 70], ["essential for", "UNCERTAINTY", 26, 39], ["infectious particle", "OBSERVATION", 40, 59]]], ["The most efficient trans-packaging has been obtained with Core-NS2 [28] .", [["NS2", "PROTEIN", 63, 66]]], ["In parallel, it was found that the NS2-NS5B replicon could be packaged by the Core-p7 region.", [["NS2", "GENE_OR_GENE_PRODUCT", 35, 38], ["NS2-NS5B replicon", "DNA", 35, 52], ["Core-p7 region", "DNA", 78, 92], ["the NS2-NS5B replicon", "TREATMENT", 31, 52], ["NS5B replicon", "OBSERVATION", 39, 52]]], ["However, the trans-packaging efficiency was higher with the NS3-NS5B replicon and the Core-NS2 sequence [26] .Trans-packaging particle productionIn the case of full-length defective genomes, trans-packaging has been observed with Core-NS2, Core-NS3 and E1-NS2 constructs [29, 33] .", [["Core-NS3", "GENE_OR_GENE_PRODUCT", 240, 248], ["E1", "GENE_OR_GENE_PRODUCT", 253, 255], ["NS3-NS5B replicon", "DNA", 60, 77], ["Core-NS2 sequence", "DNA", 86, 103], ["full-length defective genomes", "DNA", 160, 189], ["Core-NS2, Core-NS3 and E1-NS2 constructs", "DNA", 230, 270], ["the NS3-NS5B replicon", "TREATMENT", 56, 77], ["full-length defective genomes", "TREATMENT", 160, 189], ["particle", "OBSERVATION_MODIFIER", 126, 134]]], ["The efficiency was greatest with Core-NS2 [33] .Trans-packaging particle productionIn turn, the pseudo-infectious particles' physical and antigenic properties have been compared with those observed for wt virus [26] [27] [28] 30, 35] .", [["the pseudo-infectious particles", "PROBLEM", 92, 123], ["wt virus", "PROBLEM", 202, 210], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["packaging particle", "OBSERVATION_MODIFIER", 54, 72], ["infectious", "OBSERVATION", 103, 113]]], ["The particle density was similar to that seen in HCVcc particles.", [["particle", "ANATOMY", 4, 12], ["HCVcc", "ORGANISM", 49, 54], ["The particle density", "PROBLEM", 0, 20], ["particle", "OBSERVATION_MODIFIER", 4, 12], ["density", "OBSERVATION", 13, 20]]], ["Neutralization assays with anti-CD81 [27] [28] [29] [30] [31] 35] , anti-E2 [26] , anti-SCARB-1 and anti-claudin-1 [28] antibodies have shown that pseudo-infectious particles use both E2 glycoprotein and HCV entry receptors for cell entry.", [["cell", "ANATOMY", 228, 232], ["anti-CD81 [27] [28] [29] [30] [31] 35", "CHEMICAL", 27, 64], ["E2", "CHEMICAL", 184, 186], ["anti-CD81 [27] [28] [29] [30] [31] 35", "SIMPLE_CHEMICAL", 27, 64], ["anti-E2 [26]", "SIMPLE_CHEMICAL", 68, 80], ["anti-SCARB-1", "GENE_OR_GENE_PRODUCT", 83, 95], ["anti-claudin-1", "GENE_OR_GENE_PRODUCT", 100, 114], ["E2 glycoprotein", "GENE_OR_GENE_PRODUCT", 184, 199], ["HCV", "ORGANISM", 204, 207], ["cell", "CELL", 228, 232], ["anti-SCARB", "PROTEIN", 83, 93], ["anti-claudin-1 [28] antibodies", "PROTEIN", 100, 130], ["E2 glycoprotein", "PROTEIN", 184, 199], ["HCV entry receptors", "PROTEIN", 204, 223], ["HCV", "SPECIES", 204, 207], ["Neutralization assays", "TEST", 0, 21], ["anti-CD81", "TEST", 27, 36], ["anti-E2", "TEST", 68, 75], ["anti-SCARB", "TEST", 83, 93], ["anti-claudin", "TEST", 100, 112], ["antibodies", "TEST", 120, 130], ["pseudo-infectious particles", "PROBLEM", 147, 174], ["E2 glycoprotein", "TREATMENT", 184, 199], ["HCV entry receptors", "TREATMENT", 204, 223], ["infectious", "OBSERVATION", 154, 164]]], ["Ishii et al. [27] have observed particles under the electron microscope and have confirmed similarities with HCVcc particles.", [["the electron microscope", "TEST", 48, 71], ["HCVcc particles", "PROBLEM", 109, 124]]], ["These pseudo-infectious particles were capable of a only single round of infection and the defective genome had been clearly encapsidated [27, 30, 35] .Trans-packaging particle productionSeveral research groups have developed assays for transpackaged particles [26] [27] [28] 30, 35] , whereas others have only observed the particles' features and estimated the efficiency of trans-encapsidation [29, 31, 33] .", [["infection", "DISEASE", 73, 82], ["defective genome", "DNA", 91, 107], ["These pseudo-infectious particles", "PROBLEM", 0, 33], ["infection", "PROBLEM", 73, 82], ["the defective genome", "PROBLEM", 87, 107], ["transpackaged particles", "PROBLEM", 237, 260], ["infectious", "OBSERVATION", 13, 23], ["infection", "OBSERVATION", 73, 82], ["defective genome", "OBSERVATION", 91, 107], ["encapsidated", "OBSERVATION_MODIFIER", 125, 137], ["particle", "OBSERVATION_MODIFIER", 168, 176]]], ["Various titres of pseudo-infectious particles have been obtained: 3.4 AE 0.6 10 2 focus-forming units (FFU)/mL according to Ishii et al., 10 4 tissue culture infectivity dose (TCID) 50 /mL according Table 3 Summary of infectious particles generated by cotransfection of deleted subgenomic replicons with structural proteins expressed in trans.", [["tissue", "ANATOMY", 143, 149], ["subgenomic replicons", "DNA", 278, 298], ["structural proteins", "PROTEIN", 304, 323], ["Various titres of pseudo-infectious particles", "PROBLEM", 0, 45], ["tissue culture infectivity dose (TCID)", "TREATMENT", 143, 181], ["infectious particles", "PROBLEM", 218, 238], ["deleted subgenomic replicons", "PROBLEM", 270, 298], ["structural proteins", "PROBLEM", 304, 323], ["infectious", "OBSERVATION", 25, 35], ["infectious", "OBSERVATION", 218, 228], ["subgenomic replicons", "OBSERVATION", 278, 298]]], ["The comparison of the respective systems' yields is difficult because of heterogeneity of the infectious units used and differences in detection experiments.", [["the infectious units", "TREATMENT", 90, 110], ["infectious", "OBSERVATION", 94, 104]]], ["Several groups have tried to improve their trans-packaging systems by introducing the above-mentioned adaptive mutations into subgenomic replicons [30, 32, 35] or complemented structural protein regions [26] .", [["subgenomic replicons", "DNA", 126, 146], ["structural protein regions", "PROTEIN", 176, 202], ["the above-mentioned adaptive mutations", "TREATMENT", 82, 120], ["subgenomic replicons", "TREATMENT", 126, 146]]], ["For example, the V2440L mutation has been introduced into C-terminal region of NS5A and was found to enhance production [36] .", [["C", "CHEMICAL", 58, 59], ["V2440L", "GENE_OR_GENE_PRODUCT", 17, 23], ["NS5A", "GENE_OR_GENE_PRODUCT", 79, 83], ["V2440L", "DNA", 17, 23], ["C-terminal region", "PROTEIN", 58, 75], ["NS5A", "PROTEIN", 79, 83], ["the V2440L mutation", "PROBLEM", 13, 32], ["C-terminal region of NS5A", "TREATMENT", 58, 83], ["terminal", "ANATOMY_MODIFIER", 60, 68], ["NS5A", "OBSERVATION", 79, 83]]], ["Using JFH1DE1E2 replicons, Li et al.'s group inserted an M1051L mutation into NS3 region and a C2219R mutation into NS5A.", [["Li", "CHEMICAL", 27, 29], ["NS5A", "GENE_OR_GENE_PRODUCT", 116, 120], ["JFH1DE1E2 replicons", "DNA", 6, 25], ["NS3 region", "DNA", 78, 88], ["NS5A", "PROTEIN", 116, 120], ["JFH1DE1E2 replicons", "TREATMENT", 6, 25], ["an M1051L mutation into NS3 region", "TREATMENT", 54, 88], ["a C2219R mutation into NS5A", "TREATMENT", 93, 120]]], ["They obtained a peak titre of 5 9 10 3 IU/mL [35] .", [["a peak titre", "TEST", 14, 26]]], ["Similar observations have been obtained with baculovirus systems and the introduction of F172C and P173S mutations in the C-terminal part of Core [26, 37] .", [["C", "CHEMICAL", 122, 123], ["baculovirus", "ORGANISM", 45, 56], ["F172C", "GENE_OR_GENE_PRODUCT", 89, 94], ["P173S", "GENE_OR_GENE_PRODUCT", 99, 104], ["baculovirus", "SPECIES", 45, 56], ["baculovirus systems", "TREATMENT", 45, 64], ["P173S mutations", "PROBLEM", 99, 114]]], ["Lastly, mutations in E2 (N417S), p7 (N765D) and NS2 (Q1012R) were introduced into the core-NS2 expression plasmid pCAGC and resulted in a more than fourfold increase in pseudoparticle production [32] .Deleted subgenomic repliconsIn parallel, heterologous trans-packaging assays have been developed.", [["E2", "CHEMICAL", 21, 23], ["E2", "GENE_OR_GENE_PRODUCT", 21, 23], ["p7 (N765D)", "GENE_OR_GENE_PRODUCT", 33, 43], ["NS2 (Q1012R)", "GENE_OR_GENE_PRODUCT", 48, 60], ["pseudoparticle", "SIMPLE_CHEMICAL", 169, 183], ["p7 (N765D)", "DNA", 33, 43], ["NS2 (Q1012R)", "DNA", 48, 60], ["core-NS2 expression plasmid pCAGC", "DNA", 86, 119], ["subgenomic replicons", "DNA", 209, 229], ["mutations in E2", "TEST", 8, 23], ["NS2", "TREATMENT", 48, 51], ["NS2 expression plasmid pCAGC", "TREATMENT", 91, 119], ["pseudoparticle production", "PROBLEM", 169, 194], ["Deleted subgenomic replicons", "TREATMENT", 201, 229], ["increase", "OBSERVATION_MODIFIER", 157, 165], ["subgenomic replicons", "OBSERVATION", 209, 229]]], ["The first group to do so was Steinmann et al., who tested the JFH1-Luc-NS3-NS5B replicon with Con1/C3 (1b/JFH1) and Jc1 (J6-2a/JFH1) chimeras.", [["JFH1", "ORGANISM", 62, 66], ["Luc", "GENE_OR_GENE_PRODUCT", 67, 70], ["NS3", "GENE_OR_GENE_PRODUCT", 71, 74], ["Con1/C3", "GENE_OR_GENE_PRODUCT", 94, 101], ["Jc1", "GENE_OR_GENE_PRODUCT", 116, 119], ["J6-2a", "GENE_OR_GENE_PRODUCT", 121, 126], ["JFH1-Luc-NS3-NS5B replicon", "DNA", 62, 88], ["Con1", "PROTEIN", 94, 98], ["C3", "PROTEIN", 99, 101], ["Jc1", "PROTEIN", 116, 119], ["J6", "PROTEIN", 121, 123], ["NS3", "TEST", 71, 74], ["NS5B replicon", "TREATMENT", 75, 88], ["Con1", "TEST", 94, 98], ["JFH1", "TEST", 106, 110], ["Jc1", "TEST", 116, 119], ["J6", "TEST", 121, 123], ["Luc", "ANATOMY", 67, 70], ["NS5B replicon", "OBSERVATION", 75, 88]]], ["Infectious, trans-packaging particles were obtained with each of the two chimeras but Jc1 gave the best yield [30] .", [["Jc1", "SIMPLE_CHEMICAL", 86, 89], ["Jc1", "PROTEIN", 86, 89]]], ["Li et al. [35] chose heterologous trans-encapsidation of JFH1DE1E2 replicons with HCV J6 [2] , H77 (1a) and Con1 (1b) envelope glycoproteins.", [["Li", "CHEMICAL", 0, 2], ["JFH1DE1E2", "GENE_OR_GENE_PRODUCT", 57, 66], ["H77 (1a", "GENE_OR_GENE_PRODUCT", 95, 102], ["Con1 (1b) envelope glycoproteins", "GENE_OR_GENE_PRODUCT", 108, 140], ["JFH1DE1E2 replicons", "DNA", 57, 76], ["HCV J6 [2] , H77 (1a) and Con1 (1b) envelope glycoproteins", "PROTEIN", 82, 140], ["HCV", "SPECIES", 82, 85], ["heterologous trans", "TREATMENT", 21, 39], ["JFH1DE1E2 replicons", "TREATMENT", 57, 76], ["HCV J6", "TEST", 82, 88], ["Con1", "TEST", 108, 112], ["envelope glycoproteins", "TEST", 118, 140]]], ["Only J6 (2a) envelope proteins were able to rescue pseudo-infectious particle production.", [["J6 (2a) envelope", "GENE_OR_GENE_PRODUCT", 5, 21], ["J6 (2a) envelope proteins", "PROTEIN", 5, 30], ["J6 (2a) envelope proteins", "TREATMENT", 5, 30], ["infectious particle production", "PROBLEM", 58, 88], ["infectious", "OBSERVATION", 58, 68]]], ["Intergenotype compatibility between envelope proteins and the other proteins may be essential in the assembly process [35] .CONCLUSIONSThe new JFH1-based culture system has enabled the development of trans-complementation systems that have facili-tated studies of (i) genomic and protein functions and (ii) interactions between HCV proteins.", [["JFH1", "ORGANISM", 143, 147], ["HCV", "ORGANISM", 328, 331], ["envelope proteins", "PROTEIN", 36, 53], ["HCV proteins", "PROTEIN", 328, 340], ["HCV", "SPECIES", 328, 331], ["Intergenotype compatibility", "PROBLEM", 0, 27], ["envelope proteins", "PROBLEM", 36, 53], ["the other proteins", "PROBLEM", 58, 76], ["new JFH1-based culture system", "TEST", 139, 168], ["trans-complementation systems", "PROBLEM", 200, 229], ["facili", "TEST", 240, 246], ["protein functions", "TEST", 280, 297], ["HCV proteins", "PROBLEM", 328, 340]]], ["Trans-complementation based on NS regions has shown that (i) NS5A region carrying mutations in the LCS1 domain or deletions in domain III can be complemented by the minimal sequence NS3-NS5A, (ii) NS2 can be efficiency trans-complemented by wt NS2 and (iii) NS4B trans-complementation exists for mutations in unstructured regions but is weak.", [["NS regions", "DNA", 31, 41], ["NS5A region", "PROTEIN", 61, 72], ["LCS1 domain", "DNA", 99, 110], ["domain III", "PROTEIN", 127, 137], ["NS3", "PROTEIN", 182, 185], ["NS5A", "PROTEIN", 186, 190], ["NS2", "PROTEIN", 197, 200], ["NS2", "PROTEIN", 244, 247], ["NS4B", "PROTEIN", 258, 262], ["NS regions", "TREATMENT", 31, 41], ["NS5A region carrying mutations", "PROBLEM", 61, 91], ["the LCS1 domain", "PROBLEM", 95, 110], ["deletions in domain III", "PROBLEM", 114, 137], ["the minimal sequence NS3", "TREATMENT", 161, 185], ["NS5A, (ii) NS2", "TREATMENT", 186, 200], ["NS4B trans-complementation", "TREATMENT", 258, 284], ["mutations in unstructured regions", "PROBLEM", 296, 329], ["weak", "OBSERVATION", 337, 341]]], ["As expected, genomic trans-complementation in HCV replication systems is limited and NS HCV proteins act preferentially in cis.", [["HCV", "ORGANISM", 46, 49], ["NS HCV", "ORGANISM", 85, 91], ["NS HCV proteins", "PROTEIN", 85, 100], ["HCV", "SPECIES", 46, 49], ["HCV", "SPECIES", 88, 91], ["genomic trans-complementation", "TREATMENT", 13, 42], ["HCV replication systems", "TREATMENT", 46, 69], ["NS HCV proteins", "TREATMENT", 85, 100]]], ["These trans-complementation studies have increased our knowledge of non-structural proteins' functions and interactions in HCV.", [["HCV", "ORGANISM", 123, 126], ["non-structural proteins", "PROTEIN", 68, 91], ["HCV", "SPECIES", 123, 126], ["These trans-complementation studies", "TEST", 0, 35], ["non-structural proteins' functions", "PROBLEM", 68, 102], ["HCV", "PROBLEM", 123, 126]]], ["They have demonstrated that NS5A domain III is a major determinant of HCV assembly.", [["NS5A domain III", "GENE_OR_GENE_PRODUCT", 28, 43], ["HCV", "ORGANISM", 70, 73], ["NS5A domain III", "PROTEIN", 28, 43], ["HCV", "SPECIES", 70, 73], ["NS5A domain III", "TREATMENT", 28, 43], ["HCV", "PROBLEM", 70, 73], ["NS5A", "OBSERVATION", 28, 32], ["HCV", "OBSERVATION", 70, 73]]], ["NS4B is involved in RNA replication but also contributes to virus assembly and release.", [["NS4B", "GENE_OR_GENE_PRODUCT", 0, 4], ["NS4B", "PROTEIN", 0, 4], ["NS4B", "TREATMENT", 0, 4], ["RNA replication", "TREATMENT", 20, 35], ["virus", "PROBLEM", 60, 65], ["RNA replication", "OBSERVATION", 20, 35], ["virus", "OBSERVATION", 60, 65]]], ["NS2 is involved in the viral assembly process; in a late-post assembly maturation step (perhaps in concert with NS5A) and, it confers infectivity on the HCV particle.", [["NS2", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS5A", "GENE_OR_GENE_PRODUCT", 112, 116], ["HCV", "ORGANISM", 153, 156], ["NS2", "PROTEIN", 0, 3], ["NS5A", "PROTEIN", 112, 116], ["HCV", "SPECIES", 153, 156], ["NS2", "TREATMENT", 0, 3], ["NS5A", "TREATMENT", 112, 116], ["viral", "OBSERVATION", 23, 28]]], ["Moreover, NS2 generates a strict cis requirement for the core region, to allow efficient trans-packaging of the subgenomic RNArevealing the complex interplay between NS2 and core genes [29] .", [["NS2", "GENE_OR_GENE_PRODUCT", 166, 169], ["NS2", "PROTEIN", 10, 13], ["core region", "DNA", 57, 68], ["NS2", "PROTEIN", 166, 169], ["core genes", "DNA", 174, 184], ["NS2", "PROBLEM", 10, 13]]], ["Overall, these results have confirmed that NS proteins are involved in viral assembly and release.CONCLUSIONSTrans-complementation of the structural region has shown that Core can be trans-complemented by wt Core.", [["NS proteins", "GENE_OR_GENE_PRODUCT", 43, 54], ["NS proteins", "PROTEIN", 43, 54], ["NS proteins", "TREATMENT", 43, 54], ["viral assembly", "TREATMENT", 71, 85]]], ["Core recruits NS proteins and replication complexes to LDassociated membranes.", [["membranes", "ANATOMY", 68, 77], ["LDassociated membranes", "CELLULAR_COMPONENT", 55, 77], ["NS proteins", "PROTEIN", 14, 25], ["replication complexes", "PROTEIN", 30, 51], ["Core recruits NS proteins", "TREATMENT", 0, 25], ["replication complexes", "TREATMENT", 30, 51], ["LDassociated membranes", "PROBLEM", 55, 77], ["NS proteins", "OBSERVATION", 14, 25], ["replication complexes", "OBSERVATION", 30, 51], ["LDassociated membranes", "OBSERVATION", 55, 77]]], ["This recruitment is critical for producing infectious viruses and residues 170 and 174-177 are important for the production of infectious viruses.", [["infectious viruses", "DISEASE", 127, 145], ["producing infectious viruses", "PROBLEM", 33, 61], ["infectious viruses", "PROBLEM", 127, 145], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["infectious viruses", "OBSERVATION", 127, 145]]], ["Likewise, p7 can be trans-complemented by the E2-p7-NS2 sequence. p7 is absolutely essential for the production of pseudo-infectious HCV particles; it can operate independently of an upstream signal sequence and a tyrosine residue close to its conserved, dibasic motif is important for optimal virus production in genotype 2a viruses.", [["E2", "CHEMICAL", 46, 48], ["tyrosine", "CHEMICAL", 214, 222], ["tyrosine", "CHEMICAL", 214, 222], ["p7", "GENE_OR_GENE_PRODUCT", 10, 12], ["E2", "GENE_OR_GENE_PRODUCT", 46, 48], ["p7", "GENE_OR_GENE_PRODUCT", 66, 68], ["HCV", "ORGANISM", 133, 136], ["tyrosine", "AMINO_ACID", 214, 222], ["genotype 2a viruses", "ORGANISM", 314, 333], ["p7", "PROTEIN", 10, 12], ["E2-p7-NS2 sequence", "DNA", 46, 64], ["p7", "PROTEIN", 66, 68], ["upstream signal sequence", "DNA", 183, 207], ["HCV", "SPECIES", 133, 136], ["pseudo-infectious HCV particles", "PROBLEM", 115, 146], ["an upstream signal sequence", "TEST", 180, 207], ["a tyrosine residue", "PROBLEM", 212, 230], ["dibasic motif", "TREATMENT", 255, 268], ["optimal virus production", "PROBLEM", 286, 310]]], ["These results have clarified the role of Core, p7 and LDs in pseudo-infectious particle production and have indicated that some steps of virus assembly take place around LDs.CONCLUSIONSVarious trans-packaging systems have been developed with subgenomic replicons.", [["Core", "GENE_OR_GENE_PRODUCT", 41, 45], ["p7", "GENE_OR_GENE_PRODUCT", 47, 49], ["LDs", "GENE_OR_GENE_PRODUCT", 54, 57], ["Core, p7 and LDs", "PROTEIN", 41, 57], ["subgenomic replicons", "DNA", 242, 262], ["some steps of virus", "PROBLEM", 123, 142], ["LDs.CONCLUSIONSVarious trans-packaging systems", "TREATMENT", 170, 216], ["subgenomic replicons", "TREATMENT", 242, 262], ["infectious particle", "OBSERVATION", 68, 87], ["subgenomic replicons", "OBSERVATION", 242, 262]]], ["The structural proteins were expressed in trans using helper replicons, helper plasmids, stable cell lines or viral vectors.", [["plasmids", "ANATOMY", 79, 87], ["cell lines", "ANATOMY", 96, 106], ["cell lines", "CELL", 96, 106], ["helper plasmids", "DNA", 72, 87], ["stable cell lines", "CELL_LINE", 89, 106], ["The structural proteins", "PROBLEM", 0, 23], ["helper replicons", "TREATMENT", 54, 70], ["helper plasmids", "TREATMENT", 72, 87], ["stable cell lines", "TREATMENT", 89, 106], ["viral vectors", "TREATMENT", 110, 123], ["stable cell lines", "OBSERVATION", 89, 106], ["viral vectors", "OBSERVATION", 110, 123]]], ["Although the respective [34] 1100 FFU/mL pcDNA-E1-p7 Transient expression system efficiencies of these systems cannot be compared directly, the titres of trans-packaged infectious particles (around 10 2 FFU/mL) were generally lower than wt particle titres (about 10 3 -10 4 FFU/mL for the JFH1 strain).", [["pcDNA", "GENE_OR_GENE_PRODUCT", 41, 46], ["JFH1", "ORGANISM", 289, 293], ["E1", "PROTEIN", 47, 49], ["p7", "PROTEIN", 50, 52], ["FFU", "TEST", 34, 37], ["pcDNA", "TEST", 41, 46], ["Transient expression system efficiencies of these systems", "PROBLEM", 53, 110], ["trans-packaged infectious particles", "TREATMENT", 154, 189], ["the JFH1 strain", "PROBLEM", 285, 300], ["infectious", "OBSERVATION", 169, 179]]], ["Nonetheless, these titres have been improved by the introduction of adaptive mutations that favour particle production with defective replicons or structural regions expressed in trans.", [["adaptive mutations", "TREATMENT", 68, 86], ["particle production", "PROBLEM", 99, 118], ["defective replicons", "PROBLEM", 124, 143], ["structural regions", "PROBLEM", 147, 165], ["improved", "OBSERVATION_MODIFIER", 36, 44]]], ["However, some limits exist with heterologous glycoproteins and intergenotype compatibility seems to be required for some proteins.CONCLUSIONSFlaviviridae trans-complementation studies have enabled the production of vaccine-like preparations based on transpackaging particles.", [["heterologous glycoproteins", "PROTEIN", 32, 58], ["heterologous glycoproteins", "PROBLEM", 32, 58], ["intergenotype compatibility", "PROBLEM", 63, 90], ["some proteins.CONCLUSIONSFlaviviridae trans-complementation studies", "TEST", 116, 183], ["vaccine", "TREATMENT", 215, 222], ["transpackaging particles", "TREATMENT", 250, 274]]], ["In particular, it has been reported that the envelope glycoprotein Erns in classical swine fever virus (a pestivirus) can be complemented in trans by an SK6 cell line that constitutively expresses this protein [38] .", [["SK6 cell line", "ANATOMY", 153, 166], ["swine fever", "DISEASE", 85, 96], ["Erns", "GENE_OR_GENE_PRODUCT", 67, 71], ["classical swine fever virus", "ORGANISM", 75, 102], ["pestivirus", "CANCER", 106, 116], ["SK6 cell line", "CELL", 153, 166], ["envelope glycoprotein Erns", "PROTEIN", 45, 71], ["SK6 cell line", "CELL_LINE", 153, 166], ["swine fever virus", "SPECIES", 85, 102], ["swine fever virus", "SPECIES", 85, 102], ["the envelope glycoprotein", "TREATMENT", 41, 66], ["classical swine fever virus", "PROBLEM", 75, 102], ["a pestivirus", "PROBLEM", 104, 116], ["an SK6 cell line", "TREATMENT", 150, 166], ["cell line", "OBSERVATION", 157, 166]]], ["Pigs vaccinated with these defective viral particles were protected against a lethal challenge with the virulent Brescia strain.", [["Pigs", "ORGANISM", 0, 4], ["Brescia strain", "ORGANISM", 113, 127], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs vaccinated", "TREATMENT", 0, 15], ["these defective viral particles", "TREATMENT", 21, 52], ["a lethal challenge", "TREATMENT", 76, 94], ["the virulent Brescia strain", "PROBLEM", 100, 127], ["viral particles", "OBSERVATION", 37, 52], ["virulent", "OBSERVATION_MODIFIER", 104, 112], ["Brescia strain", "OBSERVATION", 113, 127]]], ["This observation opened up new perspectives in the development of modified, live-attenuated vaccines.", [["live-attenuated vaccines", "TREATMENT", 76, 100]]], ["However, there are no reports of in vivo vaccine activity or neutralizing antibody production with HCV trans-complementation particles.", [["HCV", "SPECIES", 99, 102], ["neutralizing antibody production", "PROBLEM", 61, 93], ["HCV trans", "TREATMENT", 99, 108], ["no reports of", "UNCERTAINTY", 19, 32]]], ["One possible explanation is that immunization studies require high infectious titres (in the order to 10 7 or 10 8 FFU/mL) but trans-packaging particle production is low (about 10 2 FFU/mL).", [["immunization studies", "TEST", 33, 53], ["high infectious titres", "PROBLEM", 62, 84], ["low", "OBSERVATION_MODIFIER", 166, 169]]], ["Additional studies are needed to increase pseudo-infectious particle yields for vaccine assays.CONCLUSIONSLastly, HCV trans-complementation is a natural phenomenon that can be observed with native defective subgenomic RNAs identified in infected patients and encapsidated by helper viruses.CONCLUSIONSIn conclusion, HCV trans-complementation systems have been a valuable tool for improving our knowledge of the HCV life cycle.", [["patients", "ORGANISM", 246, 254], ["HCV", "ORGANISM", 411, 414], ["subgenomic RNAs", "RNA", 207, 222], ["patients", "SPECIES", 246, 254], ["HCV", "SPECIES", 114, 117], ["HCV", "SPECIES", 316, 319], ["HCV", "SPECIES", 411, 414], ["Additional studies", "TEST", 0, 18], ["vaccine assays", "TREATMENT", 80, 94], ["HCV trans-complementation", "PROBLEM", 114, 139], ["a natural phenomenon", "PROBLEM", 143, 163], ["native defective subgenomic RNAs", "PROBLEM", 190, 222], ["natural phenomenon", "OBSERVATION", 145, 163], ["subgenomic RNAs", "OBSERVATION", 207, 222], ["infected", "OBSERVATION_MODIFIER", 237, 245]]]], "29d374c381ed152a0a2550370fa8ff2234d8533b": [["Regulatory network Protein regulation Disease classification A B S T R A C TObjective: To develop regulatory network to explore and model the regulatory relationships of protein biomarkers and classify different disease groups.", [["protein biomarkers", "TEST", 170, 188], ["different disease groups", "PROBLEM", 202, 226], ["Protein regulation Disease", "OBSERVATION", 19, 45]]], ["Methods: Regulatory network is constructed to be a hopfield-like network with nodes representing biomarkers and directional connections to be regulations in between.", [["a hopfield-like network with nodes representing biomarkers", "PROBLEM", 49, 107], ["nodes", "OBSERVATION", 78, 83]]], ["The input to the network is the measured expression levels of biomarkers, and the output is the summation of regulatory strengths from other biomarkers.", [["the output", "TEST", 78, 88], ["other biomarkers", "TEST", 135, 151]]], ["To simulate more complicated regulations, a sigmoid kernel function is imposed on each node to construct a non-linear regulatory network.", [["node", "ANATOMY", 87, 91], ["more complicated", "OBSERVATION_MODIFIER", 12, 28], ["sigmoid", "ANATOMY", 44, 51], ["kernel function", "OBSERVATION", 52, 67], ["node", "OBSERVATION", 87, 91]]], ["Results: Two datasets have been used as test beds, one dataset includes patients of nasopharyngeal carcinoma with different responses to chemotherapy drug, and the other consists of patients of severe acute respiratory syndrome, influenza, and control normals.", [["nasopharyngeal carcinoma", "ANATOMY", 84, 108], ["nasopharyngeal carcinoma", "DISEASE", 84, 108], ["acute respiratory syndrome", "DISEASE", 201, 227], ["influenza", "DISEASE", 229, 238], ["patients", "ORGANISM", 72, 80], ["nasopharyngeal carcinoma", "CANCER", 84, 108], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 182, 190], ["test beds", "TREATMENT", 40, 49], ["nasopharyngeal carcinoma", "PROBLEM", 84, 108], ["chemotherapy drug", "TREATMENT", 137, 154], ["severe acute respiratory syndrome", "PROBLEM", 194, 227], ["influenza", "PROBLEM", 229, 238], ["nasopharyngeal", "ANATOMY", 84, 98], ["carcinoma", "OBSERVATION", 99, 108], ["severe", "OBSERVATION_MODIFIER", 194, 200], ["acute", "OBSERVATION_MODIFIER", 201, 206], ["respiratory syndrome", "OBSERVATION", 207, 227]]], ["The regulatory networks among protein biomarkers were reconstructed for different disease conditions in each dataset.", [["protein biomarkers", "TEST", 30, 48], ["different disease conditions", "PROBLEM", 72, 100]]], ["We demonstrated our methods have better classification capability when comparing with conventional methods including Fisher linear discriminant (FLD), K-nearest neighborhood (KNN), linear support vector machines (linSVM) and radial basis function based support vector machines (rbfSVM).", [["conventional methods", "TEST", 86, 106], ["linear support vector machines", "TREATMENT", 181, 211], ["radial basis function", "TREATMENT", 225, 246], ["radial", "ANATOMY_MODIFIER", 225, 231]]], ["Conclusion: The derived networks can effectively capture the unique regulatory patterns of protein markers associated with different patient groups and hence can be used for disease classification.", [["patient", "ORGANISM", 133, 140], ["protein markers", "PROTEIN", 91, 106], ["patient", "SPECIES", 133, 140], ["protein markers", "TEST", 91, 106], ["disease classification", "PROBLEM", 174, 196]]], ["The discovered regulation relationships can potentially provide insights to revealing the molecular signaling pathways.Regulatory network Protein regulation Disease classification A B S T R A C TIn this paper, a novel technique of regulatory network is proposed on purpose of modeling biomarker regulations and classifying different disease groups.", [["A C TIn this paper", "TREATMENT", 190, 208], ["a novel technique of regulatory network", "TREATMENT", 210, 249], ["modeling biomarker regulations", "TREATMENT", 276, 306], ["different disease groups", "PROBLEM", 323, 347], ["Protein regulation Disease", "OBSERVATION", 138, 164]]], ["The network is composed of a certain number of nodes that are directionally connected in between in which nodes denote predictors and connections to be the regulation relationship.", [["nodes", "OBSERVATION", 47, 52], ["nodes", "OBSERVATION", 106, 111]]], ["The network is optimized towards minimizing its energy function with biomarker expression data acquired from a specific patient group, thus the optimized network can model the regulatory relationship of biomarkers under the same circumstance.", [["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["biomarker expression data", "TEST", 69, 94]]], ["To simulate more complicated regulations, a sigmoid kernel function is imposed on each node to construct a non-linear regulatory network.", [["node", "ANATOMY", 87, 91], ["more complicated", "OBSERVATION_MODIFIER", 12, 28], ["sigmoid", "ANATOMY", 44, 51], ["kernel function", "OBSERVATION", 52, 67], ["node", "OBSERVATION", 87, 91]]], ["The regulatory network can extract unique features of each disease condition, thus one immediate application of regulatory network is to classifying different diseases.", [["each disease condition", "PROBLEM", 54, 76], ["different diseases", "PROBLEM", 149, 167], ["different", "OBSERVATION_MODIFIER", 149, 158], ["diseases", "OBSERVATION", 159, 167]]], ["We demonstrated that regulatory network is capable of performing disease classification through comparing with conventional methods including FLD, KNN, linSVM and rbfSVM on two protein datasets.", [["FLD", "DNA", 142, 145], ["linSVM", "DNA", 152, 158], ["rbfSVM", "PROTEIN", 163, 169], ["performing disease classification", "PROBLEM", 54, 87], ["conventional methods", "TEST", 111, 131], ["FLD", "TEST", 142, 145], ["KNN", "TEST", 147, 150], ["linSVM", "TEST", 152, 158]]], ["We believe our method is promising in mining knowledge of protein regulations and be powerful for disease classification.Regulatory network Protein regulation Disease classification A B S T R A C T\u00df 2009 Elsevier B.V. All rights reserved.Regulatory network Protein regulation Disease classification A B S T R A C Tdue to its high-dimensionality and small-sample nature.", [["protein regulations", "TREATMENT", 58, 77], ["disease classification", "PROBLEM", 98, 120], ["Protein regulation Disease", "OBSERVATION", 140, 166], ["Protein regulation Disease", "OBSERVATION", 257, 283], ["small", "OBSERVATION_MODIFIER", 349, 354], ["-sample nature", "OBSERVATION_MODIFIER", 354, 368]]], ["The most popular way to utilize the array data is to identifying biomarkers for specific diseases [3, 5, 6, 8] or building classification models [4, 7, 8] .", [["the array data", "TEST", 32, 46], ["specific diseases", "PROBLEM", 80, 97]]], ["Biomarker can vary drastically in different circumstances, suggesting it is risky to rely on individual biomarkers without knowing its regulations in between.Regulatory network Protein regulation Disease classification A B S T R A C TRecently there is an obvious trend to discover molecular regulations through analyzing microarray data.", [["Biomarker", "TEST", 0, 9], ["individual biomarkers", "TEST", 93, 114], ["analyzing microarray data", "TEST", 311, 336], ["Protein regulation Disease", "OBSERVATION", 177, 203]]], ["In particular, Antonov et al. believed that molecular patterns vary in different patient groups, and proposed to extract regulatory relationships by using linear programming methods [13] .", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["molecular patterns", "PROBLEM", 44, 62], ["linear programming methods", "TREATMENT", 155, 181]]], ["One disadvantage of aforementioned methods is that the regulation relationship is constructed for all groups, thus no unique feature can be extracted for individual patient group [16] .Regulatory network Protein regulation Disease classification A B S T R A C TFrom a biological viewpoint, there exists an underlying regulatory network which is responsible for tumor genesis [17, 18] .", [["tumor", "ANATOMY", 361, 366], ["tumor", "DISEASE", 361, 366], ["patient", "ORGANISM", 165, 172], ["T R A C", "GENE_OR_GENE_PRODUCT", 252, 259], ["tumor", "CANCER", 361, 366], ["patient", "SPECIES", 165, 172], ["an underlying regulatory network", "PROBLEM", 303, 335], ["tumor genesis", "PROBLEM", 361, 374], ["Protein regulation Disease", "OBSERVATION", 204, 230], ["responsible for", "UNCERTAINTY", 345, 360], ["tumor", "OBSERVATION", 361, 366]]], ["In brief, a RN is constructed to be a hopfield-like network with nodes representing biomarkers and directional connections to be regulations in between.", [["nodes", "MULTI-TISSUE_STRUCTURE", 65, 70], ["nodes representing biomarkers", "PROBLEM", 65, 94], ["nodes", "OBSERVATION", 65, 70]]], ["The input to the network is the measured expression levels of biomarkers, and the output is the summation of regulatory strengths from other biomarkers.", [["the output", "TEST", 78, 88], ["other biomarkers", "TEST", 135, 151]]], ["An energy function is defined as the measure of the disagreement between the input and output of the network.", [["energy function", "OBSERVATION", 3, 18]]], ["Minimizing the energy function can thus reconstruct the regulatory relationships among biomarkers.", [["energy function", "OBSERVATION", 15, 30]]], ["Since RN can extract unique features of each disease condition, one immediate application of RN is to classify different diseases.", [["each disease condition", "PROBLEM", 40, 62], ["different diseases", "PROBLEM", 111, 129], ["diseases", "OBSERVATION", 121, 129]]], ["To simulate more complicated regulations, a sigmoid kernel function is imposed on each node to construct a non-linear regulatory network (NRN), which will be shown can enjoy higher stability and accuracy in disease classification.Regulatory network Protein regulation Disease classification A B S T R A C TOur methods were applied to model protein regulations in different disease conditions.", [["node", "ANATOMY", 87, 91], ["NRN", "CELL_LINE", 138, 141], ["a sigmoid kernel function", "TEST", 42, 67], ["A B S T R A C TOur methods", "TREATMENT", 291, 317], ["model protein regulations", "TREATMENT", 334, 359], ["different disease conditions", "PROBLEM", 363, 391], ["more complicated", "OBSERVATION_MODIFIER", 12, 28], ["sigmoid", "ANATOMY", 44, 51], ["kernel function", "OBSERVATION", 52, 67], ["node", "OBSERVATION", 87, 91], ["Protein regulation Disease", "OBSERVATION", 249, 275]]], ["Unlike genome, which is relatively constant and simple, proteome is much more complicated due to its extensive interactions with other molecules and environmental conditions.", [["genome", "OBSERVATION", 7, 13], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["constant", "OBSERVATION_MODIFIER", 35, 43]]], ["For instance, many proteins only function in the presence of other molecules, and some proteins may cooperatively form complexes that could be involved in the translational modification of other proteins.", [["other molecules", "PROBLEM", 61, 76], ["some proteins", "PROBLEM", 82, 95]]], ["Proteinchip of SELDI-TOF-MS (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry) is a high-throughput technique that can simultaneously interrogate thousands of proteins, thus providing abundant information of protein expressions in an organism.", [["Proteinchip", "TEST", 0, 11], ["SELDI", "TEST", 15, 20], ["TOF", "TEST", 21, 24], ["MS", "PROBLEM", 25, 27], ["laser desorption", "TEST", 46, 62], ["ionization time", "TEST", 63, 78], ["protein expressions", "PROBLEM", 237, 256]]], ["Two datasets have been used as test beds, one dataset includes patients of nasopharyngeal carcinoma (NPC) with different responses to chemotherapy drug, and the other consists of patients of severe acute respiratory syndrome (SARS), influenza, and control normals.", [["nasopharyngeal carcinoma", "ANATOMY", 75, 99], ["NPC", "ANATOMY", 101, 104], ["nasopharyngeal carcinoma", "DISEASE", 75, 99], ["NPC", "DISEASE", 101, 104], ["acute respiratory syndrome", "DISEASE", 198, 224], ["SARS", "DISEASE", 226, 230], ["influenza", "DISEASE", 233, 242], ["patients", "ORGANISM", 63, 71], ["nasopharyngeal carcinoma", "CANCER", 75, 99], ["NPC", "CANCER", 101, 104], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 179, 187], ["test beds", "TREATMENT", 31, 40], ["nasopharyngeal carcinoma", "PROBLEM", 75, 99], ["chemotherapy drug", "TREATMENT", 134, 151], ["severe acute respiratory syndrome", "PROBLEM", 191, 224], ["influenza", "PROBLEM", 233, 242], ["nasopharyngeal", "ANATOMY", 75, 89], ["carcinoma", "OBSERVATION", 90, 99], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["respiratory syndrome", "OBSERVATION", 204, 224]]], ["The regulatory networks among protein biomarkers were reconstructed for different disease conditions in each dataset.", [["protein biomarkers", "TEST", 30, 48], ["different disease conditions", "PROBLEM", 72, 100]]], ["We demonstrated our methods have better classification capability when comparing with conventional methods including Fisher linear discriminant (FLD), K-nearest neighborhood (KNN), linear support vector machines (linSVM) and radial basis function based support vector machines (rbfSVM)).Data setsOur approach was validated through two real-world protein profiling datasets.", [["conventional methods", "TEST", 86, 106], ["linear support vector machines", "TREATMENT", 181, 211], ["radial", "ANATOMY_MODIFIER", 225, 231]]], ["The NPC dataset [19] includes 54 patients that are categorized into two groups: 10 chemo-responders (RS) and 44 nonresponders (NR).", [["NPC", "ANATOMY", 4, 7], ["NPC", "CANCER", 4, 7], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["chemo", "TREATMENT", 83, 88]]], ["The SARS dataset [20] includes 74 patients from three disease groups: 44 SARS patients, 20 IFZ (influenzainfected) patients, and 10 control normals.", [["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 73, 77], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 115, 123], ["The SARS dataset", "TEST", 0, 16]]], ["These data sets were acquired by the department of oncology of Hong Kong Queen Elizabeth Hospital using SELDI-TOF-MS technology.Data setsFor both two datasets, ProteinChip profiling spectra were generated from each serum fraction with proteins/peptides displayed as unique peaks based on their mass-to-charge ratio (m/z) as analyzed by Ciphergen ProteinChip Software 3.0.2.", [["serum", "ANATOMY", 215, 220], ["serum", "ORGANISM_SUBSTANCE", 215, 220], ["Data sets", "TEST", 128, 137], ["ProteinChip profiling spectra", "TEST", 160, 189], ["each serum fraction", "TEST", 210, 229], ["proteins/peptides", "TEST", 235, 252], ["their mass", "PROBLEM", 288, 298], ["mass", "OBSERVATION", 294, 298]]], ["Each peak was first baseline subtracted, then normalized with mean total ion current and included for analysis with a cutoff signal-tonoise ratio >5 for the 1st pass and >2 for the 2nd.", [["analysis", "TEST", 102, 110], ["a cutoff signal", "TEST", 116, 131], ["tonoise ratio", "TEST", 132, 145]]], ["After preprocessing, the NPC dataset contains 530 proteins, and the SARS dataset contains 103 proteins.Construction and optimization of regulatory networksIn brief, the RN is constructed by employing a hopfield-like network to highlight the mutual relationships among biomarkers, as shown in Fig. 1 .", [["NPC", "ANATOMY", 25, 28], ["NPC", "CANCER", 25, 28], ["NPC", "PROTEIN", 25, 28], ["103 proteins", "PROTEIN", 90, 102], ["RN", "DNA", 169, 171], ["the NPC dataset", "TREATMENT", 21, 36], ["the SARS dataset", "TEST", 64, 80]]], ["Each node represents a biomarker and arrow lines denote the regulatory relationships.", [["node", "ANATOMY", 5, 9], ["arrow lines", "ANATOMY", 37, 48], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["arrow lines", "CELL", 37, 48], ["a biomarker and arrow lines", "PROBLEM", 21, 48], ["node", "OBSERVATION", 5, 9], ["arrow lines", "OBSERVATION", 37, 48]]], ["Without loss of generality, assume that there are p biomarkers whose expression levels are denoted by a vector x = [x 1 , x 2 , . . ., x p ] T and the regulatory matrix of the RN is denoted as A = {a ij 2 R; i, j = 1, 2, . . ., p} with the element a ij representing the regulatory coefficient from the jth node to the ith node.", [["node", "ANATOMY", 306, 310], ["node", "ANATOMY", 322, 326], ["matrix", "CELLULAR_COMPONENT", 162, 168], ["node", "MULTI-TISSUE_STRUCTURE", 306, 310], ["node", "MULTI-TISSUE_STRUCTURE", 322, 326], ["RN", "DNA", 176, 178], ["loss of generality", "PROBLEM", 8, 26], ["p biomarkers", "TEST", 50, 62], ["expression levels", "TEST", 69, 86], ["the element a ij", "PROBLEM", 236, 252], ["ij", "ANATOMY", 250, 252], ["jth node", "ANATOMY", 302, 310], ["ith node", "ANATOMY", 318, 326]]], ["Let x and y = [y 1 , y 2 , . . ., y p ] T be the input and output of the network, the RN can be modeled asConstruction and optimization of regulatory networks; or written as yConstruction and optimization of regulatory networkswhere b i , i = 1, 2, . . ., p, is a constant bias.", [["regulatory networks", "PROTEIN", 139, 158]]], ["For the matrix A, since interaction of a biomarker to itself is meaningless, the following constraint is naturally imposed:Construction and optimization of regulatory networksAlthough some classic neural networks (such as Hopfield network [21] ) assume the connection matrix is symmetrical, no assumption is made to the regulation matrix of the RN because two biomarkers incline to regulate each other with different strengths from a biological viewpoint.Construction and optimization of regulatory networksA critical issue of building the RN is how to characterize and analyze the RN.", [["neural networks", "ANATOMY", 197, 212], ["matrix A", "GENE_OR_GENE_PRODUCT", 8, 16], ["neural networks", "MULTI-TISSUE_STRUCTURE", 197, 212], ["matrix", "CELLULAR_COMPONENT", 268, 274], ["matrix", "CELLULAR_COMPONENT", 331, 337], ["regulatory networks", "PROTEIN", 156, 175], ["neural networks", "OBSERVATION", 197, 212]]], ["(3), the energy function can be rewritten as the following form:Construction and optimization of regulatory networksThe definition of the energy function indicates that lower energy status corresponds to higher agreement between input and output.", [["regulatory networks", "PROTEIN", 97, 116], ["the energy function", "TEST", 134, 153], ["lower energy status", "PROBLEM", 169, 188]]], ["If high agreement state remains true for all of the samples in a specific patient group, then the connection matrix of the network can reflect the consistent patterns of biomarker interactions specific to the patient group.", [["patient", "ORGANISM", 74, 81], ["matrix", "CELLULAR_COMPONENT", 109, 115], ["patient", "ORGANISM", 209, 216], ["patient", "SPECIES", 74, 81], ["patient", "SPECIES", 209, 216], ["the samples", "TEST", 48, 59], ["biomarker interactions", "PROBLEM", 170, 192]]], ["The unique patterns of interactions can be used for disease classification.", [["disease classification", "PROBLEM", 52, 74]]], ["What follows presents the obtainment and optimization of the regulation matrix.Construction and optimization of regulatory networksLet X = [x 1 , x 2 , . . ., x l ] be the biomarker profiling observations of a specific group of patients.", [["matrix", "CELLULAR_COMPONENT", 72, 78], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["the biomarker", "TEST", 168, 181]]], ["The optimal connection matrix A can be achieved through solving the following objective function upon the data X:Construction and optimization of regulatory networkswhere I is the identity matrix.", [["matrix", "CELLULAR_COMPONENT", 189, 195]]], ["Let\u00c3 \u00bc \u00f0A \u00c0 I\u00de, the objective function can be rewritten asConstruction and optimization of regulatory networkswhere the diagonal elements\u00e3 ii of\u00c3 satisfy:Construction and optimization of regulatory networksBy rewriting\u00c3 as \u00bd\u00c3 1 ;\u00c3 2 ; . . . ;\u00c3 p , Eq.", [["diagonal elements", "DNA", 120, 137]]], ["(6) is expanded to the following form:Construction and optimization of regulatory networkswhere e is a l-dimensional row vector whose elements equal one.Construction and optimization of regulatory networksThe present work only considers the simple case of zero bias, i.e., b i = 0, i = 1, 2, . . ., p.", [["l-dimensional row vector", "DNA", 103, 127], ["a l-dimensional row vector", "TREATMENT", 101, 127]]], ["In this case, the objective function becomesConstruction and optimization of regulatory networksBy rewriting the ith row vector of X asConstruction and optimization of regulatory networksis then converted intoConstruction and optimization of regulatory networks. . . ; a i\u00f0i\u00c01\u00de ; a i\u00f0i\u00fe1\u00de ; . . . ; a i p \u00c2 \u00c3 T is unknown.", [["regulatory networks", "PROTEIN", 242, 261], ["the ith row vector of X asConstruction", "TREATMENT", 109, 147], ["regulatory networksis", "TREATMENT", 168, 189]]], ["(11), the regulatory coefficients can be obtained as follows:Construction and optimization of regulatory networksIn case that the inverse of Z T i Z i does not exists, the pseudoinverse can be used to compute the solution.Construction and optimization of regulatory networksAlthough the linear RN is straightforward and easy to explain, the solution may hardly converge in a robust way due to the large variations existed in the data points (especially in marginal data points).", [["regulatory networks", "PROTEIN", 94, 113], ["the solution", "TREATMENT", 337, 349], ["the large variations", "PROBLEM", 393, 413], ["linear", "OBSERVATION_MODIFIER", 287, 293], ["large", "OBSERVATION_MODIFIER", 397, 402], ["variations", "OBSERVATION", 403, 413]]], ["To further improve the robustness of the algorithm, we propose to construct the NRN (non-linear regulatory networks) based on the linear RN: adding a sigmoid kernel transformation unit between the input and output of the RN.", [["NRN", "DNA", 80, 83], ["linear RN", "DNA", 130, 139], ["sigmoid kernel transformation unit", "DNA", 150, 184], ["a sigmoid kernel transformation", "TREATMENT", 148, 179], ["sigmoid", "ANATOMY", 150, 157], ["kernel transformation", "OBSERVATION", 158, 179]]], ["The sigmoid unit takes x as input and outputs the following vector:Construction and optimization of regulatory networkswhere b 2 (0, 1] is a tunable sigmoid parameter, and m i \u00bcConstruction and optimization of regulatory networksr are the mean and standard deviation of the expression data of ith biomarkers, respectively.", [["sigmoid unit", "DNA", 4, 16], ["regulatory networksr", "PROTEIN", 210, 230], ["a tunable sigmoid parameter", "TREATMENT", 139, 166], ["sigmoid", "ANATOMY", 4, 11], ["sigmoid", "ANATOMY", 149, 156]]], ["Then, the new vector v is fed to the linear RN unit to form the NRN.", [["linear RN unit", "DNA", 37, 51], ["NRN", "DNA", 64, 67]]], ["For NRN, in terms of Eqs.", [["NRN", "PROTEIN", 4, 7]]], ["(4) and (13), the corresponding energy function becomesConstruction and optimization of regulatory networksWith this new energy function, the structure of the non-linear network can be determined similar to that of the linear network.", [["regulatory networks", "PROTEIN", 88, 107], ["new", "OBSERVATION_MODIFIER", 117, 120], ["energy function", "OBSERVATION", 121, 136]]], ["In addition, the NRN can be optimized by tuning the sigmoid parameter b in Eq.", [["NRN", "DNA", 17, 20], ["sigmoid", "ANATOMY", 52, 59]]], ["(13).Disease classification with the regulatory network and biomarker selectionThe information of mutual regulations among biomarkers is stored in the connection matrix of RN.", [["matrix", "CELLULAR_COMPONENT", 162, 168], ["Disease classification", "PROBLEM", 5, 27], ["biomarker selection", "TEST", 60, 79]]], ["As described above, since the network is optimized towards minimizing its energy function for all the training samples in a group of patients, the connection matrix reserves the unique pattern of this specific group.", [["patients", "ORGANISM", 133, 141], ["matrix", "CELLULAR_COMPONENT", 158, 164], ["patients", "SPECIES", 133, 141]]], ["In other words, for a sample belonging to this group the network will approach a low energy status, and otherwise, the network has high energy.", [["high energy", "PROBLEM", 131, 142]]], ["Without loss of generality, consider a G-class disease classification problem, we can first obtain G RNs using the network modeling algorithm as described above, which correspond to the G groups.", [["loss of generality", "PROBLEM", 8, 26], ["a G-class disease classification problem", "PROBLEM", 37, 77], ["the network modeling algorithm", "TEST", 111, 141]]], ["Based on the G RNs, a classification function can be designed as follows:Disease classification with the regulatory network and biomarker selectionwhere u represents an unknown sample, D u 2 {1, 2, . . ., G} is the predicted class label, and E g is the energy function of the gth RN.", [["gth RN", "PROTEIN", 276, 282], ["Disease classification", "PROBLEM", 73, 95]]], ["We develop a three-step selection procedure to select key proteins.", [["a three-step selection procedure", "TREATMENT", 11, 43]]], ["First, the regulation probability method (RPM) [22, 23] is used to pre-select a number of discriminative biomarker candidates to form a biomarker panel.", [["a biomarker panel", "TEST", 134, 151]]], ["Second, different numbers (p = 2, 3, 4, . . .) of biomarkers from the panel are exhaustively combined, and based on each combination, the RN classification algorithm is applied.", [["different numbers", "TEST", 8, 25], ["p", "TEST", 27, 28], ["biomarkers from the panel", "TEST", 50, 75], ["different", "OBSERVATION_MODIFIER", 8, 17], ["numbers", "OBSERVATION_MODIFIER", 18, 25]]], ["In the evaluation, to eliminate the influence of the unbalance of sample sizes of different groups the following LOOCV accuracy (Accu) is adopted:Disease classification with the regulatory network and biomarker selectionwhere t g is the number of correctly classified samples and l g is the sample number in gth class.", [["samples", "ANATOMY", 268, 275], ["the evaluation", "TEST", 3, 17], ["Disease classification", "PROBLEM", 146, 168]]], ["Based on the biomarker set, the final RN classifier is constructed using all training samples.Analysis on the NPC datasetThe NPC dataset was randomly divided into training set and validation set, each with 22 nonresponders and 5 responders.", [["NPC", "ANATOMY", 110, 113], ["NPC", "ANATOMY", 125, 128], ["NPC", "CANCER", 110, 113], ["NPC", "CANCER", 125, 128], ["NPC dataset", "DNA", 110, 121], ["NPC", "PROTEIN", 125, 128], ["all training samples", "TREATMENT", 73, 93], ["The NPC dataset", "TREATMENT", 121, 136], ["validation set", "TEST", 180, 194]]], ["Firstly, we performed the three-step selection procedure on the training data to select differently expressed proteins.", [["the three-step selection procedure", "TREATMENT", 22, 56], ["the training data", "TEST", 60, 77]]], ["To determine the size of the biomarker panel, based on the regulation probability method introduced in [23], a permutation test experiment with 50 permutations was performed to calculate the significance level for each protein.", [["the biomarker panel", "TEST", 25, 44], ["a permutation test experiment", "TEST", 109, 138], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["After that, we implemented the linear and non-linear regulatory network approaches to the NPC data, respectively.", [["NPC", "ANATOMY", 90, 93], ["NPC", "CANCER", 90, 93], ["NPC", "PROTEIN", 90, 93], ["NPC", "ANATOMY", 90, 93]]], ["For the NRN classifier, the parameter b of the sigmoid function was optimized in the set of {0.001, 0.01, 0.1, 0.5 and 1} through leaveone-out cross-validation.", [["sigmoid", "MULTI-TISSUE_STRUCTURE", 47, 54], ["cross-validation", "TEST", 143, 159], ["sigmoid", "ANATOMY", 47, 54]]], ["Since small-scale network is more computationally preferable, the number of network nodes p was initially set to 2, and then was gradually increased.", [["network nodes", "ANATOMY", 76, 89], ["network nodes", "MULTI-TISSUE_STRUCTURE", 76, 89], ["small", "OBSERVATION_MODIFIER", 6, 11], ["-scale", "OBSERVATION_MODIFIER", 11, 17], ["nodes", "OBSERVATION", 84, 89], ["increased", "OBSERVATION_MODIFIER", 139, 148]]], ["Considering increasingly heavy computational burden, our experiments were performed with no more than 6 nodes.", [["increasingly heavy computational burden", "PROBLEM", 12, 51], ["our experiments", "TEST", 53, 68], ["heavy", "OBSERVATION_MODIFIER", 25, 30], ["nodes", "OBSERVATION", 104, 109]]], ["Fig. 3(A) and (B) shows the changing curves of the classification performances of the RN and NRN classifiers while p is increasing.Analysis on the NPC datasetFrom the two figures, it can be found that the accuracies of both RN and NRN tend to increase with more proteins were involved, suggesting that more regulatory information is available with more biomarkers for NPC classification.", [["NPC", "ANATOMY", 147, 150], ["NPC", "ANATOMY", 368, 371], ["NPC", "CANCER", 147, 150], ["NPC", "CANCER", 368, 371], ["NRN", "PROTEIN", 231, 234], ["the NPC dataset", "TEST", 143, 158], ["NPC classification", "TREATMENT", 368, 386], ["increasing", "OBSERVATION_MODIFIER", 120, 130]]], ["Moreover, the testing accuracies of RN and NRN reached their peaks while 5 biomarkers used, indicating that five proteins can stably support the feature space to distinguish the two groups of patients.", [["patients", "ORGANISM", 192, 200], ["NRN", "DNA", 43, 46], ["patients", "SPECIES", 192, 200], ["5 biomarkers", "TEST", 73, 85], ["five proteins", "PROBLEM", 108, 121]]], ["The figures also illustrate that NRN achieved a higher testing accuracy of 93% (2 errors among 27 testing samples) compared to RN (89%, 3 errors among 27 testing samples), which suggests that NRN tends to have better classification capability.", [["samples", "CANCER", 106, 113], ["samples", "CANCER", 162, 169], ["NRN", "PROTEIN", 192, 195], ["testing samples", "TEST", 98, 113], ["RN", "TEST", 127, 129], ["errors", "TEST", 138, 144], ["testing samples", "TEST", 154, 169]]], ["Fig. 3 also shows that the testing accuracies were consistent with the LOOCV accuracies for both RN and NRN classifiers, which further indicated RN and NRN have the good generalization ability.", [["the testing accuracies", "TEST", 23, 45]]], ["Fig. 4 illustrates the expression levels of the 5 proteins derived by 5-node NRN in RS and NR groups, it can be seen that two proteins are down-regulated and three are upregulated.", [["5 proteins", "PROTEIN", 48, 58]]], ["Although proteins are distinctly expressed, their expression ranges over two groups have quite large overlap.", [["expression", "OBSERVATION_MODIFIER", 50, 60], ["ranges", "OBSERVATION_MODIFIER", 61, 67], ["large", "OBSERVATION_MODIFIER", 95, 100], ["overlap", "OBSERVATION", 101, 108]]], ["Fig. 5 illustrates the two NRNs derived from RS and NR groups.", [["NRNs", "CANCER", 27, 31]]], ["The positive interaction strengths represent promotional regulation and the negative ones represent repressive regulation.", [["positive", "OBSERVATION_MODIFIER", 4, 12], ["interaction strengths", "OBSERVATION", 13, 34]]], ["It can be found that the connection metric of the two networks is remarkably different, suggesting the regulation patterns varied in the different chemo-response groups.", [["remarkably", "OBSERVATION_MODIFIER", 66, 76], ["different", "OBSERVATION_MODIFIER", 77, 86], ["patterns", "OBSERVATION_MODIFIER", 114, 122], ["varied", "OBSERVATION_MODIFIER", 123, 129]]], ["For example, interaction coefficients between protein M7993_48 and M2193_50 in RS group are 0.26 and 0.32, suggesting mutual promotion between the two proteins.", [["M7993_48", "GENE_OR_GENE_PRODUCT", 54, 62], ["protein M7993_48", "PROTEIN", 46, 62], ["M2193_50", "PROTEIN", 67, 75], ["protein", "TEST", 46, 53]]], ["However, the regulatory strengths become negative, suggesting mutual repression between them.", [["negative", "OBSERVATION", 41, 49]]], ["Moreover, in the network of RS group, the mutual regulations between M7993_48 and M9209_62 are very weak (0.035, 0.025), but the regulation from protein M9209_62 to M7993_48 becomes very strong (12.15) .", [["M7993_48", "GENE_OR_GENE_PRODUCT", 69, 77], ["M9209_62", "GENE_OR_GENE_PRODUCT", 82, 90], ["protein M9209_62", "PROTEIN", 145, 161], ["very weak", "PROBLEM", 95, 104]]], ["Furthermore, both of the NRNs have different dominant biomarkers with greater regulatory coefficients than any others, as marked in the hexagon nodes in Fig. 5(A) and (B) .", [["NRNs", "GENE_OR_GENE_PRODUCT", 25, 29], ["hexagon nodes", "MULTI-TISSUE_STRUCTURE", 136, 149], ["NRNs", "DNA", 25, 29], ["different dominant biomarkers", "PROBLEM", 35, 64], ["different", "OBSERVATION_MODIFIER", 35, 44], ["dominant", "OBSERVATION_MODIFIER", 45, 53], ["biomarkers", "OBSERVATION", 54, 64], ["greater", "OBSERVATION_MODIFIER", 70, 77], ["marked", "OBSERVATION_MODIFIER", 122, 128], ["hexagon nodes", "OBSERVATION", 136, 149]]], ["Such dominant biomarkers may dominate the networks associated with cancer and are the hub biomarkers of the networks, which play a crucial role in cancer development [24] .", [["cancer", "ANATOMY", 67, 73], ["cancer", "ANATOMY", 147, 153], ["cancer", "DISEASE", 67, 73], ["cancer", "DISEASE", 147, 153], ["cancer", "CANCER", 67, 73], ["cancer", "CANCER", 147, 153], ["Such dominant biomarkers", "PROBLEM", 0, 24], ["cancer", "PROBLEM", 67, 73], ["cancer", "OBSERVATION", 67, 73]]], ["The biomarkers having smaller regulatory coefficients than others are marked in the smaller circle nodes in Fig. 5(A) and (B) , which may locate at the far end of the cancer regulation pathway.", [["cancer", "ANATOMY", 167, 173], ["cancer", "DISEASE", 167, 173], ["circle nodes", "MULTI-TISSUE_STRUCTURE", 92, 104], ["5", "ORGANISM", 113, 114], ["cancer", "CANCER", 167, 173], ["The biomarkers", "TEST", 0, 14], ["smaller regulatory coefficients", "PROBLEM", 22, 53], ["smaller", "OBSERVATION_MODIFIER", 22, 29], ["coefficients", "OBSERVATION_MODIFIER", 41, 53], ["marked", "OBSERVATION_MODIFIER", 70, 76], ["smaller", "OBSERVATION_MODIFIER", 84, 91], ["circle nodes", "OBSERVATION", 92, 104], ["Fig.", "ANATOMY", 108, 112], ["cancer", "OBSERVATION", 167, 173]]], ["These differences of regulative patterns captured by our regulatory networks play crucial roles in the RN classifier, which could be potentially meaningful in revealing the molecular mechanism of proteins in cancer development.Analysis on the NPC datasetWe then compared the classification performance of the NRN classifiers with those of conventional methods including FLD, KNN with k = 3, linSVM and rbfSVM.", [["cancer", "ANATOMY", 208, 214], ["NPC", "ANATOMY", 243, 246], ["cancer", "DISEASE", 208, 214], ["cancer", "CANCER", 208, 214], ["NPC", "CANCER", 243, 246], ["NPC datasetWe", "PROTEIN", 243, 256], ["NRN classifiers", "DNA", 309, 324], ["rbfSVM", "DNA", 402, 408], ["cancer development", "PROBLEM", 208, 226], ["conventional methods", "TEST", 339, 359], ["FLD", "TEST", 370, 373], ["KNN", "TEST", 375, 378], ["k", "TEST", 384, 385], ["linSVM", "TEST", 391, 397], ["rbfSVM", "TEST", 402, 408], ["cancer", "OBSERVATION", 208, 214]]], ["These methods are either linear or non-linear, and are widely used in bioinformatics and pattern recognition [25] [26] [27] [28] [29] , among them SVM has been demonstrated to have superior classification performance in various application areas [30] .", [["[25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 109, 133], ["linear", "OBSERVATION_MODIFIER", 25, 31]]], ["In this comparison analysis, rbfSVM parameters, namely the regularization and kernel width, were optimized via two-dimensional grid search and leave-one-out cross-validation.", [["this comparison analysis", "TEST", 3, 27], ["rbfSVM parameters", "TEST", 29, 46]]], ["Fig. 6 shows the classification results of NRN and other methods on the independent test set while different numbers of proteins (p) were selected.", [["proteins (p)", "PROTEIN", 120, 132], ["the independent test", "TEST", 68, 88]]], ["It can be seen that when p = 2 or 3, the results of NRN, KNN and rbfSVM were really close.", [["NRN", "TEST", 52, 55], ["KNN", "TEST", 57, 60], ["rbfSVM", "TEST", 65, 71]]], ["NRN classifier got its best accuracy of 93% when p = 5.Analysis on the SARS dataThe SARS dataset was split to training set and test set and each with 37 samples including 22 SARS, 10 IFZ, and 5 control normals.", [["samples", "ANATOMY", 153, 160], ["SARS", "DISEASE", 174, 178], ["IFZ", "CANCER", 183, 186], ["the SARS data", "TEST", 67, 80], ["test set", "TEST", 127, 135], ["22 SARS", "TEST", 171, 178], ["IFZ", "TEST", 183, 186]]], ["Similar to NPC data analysis, a panel of significant proteins was first picked out by using regulation probability methods.", [["NPC", "ANATOMY", 11, 14], ["NPC", "CANCER", 11, 14], ["NPC", "PROTEIN", 11, 14], ["NPC data analysis", "TEST", 11, 28], ["a panel", "TEST", 30, 37], ["significant proteins", "PROBLEM", 41, 61]]], ["Best protein combinations were sought through searching the panel with cross-validation training RN and NRN on the training data.", [["Best protein combinations", "TREATMENT", 0, 25], ["the training data", "TEST", 111, 128]]], ["It can be seen that both for RN and NRN, the testing accuracies increased when more proteins were involved and similar trend on LOOCV accuracies.", [["the testing accuracies", "TEST", 41, 63]]], ["The best test accuracy of 89% was achieved by NRN when 5 proteins were involved.", [["NRN", "PROTEIN", 46, 49], ["The best test accuracy", "TEST", 0, 22]]], ["Fig. 8 illustrates the expression range of the 5 proteins, in which it can be seen that C03278_7 and C08131_5 highly expressed for SARS group, C08989_3 and C08954_7 highly expressed for IFZ group, and all the proteins down-regulated for control normals.", [["SARS", "DISEASE", 131, 135], ["C03278_7", "GENE_OR_GENE_PRODUCT", 88, 96], ["C08131_5", "GENE_OR_GENE_PRODUCT", 101, 109], ["IFZ", "GENE_OR_GENE_PRODUCT", 186, 189], ["5 proteins", "PROTEIN", 47, 57], ["IFZ group", "PROTEIN", 186, 195], ["the proteins", "TEST", 205, 217]]], ["Fig. 9 illustrates the three NRNs captured by the 5-node NRN classifier.", [["NRNs", "CANCER", 29, 33], ["NRNs", "DNA", 29, 33], ["5-node NRN classifier", "DNA", 50, 71]]], ["It can be found that the connection metrics of the three networks are remarkably different, suggesting the regulation patterns change in the three patient groups.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["different", "OBSERVATION_MODIFIER", 81, 90], ["regulation", "OBSERVATION_MODIFIER", 107, 117], ["patterns", "OBSERVATION_MODIFIER", 118, 126], ["change", "OBSERVATION_MODIFIER", 127, 133]]], ["For example, the regulations between C08989_3 and C3278_7 are weak in SARS (\u00c00.10, \u00c00.12) and normal (0.09, 0.14), while in IFZ group, the repression strength from C3278_7 to C08989_3 becomes very strong.", [["SARS", "DISEASE", 70, 74], ["C08989_3", "GENE_OR_GENE_PRODUCT", 37, 45], ["C3278_7", "GENE_OR_GENE_PRODUCT", 50, 57], ["IFZ", "CANCER", 124, 127], ["C08989_3", "DNA", 37, 45], ["SARS", "TEST", 70, 74], ["weak", "OBSERVATION_MODIFIER", 62, 66], ["very", "OBSERVATION_MODIFIER", 192, 196], ["strong", "OBSERVATION", 197, 203]]], ["Also in SARS group, regulatory coefficients between protein C05909_7 and C08989_3 are 0.23 and 0.30, suggesting mutual promotion between the two proteins; while in normal and IFZ groups, their regulatory coefficients become negative, suggesting mutual repression in between.", [["SARS", "DISEASE", 8, 12], ["protein C05909_7", "PROTEIN", 52, 68], ["protein C05909_7", "TEST", 52, 68], ["mutual repression", "OBSERVATION", 245, 262]]], ["Similar to the analysis on the NPC data, the dominant and minor biomarkers of the regulatory network of each patient group are marked in hexagon and smaller circle nodes respectively.", [["NPC", "ANATOMY", 31, 34], ["circle nodes", "ANATOMY", 157, 169], ["NPC", "CANCER", 31, 34], ["patient", "ORGANISM", 109, 116], ["circle nodes", "MULTI-TISSUE_STRUCTURE", 157, 169], ["NPC", "PROTEIN", 31, 34], ["patient", "SPECIES", 109, 116], ["the analysis", "TEST", 11, 23], ["the NPC data", "TEST", 27, 39], ["dominant", "OBSERVATION_MODIFIER", 45, 53], ["minor", "OBSERVATION_MODIFIER", 58, 63], ["marked", "OBSERVATION_MODIFIER", 127, 133], ["hexagon", "OBSERVATION_MODIFIER", 137, 144], ["smaller", "OBSERVATION_MODIFIER", 149, 156], ["circle nodes", "OBSERVATION", 157, 169]]], ["It is observed that the three NRNs have different dominant and minor biomarkers.", [["NRNs", "GENE_OR_GENE_PRODUCT", 30, 34], ["different", "OBSERVATION_MODIFIER", 40, 49], ["dominant", "OBSERVATION", 50, 58], ["minor", "OBSERVATION_MODIFIER", 63, 68]]], ["In summary, the obtained NRNs can remarkably discriminate the three groups from the aspect of protein regulations.Analysis on the SARS dataWe then compared the results of our NRN classifier with those of conventional approaches.", [["NRNs", "SIMPLE_CHEMICAL", 25, 29]]], ["Similar to that in the NPC experiment, the regularization parameter and the width of the radial basis function kernel of rbfSVM were optimized through two-dimensional grid search and cross-validation.", [["NPC", "ANATOMY", 23, 26], ["NPC", "CANCER", 23, 26], ["rbfSVM", "PROTEIN", 121, 127], ["the regularization parameter", "TEST", 39, 67], ["cross-validation", "TEST", 183, 199], ["radial", "ANATOMY_MODIFIER", 89, 95]]], ["Fig. 10 shows the comparison results, from which it can be found that NRN can always enjoy the best testing accuracies for different number of biomarkers compared to other methods, and it reached its best accuracy of 89% when p = 5. rbfSVM classifier achieved its best accuracy of 84% when 6 proteins were involved.Stability of the algorithmFrom the above two applications, it can be seen that the nonlinear regulatory network performs better than its linear version.", [["rbfSVM", "PROTEIN", 233, 239]]], ["Hence we believe that the non-linear transformation in the NRN To check more details, we further compute the deviations of the five regulatory coefficient values of a protein relation.", [["NRN", "DNA", 59, 62], ["the non-linear transformation", "PROBLEM", 22, 51]]], ["Fig. 12 shows the probability distribution of the deviations for each patient group, indicating that the deviations approach zero.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["the deviations", "PROBLEM", 46, 60], ["the deviations approach zero", "PROBLEM", 101, 129]]], ["The results suggest that our proposed regulatory network approach can obtain the stable and reliable regulatory relationships as long as the sigmoid parameter is properly set.Sensitivity and specificity analysisSensitivity and specificity are another two important criteria for the evaluation of classification performance.", [["Sensitivity", "TEST", 175, 186], ["specificity analysisSensitivity", "TEST", 191, 222], ["the evaluation", "TEST", 278, 292], ["stable", "OBSERVATION_MODIFIER", 81, 87], ["sigmoid", "ANATOMY", 141, 148]]], ["In general, sensitivity is considered to be capable of reflecting how good a test is at picking out patients with a disease, and specificity refers to the ability of the test to pick out patients who do not have the disease.", [["patients", "ORGANISM", 100, 108], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 187, 195], ["a disease", "PROBLEM", 114, 123], ["the test", "TEST", 166, 174], ["the disease", "PROBLEM", 212, 223], ["disease", "OBSERVATION", 216, 223]]], ["As an example, for the NPC dataset, we set the nonresponder group as the positive class and responder group to be negative.", [["NPC", "ANATOMY", 23, 26], ["NPC", "CANCER", 23, 26], ["the NPC dataset", "TEST", 19, 34]]], ["For SARS dataset, we take one class as the positive class and the left two classes as negative in turn to make evaluation.", [["evaluation", "TEST", 111, 121], ["left", "ANATOMY_MODIFIER", 66, 70], ["negative", "OBSERVATION", 86, 94]]], ["As a result, the sensitivities and specificities of our NRN classifiers and the three methods, KNN, linSVM and rbfSVM, are shown in Table 1 .", [["NRN classifiers", "DNA", 56, 71], ["linSVM", "DNA", 100, 106], ["rbfSVM", "DNA", 111, 117], ["the sensitivities", "TEST", 13, 30], ["our NRN classifiers", "TEST", 52, 71], ["KNN", "TEST", 95, 98]]], ["It can be found that all sensitivity and specificity values of our NRN classifier are higher than 80%, which are better than those of the three previous approaches.", [["all sensitivity", "TEST", 21, 36], ["specificity values", "TEST", 41, 59], ["our NRN classifier", "TEST", 63, 81], ["higher", "OBSERVATION_MODIFIER", 86, 92]]], ["It is also observed that irrespective the NPC dataset or the SARS dataset, the NRN classifier has less variation between sensitivity and specificity than any of the three previous approaches.", [["NPC", "ANATOMY", 42, 45], ["NPC", "CANCER", 42, 45], ["NPC dataset", "DNA", 42, 53]]], ["This advantage should be due to the capsulation of the optimized regulatory networks for each group in the NRN classifier.ConclusionsIn this paper, we proposed a novel approach of regulatory network for regulatory pattern extraction and disease classification.", [["regulatory pattern extraction", "TREATMENT", 203, 232], ["disease classification", "PROBLEM", 237, 259]]], ["The derived networks can effectively capture the unique regulatory patterns of protein markers associated with different patient groups and hence can be used for disease classification.", [["patient", "ORGANISM", 121, 128], ["protein markers", "PROTEIN", 79, 94], ["patient", "SPECIES", 121, 128], ["protein markers", "TEST", 79, 94], ["disease classification", "PROBLEM", 162, 184]]], ["In the experimental section, the proposed regulatory networks have been validated on two real-world protein profiling dataset, NPC and SARS.", [["NPC", "ANATOMY", 127, 130], ["SARS", "DISEASE", 135, 139], ["NPC", "CANCER", 127, 130], ["NPC", "PROTEIN", 127, 130], ["SARS", "PROBLEM", 135, 139]]], ["The comparisons of our method and the conventional methods, including FLD, KNN, linSVM and rbfSVM have been made as well.", [["FLD, KNN, linSVM and rbfSVM", "DNA", 70, 97], ["our method", "TEST", 19, 29], ["the conventional methods", "TEST", 34, 58], ["FLD", "TEST", 70, 73], ["KNN", "TEST", 75, 78]]], ["Experimental results showed the effectiveness and efficiency of our networks in capturing the regulatory patterns of various diseases as well as the excellent discriminative power.", [["various diseases", "PROBLEM", 117, 133], ["various diseases", "OBSERVATION", 117, 133]]], ["In contrast to conventional methods, the proposed approach can characterize complex regulation relationships and perform disease classification in an accurate manner.", [["disease classification", "TEST", 121, 143]]], ["The regulatory patterns of disease classes were encapsulated in the regulatory coefficients of the RNs.", [["disease classes", "PROBLEM", 27, 42], ["patterns", "OBSERVATION_MODIFIER", 15, 23], ["disease", "OBSERVATION", 27, 34]]], ["From a biological viewpoint, the positive coefficients represent up-regulation which promotes the expression of the regulated genes, while the negative coefficients represent downregulation which represses the expression of the regulated genes, and the absolute values of the coefficients indicate the corresponding regulation strengths.", [["regulated genes", "DNA", 116, 131], ["regulated genes", "DNA", 228, 243], ["the positive coefficients", "PROBLEM", 29, 54]]], ["The discovered regulation relationships The best results of different methods upon the two datasets (NPC and SARS) are shown in bold values. can potentially provide insights to revealing the molecular signaling pathways.", [["NPC", "CANCER", 101, 104], ["SARS", "PROBLEM", 109, 113]]]], "a1736b3ce5793bf8433ca34c1dd764c8615662dd": [["IntroductionThe number of adults affected by COVID-19 overwhelmingly exceeds pediatric patients, and therefore, the vast majority of studies on renal involvement in have been performed in adults.", [["renal", "ANATOMY", 144, 149], ["COVID-19", "CHEMICAL", 45, 53], ["adults", "ORGANISM", 26, 32], ["patients", "ORGANISM", 87, 95], ["renal", "ORGAN", 144, 149], ["patients", "SPECIES", 87, 95], ["renal", "ANATOMY", 144, 149]]], ["The incidence and etiology of acute kidney injury (AKI) amongst pediatric patients remains largely unknown.", [["kidney", "ANATOMY", 36, 42], ["acute kidney injury", "DISEASE", 30, 49], ["AKI", "DISEASE", 51, 54], ["kidney", "ORGAN", 36, 42], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["acute kidney injury", "PROBLEM", 30, 49], ["AKI", "PROBLEM", 51, 54], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["kidney", "ANATOMY", 36, 42], ["injury", "OBSERVATION", 43, 49]]], ["Complement activation has been postulated to underlie some pathophysiology of disease in COVID-19 infections, including thrombotic microangiopathy (TMA).", [["infections", "DISEASE", 98, 108], ["thrombotic microangiopathy", "DISEASE", 120, 146], ["TMA", "DISEASE", 148, 151], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["COVID-19", "SPECIES", 89, 97], ["disease in COVID-19 infections", "PROBLEM", 78, 108], ["thrombotic microangiopathy", "PROBLEM", 120, 146], ["disease", "OBSERVATION", 78, 85], ["thrombotic", "OBSERVATION_MODIFIER", 120, 130], ["microangiopathy", "OBSERVATION", 131, 146]]], ["To our knowledge, we present the first pediatric case of COVID-19 and severe AKI due to TMA, treated with eculizumab.Case presentationWe present the case of a 14 year old female with obesity and asthma, who was admitted to the Pediatric Intensive Care Unit with fever for 7 days, and complaints of abdominal pain, diarrhea, vomiting, myalgias, and chest pain.", [["abdominal", "ANATOMY", 298, 307], ["chest", "ANATOMY", 348, 353], ["AKI", "DISEASE", 77, 80], ["TMA", "DISEASE", 88, 91], ["eculizumab", "CHEMICAL", 106, 116], ["obesity", "DISEASE", 183, 190], ["asthma", "DISEASE", 195, 201], ["fever", "DISEASE", 262, 267], ["abdominal pain", "DISEASE", 298, 312], ["diarrhea", "DISEASE", 314, 322], ["vomiting", "DISEASE", 324, 332], ["myalgias", "DISEASE", 334, 342], ["chest pain", "DISEASE", 348, 358], ["eculizumab", "CHEMICAL", 106, 116], ["eculizumab", "SIMPLE_CHEMICAL", 106, 116], ["female", "ORGANISM", 171, 177], ["abdominal", "ORGANISM_SUBDIVISION", 298, 307], ["chest", "ORGANISM_SUBDIVISION", 348, 353], ["COVID", "TEST", 57, 62], ["severe AKI", "PROBLEM", 70, 80], ["TMA", "PROBLEM", 88, 91], ["eculizumab", "TREATMENT", 106, 116], ["obesity", "PROBLEM", 183, 190], ["asthma", "PROBLEM", 195, 201], ["fever", "PROBLEM", 262, 267], ["abdominal pain", "PROBLEM", 298, 312], ["diarrhea", "PROBLEM", 314, 322], ["vomiting", "PROBLEM", 324, 332], ["myalgias", "PROBLEM", 334, 342], ["chest pain", "PROBLEM", 348, 358], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["AKI", "OBSERVATION", 77, 80], ["TMA", "OBSERVATION", 88, 91], ["obesity", "OBSERVATION", 183, 190], ["asthma", "OBSERVATION", 195, 201], ["fever", "OBSERVATION", 262, 267], ["abdominal", "ANATOMY", 298, 307], ["pain", "OBSERVATION", 308, 312], ["diarrhea", "OBSERVATION", 314, 322], ["myalgias", "OBSERVATION", 334, 342], ["chest", "ANATOMY", 348, 353]]], ["On admission, she was febrile, tachypneic, and tachycardic, but normotensive.", [["febrile", "DISEASE", 22, 29], ["tachypneic", "DISEASE", 31, 41], ["febrile", "PROBLEM", 22, 29], ["tachypneic", "PROBLEM", 31, 41], ["tachycardic", "PROBLEM", 47, 58], ["normotensive", "PROBLEM", 64, 76]]], ["Initial SARS-CoV-2 PCR was negative.", [["SARS-CoV-2 PCR", "DNA", 8, 22], ["Initial SARS", "TEST", 0, 12], ["CoV-2 PCR", "TEST", 13, 22]]], ["On hospital day 2, she became hypotensive, requiring pressor support, and had worsening respiratory distress with oxygen desaturation, requiring intubation.", [["respiratory", "ANATOMY", 88, 99], ["hypotensive", "DISEASE", 30, 41], ["respiratory distress", "DISEASE", 88, 108], ["oxygen", "CHEMICAL", 114, 120], ["desaturation", "DISEASE", 121, 133], ["oxygen", "CHEMICAL", 114, 120], ["oxygen", "SIMPLE_CHEMICAL", 114, 120], ["hypotensive", "PROBLEM", 30, 41], ["pressor support", "TREATMENT", 53, 68], ["worsening respiratory distress", "PROBLEM", 78, 108], ["oxygen desaturation", "PROBLEM", 114, 133], ["intubation", "TREATMENT", 145, 155], ["hypotensive", "OBSERVATION", 30, 41], ["worsening", "OBSERVATION_MODIFIER", 78, 87], ["respiratory distress", "OBSERVATION", 88, 108], ["oxygen desaturation", "OBSERVATION", 114, 133]]], ["Repeated SARS COV-2 PCR was indeterminate, and antibody testing (IgG) was positive.Case presentationLaboratory results demonstrated elevated inflammatory markers, with ferritin > 100,000 ng/mL, CRP > 300 mg/dL, and WBC 33,000/\u00b5L.", [["ferritin", "GENE_OR_GENE_PRODUCT", 168, 176], ["CRP", "GENE_OR_GENE_PRODUCT", 194, 197], ["IgG", "PROTEIN", 65, 68], ["inflammatory markers", "PROTEIN", 141, 161], ["ferritin", "PROTEIN", 168, 176], ["CRP", "PROTEIN", 194, 197], ["Repeated SARS COV-2 PCR", "TEST", 0, 23], ["antibody testing", "TEST", 47, 63], ["IgG", "TEST", 65, 68], ["elevated inflammatory markers", "PROBLEM", 132, 161], ["ferritin", "TEST", 168, 176], ["CRP", "TEST", 194, 197], ["WBC", "TEST", 215, 218], ["indeterminate", "OBSERVATION_MODIFIER", 28, 41], ["elevated", "OBSERVATION_MODIFIER", 132, 140], ["inflammatory markers", "OBSERVATION", 141, 161]]], ["Serum creatinine (Cr) on admission was 0.7 mg/dL (eGFR 85 mL/min/1.73 m 2 by modified Schwartz formula), but she developed oliguric AKI on hospital day 3, and her peak Cr was 8.97 mg/dL on hospital day 7.", [["Serum", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 6, 16], ["Cr", "CHEMICAL", 18, 20], ["AKI", "DISEASE", 132, 135], ["Cr", "CHEMICAL", 168, 170], ["creatinine", "CHEMICAL", 6, 16], ["Cr", "CHEMICAL", 18, 20], ["Cr", "CHEMICAL", 168, 170], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 6, 16], ["Cr", "SIMPLE_CHEMICAL", 18, 20], ["Serum creatinine", "TEST", 0, 16], ["Cr", "TEST", 18, 20], ["eGFR", "TEST", 50, 54], ["oliguric AKI", "PROBLEM", 123, 135], ["her peak Cr", "TEST", 159, 170], ["oliguric", "OBSERVATION_MODIFIER", 123, 131], ["AKI", "OBSERVATION", 132, 135]]], ["Although she was responsive to diuretic treatment with moderate increase in urine output, she developed progressive fluid overload with worsening uremia (BUN 170 mg/dL) and metabolic acidosis.", [["urine", "ANATOMY", 76, 81], ["fluid", "ANATOMY", 116, 121], ["increase in urine output", "DISEASE", 64, 88], ["fluid overload", "DISEASE", 116, 130], ["uremia", "DISEASE", 146, 152], ["metabolic acidosis", "DISEASE", 173, 191], ["urine", "ORGANISM_SUBSTANCE", 76, 81], ["fluid", "ORGANISM_SUBSTANCE", 116, 121], ["diuretic treatment", "TREATMENT", 31, 49], ["moderate increase in urine output", "PROBLEM", 55, 88], ["progressive fluid overload", "PROBLEM", 104, 130], ["worsening uremia", "PROBLEM", 136, 152], ["BUN", "TEST", 154, 157], ["metabolic acidosis", "PROBLEM", 173, 191], ["moderate", "OBSERVATION_MODIFIER", 55, 63], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["urine output", "OBSERVATION", 76, 88], ["progressive", "OBSERVATION_MODIFIER", 104, 115], ["fluid overload", "OBSERVATION", 116, 130], ["worsening", "OBSERVATION_MODIFIER", 136, 145], ["uremia", "OBSERVATION", 146, 152], ["metabolic acidosis", "OBSERVATION", 173, 191]]], ["Urinalyses demonstrated 100-300 mg/ dL protein with moderate-large blood, with variable RBCs (ranging from 2 to 59/hpf).", [["blood", "ANATOMY", 67, 72], ["RBCs", "ANATOMY", 88, 92], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["RBCs", "CELL", 88, 92], ["dL protein", "PROTEIN", 36, 46], ["RBCs", "CELL_TYPE", 88, 92], ["Urinalyses", "TEST", 0, 10], ["dL protein", "TEST", 36, 46], ["moderate-large blood", "PROBLEM", 52, 72], ["variable RBCs", "PROBLEM", 79, 92], ["moderate", "OBSERVATION_MODIFIER", 52, 60]]], ["Creatine kinase (CK) (55,695 U/L, normal 40-308 U/L) and urine myoglobin (102 mg/L; normal 0-1 mg/L) were elevated, suggestive of viral-induced rhabdomyolysis, also contributing to AKI, but CK downtrended as creatinine worsened.Case presentationShe also had mild thrombocytopenia (platelets 126,000/ mL) and hemolytic anemia (nadir Hgb 6.8 g/dL), requiring Ruchi Mahajan and Marissa Lipton: co-lead authors, equal contributions.Case presentation* Natalie Somera Uy nsu1@cumc.columbia.edu multiple pRBC transfusions.", [["urine", "ANATOMY", 57, 62], ["platelets", "ANATOMY", 281, 290], ["Creatine", "CHEMICAL", 0, 8], ["rhabdomyolysis", "DISEASE", 144, 158], ["AKI", "DISEASE", 181, 184], ["creatinine", "CHEMICAL", 208, 218], ["thrombocytopenia", "DISEASE", 263, 279], ["hemolytic anemia", "DISEASE", 308, 324], ["Creatine", "CHEMICAL", 0, 8], ["creatinine", "CHEMICAL", 208, 218], ["Creatine kinase", "GENE_OR_GENE_PRODUCT", 0, 15], ["CK", "GENE_OR_GENE_PRODUCT", 17, 19], ["urine", "ORGANISM_SUBSTANCE", 57, 62], ["myoglobin", "GENE_OR_GENE_PRODUCT", 63, 72], ["CK", "GENE_OR_GENE_PRODUCT", 190, 192], ["creatinine", "SIMPLE_CHEMICAL", 208, 218], ["She", "ORGANISM", 245, 248], ["platelets", "CELL", 281, 290], ["pRBC", "CELL", 497, 501], ["Creatine kinase", "PROTEIN", 0, 15], ["CK", "PROTEIN", 17, 19], ["CK", "PROTEIN", 190, 192], ["platelets", "CELL_TYPE", 281, 290], ["Creatine kinase", "TEST", 0, 15], ["CK", "TEST", 17, 19], ["U/L", "TEST", 29, 32], ["U/L", "TEST", 48, 51], ["urine myoglobin", "TEST", 57, 72], ["elevated", "PROBLEM", 106, 114], ["viral-induced rhabdomyolysis", "PROBLEM", 130, 158], ["AKI", "PROBLEM", 181, 184], ["CK", "TEST", 190, 192], ["creatinine", "TEST", 208, 218], ["mild thrombocytopenia", "PROBLEM", 258, 279], ["platelets", "TEST", 281, 290], ["hemolytic anemia", "PROBLEM", 308, 324], ["nadir", "TEST", 326, 331], ["Hgb", "TEST", 332, 335], ["multiple pRBC transfusions", "TREATMENT", 488, 514], ["urine myoglobin", "ANATOMY", 57, 72], ["suggestive of", "UNCERTAINTY", 116, 129], ["viral", "OBSERVATION", 130, 135], ["rhabdomyolysis", "OBSERVATION", 144, 158], ["AKI", "OBSERVATION", 181, 184], ["mild", "OBSERVATION_MODIFIER", 258, 262], ["thrombocytopenia", "OBSERVATION", 263, 279], ["hemolytic", "OBSERVATION_MODIFIER", 308, 317], ["anemia", "OBSERVATION", 318, 324], ["pRBC transfusions", "OBSERVATION", 497, 514]]], ["Work up of anemia demonstrated normal reticulocyte count and normal haptoglobin, but elevated LDH (4087 U/L; normal 100-275 U/L) and bilirubin (6.2 mg/dL; normal 0.2-1.3 mg/dL) with schistocytes noted on peripheral smear.", [["reticulocyte", "ANATOMY", 38, 50], ["schistocytes", "ANATOMY", 182, 194], ["peripheral smear", "ANATOMY", 204, 220], ["anemia", "DISEASE", 11, 17], ["bilirubin", "CHEMICAL", 133, 142], ["bilirubin", "CHEMICAL", 133, 142], ["reticulocyte", "CELL", 38, 50], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 68, 79], ["LDH", "GENE_OR_GENE_PRODUCT", 94, 97], ["bilirubin", "GENE_OR_GENE_PRODUCT", 133, 142], ["peripheral smear", "MULTI-TISSUE_STRUCTURE", 204, 220], ["haptoglobin", "PROTEIN", 68, 79], ["LDH", "PROTEIN", 94, 97], ["anemia", "PROBLEM", 11, 17], ["reticulocyte count", "TEST", 38, 56], ["elevated LDH", "PROBLEM", 85, 97], ["U", "TEST", 104, 105], ["L", "TEST", 106, 107], ["U/L", "TEST", 124, 127], ["bilirubin", "TEST", 133, 142], ["dL", "TEST", 151, 153], ["schistocytes", "PROBLEM", 182, 194], ["peripheral smear", "TEST", 204, 220], ["anemia", "OBSERVATION", 11, 17], ["normal reticulocyte count", "OBSERVATION", 31, 56], ["haptoglobin", "OBSERVATION_MODIFIER", 68, 79], ["schistocytes", "OBSERVATION", 182, 194], ["peripheral", "ANATOMY", 204, 214], ["smear", "OBSERVATION", 215, 220]]], ["ADAMTS13 was mildly low (42, normal 68-163) but not consistent with TTP (< 10), and repeat ADAMTS13 was normal (87).", [["TTP", "DISEASE", 68, 71], ["ADAMTS13", "GENE_OR_GENE_PRODUCT", 0, 8], ["ADAMTS13", "GENE_OR_GENE_PRODUCT", 91, 99], ["ADAMTS13", "PROTEIN", 0, 8], ["ADAMTS13", "PROTEIN", 91, 99], ["ADAMTS13", "TEST", 0, 8], ["mildly low", "PROBLEM", 13, 23], ["TTP", "PROBLEM", 68, 71], ["repeat ADAMTS13", "TEST", 84, 99], ["mildly", "OBSERVATION_MODIFIER", 13, 19], ["low", "OBSERVATION_MODIFIER", 20, 23], ["not consistent with", "UNCERTAINTY", 48, 67], ["TTP", "OBSERVATION", 68, 71]]], ["Serum complements were low with C3 33 mg/dL (normal 80-162 mg/dL) and C4 4.0 mg/dL (normal 14-47 mg/dL).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["C3", "PROTEIN", 32, 34], ["Serum complements", "TEST", 0, 17], ["C3", "TEST", 32, 34], ["C4", "TEST", 70, 72], ["dL", "TEST", 80, 82]]], ["Other serology tests including ANCA, ANA, dsDNA, ASLO, anti-GBM levels were within normal limits.", [["ANCA", "GENE_OR_GENE_PRODUCT", 31, 35], ["ANA", "GENE_OR_GENE_PRODUCT", 37, 40], ["dsDNA", "CELLULAR_COMPONENT", 42, 47], ["ASLO", "SIMPLE_CHEMICAL", 49, 53], ["anti-GBM", "GENE_OR_GENE_PRODUCT", 55, 63], ["ANCA", "PROTEIN", 31, 35], ["ANA", "PROTEIN", 37, 40], ["dsDNA", "PROTEIN", 42, 47], ["ASLO", "PROTEIN", 49, 53], ["anti-GBM", "PROTEIN", 55, 63], ["Other serology tests", "TEST", 0, 20], ["ANCA", "TEST", 31, 35], ["ANA", "TEST", 37, 40], ["dsDNA", "TEST", 42, 47], ["ASLO", "TEST", 49, 53], ["anti-GBM levels", "TEST", 55, 70], ["within normal limits", "OBSERVATION", 76, 96]]], ["Renal ultrasound showed normal size and echogenicity of both kidneys, and Doppler study indicated normal vascular flow pattern.", [["Renal", "ANATOMY", 0, 5], ["kidneys", "ANATOMY", 61, 68], ["vascular", "ANATOMY", 105, 113], ["Renal", "ORGAN", 0, 5], ["kidneys", "ORGAN", 61, 68], ["vascular", "MULTI-TISSUE_STRUCTURE", 105, 113], ["Renal ultrasound", "TEST", 0, 16], ["Doppler study", "TEST", 74, 87], ["normal", "OBSERVATION", 24, 30], ["size", "OBSERVATION_MODIFIER", 31, 35], ["echogenicity", "OBSERVATION", 40, 52], ["both", "ANATOMY_MODIFIER", 56, 60], ["kidneys", "ANATOMY", 61, 68], ["normal", "OBSERVATION", 98, 104], ["vascular", "ANATOMY", 105, 113], ["flow pattern", "OBSERVATION", 114, 126]]], ["Echocardiogram revealed biventricular dysfunction and coronary artery dilatation.", [["biventricular", "ANATOMY", 24, 37], ["coronary artery", "ANATOMY", 54, 69], ["biventricular dysfunction", "DISEASE", 24, 49], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 54, 69], ["Echocardiogram", "TEST", 0, 14], ["biventricular dysfunction", "PROBLEM", 24, 49], ["coronary artery dilatation", "PROBLEM", 54, 80], ["biventricular", "ANATOMY", 24, 37], ["dysfunction", "OBSERVATION", 38, 49], ["coronary artery", "ANATOMY", 54, 69], ["dilatation", "OBSERVATION", 70, 80]]], ["Cardiac markers were elevated (proBNP 5600 pg/ mL, troponin 135 ng/mL).", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac", "ORGAN", 0, 7], ["troponin", "PROTEIN", 51, 59], ["Cardiac markers", "TEST", 0, 15], ["elevated", "PROBLEM", 21, 29], ["proBNP", "TEST", 31, 37], ["troponin", "TEST", 51, 59]]], ["She was treated with intravenous pulse steroids for acute myocarditis, and IVIG for coronary ectasia.", [["intravenous", "ANATOMY", 21, 32], ["coronary", "ANATOMY", 84, 92], ["steroids", "CHEMICAL", 39, 47], ["myocarditis", "DISEASE", 58, 69], ["coronary ectasia", "DISEASE", 84, 100], ["steroids", "CHEMICAL", 39, 47], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 32], ["IVIG", "SIMPLE_CHEMICAL", 75, 79], ["coronary", "MULTI-TISSUE_STRUCTURE", 84, 92], ["intravenous pulse steroids", "TREATMENT", 21, 47], ["acute myocarditis", "PROBLEM", 52, 69], ["IVIG", "TREATMENT", 75, 79], ["coronary ectasia", "PROBLEM", 84, 100], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["myocarditis", "OBSERVATION", 58, 69], ["coronary", "ANATOMY", 84, 92], ["ectasia", "OBSERVATION", 93, 100]]], ["She received Anakinra for 7 days given concern for severe inflammatory response and cytokine storm.", [["Anakinra", "CHEMICAL", 13, 21], ["Anakinra", "CHEMICAL", 13, 21], ["Anakinra", "SIMPLE_CHEMICAL", 13, 21], ["cytokine", "PROTEIN", 84, 92], ["Anakinra", "TREATMENT", 13, 21], ["severe inflammatory response", "PROBLEM", 51, 79], ["cytokine storm", "PROBLEM", 84, 98], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["inflammatory", "OBSERVATION", 58, 70], ["cytokine storm", "OBSERVATION", 84, 98]]], ["While her inflammatory disease, cardiac markers and hemodynamic status started to improve, she had persistent hemolytic anemia and worsening renal failure.", [["cardiac", "ANATOMY", 32, 39], ["renal", "ANATOMY", 141, 146], ["inflammatory disease", "DISEASE", 10, 30], ["hemolytic anemia", "DISEASE", 110, 126], ["renal failure", "DISEASE", 141, 154], ["cardiac", "ORGAN", 32, 39], ["renal", "ORGAN", 141, 146], ["her inflammatory disease", "PROBLEM", 6, 30], ["cardiac markers", "TEST", 32, 47], ["persistent hemolytic anemia", "PROBLEM", 99, 126], ["worsening renal failure", "PROBLEM", 131, 154], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["disease", "OBSERVATION", 23, 30], ["persistent", "OBSERVATION_MODIFIER", 99, 109], ["hemolytic", "OBSERVATION_MODIFIER", 110, 119], ["anemia", "OBSERVATION", 120, 126], ["worsening", "OBSERVATION_MODIFIER", 131, 140], ["renal", "ANATOMY", 141, 146], ["failure", "OBSERVATION", 147, 154]]], ["When her BUN/Cr reached 168/7.97 mg/dL on hospital day 10, continuous renal replacement therapy (CRRT) was initiated.", [["renal", "ANATOMY", 70, 75], ["Cr", "CHEMICAL", 13, 15], ["Cr", "CHEMICAL", 13, 15], ["BUN", "SIMPLE_CHEMICAL", 9, 12], ["Cr", "SIMPLE_CHEMICAL", 13, 15], ["renal", "ORGAN", 70, 75], ["her BUN", "TEST", 5, 12], ["Cr", "TEST", 13, 15], ["continuous renal replacement therapy", "TREATMENT", 59, 95], ["CRRT", "TREATMENT", 97, 101], ["renal", "ANATOMY", 70, 75], ["replacement", "OBSERVATION", 76, 87]]], ["Her pressor requirement dissipated, and she developed elevated blood pressure, treated with hydralazine and a calcium channel blocker.", [["blood", "ANATOMY", 63, 68], ["elevated blood pressure", "DISEASE", 54, 77], ["hydralazine", "CHEMICAL", 92, 103], ["calcium", "CHEMICAL", 110, 117], ["hydralazine", "CHEMICAL", 92, 103], ["calcium", "CHEMICAL", 110, 117], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["hydralazine", "SIMPLE_CHEMICAL", 92, 103], ["calcium channel blocker", "SIMPLE_CHEMICAL", 110, 133], ["Her pressor requirement", "PROBLEM", 0, 23], ["elevated blood pressure", "PROBLEM", 54, 77], ["hydralazine", "TREATMENT", 92, 103], ["a calcium channel blocker", "TREATMENT", 108, 133], ["elevated", "OBSERVATION", 54, 62], ["pressure", "OBSERVATION_MODIFIER", 69, 77]]], ["With worsening hypertension, along with persistent renal failure, hemolytic anemia, microscopic hematuria, and proteinuria, TMA was suspected.", [["renal", "ANATOMY", 51, 56], ["hypertension", "DISEASE", 15, 27], ["renal failure", "DISEASE", 51, 64], ["hemolytic anemia", "DISEASE", 66, 82], ["hematuria", "DISEASE", 96, 105], ["proteinuria", "DISEASE", 111, 122], ["TMA", "DISEASE", 124, 127], ["renal", "ORGAN", 51, 56], ["worsening hypertension", "PROBLEM", 5, 27], ["persistent renal failure", "PROBLEM", 40, 64], ["hemolytic anemia", "PROBLEM", 66, 82], ["microscopic hematuria", "PROBLEM", 84, 105], ["proteinuria", "PROBLEM", 111, 122], ["TMA", "PROBLEM", 124, 127], ["worsening", "OBSERVATION_MODIFIER", 5, 14], ["hypertension", "OBSERVATION", 15, 27], ["persistent", "OBSERVATION_MODIFIER", 40, 50], ["renal", "ANATOMY", 51, 56], ["failure", "OBSERVATION", 57, 64], ["hemolytic", "OBSERVATION_MODIFIER", 66, 75], ["anemia", "OBSERVATION", 76, 82], ["microscopic", "OBSERVATION_MODIFIER", 84, 95], ["hematuria", "OBSERVATION", 96, 105], ["proteinuria", "OBSERVATION", 111, 122]]], ["She also developed bloody endotracheal tube secretions, concerning for pulmonary involvement of TMA.", [["bloody endotracheal tube secretions", "ANATOMY", 19, 54], ["pulmonary", "ANATOMY", 71, 80], ["TMA", "DISEASE", 96, 99], ["pulmonary", "ORGAN", 71, 80], ["bloody endotracheal tube secretions", "PROBLEM", 19, 54], ["pulmonary involvement of TMA", "PROBLEM", 71, 99], ["bloody", "OBSERVATION_MODIFIER", 19, 25], ["endotracheal tube", "OBSERVATION", 26, 43], ["secretions", "OBSERVATION", 44, 54], ["concerning for", "UNCERTAINTY", 56, 70], ["pulmonary", "ANATOMY", 71, 80], ["involvement", "OBSERVATION", 81, 92], ["TMA", "OBSERVATION", 96, 99]]], ["Renal biopsy was not performed due to unstable clinical condition.", [["Renal", "ANATOMY", 0, 5], ["Renal biopsy", "MULTI-TISSUE_STRUCTURE", 0, 12], ["Renal biopsy", "TEST", 0, 12], ["unstable clinical condition", "PROBLEM", 38, 65], ["biopsy", "OBSERVATION", 6, 12]]], ["She was found to have elevated C5b9 level (1669 ng/L; normal < 244), and given high suspicion for complement-mediated TMA, she was treated with eculizumab 900 mg IV weekly \u00d7 3 doses.", [["TMA", "DISEASE", 118, 121], ["eculizumab", "CHEMICAL", 144, 154], ["eculizumab", "CHEMICAL", 144, 154], ["She", "ORGANISM", 0, 3], ["C5b9", "GENE_OR_GENE_PRODUCT", 31, 35], ["eculizumab", "SIMPLE_CHEMICAL", 144, 154], ["C5b9", "PROTEIN", 31, 35], ["elevated C5b9 level", "PROBLEM", 22, 41], ["complement-mediated TMA", "PROBLEM", 98, 121], ["eculizumab", "TREATMENT", 144, 154], ["elevated", "OBSERVATION", 22, 30], ["TMA", "OBSERVATION", 118, 121]]], ["CRRT was discontinued after 24 h of eculizumab initiation, and her renal function returned to baseline after 3 weeks (Fig. 1) .", [["renal", "ANATOMY", 67, 72], ["eculizumab", "CHEMICAL", 36, 46], ["eculizumab", "CHEMICAL", 36, 46], ["eculizumab", "SIMPLE_CHEMICAL", 36, 46], ["renal", "ORGAN", 67, 72], ["CRRT", "TREATMENT", 0, 4], ["eculizumab initiation", "TREATMENT", 36, 57], ["her renal function", "TEST", 63, 81], ["renal", "ANATOMY", 67, 72]]], ["Her hemoglobin remained stable, and she did not require further transfusions after initial eculizumab dose.", [["eculizumab", "CHEMICAL", 91, 101], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 4, 14], ["eculizumab", "SIMPLE_CHEMICAL", 91, 101], ["hemoglobin", "PROTEIN", 4, 14], ["Her hemoglobin", "TEST", 0, 14], ["further transfusions", "TREATMENT", 56, 76], ["initial eculizumab dose", "TREATMENT", 83, 106], ["stable", "OBSERVATION_MODIFIER", 24, 30]]], ["Platelets were slow to recover, and decreased further (50,000/mL) but improved to 199,000/ mL at discharge.", [["Platelets", "ANATOMY", 0, 9], ["Platelets", "CELL", 0, 9], ["Platelets", "CELL_TYPE", 0, 9], ["Platelets", "TEST", 0, 9], ["slow", "OBSERVATION_MODIFIER", 15, 19], ["to recover", "OBSERVATION_MODIFIER", 20, 30], ["decreased", "OBSERVATION_MODIFIER", 36, 45]]], ["Serum complements normalized.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum complements", "TEST", 0, 17]]], ["Hypertension, proteinuria and hematuria resolved after 3 weeks.", [["Hypertension", "DISEASE", 0, 12], ["proteinuria", "DISEASE", 14, 25], ["hematuria", "DISEASE", 30, 39], ["Hypertension", "PROBLEM", 0, 12], ["proteinuria", "PROBLEM", 14, 25], ["hematuria", "PROBLEM", 30, 39], ["proteinuria", "OBSERVATION", 14, 25], ["hematuria", "OBSERVATION", 30, 39]]], ["Repeat C5b9 level improved to 275 ng/L prior to discharge.", [["C5b9", "DNA", 7, 11], ["Repeat C5b9 level", "TEST", 0, 17]]], ["Eculizumab was discontinued after 3 doses given significant clinical improvement, while genetic testing for aHUS/TMA remains pending.DiscussionCOVID-19 caused by SARS-CoV-2 virus can cause multiple organ failure including AKI.", [["organ", "ANATOMY", 198, 203], ["Eculizumab", "CHEMICAL", 0, 10], ["aHUS", "DISEASE", 108, 112], ["TMA", "DISEASE", 113, 116], ["organ failure", "DISEASE", 198, 211], ["AKI", "DISEASE", 222, 225], ["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV-2 virus", "ORGANISM", 162, 178], ["organ", "ORGAN", 198, 203], ["CoV-2 virus", "SPECIES", 167, 178], ["SARS-CoV-2 virus", "SPECIES", 162, 178], ["Eculizumab", "TREATMENT", 0, 10], ["genetic testing", "TEST", 88, 103], ["aHUS/TMA", "TEST", 108, 116], ["DiscussionCOVID", "TEST", 133, 148], ["SARS", "PROBLEM", 162, 166], ["multiple organ failure", "PROBLEM", 189, 211], ["AKI", "PROBLEM", 222, 225], ["organ", "ANATOMY", 198, 203], ["failure", "OBSERVATION", 204, 211], ["AKI", "OBSERVATION", 222, 225]]], ["Reported incidence of AKI in critically ill adult patients in New York has been as high as 36.6% [1] .", [["AKI", "DISEASE", 22, 25], ["critically ill", "DISEASE", 29, 43], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["AKI", "PROBLEM", 22, 25], ["AKI", "OBSERVATION", 22, 25]]], ["The etiology of AKI in COVID-19 patients has not been fully elucidated, and likely goes beyond the common AKI causes often seen in critically ill patients such as nephrotoxic exposures, hemodynamic instability, and decreased renal perfusion.", [["renal", "ANATOMY", 225, 230], ["AKI", "DISEASE", 16, 19], ["AKI", "DISEASE", 106, 109], ["critically ill", "DISEASE", 131, 145], ["nephrotoxic", "DISEASE", 163, 174], ["hemodynamic instability", "DISEASE", 186, 209], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 146, 154], ["renal", "ORGAN", 225, 230], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 146, 154], ["AKI", "PROBLEM", 16, 19], ["COVID", "TEST", 23, 28], ["the common AKI", "PROBLEM", 95, 109], ["nephrotoxic exposures", "PROBLEM", 163, 184], ["hemodynamic instability", "PROBLEM", 186, 209], ["decreased renal perfusion", "PROBLEM", 215, 240], ["AKI", "OBSERVATION", 16, 19], ["AKI", "OBSERVATION", 106, 109], ["hemodynamic instability", "OBSERVATION", 186, 209], ["decreased", "OBSERVATION_MODIFIER", 215, 224], ["renal", "ANATOMY", 225, 230], ["perfusion", "OBSERVATION", 231, 240]]], ["Increasing evidence has suggested additional etiologies, including viral-induced rhabdomyolysis, cytokine storm, complement dysregulation, and direct viral invasion [2] , which likely contributed to our patient's AKI.DiscussionAdditionally, critically ill COVID-19 patients have been described to have a high incidence of thrombotic complications [3] .", [["rhabdomyolysis", "DISEASE", 81, 95], ["AKI", "DISEASE", 213, 216], ["thrombotic complications", "DISEASE", 322, 346], ["patient", "ORGANISM", 203, 210], ["patients", "ORGANISM", 265, 273], ["cytokine", "PROTEIN", 97, 105], ["patient", "SPECIES", 203, 210], ["patients", "SPECIES", 265, 273], ["viral-induced rhabdomyolysis", "PROBLEM", 67, 95], ["cytokine storm", "PROBLEM", 97, 111], ["complement dysregulation", "PROBLEM", 113, 137], ["direct viral invasion", "PROBLEM", 143, 164], ["our patient's AKI", "PROBLEM", 199, 216], ["thrombotic complications", "PROBLEM", 322, 346], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["rhabdomyolysis", "OBSERVATION", 81, 95], ["viral invasion", "OBSERVATION", 150, 164], ["AKI", "OBSERVATION", 213, 216], ["thrombotic", "OBSERVATION", 322, 332]]], ["The etiology of these events remains unclear, although studies are ongoing.", [["these events", "PROBLEM", 16, 28], ["studies", "TEST", 55, 62]]], ["Histopathology of patients from Wuhan have reported finding microthrombi in pulmonary vasculature on autopsy [4] .", [["pulmonary vasculature", "ANATOMY", 76, 97], ["patients", "ORGANISM", 18, 26], ["microthrombi", "CANCER", 60, 72], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 76, 97], ["patients", "SPECIES", 18, 26], ["microthrombi in pulmonary vasculature", "PROBLEM", 60, 97], ["autopsy", "TEST", 101, 108], ["microthrombi", "OBSERVATION", 60, 72], ["pulmonary vasculature", "ANATOMY", 76, 97]]], ["A case series from 5 patients in New York demonstrated a pattern of tissue damage consistent with complement-mediated microvascular injury in the lungs and skin [5] .DiscussionTMA has been implicated in AKI through several etiologies.", [["tissue", "ANATOMY", 68, 74], ["microvascular", "ANATOMY", 118, 131], ["lungs", "ANATOMY", 146, 151], ["skin", "ANATOMY", 156, 160], ["tissue damage", "DISEASE", 68, 81], ["microvascular injury", "DISEASE", 118, 138], ["AKI", "DISEASE", 203, 206], ["patients", "ORGANISM", 21, 29], ["tissue", "TISSUE", 68, 74], ["microvascular", "TISSUE", 118, 131], ["lungs", "ORGAN", 146, 151], ["skin", "ORGAN", 156, 160], ["patients", "SPECIES", 21, 29], ["A case series", "TEST", 0, 13], ["tissue damage", "PROBLEM", 68, 81], ["complement-mediated microvascular injury in the lungs", "PROBLEM", 98, 151], ["AKI", "PROBLEM", 203, 206], ["tissue damage", "OBSERVATION", 68, 81], ["consistent with", "UNCERTAINTY", 82, 97], ["microvascular", "ANATOMY", 118, 131], ["injury", "OBSERVATION", 132, 138], ["lungs", "ANATOMY", 146, 151], ["skin", "ANATOMY", 156, 160], ["AKI", "OBSERVATION", 203, 206]]], ["In pediatric patients, acquired HUS is commonly associated with infection (i.e. Shiga toxin-producing Escherichia coli or Streptococcus pneumoniae) [6] .", [["HUS", "DISEASE", 32, 35], ["infection", "DISEASE", 64, 73], ["Shiga toxin", "CHEMICAL", 80, 91], ["patients", "ORGANISM", 13, 21], ["Shiga toxin-producing", "GENE_OR_GENE_PRODUCT", 80, 101], ["Escherichia coli", "ORGANISM", 102, 118], ["Streptococcus pneumoniae", "ORGANISM", 122, 146], ["patients", "SPECIES", 13, 21], ["Escherichia coli", "SPECIES", 102, 118], ["Streptococcus pneumoniae", "SPECIES", 122, 146], ["Escherichia coli", "SPECIES", 102, 118], ["Streptococcus pneumoniae", "SPECIES", 122, 146], ["acquired HUS", "PROBLEM", 23, 35], ["infection", "PROBLEM", 64, 73], ["Shiga toxin", "TEST", 80, 91], ["Escherichia coli", "PROBLEM", 102, 118], ["Streptococcus pneumoniae)", "PROBLEM", 122, 147], ["infection", "OBSERVATION", 64, 73], ["Escherichia coli", "OBSERVATION", 102, 118], ["Streptococcus pneumoniae", "OBSERVATION", 122, 146]]], ["While TMA is a pathologic diagnosis made by tissue biopsy, it can commonly be inferred clinically, in the observation of microangiopathic hemolytic anemia and thrombocytopenia.", [["tissue biopsy", "ANATOMY", 44, 57], ["TMA", "DISEASE", 6, 9], ["microangiopathic hemolytic anemia", "DISEASE", 121, 154], ["thrombocytopenia", "DISEASE", 159, 175], ["TMA", "CANCER", 6, 9], ["tissue biopsy", "MULTI-TISSUE_STRUCTURE", 44, 57], ["tissue biopsy", "TEST", 44, 57], ["microangiopathic hemolytic anemia", "PROBLEM", 121, 154], ["thrombocytopenia", "PROBLEM", 159, 175], ["microangiopathic", "OBSERVATION_MODIFIER", 121, 137], ["hemolytic", "OBSERVATION_MODIFIER", 138, 147], ["anemia", "OBSERVATION", 148, 154], ["thrombocytopenia", "OBSERVATION", 159, 175]]], ["In addition, genetic causes of complement-mediated HUS have been described, which lead to complement activation and formation of the membrane attack complex, lysing target cells and resulting in cell death.", [["membrane", "ANATOMY", 133, 141], ["cells", "ANATOMY", 172, 177], ["cell", "ANATOMY", 195, 199], ["HUS", "DISEASE", 51, 54], ["death", "DISEASE", 200, 205], ["complement", "GENE_OR_GENE_PRODUCT", 31, 41], ["membrane", "CELLULAR_COMPONENT", 133, 141], ["cells", "CELL", 172, 177], ["cell", "CELL", 195, 199], ["membrane attack complex", "PROTEIN", 133, 156], ["lysing target cells", "CELL_TYPE", 158, 177], ["complement-mediated HUS", "PROBLEM", 31, 54], ["the membrane attack complex", "PROBLEM", 129, 156], ["cell death", "PROBLEM", 195, 205], ["cell death", "OBSERVATION", 195, 205]]], ["C3 may be low in complement-mediated HUS, depending on the location of complement pathway disruption and degree of consumption.", [["HUS", "DISEASE", 37, 40], ["C3", "GENE_OR_GENE_PRODUCT", 0, 2], ["C3", "PROTEIN", 0, 2], ["low in complement-mediated HUS", "PROBLEM", 10, 40], ["complement pathway disruption", "PROBLEM", 71, 100], ["low", "OBSERVATION_MODIFIER", 10, 13], ["degree", "OBSERVATION_MODIFIER", 105, 111]]], ["C5b9 is one of several proteins that make up the membrane attack complex, and a high level is suggestive of activation of the complement pathway.", [["membrane", "ANATOMY", 49, 57], ["C5b9", "CHEMICAL", 0, 4], ["C5b9", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["C5b9", "PROTEIN", 0, 4], ["membrane attack complex", "PROTEIN", 49, 72], ["several proteins", "PROBLEM", 15, 31], ["suggestive of", "UNCERTAINTY", 94, 107]]], ["Over activation of the complement pathway also results in damage to endothelium; this, in turn, propagates the coagulation cascade and triggers the formation of microthrombi in vessels and hemolytic anemia.", [["endothelium", "ANATOMY", 68, 79], ["microthrombi", "ANATOMY", 161, 173], ["vessels", "ANATOMY", 177, 184], ["hemolytic anemia", "DISEASE", 189, 205], ["endothelium", "TISSUE", 68, 79], ["vessels", "MULTI-TISSUE_STRUCTURE", 177, 184], ["damage to endothelium", "PROBLEM", 58, 79], ["the coagulation cascade", "PROBLEM", 107, 130], ["microthrombi in vessels", "PROBLEM", 161, 184], ["hemolytic anemia", "PROBLEM", 189, 205], ["damage", "OBSERVATION", 58, 64], ["endothelium", "ANATOMY", 68, 79], ["microthrombi", "OBSERVATION", 161, 173], ["vessels", "ANATOMY", 177, 184], ["hemolytic", "OBSERVATION_MODIFIER", 189, 198], ["anemia", "OBSERVATION", 199, 205]]], ["It is the microthrombi that lead to the end organ damage that is seen in HUS.DiscussionEculizumab is a monoclonal antibody against C5, preventing the formation of C5b and therefore complement activation.", [["organ", "ANATOMY", 44, 49], ["microthrombi", "DISEASE", 10, 22], ["organ damage", "DISEASE", 44, 56], ["HUS", "DISEASE", 73, 76], ["DiscussionEculizumab", "CHEMICAL", 77, 97], ["DiscussionEculizumab", "CHEMICAL", 77, 97], ["organ", "ORGAN", 44, 49], ["DiscussionEculizumab", "SIMPLE_CHEMICAL", 77, 97], ["C5", "GENE_OR_GENE_PRODUCT", 131, 133], ["C5b", "GENE_OR_GENE_PRODUCT", 163, 166], ["monoclonal antibody", "PROTEIN", 103, 122], ["C5", "PROTEIN", 131, 133], ["C5b", "PROTEIN", 163, 166], ["the microthrombi", "PROBLEM", 6, 22], ["the end organ damage", "PROBLEM", 36, 56], ["HUS", "TEST", 73, 76], ["a monoclonal antibody against C5", "PROBLEM", 101, 133], ["microthrombi", "OBSERVATION", 10, 22], ["organ", "ANATOMY", 44, 49], ["damage", "OBSERVATION", 50, 56]]], ["The drug gained FDA approval for treatment of atypical (complement-mediated) HUS (aHUS), and paroxysmal nocturnal hemoglobinuria, with recent expansion to treat neuroinflammatory diseases [7] .", [["HUS", "DISEASE", 77, 80], ["aHUS", "DISEASE", 82, 86], ["paroxysmal nocturnal hemoglobinuria", "DISEASE", 93, 128], ["neuroinflammatory diseases", "DISEASE", 161, 187], ["treatment", "TREATMENT", 33, 42], ["atypical (complement-mediated) HUS", "PROBLEM", 46, 80], ["aHUS", "PROBLEM", 82, 86], ["paroxysmal nocturnal hemoglobinuria", "PROBLEM", 93, 128], ["recent expansion", "PROBLEM", 135, 151], ["neuroinflammatory diseases", "PROBLEM", 161, 187], ["paroxysmal", "OBSERVATION_MODIFIER", 93, 103], ["nocturnal hemoglobinuria", "OBSERVATION", 104, 128], ["neuroinflammatory diseases", "OBSERVATION", 161, 187]]], ["Short treatment with eculizumab has also been shown to contribute to improvement in patients with secondary aHUS whose TMA had persisted despite treatment of the underlying cause [8] .", [["eculizumab", "CHEMICAL", 21, 31], ["aHUS", "DISEASE", 108, 112], ["TMA", "DISEASE", 119, 122], ["eculizumab", "CHEMICAL", 21, 31], ["eculizumab", "SIMPLE_CHEMICAL", 21, 31], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Short treatment", "TREATMENT", 0, 15], ["eculizumab", "TREATMENT", 21, 31], ["secondary aHUS", "PROBLEM", 98, 112], ["TMA", "PROBLEM", 119, 122], ["treatment", "TREATMENT", 145, 154]]], ["In our case, 3 doses of eculizumab were given and discontinued after clinical improvement.DiscussionSeveral studies have suggested that complement activation contributes to COVID-19 disease, and targeting this cascade may be a potential treatment.", [["eculizumab", "CHEMICAL", 24, 34], ["eculizumab", "CHEMICAL", 24, 34], ["eculizumab", "SIMPLE_CHEMICAL", 24, 34], ["COVID-19", "GENE_OR_GENE_PRODUCT", 173, 181], ["eculizumab", "TREATMENT", 24, 34], ["DiscussionSeveral studies", "TEST", 90, 115], ["COVID-19 disease", "PROBLEM", 173, 189], ["this cascade", "TREATMENT", 205, 217], ["a potential treatment", "TREATMENT", 225, 246]]], ["Complement inhibition in murine studies involving SARS-CoV and MERS-CoV infections have shown promise [9] .", [["infections", "DISEASE", 72, 82], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["murine", "ORGANISM", 25, 31], ["SARS-CoV", "ORGANISM", 50, 58], ["MERS-CoV", "ORGANISM", 63, 71], ["murine", "SPECIES", 25, 31], ["SARS-CoV", "SPECIES", 50, 58], ["MERS-CoV", "SPECIES", 63, 71], ["Complement inhibition", "TREATMENT", 0, 21], ["murine studies", "TEST", 25, 39], ["SARS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["MERS", "PROBLEM", 63, 67], ["CoV infections", "PROBLEM", 68, 82]]], ["Additionally, a case series of critically-ill Italian COVID-19 patients with ARDS produced encouraging results; all four patients who received eculizumab (900 mg, up to 4 doses) have recovered [10] .", [["critically-ill", "DISEASE", 31, 45], ["ARDS", "DISEASE", 77, 81], ["eculizumab", "CHEMICAL", 143, 153], ["eculizumab", "CHEMICAL", 143, 153], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 121, 129], ["eculizumab", "SIMPLE_CHEMICAL", 143, 153], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 121, 129], ["ARDS", "PROBLEM", 77, 81], ["eculizumab", "TREATMENT", 143, 153]]], ["Eculizumab is currently enrolled in a SOLID-C19 compassionate use study for adult patients in the US [11] .", [["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Eculizumab", "TREATMENT", 0, 10]]], ["In addition to tissue samples consistent with complementmediated injury in the lungs [5] , a study by Diao et al. [12] observed complement C5b9 deposition in renal tubules of six patients with SARS-CoV-2 infection, suggestive of cascade presence in the kidney.", [["tissue samples", "ANATOMY", 15, 29], ["lungs", "ANATOMY", 79, 84], ["renal tubules", "ANATOMY", 158, 171], ["kidney", "ANATOMY", 253, 259], ["SARS-CoV-2 infection", "DISEASE", 193, 213], ["tissue samples", "TISSUE", 15, 29], ["lungs", "ORGAN", 79, 84], ["C5b9", "GENE_OR_GENE_PRODUCT", 139, 143], ["renal tubules", "MULTI-TISSUE_STRUCTURE", 158, 171], ["patients", "ORGANISM", 179, 187], ["CoV-2", "ORGANISM", 198, 203], ["kidney", "ORGAN", 253, 259], ["C5b9", "PROTEIN", 139, 143], ["patients", "SPECIES", 179, 187], ["SARS-CoV-2", "SPECIES", 193, 203], ["tissue samples", "TEST", 15, 29], ["complementmediated injury in the lungs", "PROBLEM", 46, 84], ["a study", "TEST", 91, 98], ["complement C5b9 deposition in renal tubules", "PROBLEM", 128, 171], ["SARS", "PROBLEM", 193, 197], ["CoV", "PROBLEM", 198, 201], ["2 infection", "PROBLEM", 202, 213], ["cascade presence in the kidney", "PROBLEM", 229, 259], ["consistent with", "UNCERTAINTY", 30, 45], ["complementmediated", "OBSERVATION_MODIFIER", 46, 64], ["injury", "OBSERVATION", 65, 71], ["lungs", "ANATOMY", 79, 84], ["renal", "ANATOMY", 158, 163], ["tubules", "ANATOMY_MODIFIER", 164, 171], ["SARS", "OBSERVATION", 193, 197], ["infection", "OBSERVATION", 204, 213], ["suggestive of", "UNCERTAINTY", 215, 228], ["cascade", "OBSERVATION", 229, 236], ["kidney", "ANATOMY", 253, 259]]], ["Thus, we present this case as the first use of eculizumab for complement inhibition in pediatric complement-mediated AKI, associated with COVID-19 infection.DiscussionAs children account for a very small proportion of patients affected with primary acute COVID-19 infection [13] , limited data exist on AKI in this population.", [["eculizumab", "CHEMICAL", 47, 57], ["AKI", "DISEASE", 117, 120], ["infection", "DISEASE", 147, 156], ["infection", "DISEASE", 264, 273], ["AKI", "DISEASE", 303, 306], ["eculizumab", "CHEMICAL", 47, 57], ["eculizumab", "SIMPLE_CHEMICAL", 47, 57], ["children", "ORGANISM", 170, 178], ["patients", "ORGANISM", 218, 226], ["children", "SPECIES", 170, 178], ["patients", "SPECIES", 218, 226], ["eculizumab", "TREATMENT", 47, 57], ["complement inhibition", "TREATMENT", 62, 83], ["AKI", "PROBLEM", 117, 120], ["COVID-19 infection", "PROBLEM", 138, 156], ["primary acute COVID-19 infection", "PROBLEM", 241, 273], ["AKI", "PROBLEM", 303, 306], ["AKI", "OBSERVATION", 117, 120], ["infection", "OBSERVATION", 147, 156], ["AKI", "OBSERVATION", 303, 306]]], ["Children have been implicated in an emerging condition, Multisystem Inflammatory Syndrome in Children (MIS-C), thought to be a post-viral syndrome associated with COVID-19.", [["Multisystem Inflammatory Syndrome", "DISEASE", 56, 89], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["Children", "SPECIES", 93, 101], ["Multisystem Inflammatory Syndrome", "PROBLEM", 56, 89], ["a post-viral syndrome", "PROBLEM", 125, 146], ["COVID", "TEST", 163, 168], ["Multisystem", "OBSERVATION_MODIFIER", 56, 67], ["Inflammatory Syndrome", "OBSERVATION", 68, 89], ["post-viral syndrome", "OBSERVATION", 127, 146]]], ["MIS-C is a hyperinflammatory state, characterized by persistent fever with a constellation of symptoms including hypotension, elevated inflammatory markers, and multi-organ involvement (e.g., cardiac, gastrointestinal, renal, hematologic, dermatologic and neurologic).", [["multi-organ", "ANATOMY", 161, 172], ["cardiac", "ANATOMY", 192, 199], ["gastrointestinal", "ANATOMY", 201, 217], ["renal", "ANATOMY", 219, 224], ["neurologic", "ANATOMY", 256, 266], ["fever", "DISEASE", 64, 69], ["hypotension", "DISEASE", 113, 124], ["cardiac, gastrointestinal, renal, hematologic, dermatologic and neurologic", "DISEASE", 192, 266], ["MIS-C", "GENE_OR_GENE_PRODUCT", 0, 5], ["cardiac", "ORGAN", 192, 199], ["gastrointestinal", "ORGAN", 201, 217], ["renal", "ORGAN", 219, 224], ["inflammatory markers", "PROTEIN", 135, 155], ["a hyperinflammatory state", "PROBLEM", 9, 34], ["persistent fever", "PROBLEM", 53, 69], ["symptoms", "PROBLEM", 94, 102], ["hypotension", "PROBLEM", 113, 124], ["elevated inflammatory markers", "PROBLEM", 126, 155], ["multi-organ involvement", "PROBLEM", 161, 184], ["cardiac, gastrointestinal, renal, hematologic, dermatologic and neurologic)", "PROBLEM", 192, 267], ["persistent", "OBSERVATION_MODIFIER", 53, 63], ["fever", "OBSERVATION", 64, 69], ["hypotension", "OBSERVATION", 113, 124], ["elevated", "OBSERVATION_MODIFIER", 126, 134], ["inflammatory markers", "OBSERVATION", 135, 155], ["multi-organ", "ANATOMY", 161, 172], ["cardiac", "ANATOMY", 192, 199], ["gastrointestinal", "ANATOMY", 201, 217], ["renal", "ANATOMY", 219, 224]]], ["Cardiac findings include elevated BNP and troponin levels; and diminished left ventricular systolic function with or without coronary artery changes on echocardiogram [14] .", [["Cardiac", "ANATOMY", 0, 7], ["left ventricular", "ANATOMY", 74, 90], ["coronary artery", "ANATOMY", 125, 140], ["Cardiac", "ORGAN", 0, 7], ["BNP", "GENE_OR_GENE_PRODUCT", 34, 37], ["troponin", "GENE_OR_GENE_PRODUCT", 42, 50], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 74, 90], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 125, 140], ["BNP", "PROTEIN", 34, 37], ["troponin", "PROTEIN", 42, 50], ["Cardiac findings", "TEST", 0, 16], ["elevated BNP", "PROBLEM", 25, 37], ["troponin levels", "TEST", 42, 57], ["diminished left ventricular systolic function", "PROBLEM", 63, 108], ["coronary artery changes", "PROBLEM", 125, 148], ["echocardiogram", "TEST", 152, 166], ["elevated", "OBSERVATION_MODIFIER", 25, 33], ["BNP", "OBSERVATION", 34, 37], ["diminished", "OBSERVATION_MODIFIER", 63, 73], ["left ventricular", "ANATOMY", 74, 90], ["systolic function", "OBSERVATION", 91, 108], ["without", "UNCERTAINTY", 117, 124], ["coronary artery", "ANATOMY", 125, 140]]], ["The incidence of AKI in this syndrome is also unknown, with cases only very recently reported.", [["AKI", "DISEASE", 17, 20], ["AKI", "PROBLEM", 17, 20], ["this syndrome", "PROBLEM", 24, 37], ["AKI", "OBSERVATION", 17, 20]]], ["Our patient displays features of both primary COVID-19 infection and MIS-C [15] , and it is not known whether the etiologies of AKI in MIS-C overlap with acute infection, or if the mechanisms differ for patients in a post-viral inflammatory state.ConclusionComplement-mediated TMA should be considered as an etiology for AKI in COVID-19 patients.", [["primary COVID-19 infection", "DISEASE", 38, 64], ["AKI", "DISEASE", 128, 131], ["acute infection", "DISEASE", 154, 169], ["TMA", "DISEASE", 277, 280], ["AKI", "DISEASE", 321, 324], ["patient", "ORGANISM", 4, 11], ["MIS-C", "GENE_OR_GENE_PRODUCT", 69, 74], ["MIS-C", "GENE_OR_GENE_PRODUCT", 135, 140], ["patients", "ORGANISM", 203, 211], ["TMA", "SIMPLE_CHEMICAL", 277, 280], ["patients", "ORGANISM", 337, 345], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 337, 345], ["both primary COVID-19 infection", "PROBLEM", 33, 64], ["MIS", "TEST", 69, 72], ["AKI in MIS", "PROBLEM", 128, 138], ["acute infection", "PROBLEM", 154, 169], ["a post-viral inflammatory state", "PROBLEM", 215, 246], ["ConclusionComplement-mediated TMA", "TREATMENT", 247, 280], ["AKI", "PROBLEM", 321, 324], ["COVID", "TEST", 328, 333], ["infection", "OBSERVATION", 55, 64], ["AKI", "OBSERVATION", 128, 131], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["infection", "OBSERVATION", 160, 169], ["inflammatory", "OBSERVATION", 228, 240], ["TMA", "OBSERVATION", 277, 280]]], ["We present a case of complement cascade inhibition using eculizumab as a strategy for treating severe AKI in a pediatric patient.", [["eculizumab", "CHEMICAL", 57, 67], ["AKI", "DISEASE", 102, 105], ["eculizumab", "CHEMICAL", 57, 67], ["eculizumab", "SIMPLE_CHEMICAL", 57, 67], ["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128], ["complement cascade inhibition", "TREATMENT", 21, 50], ["eculizumab", "TREATMENT", 57, 67], ["severe AKI", "PROBLEM", 95, 105], ["AKI", "OBSERVATION", 102, 105]]], ["Further investigations are needed to determine whether it can be generalized that complement inhibition is efficacious in the treatment of renal disease as well as other manifestations of COVID-19.Compliance with ethical standardsConflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.Compliance with ethical standardsEthical approval This article does not contain any studies with human participants performed by any of the authors.Informed consentThe parent of the patient has consented to submission of the case report to the journal.", [["renal", "ANATOMY", 139, 144], ["renal disease", "DISEASE", 139, 152], ["COVID-19", "CHEMICAL", 188, 196], ["renal", "ORGAN", 139, 144], ["human", "ORGANISM", 444, 449], ["patient", "ORGANISM", 529, 536], ["human", "SPECIES", 444, 449], ["participants", "SPECIES", 450, 462], ["patient", "SPECIES", 529, 536], ["human", "SPECIES", 444, 449], ["Further investigations", "TEST", 0, 22], ["renal disease", "PROBLEM", 139, 152], ["COVID", "TEST", 188, 193], ["ethical standards", "TREATMENT", 213, 230], ["ethical standards", "TREATMENT", 363, 380], ["Ethical approval", "TREATMENT", 380, 396], ["renal", "ANATOMY", 139, 144], ["disease", "OBSERVATION", 145, 152], ["no", "UNCERTAINTY", 323, 325]]]], "920acf7b75dd6f84138e5352f7b28aad1973c327": [["The presence of lung abscesses due to Acinetobacter infection is an extremely uncommon manifestation of the disease.", [["lung abscesses", "ANATOMY", 16, 30], ["lung abscesses", "DISEASE", 16, 30], ["Acinetobacter infection", "DISEASE", 38, 61], ["lung", "ORGAN", 16, 20], ["lung abscesses", "PROBLEM", 16, 30], ["Acinetobacter infection", "PROBLEM", 38, 61], ["the disease", "PROBLEM", 104, 115], ["lung", "ANATOMY", 16, 20], ["abscesses", "OBSERVATION", 21, 30], ["Acinetobacter", "OBSERVATION_MODIFIER", 38, 51], ["infection", "OBSERVATION", 52, 61], ["extremely uncommon", "OBSERVATION_MODIFIER", 68, 86], ["disease", "OBSERVATION", 108, 115]]], ["This case underlines the emergent role which these, often multi-drug resistant, bacteria may play in the future, perhaps in community infections as well.Case presentationA 16-yr-old female presented to the emergency department with a two-day history of fever up to 39\u00b0C, sore throat, productive cough and malaise.", [["infections", "DISEASE", 134, 144], ["fever", "DISEASE", 253, 258], ["sore throat", "DISEASE", 271, 282], ["cough", "DISEASE", 295, 300], ["female", "ORGANISM", 182, 188], ["bacteria", "PROBLEM", 80, 88], ["community infections", "PROBLEM", 124, 144], ["fever", "PROBLEM", 253, 258], ["sore throat", "PROBLEM", 271, 282], ["productive cough", "PROBLEM", 284, 300], ["malaise", "PROBLEM", 305, 312], ["community", "OBSERVATION_MODIFIER", 124, 133], ["infections", "OBSERVATION", 134, 144], ["fever", "OBSERVATION", 253, 258], ["sore throat", "ANATOMY", 271, 282], ["productive", "OBSERVATION_MODIFIER", 284, 294], ["cough", "OBSERVATION", 295, 300], ["malaise", "OBSERVATION", 305, 312]]], ["Initially a diagnosis of acute tonsillitis was made and the patient was treated for a seven-day period with penicillin.", [["tonsillitis", "DISEASE", 31, 42], ["penicillin", "CHEMICAL", 108, 118], ["penicillin", "CHEMICAL", 108, 118], ["patient", "ORGANISM", 60, 67], ["penicillin", "SIMPLE_CHEMICAL", 108, 118], ["patient", "SPECIES", 60, 67], ["acute tonsillitis", "PROBLEM", 25, 42], ["penicillin", "TREATMENT", 108, 118], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["tonsillitis", "OBSERVATION", 31, 42]]], ["Unfortunately the patient remained febrile up to 38\u00b0C, with persistent productive cough and malaise.", [["febrile", "DISEASE", 35, 42], ["cough", "DISEASE", 82, 87], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["febrile", "PROBLEM", 35, 42], ["persistent productive cough", "PROBLEM", 60, 87], ["malaise", "PROBLEM", 92, 99], ["febrile", "OBSERVATION", 35, 42], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["productive", "OBSERVATION_MODIFIER", 71, 81], ["cough", "OBSERVATION", 82, 87], ["malaise", "OBSERVATION", 92, 99]]], ["Ten days after her first visit she was admitted to the pulmonary department for further evaluation.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary", "ORGAN", 55, 64], ["further evaluation", "TEST", 80, 98], ["pulmonary", "ANATOMY", 55, 64]]], ["The patient until then had no significant medical history.Case presentationOn admission she had low-grade fever (37,4\u00b0C).", [["fever", "DISEASE", 106, 111], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["low-grade fever", "PROBLEM", 96, 111], ["low-grade", "OBSERVATION_MODIFIER", 96, 105], ["fever", "OBSERVATION", 106, 111]]], ["The rest of the clinical findings were unremarkable.", [["unremarkable", "OBSERVATION", 39, 51]]], ["Blood tests demonstrated normal white cell count (9500/\u03bcl), anemia (hematocrit 32,6% and hemoglobin 10,7 gr/dl), mild thrombocytosis (512000/\u03bcl), increased erythrocyte sedimentation rate (ESR = 109 mm/hr) and C-reactive protein (CRP = 49,6 mg/dl).", [["Blood", "ANATOMY", 0, 5], ["white cell", "ANATOMY", 32, 42], ["erythrocyte", "ANATOMY", 156, 167], ["anemia", "DISEASE", 60, 66], ["thrombocytosis", "DISEASE", 118, 132], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["white cell", "CELL", 32, 42], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 89, 99], ["erythrocyte", "CELL", 156, 167], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 209, 227], ["CRP", "GENE_OR_GENE_PRODUCT", 229, 232], ["hemoglobin", "PROTEIN", 89, 99], ["C-reactive protein", "PROTEIN", 209, 227], ["CRP", "PROTEIN", 229, 232], ["Blood tests", "TEST", 0, 11], ["white cell count", "TEST", 32, 48], ["anemia", "PROBLEM", 60, 66], ["hematocrit", "TEST", 68, 78], ["hemoglobin", "TEST", 89, 99], ["dl", "TEST", 108, 110], ["mild thrombocytosis", "PROBLEM", 113, 132], ["increased erythrocyte sedimentation rate", "PROBLEM", 146, 186], ["ESR", "TEST", 188, 191], ["mm/hr", "TEST", 198, 203], ["C", "TEST", 209, 210], ["reactive protein", "TEST", 211, 227], ["CRP", "TEST", 229, 232], ["normal", "OBSERVATION_MODIFIER", 25, 31], ["white cell", "OBSERVATION_MODIFIER", 32, 42], ["anemia", "OBSERVATION", 60, 66], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["thrombocytosis", "OBSERVATION", 118, 132]]], ["Serum biochemistry tests were within normal limits.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum biochemistry tests", "TEST", 0, 24], ["normal limits", "OBSERVATION", 37, 50]]], ["Arterial blood gases were normal as well.", [["Arterial blood", "ANATOMY", 0, 14], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Arterial blood gases", "TEST", 0, 20], ["normal", "OBSERVATION", 26, 32]]], ["The chest radiograph disclosed a right upper lobe consolidation with the presence of at least three abscesses within the lobe.", [["chest", "ANATOMY", 4, 9], ["right upper lobe", "ANATOMY", 33, 49], ["abscesses", "ANATOMY", 100, 109], ["lobe", "ANATOMY", 121, 125], ["abscesses", "DISEASE", 100, 109], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 39, 49], ["abscesses", "PATHOLOGICAL_FORMATION", 100, 109], ["lobe", "ORGAN", 121, 125], ["The chest radiograph", "TEST", 0, 20], ["a right upper lobe consolidation", "PROBLEM", 31, 63], ["three abscesses within the lobe", "PROBLEM", 94, 125], ["chest", "ANATOMY", 4, 9], ["right upper lobe", "ANATOMY", 33, 49], ["consolidation", "OBSERVATION", 50, 63], ["at least", "OBSERVATION_MODIFIER", 85, 93], ["three", "OBSERVATION_MODIFIER", 94, 99], ["abscesses", "OBSERVATION", 100, 109], ["lobe", "ANATOMY_MODIFIER", 121, 125]]], ["A spiral computed tomography of the chest demonstrated the consolidation within the right upper lobe with multiple lung abscesses (Figure 1 ).", [["chest", "ANATOMY", 36, 41], ["right upper lobe", "ANATOMY", 84, 100], ["lung abscesses", "ANATOMY", 115, 129], ["lung abscesses", "DISEASE", 115, 129], ["chest", "ORGAN", 36, 41], ["upper lobe", "ORGANISM_SUBDIVISION", 90, 100], ["lung", "ORGAN", 115, 119], ["A spiral computed tomography of the chest", "TEST", 0, 41], ["the consolidation within the right upper lobe", "PROBLEM", 55, 100], ["multiple lung abscesses", "PROBLEM", 106, 129], ["chest", "ANATOMY", 36, 41], ["consolidation", "OBSERVATION", 59, 72], ["right upper lobe", "ANATOMY", 84, 100], ["multiple", "OBSERVATION_MODIFIER", 106, 114], ["lung", "ANATOMY", 115, 119], ["abscesses", "OBSERVATION", 120, 129]]], ["No other evidence of parechymal damage, lymph nodes enlargement or pleural fluid was visible.", [["parechymal", "ANATOMY", 21, 31], ["lymph nodes", "ANATOMY", 40, 51], ["pleural fluid", "ANATOMY", 67, 80], ["parechymal damage", "DISEASE", 21, 38], ["parechymal", "CANCER", 21, 31], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 40, 51], ["pleural fluid", "MULTI-TISSUE_STRUCTURE", 67, 80], ["parechymal damage", "PROBLEM", 21, 38], ["lymph nodes enlargement", "PROBLEM", 40, 63], ["pleural fluid", "PROBLEM", 67, 80], ["other evidence of", "UNCERTAINTY", 3, 20], ["parechymal", "OBSERVATION_MODIFIER", 21, 31], ["damage", "OBSERVATION", 32, 38], ["lymph nodes", "OBSERVATION", 40, 51], ["enlargement", "OBSERVATION_MODIFIER", 52, 63], ["pleural", "ANATOMY", 67, 74], ["fluid", "OBSERVATION", 75, 80]]], ["Heart and great vessels visualized without any pathology.Case presentationCardiological examination including heart ultrasonographic analysis and dental examination did not demonstrate any pathological evidence.", [["Heart", "ANATOMY", 0, 5], ["vessels", "ANATOMY", 16, 23], ["heart", "ANATOMY", 110, 115], ["Heart", "ORGAN", 0, 5], ["great vessels", "MULTI-TISSUE_STRUCTURE", 10, 23], ["heart", "ORGAN", 110, 115], ["any pathology", "PROBLEM", 43, 56], ["Cardiological examination", "TEST", 74, 99], ["heart ultrasonographic analysis", "TEST", 110, 141], ["dental examination", "TEST", 146, 164], ["great vessels", "ANATOMY", 10, 23], ["without", "UNCERTAINTY", 35, 42], ["pathology", "OBSERVATION", 47, 56], ["heart", "ANATOMY", 110, 115]]], ["Skin tests for M. tuberculosis, atypical mycobacteria and Quanti-FERON TB Gold test were negative.", [["Skin", "ANATOMY", 0, 4], ["M. tuberculosis", "DISEASE", 15, 30], ["Skin", "ORGAN", 0, 4], ["M. tuberculosis", "ORGANISM", 15, 30], ["M. tuberculosis", "SPECIES", 15, 30], ["M. tuberculosis", "SPECIES", 15, 30], ["Skin tests", "TEST", 0, 10], ["M. tuberculosis", "PROBLEM", 15, 30], ["atypical mycobacteria", "PROBLEM", 32, 53], ["Quanti-FERON TB Gold test", "TEST", 58, 83], ["tuberculosis", "OBSERVATION", 18, 30], ["atypical", "OBSERVATION_MODIFIER", 32, 40], ["mycobacteria", "OBSERVATION", 41, 53]]], ["Serum component analysis, rheumatoid factor, antinuclear antibodies, antineutrophilic cytoplasmic antibodies, immunonoglobin levels, serologic tests for hepatitis A, B, C, D, human immunodeficiency virus and common viruses did not reveal any abnormality.", [["Serum", "ANATOMY", 0, 5], ["cytoplasmic", "ANATOMY", 86, 97], ["hepatitis A", "DISEASE", 153, 164], ["human immunodeficiency virus", "DISEASE", 175, 203], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 26, 43], ["antinuclear antibodies", "GENE_OR_GENE_PRODUCT", 45, 67], ["antineutrophilic cytoplasmic antibodies", "GENE_OR_GENE_PRODUCT", 69, 108], ["immunonoglobin", "GENE_OR_GENE_PRODUCT", 110, 124], ["hepatitis A", "ORGANISM", 153, 164], ["B", "GENE_OR_GENE_PRODUCT", 166, 167], ["C", "GENE_OR_GENE_PRODUCT", 169, 170], ["D", "GENE_OR_GENE_PRODUCT", 172, 173], ["human immunodeficiency virus", "ORGANISM", 175, 203], ["rheumatoid factor", "PROTEIN", 26, 43], ["antinuclear antibodies", "PROTEIN", 45, 67], ["antineutrophilic cytoplasmic antibodies", "PROTEIN", 69, 108], ["immunonoglobin", "PROTEIN", 110, 124], ["human immunodeficiency virus", "SPECIES", 175, 203], ["hepatitis A", "SPECIES", 153, 164], ["human immunodeficiency virus", "SPECIES", 175, 203], ["Serum component analysis", "TEST", 0, 24], ["rheumatoid factor", "PROBLEM", 26, 43], ["antinuclear antibodies", "TEST", 45, 67], ["antineutrophilic cytoplasmic antibodies", "TEST", 69, 108], ["immunonoglobin levels", "TEST", 110, 131], ["serologic tests", "TEST", 133, 148], ["hepatitis A", "TEST", 153, 164], ["human immunodeficiency virus", "PROBLEM", 175, 203], ["common viruses", "PROBLEM", 208, 222], ["any abnormality", "PROBLEM", 238, 253], ["rheumatoid", "OBSERVATION_MODIFIER", 26, 36], ["abnormality", "OBSERVATION", 242, 253]]], ["Finally sputum cultures in three different samples revealed the presence of Acinetobacter baumannii and the diagnosis of community-acquired pneumonia with multiple abscesses due to Acinetobacter baumannii infection were made based on this evidence.", [["sputum cultures", "ANATOMY", 8, 23], ["samples", "ANATOMY", 43, 50], ["abscesses", "ANATOMY", 164, 173], ["Acinetobacter baumannii", "DISEASE", 76, 99], ["pneumonia", "DISEASE", 140, 149], ["abscesses", "DISEASE", 164, 173], ["Acinetobacter baumannii infection", "DISEASE", 181, 214], ["sputum cultures", "CELL", 8, 23], ["Acinetobacter baumannii", "ORGANISM", 76, 99], ["abscesses", "PATHOLOGICAL_FORMATION", 164, 173], ["Acinetobacter baumannii", "ORGANISM", 181, 204], ["Acinetobacter baumannii", "SPECIES", 76, 99], ["Acinetobacter baumannii", "SPECIES", 181, 204], ["Acinetobacter baumannii", "SPECIES", 76, 99], ["Acinetobacter baumannii", "SPECIES", 181, 204], ["Finally sputum cultures", "TEST", 0, 23], ["Acinetobacter baumannii", "PROBLEM", 76, 99], ["community-acquired pneumonia", "PROBLEM", 121, 149], ["multiple abscesses", "PROBLEM", 155, 173], ["Acinetobacter baumannii infection", "PROBLEM", 181, 214], ["Acinetobacter baumannii", "OBSERVATION", 76, 99], ["pneumonia", "OBSERVATION", 140, 149], ["multiple", "OBSERVATION_MODIFIER", 155, 163], ["abscesses", "OBSERVATION", 164, 173], ["Acinetobacter", "OBSERVATION_MODIFIER", 181, 194], ["baumannii", "OBSERVATION", 195, 204]]], ["The stains were susceptible to multiple antibiotics and treatment with ciprofloxacin and amoxicillin with clavoulanic acid was initiated for a three month period of treatment.", [["ciprofloxacin", "CHEMICAL", 71, 84], ["amoxicillin", "CHEMICAL", 89, 100], ["clavoulanic acid", "CHEMICAL", 106, 122], ["ciprofloxacin", "CHEMICAL", 71, 84], ["amoxicillin", "CHEMICAL", 89, 100], ["clavoulanic acid", "CHEMICAL", 106, 122], ["ciprofloxacin", "SIMPLE_CHEMICAL", 71, 84], ["amoxicillin", "SIMPLE_CHEMICAL", 89, 100], ["clavoulanic acid", "SIMPLE_CHEMICAL", 106, 122], ["The stains", "TEST", 0, 10], ["multiple antibiotics", "TREATMENT", 31, 51], ["treatment", "TREATMENT", 56, 65], ["ciprofloxacin", "TREATMENT", 71, 84], ["amoxicillin", "TREATMENT", 89, 100], ["clavoulanic acid", "TREATMENT", 106, 122], ["treatment", "TREATMENT", 165, 174]]], ["A significant clinical improvement in the patient's condition was noted only a few days later which was reflected in her laboratory investigation as well.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["her laboratory investigation", "TEST", 117, 145], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["clinical", "OBSERVATION_MODIFIER", 14, 22], ["improvement", "OBSERVATION_MODIFIER", 23, 34]]], ["Three months later a new computed tomography scan of the chest was obtained revealing an almost completely healed right upper lobe ( Figure 2 ).", [["chest", "ANATOMY", 57, 62], ["right upper lobe", "ANATOMY", 114, 130], ["chest", "ORGAN", 57, 62], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 120, 130], ["a new computed tomography scan of the chest", "TEST", 19, 62], ["chest", "ANATOMY", 57, 62], ["almost", "OBSERVATION_MODIFIER", 89, 95], ["completely", "OBSERVATION_MODIFIER", 96, 106], ["healed", "OBSERVATION", 107, 113], ["right upper lobe", "ANATOMY", 114, 130]]], ["The patient remains asymptomatic until now.DiscussionAcinetobacter spp are aerobic gram-negative coccobacillus with preference for warm, ambient environments, which have received a great interest during the last two decades due to its ability to accumulate, with multiple mechanisms, multi-drug resistance stains.", [["patient", "ORGANISM", 4, 11], ["Acinetobacter spp", "ORGANISM", 53, 70], ["patient", "SPECIES", 4, 11], ["asymptomatic", "PROBLEM", 20, 32], ["Acinetobacter spp", "TEST", 53, 70], ["aerobic gram", "TEST", 75, 87], ["multi-drug resistance stains", "PROBLEM", 284, 312], ["asymptomatic", "OBSERVATION", 20, 32], ["negative coccobacillus", "OBSERVATION", 88, 110], ["drug resistance", "OBSERVATION", 290, 305]]], ["As a result these bacteria have become, a sometimes lethal, etiologic factor mainly in intensive care unit (ICU) infections, ventilator associated pneumonia (VAP), and in communityacquired infections and represent an emergent public health problem [1, 2] .DiscussionTypically this pathogen has been described as a cause of infection in tropical or subtropical climates, more often during summer, in ICU patients or in long term residents at health care facilities.", [["infections", "DISEASE", 113, 123], ["ventilator associated pneumonia", "DISEASE", 125, 156], ["VAP", "DISEASE", 158, 161], ["infections", "DISEASE", 189, 199], ["infection", "DISEASE", 323, 332], ["patients", "ORGANISM", 403, 411], ["patients", "SPECIES", 403, 411], ["these bacteria", "PROBLEM", 12, 26], ["ventilator associated pneumonia", "PROBLEM", 125, 156], ["VAP", "PROBLEM", 158, 161], ["communityacquired infections", "PROBLEM", 171, 199], ["this pathogen", "PROBLEM", 276, 289], ["infection", "PROBLEM", 323, 332], ["infections", "OBSERVATION", 113, 123], ["pneumonia", "OBSERVATION", 147, 156], ["infections", "OBSERVATION", 189, 199], ["infection", "OBSERVATION", 323, 332]]], ["Ventilator-depended patients are at greater risk but other factors such as recent surgery, central vascular lines, tracheotomy, enteral feeding and treatment with new generation antibiotics, like thirdgeneration cephalosporins, fluoroquinolones or carbapenems, may contribute as well.", [["central vascular lines", "ANATOMY", 91, 113], ["cephalosporins", "CHEMICAL", 212, 226], ["fluoroquinolones", "CHEMICAL", 228, 244], ["carbapenems", "CHEMICAL", 248, 259], ["cephalosporins", "CHEMICAL", 212, 226], ["fluoroquinolones", "CHEMICAL", 228, 244], ["carbapenems", "CHEMICAL", 248, 259], ["patients", "ORGANISM", 20, 28], ["central vascular lines", "CELL", 91, 113], ["thirdgeneration cephalosporins", "SIMPLE_CHEMICAL", 196, 226], ["fluoroquinolones", "SIMPLE_CHEMICAL", 228, 244], ["carbapenems", "SIMPLE_CHEMICAL", 248, 259], ["patients", "SPECIES", 20, 28], ["Ventilator", "TREATMENT", 0, 10], ["recent surgery", "TREATMENT", 75, 89], ["central vascular lines", "TREATMENT", 91, 113], ["tracheotomy", "TREATMENT", 115, 126], ["enteral feeding", "TREATMENT", 128, 143], ["treatment", "TREATMENT", 148, 157], ["new generation antibiotics", "TREATMENT", 163, 189], ["thirdgeneration cephalosporins", "TREATMENT", 196, 226], ["fluoroquinolones", "TREATMENT", 228, 244], ["carbapenems", "TREATMENT", 248, 259], ["surgery", "OBSERVATION", 82, 89], ["central", "ANATOMY_MODIFIER", 91, 98], ["vascular", "ANATOMY", 99, 107], ["lines", "OBSERVATION", 108, 113], ["tracheotomy", "OBSERVATION", 115, 126]]], ["The majority of affected patients have underlying comorbidities mainly chronic obstructive pulmonary disease, renal disease, diabetes mellitus, alcoholism and heavy smoking [1, 3, 4] .DiscussionNosocomial outbreaks have also been described due to health care professionals with colonized hands and poor personal hygiene.", [["pulmonary", "ANATOMY", 91, 100], ["renal", "ANATOMY", 110, 115], ["chronic obstructive pulmonary disease", "DISEASE", 71, 108], ["renal disease", "DISEASE", 110, 123], ["diabetes mellitus", "DISEASE", 125, 142], ["alcoholism", "DISEASE", 144, 154], ["patients", "ORGANISM", 25, 33], ["pulmonary", "ORGAN", 91, 100], ["renal", "ORGAN", 110, 115], ["hands", "ORGANISM_SUBDIVISION", 288, 293], ["patients", "SPECIES", 25, 33], ["underlying comorbidities", "PROBLEM", 39, 63], ["chronic obstructive pulmonary disease", "PROBLEM", 71, 108], ["renal disease", "PROBLEM", 110, 123], ["diabetes mellitus", "PROBLEM", 125, 142], ["alcoholism", "PROBLEM", 144, 154], ["Nosocomial outbreaks", "PROBLEM", 194, 214], ["colonized hands", "PROBLEM", 278, 293], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["obstructive", "OBSERVATION_MODIFIER", 79, 90], ["pulmonary", "ANATOMY", 91, 100], ["disease", "OBSERVATION", 101, 108], ["renal", "ANATOMY", 110, 115], ["disease", "OBSERVATION", 116, 123], ["diabetes mellitus", "OBSERVATION", 125, 142]]], ["These people could act as opportunist carriers of an epidemic stain.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["an epidemic stain", "TEST", 50, 67]]], ["Contaminated ventilators or respiratory care equipment as well as intrahospital transmission may also contribute to the beginning of an outbreak [1, 4] .DiscussionThe computed tomography scan of this 16-y-old female revealed the presence of multiple abscesses at the right upper lobe Figure 1 The computed tomography scan of this 16-y-old female revealed the presence of multiple abscesses at the right upper lobe.DiscussionAfter a three-month period of treatment a new computed tomography scan demonstrated a full recovery Figure 2 After a three-month period of treatment a new computed tomography scan demonstrated a full recovery.DiscussionRecently Turkey's earthquakes in Marmara area, as well as others physical disasters like the South Asia tsunami, demonstrated that vulnerable populations are also at risk to Acinetobacter infections due to contamination and cross-infection inside hospital settings [1].", [["abscesses", "ANATOMY", 250, 259], ["right upper lobe", "ANATOMY", 267, 283], ["abscesses", "ANATOMY", 380, 389], ["right upper lobe", "ANATOMY", 397, 413], ["abscesses", "DISEASE", 250, 259], ["abscesses", "DISEASE", 380, 389], ["Acinetobacter infections", "DISEASE", 817, 841], ["female", "ORGANISM", 209, 215], ["abscesses", "PATHOLOGICAL_FORMATION", 250, 259], ["female", "ORGANISM", 339, 345], ["abscesses", "PATHOLOGICAL_FORMATION", 380, 389], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 403, 413], ["Contaminated ventilators", "TREATMENT", 0, 24], ["respiratory care equipment", "TREATMENT", 28, 54], ["The computed tomography scan", "TEST", 163, 191], ["multiple abscesses", "PROBLEM", 241, 259], ["The computed tomography scan", "TEST", 293, 321], ["multiple abscesses at the right upper lobe", "PROBLEM", 371, 413], ["treatment", "TREATMENT", 454, 463], ["a new computed tomography scan", "TEST", 464, 494], ["treatment", "TREATMENT", 563, 572], ["a new computed tomography scan", "TEST", 573, 603], ["vulnerable populations", "PROBLEM", 774, 796], ["Acinetobacter infections", "PROBLEM", 817, 841], ["contamination", "PROBLEM", 849, 862], ["multiple", "OBSERVATION_MODIFIER", 241, 249], ["abscesses", "OBSERVATION", 250, 259], ["right upper lobe", "ANATOMY", 267, 283], ["multiple", "OBSERVATION_MODIFIER", 371, 379], ["abscesses", "OBSERVATION", 380, 389], ["right upper lobe", "ANATOMY", 397, 413]]], ["Moreover as a result of the ongoing war conflicts in Afghanistan and Iraq some cases of multi-drug resistant Acinetobacter outbreaks have also been reported bringing reminiscent of similar reports during the Korean and Vietnam wars.", [["Acinetobacter outbreaks", "DISEASE", 109, 132], ["multi-drug resistant Acinetobacter outbreaks", "PROBLEM", 88, 132]]], ["It seems that in cases like these multiple factors can contribute including contamination of wounds in the battlefield, local food, environmental spread and cross-infection in the local military or abroad hospitals [5] .DiscussionCommunity-acquired infections due to these pathogens are still rarely reported, mainly in warm and humid climates, and pneumonia.", [["wounds", "ANATOMY", 93, 99], ["wounds", "DISEASE", 93, 99], ["DiscussionCommunity-acquired infections", "DISEASE", 220, 259], ["pneumonia", "DISEASE", 349, 358], ["wounds", "PATHOLOGICAL_FORMATION", 93, 99], ["these multiple factors", "PROBLEM", 28, 50], ["contamination of wounds", "PROBLEM", 76, 99], ["acquired infections", "PROBLEM", 240, 259], ["these pathogens", "PROBLEM", 267, 282], ["pneumonia", "PROBLEM", 349, 358], ["wounds", "OBSERVATION", 93, 99], ["infections", "OBSERVATION", 249, 259], ["pathogens", "OBSERVATION", 273, 282], ["warm", "OBSERVATION_MODIFIER", 320, 324], ["humid climates", "OBSERVATION", 329, 343], ["pneumonia", "OBSERVATION", 349, 358]]], ["Fulminant course with an acute onset of dyspnea, cough, and fever, is the most common manifestation.", [["dyspnea", "DISEASE", 40, 47], ["cough", "DISEASE", 49, 54], ["fever", "DISEASE", 60, 65], ["dyspnea", "PROBLEM", 40, 47], ["cough", "PROBLEM", 49, 54], ["fever", "PROBLEM", 60, 65], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["dyspnea", "OBSERVATION", 40, 47], ["cough", "OBSERVATION", 49, 54], ["fever", "OBSERVATION", 60, 65], ["most common", "OBSERVATION_MODIFIER", 74, 85]]], ["Most patients suffer from various comorbidities.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["various comorbidities", "PROBLEM", 26, 47]]], ["Leung et al in a three-year retroprospective study involving 19 patients with community-acquired pneumonia (CAP) due to Acinetobacter baumannii and 74 patients with health care associated pneumonia (HAP) concluded that CAP appears to be a unique clinical entity with a high incidence of bacteremia, ARDS, disseminated intravascular coagulation (DIC), and death, when compared to HAP [6] .", [["intravascular", "ANATOMY", 318, 331], ["pneumonia", "DISEASE", 97, 106], ["CAP", "DISEASE", 108, 111], ["Acinetobacter baumannii", "DISEASE", 120, 143], ["pneumonia", "DISEASE", 188, 197], ["HAP", "DISEASE", 199, 202], ["CAP", "DISEASE", 219, 222], ["bacteremia", "DISEASE", 287, 297], ["ARDS", "DISEASE", 299, 303], ["disseminated intravascular coagulation", "DISEASE", 305, 343], ["DIC", "DISEASE", 345, 348], ["death", "DISEASE", 355, 360], ["HAP", "DISEASE", 379, 382], ["patients", "ORGANISM", 64, 72], ["Acinetobacter baumannii", "ORGANISM", 120, 143], ["patients", "ORGANISM", 151, 159], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 318, 331], ["patients", "SPECIES", 64, 72], ["Acinetobacter baumannii", "SPECIES", 120, 143], ["patients", "SPECIES", 151, 159], ["Acinetobacter baumannii", "SPECIES", 120, 143], ["retroprospective study", "TEST", 28, 50], ["community-acquired pneumonia", "PROBLEM", 78, 106], ["Acinetobacter baumannii", "PROBLEM", 120, 143], ["health care associated pneumonia", "PROBLEM", 165, 197], ["CAP", "PROBLEM", 219, 222], ["bacteremia", "PROBLEM", 287, 297], ["ARDS", "PROBLEM", 299, 303], ["disseminated intravascular coagulation", "PROBLEM", 305, 343], ["DIC)", "PROBLEM", 345, 349], ["death", "PROBLEM", 355, 360], ["pneumonia", "OBSERVATION", 97, 106], ["pneumonia", "OBSERVATION", 188, 197], ["bacteremia", "OBSERVATION", 287, 297], ["ARDS", "OBSERVATION", 299, 303], ["disseminated", "OBSERVATION_MODIFIER", 305, 317], ["intravascular coagulation", "OBSERVATION", 318, 343]]], ["In another study involving thirteen patients Chen et al concluded that Acinetobacter baumannii can be considered as an etiologic factor in communityacquired lobar pneumonia in patients with fulminant course in the warmer and humid periods of the year and also in younger alcoholic patients.", [["Acinetobacter baumannii", "DISEASE", 71, 94], ["pneumonia", "DISEASE", 163, 172], ["patients", "ORGANISM", 36, 44], ["Acinetobacter baumannii", "ORGANISM", 71, 94], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 281, 289], ["patients", "SPECIES", 36, 44], ["Acinetobacter baumannii", "SPECIES", 71, 94], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 281, 289], ["Acinetobacter baumannii", "SPECIES", 71, 94], ["another study", "TEST", 3, 16], ["Acinetobacter baumannii", "PROBLEM", 71, 94], ["communityacquired lobar pneumonia", "PROBLEM", 139, 172], ["fulminant course", "PROBLEM", 190, 206], ["Acinetobacter", "OBSERVATION", 71, 84], ["lobar", "OBSERVATION_MODIFIER", 157, 162], ["pneumonia", "OBSERVATION", 163, 172], ["fulminant", "OBSERVATION_MODIFIER", 190, 199]]], ["The authors also suggested that a good sputum smear originated from the lower respiratory tract if it contains >25 leukocytes per high power (100\u00d7) field on microscopic examination early on to establish the diagnosis and that a combination of a third-generation cephalosporin and an aminoglycoside is adequate as empirical treatment [7] .", [["sputum smear", "ANATOMY", 39, 51], ["lower respiratory tract", "ANATOMY", 72, 95], ["leukocytes", "ANATOMY", 115, 125], ["cephalosporin", "CHEMICAL", 262, 275], ["aminoglycoside", "CHEMICAL", 283, 297], ["cephalosporin", "CHEMICAL", 262, 275], ["aminoglycoside", "CHEMICAL", 283, 297], ["lower respiratory", "ORGANISM_SUBDIVISION", 72, 89], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["leukocytes", "CELL", 115, 125], ["cephalosporin", "SIMPLE_CHEMICAL", 262, 275], ["aminoglycoside", "SIMPLE_CHEMICAL", 283, 297], ["leukocytes", "CELL_TYPE", 115, 125], ["a good sputum smear", "TEST", 32, 51], ["the lower respiratory tract", "PROBLEM", 68, 95], ["microscopic examination", "TEST", 157, 180], ["a third-generation cephalosporin", "TREATMENT", 243, 275], ["an aminoglycoside", "TREATMENT", 280, 297], ["empirical treatment", "TREATMENT", 313, 332], ["lower", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95]]], ["Falagas et al in a recent review highlighted six case series with community-acquired Acinetobacter infections involving 80 patients.", [["Acinetobacter infections", "DISEASE", 85, 109], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["community-acquired Acinetobacter infections", "PROBLEM", 66, 109]]], ["Of these 51 had pneumonia and 56% (45 patients) died.", [["pneumonia", "DISEASE", 16, 25], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["pneumonia", "PROBLEM", 16, 25], ["pneumonia", "OBSERVATION", 16, 25]]], ["Moreover in the same review 26 case reports involving 43 patients had been identified.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["Pneumonia was present in 38 of them and from the others two had meningitis, one had native valve endocarditis, one had soft skin infection and one had an ocular infection.", [["valve", "ANATOMY", 91, 96], ["skin", "ANATOMY", 124, 128], ["ocular", "ANATOMY", 154, 160], ["Pneumonia", "DISEASE", 0, 9], ["meningitis", "DISEASE", 64, 74], ["valve endocarditis", "DISEASE", 91, 109], ["soft skin infection", "DISEASE", 119, 138], ["ocular infection", "DISEASE", 154, 170], ["valve", "PATHOLOGICAL_FORMATION", 91, 96], ["skin", "ORGAN", 124, 128], ["ocular", "ORGAN", 154, 160], ["Pneumonia", "PROBLEM", 0, 9], ["meningitis", "PROBLEM", 64, 74], ["native valve endocarditis", "PROBLEM", 84, 109], ["soft skin infection", "PROBLEM", 119, 138], ["an ocular infection", "PROBLEM", 151, 170], ["meningitis", "OBSERVATION", 64, 74], ["native valve", "ANATOMY", 84, 96], ["endocarditis", "OBSERVATION", 97, 109], ["soft", "OBSERVATION_MODIFIER", 119, 123], ["skin", "ANATOMY", 124, 128], ["infection", "OBSERVATION", 129, 138], ["ocular", "ANATOMY", 154, 160], ["infection", "OBSERVATION", 161, 170]]], ["Chronic obstructive pulmonary disease, renal disease, diabetes mellitus, excess consumption of alcohol and heavy smoking were the most common risk factors.", [["pulmonary", "ANATOMY", 20, 29], ["renal", "ANATOMY", 39, 44], ["Chronic obstructive pulmonary disease", "DISEASE", 0, 37], ["renal disease", "DISEASE", 39, 52], ["diabetes mellitus", "DISEASE", 54, 71], ["alcohol", "CHEMICAL", 95, 102], ["smoking", "CHEMICAL", 113, 120], ["alcohol", "CHEMICAL", 95, 102], ["pulmonary", "ORGAN", 20, 29], ["renal", "ORGAN", 39, 44], ["alcohol", "SIMPLE_CHEMICAL", 95, 102], ["Chronic obstructive pulmonary disease", "PROBLEM", 0, 37], ["renal disease", "PROBLEM", 39, 52], ["diabetes mellitus", "PROBLEM", 54, 71], ["obstructive", "OBSERVATION_MODIFIER", 8, 19], ["pulmonary", "ANATOMY", 20, 29], ["disease", "OBSERVATION", 30, 37], ["renal", "ANATOMY", 39, 44], ["disease", "OBSERVATION", 45, 52]]], ["According to the same review on 12 retrospective or prospective studies the range of isolation of Acinetobacter from patients suffering from community-acquired pneumonia was 1, 3% to 25, 9% [8] .DiscussionA variety of antibiotics can be used if the infection has been caused by a susceptible stain including broad-spectrum cephalosporins, \u03b2-lactam-\u03b2-lactamase inhibitor combinations, carbapenes, and fluoroquinolones alone or in combination with aminoglycosides.", [["Acinetobacter", "DISEASE", 98, 111], ["pneumonia", "DISEASE", 160, 169], ["infection", "DISEASE", 249, 258], ["cephalosporins", "CHEMICAL", 323, 337], ["\u03b2-lactam-\u03b2-lactamase inhibitor", "CHEMICAL", 339, 369], ["carbapenes", "CHEMICAL", 384, 394], ["fluoroquinolones", "CHEMICAL", 400, 416], ["aminoglycosides", "CHEMICAL", 446, 461], ["cephalosporins", "CHEMICAL", 323, 337], ["\u03b2-lactam", "CHEMICAL", 339, 347], ["carbapenes", "CHEMICAL", 384, 394], ["fluoroquinolones", "CHEMICAL", 400, 416], ["aminoglycosides", "CHEMICAL", 446, 461], ["patients", "ORGANISM", 117, 125], ["broad-spectrum cephalosporins", "SIMPLE_CHEMICAL", 308, 337], ["\u03b2-lactam-\u03b2-lactamase", "SIMPLE_CHEMICAL", 339, 359], ["carbapenes", "SIMPLE_CHEMICAL", 384, 394], ["fluoroquinolones", "SIMPLE_CHEMICAL", 400, 416], ["aminoglycosides", "SIMPLE_CHEMICAL", 446, 461], ["patients", "SPECIES", 117, 125], ["prospective studies", "TEST", 52, 71], ["Acinetobacter", "PROBLEM", 98, 111], ["community-acquired pneumonia", "PROBLEM", 141, 169], ["antibiotics", "TREATMENT", 218, 229], ["the infection", "PROBLEM", 245, 258], ["a susceptible stain", "PROBLEM", 278, 297], ["broad-spectrum cephalosporins", "TREATMENT", 308, 337], ["\u03b2-lactam", "TREATMENT", 339, 347], ["lactamase inhibitor combinations", "TREATMENT", 350, 382], ["carbapenes", "TREATMENT", 384, 394], ["fluoroquinolones", "TREATMENT", 400, 416], ["aminoglycosides", "TREATMENT", 446, 461], ["Acinetobacter", "OBSERVATION", 98, 111], ["pneumonia", "OBSERVATION", 160, 169], ["infection", "OBSERVATION", 249, 258]]], ["Multi-drug resistant infections, including carbapenes, aminoglycosides and fluoroquinolones resistance, are challenging, however the combination of intravenous or inhaled colistin with tigercycline, imipenem, rifampicin or azithromycin seems reasonably enough to achieve satisfactory efficiency, at least in vitro, due to synergic or addictive effects which these combinations offer.", [["intravenous", "ANATOMY", 148, 159], ["infections", "DISEASE", 21, 31], ["carbapenes", "CHEMICAL", 43, 53], ["aminoglycosides", "CHEMICAL", 55, 70], ["fluoroquinolones", "CHEMICAL", 75, 91], ["colistin", "CHEMICAL", 171, 179], ["tigercycline", "CHEMICAL", 185, 197], ["imipenem", "CHEMICAL", 199, 207], ["rifampicin", "CHEMICAL", 209, 219], ["azithromycin", "CHEMICAL", 223, 235], ["carbapenes", "CHEMICAL", 43, 53], ["aminoglycosides", "CHEMICAL", 55, 70], ["fluoroquinolones", "CHEMICAL", 75, 91], ["colistin", "CHEMICAL", 171, 179], ["tigercycline", "CHEMICAL", 185, 197], ["imipenem", "CHEMICAL", 199, 207], ["rifampicin", "CHEMICAL", 209, 219], ["azithromycin", "CHEMICAL", 223, 235], ["carbapenes", "SIMPLE_CHEMICAL", 43, 53], ["aminoglycosides", "SIMPLE_CHEMICAL", 55, 70], ["fluoroquinolones", "SIMPLE_CHEMICAL", 75, 91], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 148, 159], ["colistin", "SIMPLE_CHEMICAL", 171, 179], ["tigercycline", "SIMPLE_CHEMICAL", 185, 197], ["imipenem", "SIMPLE_CHEMICAL", 199, 207], ["rifampicin", "SIMPLE_CHEMICAL", 209, 219], ["azithromycin", "SIMPLE_CHEMICAL", 223, 235], ["Multi-drug resistant infections", "PROBLEM", 0, 31], ["carbapenes", "TREATMENT", 43, 53], ["aminoglycosides", "TREATMENT", 55, 70], ["fluoroquinolones resistance", "TREATMENT", 75, 102], ["intravenous", "TREATMENT", 148, 159], ["inhaled colistin", "TREATMENT", 163, 179], ["tigercycline", "TREATMENT", 185, 197], ["imipenem", "TREATMENT", 199, 207], ["rifampicin", "TREATMENT", 209, 219], ["azithromycin", "TREATMENT", 223, 235], ["synergic or addictive effects", "PROBLEM", 322, 351], ["drug resistant infections", "OBSERVATION", 6, 31]]], ["On the other hand it's unclear if these antibiotic combinations provide adequate therapeutically results in vivo [1, 2, 9, 10] .DiscussionTo our knowledge only three other cases of lung abscesses and three more of pneumatoceles due to Acinetobacter infection that have been described until now but none has been presented with multiple abscesses on admission.", [["lung abscesses", "ANATOMY", 181, 195], ["pneumatoceles", "ANATOMY", 214, 227], ["abscesses", "ANATOMY", 336, 345], ["lung abscesses", "DISEASE", 181, 195], ["pneumatoceles", "DISEASE", 214, 227], ["Acinetobacter infection", "DISEASE", 235, 258], ["abscesses", "DISEASE", 336, 345], ["lung", "ORGAN", 181, 185], ["pneumatoceles", "CANCER", 214, 227], ["abscesses", "PATHOLOGICAL_FORMATION", 336, 345], ["these antibiotic combinations", "TREATMENT", 34, 63], ["lung abscesses", "PROBLEM", 181, 195], ["pneumatoceles", "PROBLEM", 214, 227], ["Acinetobacter infection", "PROBLEM", 235, 258], ["multiple abscesses", "PROBLEM", 327, 345], ["lung", "ANATOMY", 181, 185], ["abscesses", "OBSERVATION", 186, 195], ["Acinetobacter", "OBSERVATION", 235, 248], ["multiple", "OBSERVATION_MODIFIER", 327, 335], ["abscesses", "OBSERVATION", 336, 345]]], ["Myrianthefs et al reported a case of a 77-year old woman with multi-drug resistant Acinetobacter baumannii lung abscesses who underwent splenectomy after multiple traumas and remained for a long period in an ICU.", [["lung", "ANATOMY", 107, 111], ["Acinetobacter baumannii lung abscesses", "DISEASE", 83, 121], ["traumas", "DISEASE", 163, 170], ["woman", "ORGANISM", 51, 56], ["Acinetobacter baumannii", "ORGANISM", 83, 106], ["lung", "ORGAN", 107, 111], ["woman", "SPECIES", 51, 56], ["Acinetobacter baumannii", "SPECIES", 83, 106], ["Acinetobacter baumannii", "SPECIES", 83, 106], ["multi-drug resistant Acinetobacter baumannii lung abscesses", "PROBLEM", 62, 121], ["splenectomy", "TREATMENT", 136, 147], ["multiple traumas", "PROBLEM", 154, 170], ["drug resistant", "OBSERVATION_MODIFIER", 68, 82], ["Acinetobacter", "OBSERVATION_MODIFIER", 83, 96], ["baumannii", "OBSERVATION_MODIFIER", 97, 106], ["lung", "ANATOMY", 107, 111], ["abscesses", "OBSERVATION", 112, 121], ["splenectomy", "OBSERVATION", 136, 147], ["multiple", "OBSERVATION_MODIFIER", 154, 162], ["traumas", "OBSERVATION", 163, 170]]], ["Fortunately this patient recovered [11] .", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["Hunt et al reported three cases of ICU pneumonia with the formation of pneumatoceles due to Acinetobacter infection.", [["pneumatoceles", "ANATOMY", 71, 84], ["pneumonia", "DISEASE", 39, 48], ["pneumatoceles", "DISEASE", 71, 84], ["Acinetobacter infection", "DISEASE", 92, 115], ["pneumatoceles", "CANCER", 71, 84], ["ICU pneumonia", "PROBLEM", 35, 48], ["pneumatoceles", "PROBLEM", 71, 84], ["Acinetobacter infection", "PROBLEM", 92, 115], ["pneumonia", "OBSERVATION", 39, 48], ["Acinetobacter", "OBSERVATION_MODIFIER", 92, 105], ["infection", "OBSERVATION", 106, 115]]], ["Yen et al in a 23 cases retrospective review of pediatric lung abscesses reported only one case of secondary abscess due to Acinetobacter baumannii infection.", [["lung abscesses", "ANATOMY", 58, 72], ["abscess", "ANATOMY", 109, 116], ["lung abscesses", "DISEASE", 58, 72], ["abscess", "DISEASE", 109, 116], ["Acinetobacter baumannii infection", "DISEASE", 124, 157], ["lung", "ORGAN", 58, 62], ["abscess", "PATHOLOGICAL_FORMATION", 109, 116], ["Acinetobacter baumannii", "ORGANISM", 124, 147], ["Acinetobacter baumannii", "SPECIES", 124, 147], ["Acinetobacter baumannii", "SPECIES", 124, 147], ["pediatric lung abscesses", "PROBLEM", 48, 72], ["secondary abscess", "PROBLEM", 99, 116], ["Acinetobacter baumannii infection", "PROBLEM", 124, 157], ["lung", "ANATOMY", 58, 62], ["abscesses", "OBSERVATION", 63, 72], ["secondary", "OBSERVATION_MODIFIER", 99, 108], ["abscess", "OBSERVATION", 109, 116], ["Acinetobacter baumannii", "OBSERVATION", 124, 147]]], ["Although only two deaths occurred in this group of patients it's unclear if one of them was the Acinetobacter baumannii infected patient [13] .", [["deaths", "DISEASE", 18, 24], ["Acinetobacter baumannii infected", "DISEASE", 96, 128], ["patients", "ORGANISM", 51, 59], ["Acinetobacter baumannii", "ORGANISM", 96, 119], ["patient", "ORGANISM", 129, 136], ["patients", "SPECIES", 51, 59], ["Acinetobacter baumannii", "SPECIES", 96, 119], ["patient", "SPECIES", 129, 136], ["Acinetobacter baumannii", "SPECIES", 96, 119], ["the Acinetobacter baumannii", "PROBLEM", 92, 119], ["two", "OBSERVATION_MODIFIER", 14, 17], ["deaths", "OBSERVATION", 18, 24]]], ["Finally Yang et al reported a case of a 35-year-old male with right lobe necrotizing community-acquired pneumonia and lung abscess formation one week after his admission, who achieved a slow but fully recovery [14] .DiscussionIn conclusion we presented a case of right lobe community acquired pneumonia with the formation of multiple lung abscesses due to a susceptible Acinetobacter baumannii stain.", [["right lobe", "ANATOMY", 62, 72], ["lung abscess", "ANATOMY", 118, 130], ["right lobe community", "ANATOMY", 263, 283], ["lung abscesses", "ANATOMY", 334, 348], ["pneumonia", "DISEASE", 104, 113], ["lung abscess", "DISEASE", 118, 130], ["pneumonia", "DISEASE", 293, 302], ["lung abscesses", "DISEASE", 334, 348], ["male", "ORGANISM", 52, 56], ["lobe", "ORGAN", 68, 72], ["lung abscess", "PATHOLOGICAL_FORMATION", 118, 130], ["lobe", "ORGAN", 269, 273], ["lung", "ORGAN", 334, 338], ["Acinetobacter baumannii", "ORGANISM", 370, 393], ["Acinetobacter baumannii", "SPECIES", 370, 393], ["Acinetobacter baumannii", "SPECIES", 370, 393], ["right lobe necrotizing community-acquired pneumonia", "PROBLEM", 62, 113], ["lung abscess formation", "PROBLEM", 118, 140], ["right lobe community acquired pneumonia", "PROBLEM", 263, 302], ["multiple lung abscesses", "PROBLEM", 325, 348], ["a susceptible Acinetobacter baumannii stain", "PROBLEM", 356, 399], ["right lobe", "ANATOMY", 62, 72], ["necrotizing", "OBSERVATION_MODIFIER", 73, 84], ["pneumonia", "OBSERVATION", 104, 113], ["lung", "ANATOMY", 118, 122], ["abscess", "OBSERVATION", 123, 130], ["right lobe", "ANATOMY", 263, 273], ["pneumonia", "OBSERVATION", 293, 302], ["multiple", "OBSERVATION_MODIFIER", 325, 333], ["lung", "ANATOMY", 334, 338], ["abscesses", "OBSERVATION", 339, 348], ["susceptible", "OBSERVATION_MODIFIER", 358, 369], ["Acinetobacter baumannii", "OBSERVATION", 370, 393]]], ["This is a rare manifestation of a community acquired disease.AbbreviationsESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ICU: intensive care unit; VAP: ventilator associated pneumonia; CAP: community acquired pneumonia; HAP: health care associated pneumonia; ARDS: adult respiratory distress syndrome; DIC: disseminated intravascular coagulation.ConsentWritten informed consent was obtained from the patient's legal guardian for publication of this case report and", [["erythrocyte", "ANATOMY", 79, 90], ["respiratory", "ANATOMY", 286, 297], ["intravascular", "ANATOMY", 335, 348], ["VAP", "DISEASE", 162, 165], ["pneumonia", "DISEASE", 189, 198], ["CAP", "DISEASE", 200, 203], ["pneumonia", "DISEASE", 224, 233], ["HAP", "DISEASE", 235, 238], ["pneumonia", "DISEASE", 263, 272], ["ARDS", "DISEASE", 274, 278], ["respiratory distress syndrome", "DISEASE", 286, 315], ["DIC", "DISEASE", 317, 320], ["intravascular coagulation", "DISEASE", 335, 360], ["erythrocyte", "CELL", 79, 90], ["CRP", "GENE_OR_GENE_PRODUCT", 111, 114], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 335, 348], ["patient", "ORGANISM", 415, 422], ["CRP", "PROTEIN", 111, 114], ["patient", "SPECIES", 415, 422], ["a community acquired disease", "PROBLEM", 32, 60], ["erythrocyte sedimentation rate", "TEST", 79, 109], ["CRP", "TEST", 111, 114], ["ventilator associated pneumonia", "PROBLEM", 167, 198], ["community acquired pneumonia", "PROBLEM", 205, 233], ["pneumonia", "PROBLEM", 263, 272], ["ARDS", "PROBLEM", 274, 278], ["adult respiratory distress syndrome", "PROBLEM", 280, 315], ["disseminated intravascular coagulation", "PROBLEM", 322, 360], ["community acquired", "OBSERVATION", 34, 52], ["erythrocyte sedimentation", "OBSERVATION", 79, 104], ["pneumonia", "OBSERVATION", 189, 198], ["pneumonia", "OBSERVATION", 224, 233], ["pneumonia", "OBSERVATION", 263, 272], ["ARDS", "OBSERVATION", 274, 278], ["respiratory distress", "OBSERVATION", 286, 306], ["disseminated", "OBSERVATION_MODIFIER", 322, 334], ["intravascular coagulation", "OBSERVATION", 335, 360]]]]}